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foreword
Today, 47 million people live with dementia worldwide, more than the population of Spain. 
This number is projected to increase to more than 131 million by 2050, as populations 
age. Dementia also has a huge economic impact. The total estimated worldwide cost of 
dementia is US$818 billion, and it will become a trillion dollar disease by 2018.
The huge majority of people with dementia have not received a diagnosis, and so are 
unable to access care and treatment. Even when dementia is diagnosed, the care 
provided is too often fragmented, uncoordinated, and unresponsive to the needs of 
people living with dementia, their carers and families. This is unacceptable.
This World Alzheimer Report 2016 reviews the state of healthcare for dementia around the 
world, and recommends ways that it can be improved. There is a clear and urgent need to 
improve the coverage of healthcare around the world, for people living with dementia now 
and those who will be in the future. Through cost modelling, the report shows that these 
improvements are affordable and achievable, but governments and societies need to 
effect transformative change to deliver them. It is essential that this happens.
We are grateful to the authors from The Global Observatory for Ageing and Dementia 
Care at King’s College London and the Personal Social Services Research Unit at 
the London School of Economics and Political Science for producing this report. We 
appreciate the support of our sponsors – GE Healthcare, Roche, Janssen, Lundbeck,  
Lilly and Biogen – which made the report possible.
ADI, the global federation of 85 Alzheimer associations, is committed to ensuring that 
dementia becomes an international health priority. We believe national dementia plans 
are the first step towards ensuring all countries are equipped to enable people to live 
well with dementia, and help to reduce the risk of dementia for future generations. There 
is now a growing list of countries which have such provision in place or are developing 
national dementia plans, but it is not enough. We hope that the adoption of a Global Plan 
on Dementia by the World Health Organization in 2017 will commit member states to act 
on many of the recommendations contained in this report.
Around the world, we need to drive forward improvements in healthcare and social care, 
as well as eliminating the stigma around dementia and ensuring that people living with 
dementia are included in society and that their human rights are recognised everywhere.
We are committed to ensuring prevention, care and inclusion happen today, and a  
cure tomorrow.
Glenn Rees
Chair 
Alzheimer’s Disease International
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coverage, QualIty and costs now and In the future
the global observatory  
for ageing and dementia care
The Global Observatory for Ageing and Dementia Care, hosted at the Health Service 
and Population Research Department, King’s College London, was founded in 2013. 
Supported by Alzheimer’s Disease International, and King’s College London, the 
Observatory has a tripartite mission:
1. To build upon ADI’s 10/66 Dementia Research Group program of population-based 
and intervention research in low and middle income countries, maximising the impact 
that research findings from our data can have upon policy and practice.
2. To develop, evaluate, and promote primary care and community interventions for 
people with dementia.
3. To synthesise global evidence for policymakers and public, in particular, continuing 
and developing our role in the preparation of high impact evidence-based reports for 
Alzheimer’s Disease International (World Alzheimer Reports 2009, 2010, 2011, 2013, 
2014 and 2015, and Nutrition and dementia), the World Health Organization (Dementia: 
a public health priority, 2012) and other relevant intergovernmental organisations.
Findings from the reviews
Models of healthcare delivery
•	 Healthcare	for	people	with	dementia	needs	to	be:
•	 Continuous:	treatment	options,	care	plans	
and	needs	for	support	must	be	monitored	
and	reviewed	as	the	condition	evolves	and	
progresses.	
•	 Holistic:	treating	the	whole	person,	not	single	
conditions,	organs	or	systems,	and	mindful	
of	that	person’s	unique	context,	values	and	
preferences.
•	 Integrated:	across	providers,	levels	of	care,	and	
health	and	social	care	systems.
•	 Currently,	healthcare	systems	struggle	to	provide	
adequate	coverage	of	diagnostic	services,	and	
care	is	too	often	fragmented,	uncoordinated,	and	
unresponsive	to	the	needs	of	people	with	dementia	
and	their	families.
•	 In	high	income	countries,	dementia	healthcare	
systems	tend	to	be	highly	specialised	(care	is	
provided	by	specialist	physicians	-	geriatricians,	
neurologists	and	psychiatrists),	from	diagnosis	
onwards,	with	very	little	formal	recognition	of	the	
role	of	primary	care	services,	or	allocation	of	tasks	
to	this	sector.	This	is	probably	also	true	for	low	
and	middle	income	countries,	where	diagnostic	
coverage	is	low.
•	 As	the	numbers	of	people	affected	and	the	
demand	for	services	increase,	it	is	unlikely	that	full	
coverage	of	dementia	healthcare	services	can	be	
attained	or	afforded	using	the	current	specialist	
care	model.
The role of primary care
•	 Dementia	is	currently	under-detected,	under-
diagnosed,	under-disclosed,	under-treated	and	
under-managed	in	primary	care.
•	 When	primary	care	physicians	do	take	
responsibility	for	dementia	care,	evidence	suggests	
that	the	care	has	similar	outcomes	to	that	provided	
by	specialists.
•	 Recognition	of	dementia	in	primary	care	can	be	
boosted	by	in-service	education	and	training.
•	 Indicated	screening	using	cognitive	tests	can	
support	timely	diagnosis.	However,	general	
screening	of	all	older	attendees	cannot	currently	be	
recommended.
•	 In	most	settings,	dementia	diagnosis	is	not	
explicitly	recognised	as	being	within	the	capacity	of	
non-specialist	services.	Nevertheless,	we	identified	
several	successful	examples	of	memory	clinics	
established	in	primary	care,	and	run	by	primary	
care	physicians	supported	by	nurse	practitioners.
•	 The	post-diagnostic	phase	bridges	from	the	
‘diagnosis	well-made’	to	a	system	of	continuing	
care	in	the	context	of	declining	function	and	
increasing	needs	for	care	and	support.	
•	 The	potential	benefits	of	the	full	range	of	post-
diagnostic	support	activities	have	yet	to	be	
evaluated.
•	 Primary	care	services	struggle	to	deliver	high	
quality	continuing	care	for	people	with	dementia,	
even	in	systems	where	their	role	has	been	made	
more	explicit.
•	 There	have,	as	yet,	been	no	evaluations	of	case	
management	located	within	primary	care.
•	 Attention	needs	to	be	given	to	the	optimal	roles	
of	specialists	within	a	more	task-shifted	and	
task-shared	healthcare	model.	Task-shifting	is	
defined	as	delegating	selected	tasks	to	existing	
or	new	health	professional	cadres	with	either	less	
training	or	narrowly	tailored	training.	This	may	
involve	shifting	tasks	from	higher-	to	lower-skilled	
health	workers	–	for	example,	from	a	neurologist	
to	a	primary	care	physician	–	or	creating	new	
professional	roles,	so	tasks	can	be	shifted	from	
workers	with	more	general	training	to	workers	with	
specific	training	for	a	particular	task	–	for	example,	
from	a	primary	care	physician	to	a	dementia	case	
manager.
•	 Task-shifted	models	of	care	require	specialist	
support.	Specialist	services	will	need	to	take	on	
a	more	prominent	role	in	training,	mentoring	and	
supervising	non-specialists,	with	explicit	referral	
guidelines	and	pathways.
Care coordination, through case 
management
•	 The	effectiveness	of	case	management	remains	
unclear	as	research	is	lacking.	Positive	effects	of	
case	management	(reduced	or	delayed	transition	
into	care	homes,	better	adherence	to	care	
standards,	and	reduced	unmet	needs)	were	found	
in	some	studies.
•	 There	is	a	lack	of	evidence	regarding	the	impact	
of	case	management	on	the	efficiency	with	which	
healthcare	is	delivered,	mainly	because	most	
studies	do	not	report	on	the	relevant	outcomes.
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•	 Effects	of	case	management	on	hospitalisation	
were	generally	not	significant	and	the	absence	of	
evidence	on	cost-effectiveness	studies	is	striking.
•	 Evidence	to	date	suggests	that	effectiveness	may	
be	enhanced	when	there	is:
•	 A	manageable	caseload	for	delivering	
interventions	with	the	required	intensity;	
•	 A	clear	role	definition	with	adequate	preparation	
and	training;	and	
•	 Empowerment	of	the	case	manager	to	access	
and	coordinate	care	across	providers	and	
sectors.
•	 Future	evaluations	need	to	include	a	
comprehensive	set	of	process	and	outcome	
measures,	which	should	include	service	
utilisation	and	cost,	effective	components	of	case	
management,	as	well	as	clinical	and	quality	of	life	
outcomes	for	the	person	with	dementia	and	carer.
Hospital care
•	 People	with	dementia	are	more	likely	to	be	
admitted	to	general	hospital	than	people	of	
similar	age	and	medical	infirmity,	particularly	for	
falls-related	accidents	and	injuries,	urinary	tract	
and	respiratory	infections,	and	chronic	disease	
complications	that	might	have	been	averted	with	
better	management	in	the	community.
•	 People	with	dementia	are	less	likely	to	be	admitted	
for	interventional	procedures	that	could	enhance	
quality	of	life,	including	cataract	surgery,	vascular	
catheterisation	and	stenting,	cholecystectomy,	and	
cancer	care.	
•	 In	high	income	countries	the	costs	of	healthcare	
are	substantially	higher	for	people	with	dementia	
than	age-matched	controls,	with	a	substantial	
proportion	of	costs	arising	from	hospitalisation.	
•	 The	process	of	hospital	care	is	more	complicated	
for	people	with	dementia,	with	significant	cost	
implications.	They	have	longer	hospital	stays,	and	
require	more	nursing	resources	than	others.
•	 People	with	dementia	are	particularly	vulnerable	
to	harm	and	poor	outcomes	in	the	context	of	an	
admission,	particularly	from	hospital	acquired	
infections,	delirium,	agitation	and	falls,	all	of	which	
impact	adversely	on	length	of	stay.	
•	 Mortality	rates	are	exceptionally	high	during	
admission	and	somewhat	higher	after	discharge.	
However,	the	high	mortality	rates	may	reflect,	in	
part,	a	tendency	to	admit	people	with	dementia	to	
hospital	at	the	very	end-of-life.	
•	 More	research	is	need	into	service	and	system	
level	interventions	to	avoid	hospitalisation,	
specifically	of	people	with	dementia.	Community	
interventions	have	been	mostly	ineffective,	
although	there	is	more	evidence	to	support	
multidisciplinary	assessment	and	management,	
than	case	management.	
•	 Emergency	Departments	are	often	the	portal	
of	admission	for	people	with	dementia,	and	
represent	a	last	chance	to	prevent	unnecessary	
hospitalisation.	The	literature	highlights	the	need	
for	comprehensive	multidimensional	geriatric	
assessment,	including	detection	of	dementia	and	
delirium.	
•	 ‘Hospital	at	home’	refers	to	services	provided	by	
health	professionals	in	the	person’s	own	home,	
in	situations	when	inpatient	hospitalisation	would	
otherwise	be	necessary.	While	we	identified	several	
examples	of	such	services	being	established	for	
people	with	dementia,	we	could	find	no	formal	
evaluations.
•	 Reducing	rates	of	hospitalisation	for	people	with	
dementia	will	likely	require	community-based	and	
outreach	services	that	are	resource-intensive	and	
maintained	over	relatively	long	periods	of	time.	
Costs	then	would	be	shifted	from	acute	hospital	
to	community	health	and	social	care,	which	would	
require	adjustments	to	budgets	and	resource	
allocation.	
•	 For	people	with	dementia	who	are	admitted	
to	general	hospital,	there	is	a	tension	between	
prioritisation	of	task-centred	acute	care	for	the	
cause	for	admission,	and	the	acknowledged	need	
to	provide	person-centred	dementia	care.	
•	 Advocated	actions	are	mainly	at	the	systems	
level,	focusing	on	managerial	and	workforce	
development;	providing	an	appropriate	care	
environment;	fostering	a	positive	care	culture;	
changing	attitudes;	and	cultivating	a	better	
understanding	of	the	challenges	for	the	person	with	
dementia,	for	carers,	and	for	inpatient	healthcare	
staff.
•	 Most	reviews	and	reports	emphasise	that	simply	
introducing	a	mental	health	liaison	service,	or	a	
dementia	specialist	nurse,	or	a	special	dementia	
care	unit	will	not	suffice.	These	need	to	be	properly	
integrated	into	the	wider	hospital	and	health	
service	management	structure.
•	 Concern	is	expressed	in	all	recent	reviews	at	
the	lack	of	rigorous	evaluation	of	services	that	
commissioners	are	advocating	and	providers	
are	implementing.	Well-conducted	large	scale	
randomised	controlled	trials,	providing	clear	
evidence	of	cost-effectiveness	are	largely	lacking.	
Palliative and end-of-life care
•	 Concerns	have	been	raised	regarding	the	lack	of	
access	for	people	with	dementia	to	good	quality	
end-of-life	care,	specifically	specialist	palliative	
care	services,	although	there	is	some	evidence,	
from	some	high	income	countries,	that	the	situation	
may	be	improving.
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•	 The	applicability	of	a	palliative	approach	to	
dementia	care	continues	to	be	debated,	given	
the	lack	of	consensus	regarding	the	definition	
of	‘advanced’	dementia	and	the	lack	of	a	clearly	
demarcated	‘end-of-life’	phase.	
•	 There	may	be	no	specific	palliative	phase;	the	
specific	goals	of	dementia	care	can	include,	
at	various	phases,	and	to	different	degrees,	
prolonging	life,	improving	function,	and	achieving	
comfort	(palliation).	
•	 People	with	dementia	should	be	encouraged	and	
enabled	to	exercise	their	autonomy	in	options	
for	future	care,	consistent	with	their	values	and	
preferences,	and	it	should	be	emphasised	that	
the	palliative	care	agenda	is	focused	upon	their	
choices,	and	their	quality	of	life,	rather	than	cost	
savings.
•	 Early	discussions	with	family	carers	that	
acknowledge	the	likely	future	loss	of	decision-
making	capacity	and	their	increasing	role	as	proxy	
decision-makers	would	assist	carers	in	assuming	
this	role,	and	enhance	their	ability	to	judge	the	
person	with	dementia’s	best	interests.	
•	 Calls	have	been	made	for	a	better	systematisation	
of	palliative	care	for	people	with	dementia,	with	
structured	care	pathways,	good	practice	supported	
by	evidence,	and	identification	of	appropriate	
outcomes	to	allow	the	effects	of	interventions	to	be	
measured.	
•	 More	clarity	is	needed	regarding	the	division	of	
responsibilities	among	different	health	and	social	
care	disciplines.	
•	 There	is	also	a	policy	gap	regarding	end-of-life	care	
for	people	with	dementia.	The	focus	is	on	living	well	
with	dementia,	with	relatively	less	attention	to	the	
complex	medical,	social	and	ethical	management	
of	the	physical	decline	that	leads	to	death.
•	 There	is	an	urgent	need	for	more	research,	specific	
to	the	dementia	field,	regarding:	preferences	of	
people	with	dementia,	and	how	these	can	be	
elicited;	the	implementation,	benefits	and	harms	
of	advanced	care	planning;	and	the	relative	costs	
and	benefits	of	palliative	care	assessments	and	
services	in	the	more	advanced	phases	of	the	
condition.	Current	good	practice	guidelines	are	
almost	entirely	based	upon	expert	opinion	and	
consensus.
Dementia care pathways and the health 
system context
Reviews	of	the	care	for	people	with	dementia	in	
Canada,	China,	Indonesia,	Mexico,	South	Africa,	South	
Korea	and	Switzerland	have	identified	key	challenges	
to	the	implementation	of	better	healthcare	pathways	for	
people	with	dementia:
•	 In	most	of	the	countries,	the	low	levels	of	
awareness	and	training	of	healthcare	staff	
contribute	to	low	rates	of	diagnosis,	as	dementia	is	
considered	a	normal	part	of	ageing.	For	those	who	
are	diagnosed,	the	lack	of	professional	knowledge	
about	treatment	and	care	options	may	also	deny	
people	access	to	post-diagnostic	care,	treatment	
and	support.	
•	 Access	to	healthcare	for	people	with	dementia	
remains	a	problem	for	some	parts	of	the	population	
in	most	of	the	countries.	Access	can	be	restricted	
as	result	of	the	financing	arrangements	(particularly	
in	low	and	middle	income	countries,	some	people	
have	inadequate	or	no	public	health	cover	at	all,	
and,	even	in	high	income	countries,	the	out-of-
pocket	payments	can	be	too	high	for	those	in	low	
incomes).	People	from	some	ethnic	groups	and	
people	living	in	care	homes	have	more	difficulties	
accessing	appropriate	care	in	most	countries.
•	 Geographic	inequities	(poor	availability	of	care	in	
rural	and	remote	areas)	remain	a	problem	even	
in	high	income	countries,	although	there	are	
examples	of	the	use	of	technology	to	improve	this.
•	 In	all	the	countries	except	for	Canada	and	South	
Africa,	primary	care	does	not	have	a	gatekeeping	
role	and	people	are	able	to	access	specialist	care	
directly,	which	may	result	in	people	accessing	care	
that	is	unnecessarily	expensive,	or	even	accessing	
the	wrong	specialists.	The	ease	of	access	to	
specialist	care,	combined	with	a	perception	that	
primary	care	is	of	lower	quality,	may	be	important	
barriers	to	the	development	of	task-shifted	care	
pathways.
The costs of implementing a task-
shifted dementia healthcare pathway
We	estimated	the	costs	of	implementing	a	dementia-
specific	healthcare	task-shifted	pathway	in	in	Canada,	
China,	Indonesia,	Mexico,	South	Africa,	South	Korea	
and	Switzerland.	The	pathway	was	based	on	the	
literature	reviews	conducted	as	part	of	this	report	and	
it	involves:
•	 Diagnosis:	mostly	carried	out	in	primary	care	by	
primary	care	physicians	and	case	managers,	with	
some	people	referred	to	specialist	care.
•	 Initial	treatment	and	post-diagnostic	support:	
an	assessment	for	anti-dementia	drugs,	post-
diagnostic	support	package,	and	carer	training	and	
support).
•	 Continuing	care:	anti-dementia	medication	reviews,	
management	of	behavioural	and	psychological	
symptoms	and	case	management.
•	 End-of-life	care.	
•	 A	proportion	of	people,	those	with	more	complex	
dementia	and	co-morbidities,	would	continue	to	
access	a	specialist	care	pathway.
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We	compiled	unit	costs	for	each	of	the	countries,	
complemented	with	international	estimates	when	local	
unit	costs	were	not	available.	Results	from	costing	the	
pathway	in	each	of	the	countries	show	that:
•	 The	costs	of	the	task-shifted	pathways	are	
relatively	low	compared	to	overall	healthcare	
spending.	We	have	estimated	that	the	cost	of	the	
pathway	in	2015,	per	person	diagnosed,	would	
range	from	$39	per	year	in	Mexico	(or	$3.90	per	
person	with	dementia),	to	$2,113	in	South	Korea	
($1,057	per	person	with	dementia).	
•	 The	prescription	costs	of	anti-dementia	drugs	
are	very	high	in	some	of	the	countries	(China,	
Indonesia,	South	Africa	and	South	Korea),	
representing	more	than	80%	of	the	cost	of	the	
pathway.	This	is	in	part	because	of	drugs	remaining	
under	patent,	lack	of	consolidated	purchasing,	
and	reluctance	to	use	generic	medicines.	This	is	
aggravated	in	some	countries	by	doctors	using	
additional	prescription	fees	to	supplement	their	
incomes.		If,	by	2030,	the	use	of	generic	medicines	
was	the	norm,	the	cost	of	the	task-shifted	care	
pathway	would	be	40%	lower	than	that	of	the	
specialist	pathway	in	all	three	HIC,	making	
increased	coverage	more	affordable.
Conclusions and recommendations
Four	main	themes	emerged	from	the	reviews	
conducted	for	this	report:
1. Systematisation of care processes
Systematisation	should	include:	
•	 standards	of	care	at	different	phases	of	the	
condition;	
•	 role	specification	(‘who	does	what’);	
•	 clear	referral	indications	and	pathways;	and	
•	 relevant	process	and	outcome	indicators	to	be	
measured.	
2. Managing complexity
•	 Much	more	effort	needs	to	be	applied	to	the	
effective	management	of	complex	multimorbidities	
(multiple	health	problems)	in	dementia	healthcare,	
in	particular	chronic	physical	health	conditions.	
There	is	evidence	that	chronic	physical	health	
conditions	are	undermanaged	for	people	with	
dementia,	with	missed	opportunities	to	improve	
function	and	avoid	acute	crises	leading	to	
hospitalisation	(for	example,	nutrition,	hydration,	
falls,	infection,	delirium	and	medication	
management).	
3. Need for more research
•	 Researchers	should	work	with	policymakers	
and	providers	to	ensure	that	the	innovations	that	
they	propose	to	evaluate	are	policy	relevant,	fully	
implementable	in	the	context	of	the	research	
evaluation,	and	capable	of	being	taken	to	scale	in	
the	event	that	effectiveness	and	cost-effectiveness	
are	demonstrated.	
4. Coverage, costs and efficiency
•	 Increasing	the	coverage	of	dementia	care	will	
increase	total	costs	to	the	health	system,	since	
more	people	will	be	being	treated.	This,	coupled	
with	the	increasing	numbers	of	people	living	with	
dementia,	is	likely	to	be	a	key	driver	of	trends	in	
healthcare	costs.	
•	 In	this	context,	a	move	towards	a	less	specialised,	
more	task-shifted	model	of	care	can	be	advocated	
on	two	grounds:	
•	 First,	mobilising	the	untapped	potential	of	the	
non-specialist	primary	care	workforce	can	
alleviate	resource	constraints,	enabling	scaling	
up	to	take	place	(especially	critical	for	low	and	
middle	income	countries).	
•	 Secondly,	this	strategy	is	likely	to	optimise	
productive	efficiency.	Under	either	scenario,	the	
unit	costs	of	care	are	assumed	to	fall.	
•	 Over	time,	as	tasks	are	shifted	successfully	to	the	
primary	care	level,	commissioners	will	be	able	
to	shift	budgets	from	secondary	to	primary	care	
and	per	capita	costs	of	care	may	fall.	In	reality	
though,	the	main	benefits	of	task-shifting	may	be	
the	unlocking	of	resource	capacity	to	meet	the	
increasing	demand.	
•	 There	is	also	the	possibility	that	task-shifted	and	
task-shared	care	may	be	of	higher	quality;	more	
local,	more	holistic	and	personalised,	and	more	
comprehensive,	integrated	and	continuous.	
•	 To	improve	coverage	using	a	task-shifted	approach	
requires	that	health	systems	provide	universal	
health	coverage,	good	access	to	care	for	those	in	
rural	areas	and	from	disadvantaged	groups	and,	
crucially,	that	primary	healthcare	has	a	central	(and	
gatekeeping	role)	in	health	systems.
•	 Scaling	up	dementia	care	would	seem	to	be	
affordable,	in	principle,	in	all	countries	included	in	
our	review.
•	 The	cost	of	anti-dementia	drugs	had	a	large	
impact	on	the	total	cost	of	the	dementia	healthcare	
pathway	where	low	cost	generic	versions	of	
acetylcholinesterase	inhibitors	and	memantine	
were	not	yet	available.	
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We	need	to	focus	on	achieving	high	coverage	of	
dementia	diagnosis	and	continuing	care,	both	to	
ensure	access	to	current	evidence-based	treatments	
and	support,	and	to	create	systems	and	platforms	
with	the	capacity	to	deliver,	with	equity,	much	more	
effective	treatments	in	the	future.
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1.1 Healthcare in context
Narratives	and	reviews	of	dementia	care	systems	have	
tended	to	emphasise	social	care,	whether	provided	by	
unpaid	family	carers,	or	services	that	are	developed	
to	support,	supplement	or	substitute	their	core	role	
in	the	journey	of	care.	This	was	the	topic	of	the	World	
Alzheimer	Report	20131.	The	focus	is	understandable	
in	many	ways.	The	goal	of	‘living	well	with	dementia’	
is	achieved	when	care	is	person-centred,	seamless	
and	co-ordinated,	and	when	the	needs	of	people	
with	dementia,	and	their	carers,	are	anticipated	and	
met	in	a	timely	fashion	throughout	the	course	of	
the	condition.	Much	remains	to	be	done	to	achieve	
this	objective	-	long	term	care	systems	around	the	
world	are	too	often	fragmented,	unresponsive,	and	
of	inadequate	quality,	and	coverage	of	core	support	
services	is	low,	particularly	in	less	well-resourced	low	
and	middle	income	countries	(LMIC)1.	There	is	also	a	
fiscal	imperative;	80-85%	of	the	global	societal	costs	
of	dementia	(currently	estimated	to	be	US$818	billion)	
arise	from	the	direct	costs	of	social	care	services,	
and	the	informal	unpaid	inputs	of	family	carers2.	In	
high	income	countries	(HIC)	informal	care	and	the	
direct	costs	of	social	care	(community	homecare,	and	
residential	care)	make	similar	contributions	to	total	
costs.	In	LMIC,	the	costs	of	informal	care	predominate,	
since	a	structured	formal	social	care	sector	has,	as	yet,	
not	been	developed.
Less	attention,	relatively	speaking,	is	paid	to	the	
systems	and	services	that	deliver	healthcare	for	people	
with	dementia.	Currently,	only	10-15%	of	total	societal	
costs	arise	from	healthcare,	regardless	of	setting2.	
Healthcare costs are modest because:
1.			Diagnostic	coverage	is	low.	In	most	HIC,	only	40-
50%	of	people	living	with	dementia	have	received	a	
diagnosis.	In	LMIC	there	are	few	available	estimates,	
but	diagnostic	coverage	is	unlikely	to	exceed	
5-10%	in	most	settings3–5.	Diagnostic	coverage	
is	important,	since	this	is	the	gateway	to	planning	
for,	and	receipt	of,	health	and	social	care	services,	
across	the	disease	course.	Increasing	the	coverage	
of	timely	dementia	diagnosis	is	a	priority	for	most	
current	national	and	regional	policies	and	plans.
2.			Dementia	specialist	care	is	underdeveloped	in	
LMIC.	There	are	very	few	geriatricians,	neurologists	
and	psychiatrists,	and	few	hospital	or	community-
based	services	dedicated	to	diagnosis	and	
continuing	care6–8.	Coverage	of	continuing	care	
services	remains	low	in	HIC,	in	part	because	of	low	
diagnostic	coverage,	but	also	because	specialist	
services	struggle	to	provide	continuous	and	
responsive	care	to	rapidly	increasing	numbers	of	
people	with	dementia9.	
3.			Even	interventions	with	a	strong	evidence-base	
(for	example	acetylcholinesterase	inhibitors	and	
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memantine)	are	not	being	delivered	to	all	who	
might	benefit,	while	others	have	scarcely	been	
implemented	at	all	(carer	education,	training	and	
support).	
4.			Other	interventions	that	have	been	proposed	and	
considered	in	some	health	systems	(for	example	
early	post-diagnostic	support,	cognitive	stimulation,	
and	case	management/coordination)	remain	thinly	
evidenced,	particularly	as	regards	their	cost-
effectiveness,	and	have	not,	as	yet,	been	taken	to	
scale	in	most	health	systems.	
5.			There	are,	as	yet,	no	treatments	that	alter	the	
course	of	dementia.	Following	on	from	the	G7-led	
Global	Action	on	Dementia,	development	of	such	
treatments	is	an	intergovernmentally	agreed	global	
public	health	priority10.	The	distribution	of	health	and	
social	care	costs	for	dementia	is	strikingly	different	
to	those,	for	example,	of	cancer	care,	where	the	
aim	is	remission	or	cure,	often	through	the	use	of	
expensive	drugs	and	diagnostic	technologies.	In	
the	event	that	such	treatments	are	identified	for	
dementia,	we	will	need	to	have	delivery	systems	
capable	of	providing	high	coverage,	with	equity.
The	salience	of	healthcare	to	achieving	better	
outcomes	for	people	living	with	dementia	is	indicated	
by	the	results	of	a	recent	research	prioritisation	
exercise,	led	by	WHO	for	the	G7	Global	Action	on	
Dementia	legacy	process,	eight	of	the	top	20	research	
avenues	identified	related	to	diagnosis,	or	the	delivery,	
or	quality	of	dementia	care.	Most	of	these	research	
avenues	either	primarily	concerned	healthcare	
services,	or	involved	potential	inputs	from	healthcare	
services	(see	Box	1.1)
1.2 Structural barriers to the delivery of 
effective healthcare for older people
The	Madrid	International	Plan	of	Action	on	Ageing	
called	for	the	elimination	of	social	and	economic	
inequalities	in	access	to	healthcare	and	the	
development	of	healthcare	and	long-term	care	to	
meet	the	needs	of	older	persons11.	It	is	important	
to	acknowledge	that	the	goal	of	age-appropriate	
healthcare	for	all	is	far	from	being	achieved12.	The	
fitness	for	purpose	of	health	services	and	systems	for	
older	adults	with	complex,	interacting,	chronic	medical	
and	social	problems	remains	open	to	question13.	
Ageist	attitudes	and	beliefs;	that	ill	health	is	inevitable,	
intervention	ineffective,	and	improved	outcomes	
inherently	less	valuable;	are	widespread	even	among	
older	people	and	healthcare	professionals14.	Health	
services	are	often	not	adequately	orientated	to	the	
assessment	and	management	of	complex	cognitive,	
physical	and	mental	multimorbidities,	and	the	provision	
of	continuing	rather	than	curative	care13,15.	Structural	
barriers	to	accessing	healthcare	include	the	high	cost	
of	chronic	disease	care	when	incomes	are	insecure,	
Box 1.1
Dementia research priorities 
relevant to the healthcare sector 
(WHO Research Prioritization 
exercise) 
•	 Identify clinical practice and health system-
based interventions that would promote a 
timely and accurate diagnosis of dementia in 
primary healthcare practices. (Diagnosis)
•	 Evaluate the relative effectiveness and 
identify the optimal models of care and 
support for people with dementia and their 
carers in the community (e.g. collaborative 
care, integrated health and social care, case 
management) across the disease course. 
(Delivery of care)
•	 Identify strategies to anticipate and deliver 
effective and cost-effective late life and 
end of life care for people with dementia, 
including advance care planning. (Delivery of 
care)
•	 Determine the most effective interventions 
for educating, training and supporting formal 
and informal carer(s) of people with dementia. 
(Quality of care)
•	 Determine and ensure optimal use of 
psychological and pharmacological 
treatments for Behavioral and Psychological 
symptoms of Dementia (BPSD) to maximize 
patients’ quality of life and caregiver burden 
reduction. (Quality of care)
•	 Understand the role of assistive and 
technological devices, including e-health 
and mobile health technology strategies, for 
people with dementia and/or their carer(s). 
(Delivery of care)
•	 Develop and evaluate policies, investments 
and plans for increasing the capacity, 
knowledge, skills and interest of the health 
and social care workforce in the field of 
dementia. (Quality of care)
•	 Establish norms and standards for the 
highest quality of care in residential and 
nursing homes and approaches to assist 
families of people with dementia to determine 
the optimal time to consider placement. 
(Quality of care)
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healthcare	is	financed	by	out	of	pocket	payments	and	
insurance	coverage	is	incomplete16–18.	
1.3 Purposes of healthcare for dementia
In	the	USA,	the	Advisory	Council	for	Alzheimer’s	
Research,	Care	and	Dementia	interdisciplinary	
Dementia	Measures	Work	Group	recently	defined	the	
objectives	of	clinical	care	as:
“preserving,	to	the	maximum	possible	extent,	
cognitive	and	functional	abilities,	reducing	the	
frequency,	severity,	and	adverse	impact	of	
neuropsychiatric	and	behavioral	symptoms,	
sustaining	the	best	achievable	general	health,	
reducing	risks	to	health	and	safety,	and	enhancing	
caregiver	wellbeing,	skill,	and	comfort	with	
managing	the	patients	with	dementia	in	partnership	
with	health	care	providers.”19
1.4 Healthcare resources
In	many	high	income	country	health	systems	it	
is	possible	to	discern	two	branches	of	dementia	
specialist	healthcare	service,	which	have	been	
characterised	as	an	‘early	intervention’	stream	
(mainly	outpatient	memory	clinics,	focussing	on	early	
differential	diagnosis	and	early	intervention	to	minimise	
future	harm,	risk	and	cost	for	the	patient)	and	a	‘serious	
mental	illness’	stream	(co-ordinating	community	care	
in	the	more	advanced	stages	of	the	disease	treating	
severe	and	complex	disorders	with	high	levels	of	risk	
and	co-morbidity)20.	
There	are	very	few	comparable	data	available	
internationally	regarding	the	extent	of	specialist	
healthcare	resources	for	dementia	care.	This	will	
change,	with	the	establishment	in	2016/17	of	the	WHO	
Global	Dementia	Observatory,	with	one	core	activity	
being	to	obtain	detailed	information	from	Ministries	
of	Health	on	healthcare	resources,	and	coverage	of	
services.
In	the	UK	a	national	audit	of	memory	clinic	services	
indicated	that,	in	2014	there	were	222	memory	
clinics	(one	for	every	3400	people	with	dementia)9.	
Numbers	of	assessments	increased	31%	in	one	year	
(2013-2014),	but	without	any	equivalent	increase	
in	resourcing	or	capacity.	Average	waiting	time	for	
assessment	and	diagnosis	post	assessment	both	
increased	slightly	over	the	same	period,	as	did	the	
range	of	waiting	times	(from	one	week	to	32	weeks).	
In	the	Netherlands,	where	this	process	was	monitored	
between	1998	and	2009,	the	number	of	clinics	
increased	from	12	to	63,	the	number	of	new	clients	
seen	annually	has	risen	from	1,700	to	14,175,	and	the	
estimated	proportion	of	all	incident	cases	of	dementia	
in	the	Dutch	population	that	receive	a	formal	diagnosis	
through	a	memory	clinic	rose	from	5%	to	27%21.	Such	
specialist	services	have	also	begun	to	be	developed	in	
low	and	middle	income	countries,	typically	on	western	
lines22,	but	in	a	sporadic	and	unplanned	fashion,	and	
with	low	levels	of	national	coverage.	Thus,	in	India	
there	were	estimated,	in	2013,	to	be	approximately	
100	memory	clinics	nationally	(approximately	one	
clinic	per	37,000	people	with	dementia),	two-thirds	
supported	by	a	pharmaceutical	company23.	Almost	
all	the	federal	government	super	specialty	hospitals,	
with	neurology	and	psychiatry	services,	had	a	memory	
clinic	or	specialty	clinic	for	people	with	dementia,	but	
with	almost	no	clinics	in	other	government	hospitals23.	
In	China,	a	survey	of	36	tier	3	hospitals	(randomly	
selected	from	995	nationwide)	indicated	that	only	one	
sixth	had	functioning	memory	clinic	services,	and	that	
there	were	only	a	small	number	of	neurologists	with	
competencies	as	dementia	practitioners24.	This	would	
suggest	around	166	memory	clinics	nationally,	or	one	
for	every	48,000	people	with	dementia.	Only	0.1%	of	
outpatients	received	a	diagnosis	of	dementia.	After	
the	institution	of	a	training	programme	memory	clinic	
services	were	introduced	in	all	of	the	hospitals,	and	
the	proportion	of	outpatients	diagnosed	increased	
fourfold,	to	0.4%24.	In	the	30	hospitals	previously	
without	memory	clinics	the	proportion	of	outpatients	
diagnosed	increased	from	0.03%	to	0.38%.	Overall,	
the	proportion	of	patients	diagnosed	according	to	
standard	procedures	increased	from	23.1%	to	97.5%.	
The	proportion	of	those	diagnosed	with	Alzheimer’s	
disease	prescribed	acetylcholinesterase	inhibitors	
increased	from	19.7%	to	66.6%	and	receiving	
memantine	from	4.1%	to	21.5%.	
The	three	studies	described	here	confirm	the	general	
sense	that:
1.			Services	in	many	high	income	countries	provide	
comprehensive	geographic	coverage,	but	may	
struggle	to	meet	increasing	demand
2.			In	middle	income	countries,	services	are	very	
limited,	and	are	largely	restricted	to	tertiary	care	
hospitals	in	major	population	centres.
The	default	option,	worldwide,	is	for	healthcare	for	
people	with	dementia	to	be	provided	by	primary	
healthcare	services.	Again,	we	do	not	know	what	
proportion	of	diagnoses,	and	continuing	care	
for	dementia	is	being	provided	by	primary	care	
practitioners	(PCPs).	In	North	America,	it	seems	that	
PCPs	may	play	an	important	role,	in	part	because	of	
difficulties	in	accessing	specialist	services25–28.	For	
low	and	middle	income	countries	it	seems	likely	that	
diagnosis	in	primary	care	is	currently	very	infrequent,	
and	as	such,	while	general	healthcare	may	be	being	
provided,	there	would	also	be	almost	no	dementia-
specific	structured	continuing	care	and	support	
provided	at	this	level	of	the	health	system29,30.			
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1.5 Functions and processes of 
healthcare for dementia
Dementia risk reduction
Prevention	is	traditionally	the	province	of	government	
public	health	and	disease	control	agencies.	However,	
the	healthcare	sector,	in	particular	primary	care,	has	
an	important	role	in	promotion,	prevention	and	early	
intervention	with	respect	to	the	emerging	consensus	
on	modifiable	risk	factors	for	dementia	(hypertension,	
diabetes,	smoking,	and	underactivity)31,32.
Detection and diagnosis
The	diagnosis	of	dementia	requires	a	careful	medical	
history	and	examination,	cognitive	testing,	and	
assessment	of	functional	impairment.	Progressive	
dementia	needs	to	be	distinguished	from	normal	
ageing.	Differential	diagnosis	entails	exclusion	of	other	
possible	causes	of	cognitive	decline	(for	example,	
delirium	or	depression)	and	possible	causes	of	
secondary	dementia	need	to	be	identified	and	treated	
where	present.	Formal	diagnoses,	and	dementia	sub-
typing	are	often	made	by	specialist	teams	working	in	
memory	clinics	or	other	diagnostic	services,	and	in	
some	healthcare	settings	access	to	certain	dementia	
drugs,	services	and	benefits	are	dependent	upon	
this.	However,	non-specialists,	particularly	in	the	
primary	care	sector	have	an	important	part	to	play.	
While	screening	for	dementia	remains	controversial	
(see	section	2.4),	there	is	broad	agreement	that,	if	
appropriate,	it	is	best	conducted	in	primary	care33.	In	
many	health	systems,	primary	healthcare	services	are	
the	natural	‘first	port	of	call’	for	those	seeking	help	for	
a	new	health	problem,	and	PCPs	play	an	important	
gate-keeper	role,	deciding	which	patients	should	and	
should	not	be	referred	on	for	specialist	assessment	
and	treatment.	In	a	case-note	study	from	the	UK,	96%	
of	patients	on	a	primary	care	register	with	confirmed	
or	suspected	dementia	had	their	diagnosis	first	made	
in	primary	care,	and	two-thirds	of	those	identified	
in	primary	care	were	then	referred	immediately	for	
specialist	attention34.	
Managing comorbidity (and complexity)
People	with	dementia	are	highly	likely	to	be	living	
with	complex	multimorbidities,	with	both	mental	and	
chronic	physical	health	conditions.	It	is	important	
that	these	are	addressed,	to	minimise	cognitive	and	
functional	disabilities,	to	prevent	and	treat	newly	
emerging	behavioural	symptoms,	and	to	optimise	
quality	of	life.	This	needs	to	be	done	in	a	holistic	
manner,	accounting	for	the	preferences	of	people	with	
dementia	and	carers,	and	with	coordination	to	increase	
efficiency,	reduce	burden	on	people	with	dementia,	
and	limit	potential	adverse	effects.	
Avoiding unnecessary and/or 
counterproductive patterns of use of 
healthcare services
In	many	HIC	settings,	avoidance	of	hospitalisation	
(particularly	emergency	department	attendance	
and	non-elective	admission)	of	people	living	with	
dementia	has	become	an	explicit	policy	aim,	with	
recommendations	to	better	manage	admissions,	
reduce	length	of	stay,	and	facilitate	discharge.	
While	the	hazards	of	hospitalisation	and	the	poor	
outcomes	achieved	are	increasingly	understood,	it	
is	also	possible	that	people	with	dementia	may	be	
being	denied	the	right	to	receive	hospital-based	
medical	interventions	that	might	improve	their	overall	
functioning	and	quality	of	life	(through	a	variety	of	
mechanisms	including	diagnostic	overshadowing,	
misperceived	contraindications,	and	failure	to	
address	lack	of	capacity	to	consent).	Even	where	
hospitalizations	might	be	better	avoided,	or	shortened,	
alternative	home-based	care	options	(for	example,	
‘hospital	at	home’)	need	to	be	developed,	evaluated	
and	resourced.
Interactions with social care
Health	and	social	care	assessments	and	interventions	
should	be	closely	aligned.	Carer	demands	and	carer	
strain	increase	when	morbidity	is	under-diagnosed	and	
undertreated	(for	example	pain,	bowel	and	bladder	
function,	sensory	impairments,	and	behavioural	and	
psychological	symptoms).	Services	that	supplement	
or	substitute	for	informal	care	(home	care,	respite	
care,	residential	care)	are	resource-	and	cost-
intensive,	and	healthcare	professionals	are	needed	
to	provide	input	into	social	care	needs	assessments.	
Post-diagnostic	support,	case	management,	and	
education,	and	training	and	support	interventions	for	
carers	can	bolster	informal	care,	reduce	the	need	for	
supplementary	support	and	transition	into	care	homes,	
prevent	consequential	physical	and	mental	health	
problems,	and	increase	the	efficiency	with	which	
healthcare	services	are	used.	These	are	all	examples	
of	services	that	fall	on	the	cusp	between	health	and	
social	care.	While	the	professionals	who	carry	out	and	
lead	these	activities	may	be	located	within	either	the	
health	or	social	care	sectors,	their	success	will	depend	
critically	on	the	extent	of	intersectoral	integration	and	
coordination.
1.6 Principles of healthcare for 
dementia
A public health approach
A	public	health	model	for	dementia	care	prioritises	
meeting	population	level	needs,	rather	than	merely	
optimising	the	quality	of	care	for	the	minority	who	
access	high	quality	specialist	care.	There	is,	therefore,	
a	focus	upon	increasing	coverage	(the	proportion	of	
those	in	need	that	receive	care),	and	effective	coverage	
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(the	proportion	of	those	in	need	whose	needs	are	
met).	Note	that	diagnostic	coverage	places	a	ceiling	on	
treatment	coverage,	since,	without	a	diagnosis,	it	is	not	
possible	to	deliver	comprehensive	structured	dementia	
care	(see	Figure	1.1).	Levels	of	treatment	coverage	
will	therefore	be	lower	than	the	levels	of	diagnostic	
coverage	provided	in	previous	sections,	since	many	
of	those	diagnosed	are	not	in	receipt	of	appropriate	
continuing	care.	Levels	of	effective	coverage	will	be	
lower	still.	Increasing	coverage	requires	promoting	
demand	(help-seeking)	through	increased	awareness,	
scaling	up	the	supply	of	diagnostic	and	care	services	
to	meet	the	demand,	and	a	reduction	in	the	barriers	to	
access.	Aside	from	coverage,	the	success	of	scaling	
up	initiatives	are	conventionally	judged	upon	the	
equity	with	which	care	is	delivered	(equitable	access	
to	services	based	only	upon	need),	and	the	outcomes	
achieved.	
Figure 1.1 
Dementia diagnostic and treatment coverage
Currently,	within	HIC,	models	of	health	service	care	for	
dementia	tend	to	be	highly	specialised,	from	diagnosis	
onwards,	with	very	little	formal	recognition	of	the	role	
of	primary	care	services,	or	allocation	of	tasks	to	this	
sector.	There	are	many	potential	limitations	to	this	
approach.	It	is	unlikely	that	full	coverage	of	services	
could	be	attained,	and	efficiency	has	probably	not	
been	optimised.	Those	who	have	received	a	diagnosis	
often	do	not	receive	seamless	and	continuing	care,	
which	is	beyond	the	capacity	and	reach	of	specialist	
services	working	in	isolation.	The	specialist	model	of	
dementia	care	does	not	facilitate	care-coordination	
for	those	with	complex	multimorbidities,	which	is	a	
core	function	of	primary	healthcare.	In	most	LMIC,	
specialist	services	are	far	too	under-resourced	to	
have	the	capacity	to	deal	with	current	levels	of	need,	
and	demand	(numbers	affected)	is	likely	to	increase	
more	rapidly	than	the	development	of	the	specialist	
workforce.	When	existing	healthcare	resources	are	
not	well-matched	to	the	local	healthcare	need,	then	
services	become	less	accessible,	and	even	when	they	
are	accessible,	they	are	less	affordable.	Some	degree	
of	task-shifting	to	non-specialist	healthcare	workers	
will	therefore	be	an	essential	component	of	scaling	up	
services	in	resource-poor	settings35,36.	Collaborative	or	
shared-care	models	distribute	tasks	between	primary	
and	secondary	care	services	in	a	structured	and	
organized	fashion.	
Task-shifting 
Task-shifting	is	defined	as	delegating	selected	tasks	
to	existing	or	new	health	professional	cadres	with	
either	less	training	or	narrowly	tailored	training37.	This	
may	involve	shifting	tasks	from	higher-	to	lower-skilled	
health	workers	(e.g.	from	a	neurologist	specialist	
doctor	to	a	PCP),	or	creating	new	professional	cadres,	
whereby	tasks	are	shifted	from	workers	with	more	
general	training	to	workers	with	specific	training	for	
a	particular	task	(e.g.	from	a	PCP	to	a	dementia	case	
manager).	The	two	underlying	assumptions	are	that	the	
unit	cost	of	the	task-shifted	option	is	cheaper,	and	that	
the	quality	of	care	and	its	outcomes	are	equivalent.	The	
less-specialised	cadre	are	generally	more	numerous,	
and	hence	have	the	capacity	to	alleviate	the	resource	
constraints	that	are	barriers	to	achieving	increased	
coverage.	In	technical	terms,	the	primary	objective	
of	task-shifting	is	to	increase	productive	efficiency,	
that	is,	to	increase	the	volume	of	healthcare	services	
provided	at	a	given	quality	and	cost,	or,	alternatively,	
to	provide	the	same	level	of	healthcare	services	at	a	
given	quality,	but	at	a	lower	cost37.	Hence	task-shifting	
can	be	a	relevant	strategy	for	resource-limited	LMIC	
(with	the	aim	of	increasing	coverage).	Evidence	from	
LMIC	indicates	that,	with	adaptation	and	appropriate	
training	and	supervision,	it	is	feasible	for	interventions	
developed	to	be	delivered	by	specialist	doctors	to	be	
taken	on	by	non-specialists	(and	non-doctors)	without	
an	adverse	effect	on	clinical	outcomes37–39.	Although	
this	literature	is	growing,	as	the	authors	of	one	review	
point	out	the	evidence	remains	of	moderate	extent	
and	quality,	and	more	rigorous	research	is	required37.	
One	of	the	key	findings	from	the	review	of	task-shifted	
care	was	that	quality	of	care	tended	to	suffer	when	the	
complexity	of	the	intervention	increased37.	The	quality	
of	training	is	critical,	and	there	is	a	need	for	ongoing	
support	to	maintain	motivation	and	fidelity.	Barriers	
to	task-shifting	included	institutional	and	professional	
resistance.
In	better	resourced	HIC,	it	might	be	assumed	that	
the	main	objective	of	task-shifting	might	be	to	reduce	
costs.	However,	coverage	levels	of	dementia	services	
need	to	increase,	and	as	the	numbers	of	people	with	
All people with dementia
Not diagnosed 
(diagnosis gap)
Diagnosed but not 
receiving care 
(treatment gap)
Receiving care but with 
sub-optimal outcomes 
(effectiveness gap)
People with dementia,  
who have received a diagnosis  
(diagnostic coverage)
People with dementia,  
who have received a diagnosis 
and are receiving care 
consistent with guidelines  
(treatment coverage)
People with dementia, who 
have received a diagnosis 
and are receiving care with 
acceptable outcomes  
(effective coverage)
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dementia	increase	inexorably,	resource	limitations	will	
become	increasingly	apparent.	A	key	objective	of	task-
shifting	is	to	reduce	the	time	needed	to	scale	up	the	
health	workforce,	because	the	cadres	performing	the	
shifted	tasks	require	less	training37.	It	is	quicker	and	
cheaper	to	train	practice	nurses	to	carry	out	structured	
diagnostic	assessments	in	primary	care,	than	to	train	
greatly	increased	numbers	of	neuropsychologists	and	
neurologists.	For	these	and	other	reasons	(localism,	
person-centred	care,	and	care	coordination)	there	is	
increasing	interest	in	task-shifted	community-based	
models	of	care	for	older	people.	
Task-sharing
In	reality,	almost	all	task-shifted	models	of	service	
delivery	include	an	element	of	task-sharing	between	
specialist	and	non-specialist	services.	As	a	minimum,	
this	requires	a	commitment	to	training,	and	ongoing	
supervision	and	support.	There	also	need	to	be	clearly	
defined	referral	protocols,	to	cater	for	instances	
where	the	complexity	or	severity	of	a	case,	and/or	
the	assessments	and	interventions	required	exceeds	
the	non-specialist’s	competence	to	provide	safe	
and	effective	care.	Specialists	are	often	involved	
in	the	design,	and	sometimes	the	governance	and	
management,	of	task-shifted	models	of	care40.	In	
collaborative,	or	shared	care	models	specialists	and	
non-specialists	work	together	to	provide	a	service,	
with	the	roles	and	activities	of	each,	and	their	
interaction	carefully	designed.	Such	services	may	
be	led	by	specialists	or	non-specialists.	A	critical	
feature	is	effective	sharing	of	information	between	
patient,	and	specialist	and	non-specialist.	This	is	best	
achieved	through	a	single	health	information	system,	
sometimes	held	by	the	patient.	From	the	point	of	view	
of	productive	efficiency,	the	optimal	skill	mix	is	the	
combination	of	health	professionals	that	produce	a	
given	level	of	healthcare	services	at	a	particular	quality	
for	the	lowest	cost.	
An integrated and co-ordinated approach
The	World	Health	Organization	has	defined	integrated	
care	as	
“a	concept	bringing	together	inputs,	delivery,	
management	and	organization	of	services	related	
to	diagnosis,	treatment,	care,	rehabilitation	and	
health	promotion.	Integration	is	a	means	to	
improve	services	in	relation	to	access,	quality,	user	
satisfaction	and	efficiency.”41	
Horizontal	integration	refers	to	the	linkage	of	different	
disciplines	or	elements	of	care	at	the	same	level	of	
care,	for	example	mental	and	physical	healthcare,	or	
health	and	social	care.	Vertical	integration	refers	to	the	
linkage	of	care	at	different	levels	of	specialisation,	for	
example	primary,	secondary,	and	tertiary	healthcare).	
Integrated	care	is	closely	related	to	the	concept	of	
continuity	of	care,	which	is	often	best	viewed	through	
the	patient’s	perspective	of	navigating	their	way	
through	the	health	and	social	care	systems.	There	are	
at	least	three	relevant	components	to	continuity	of	
care41:
1.			Continuity	of	information	(best	achieved	by	a	single	
information	system,	or	by	shared	access	to	records	
and	highly	effective	communication),	
2.			Continuity	across	the	primary-secondary	care	
interface	(collaborative	care	models,	clear	and	
responsive	referral	protocols	and	pathways,	
effective	communication	and	discharge	planning	
from	specialist	to	generalist	care),	and	
3.			Provider	continuity,	seeing	the	same	professional	
each	time,	with	the	opportunity	to	establish	a	
therapeutic,	trusting	relationship	(a	role	often	filled	
by	the	primary	care	physician,	a	key	worker,	or	case	
manager).
There	is	ample	evidence	that	dementia	care	systems	
have	failed	to	achieve	acceptable	levels	of	integration42.	
Care	processes	are	characterised	by	fragmentation;	
primary	and	secondary	care	health	services,	and	
social	care	often	operate	relatively	autonomously	
with	too	little	communication,	and	some	duplication	
of	activities43,44.	There	are	often	unacceptable	delays	
in	accessing	specialist	services9,45–47,	and,	in	some	
systems,	structural	barriers	to	making	referrals	from	
primary	care19,25.	Multimorbidity	is	highly	prevalent	
among	people	with	dementia,	and	poses	challenges	
for	integrated	management	of	chronic	cognitive,	mental	
and	physical	health	conditions48–51.	Multimorbidity	
increases	sharply	with	age,	and	is	strongly	associated	
with	impaired	quality	of	life52,	disability,	dependence53	
and	mortality54.	Those	with	multimorbidity	account	
for	96%	and	those	with	more	than	five	conditions	for	
68%	of	US	Medicare	expenditure,	and	unnecessary	
hospitalisations	increase	exponentially	with	increasing	
multimorbidity55,56.	Rigid	application	of	clinical	
practice	guidelines	for	single	disorders	may	contribute	
to	polypharmacy,	adverse	drug	interactions	and	
unnecessary	cost57.	A	holistic	approach	has	been	
advocated,	with	comprehensive	assessment,	leading	
to	well-integrated	continuing	care,	focussing	first	
and	foremost	upon	patient	preferences	in	an	effort	to	
streamline	care	and	increase	its	acceptability58,59.	
1.7 Health system level interventions to 
improve the quality of dementia care
Case management
The	Case	Management	Society	of	America	defines	
case	management	as	“a	collaborative	process	of	
assessment,	planning,	facilitation,	care	coordination	
and	advocacy	for	options	and	services	to	meet	an	
individual’s	and	family’s	compre	hensive	health	needs	
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through	communication	and	available	resources	to	
promote	quality	cost-effective	outcomes”.60
The	case	manager	promotes	integration	of	care,	
first,	through	provider	continuity.	They	are	a	constant	
point	of	contact	and	reference	for	the	patient	and	
their	family,	while	multiple	services	might	be	involved	
in	providing	care.	Their	core	roles	include	advocacy,	
communication,	education,	identification	of	service	
resources	and	service	facilitation60.	They	help	the	
patient	and	family	to	negotiate	the	complexities	of	
the	care	system,	promote	self-management,	and	
can	help	ensure	that	care	is	efficient,	and	prioritised	
in	a	way	that	is	consistent	with	individual	values	
and	preferences.	There	is	often	an	element	of	task-
shifting	implicit	in	case	management,	since	the	case	
manager	is	an	example	of	a	new	professional	cadre	
with	specific	training	and	skills	for	a	defined	set	of	
tasks.	In	dementia	care,	there	is	particular	interest	in	
the	concept	of	case	managers	operating	at	the	level	
of	primary	care61,62.	Primary	care	physicians	are	the	
first	health	system	contact	for	early	diagnosis	and	
management	of	dementia,	but	primary	healthcare	
systems	are	not	yet	equipped	to	deal	with	the	diverse	
needs	of	patients	and	carers	across	the	course	of	
the	condition.	Case	management	could,	in	principle,	
increase	the	capacity	of	primary	healthcare	to	attend	to	
these	needs,	improve	the	quality	of	dementia	care,	and	
provide	cost-effective	coordination	of	services.
Care pathways
What is a care pathway?
The	concept	of	the	care	pathway	has	become	
increasingly	influential	in	many	domains	of	health	
service	management	and	research,	including	
the	delivery	of	care	for	chronic	conditions.	The	
fundamental	principle	is	to	apply	a	structured	and	
organised	approach	to	the	planning,	resourcing	
and	delivery	of	continuing	care.	While	every	patient	
goes	through	a	care	process,	and	these	vary	among	
patients	with	particular	conditions,	care	pathways	are	
about	planning	and	managing	those	processes,	in	
advance,	for	defined	groups	of	individuals.	Operational	
management,	end-to-end,	of	a	care	process	differs	
from	the	more	conventional	activity	of	managing	care	
units	(in	healthcare	terms,	hospitals,	primary	healthcare	
facilities	or	services).	
There	are	several	definitions	of	care	pathways.	
Schrijvers	et	al	refer	to	“process	innovations	
that	focus	on	improving	the	organisation	of	care	
processes”63.	The	European	Pathway	Association	
defines	a	care	pathway	as	“a	complex	intervention	
for	the	mutual	decision	making	and	organization	of	
care	processes	for	a	well-defined	group	of	patients	
during	a	well-defined	period”64,65.	In	the	UK,	the	
term	“integrated	care	pathway”	is	used	to	emphasise	
the	coordination	of	different	elements	along	the	
pathway,	“a	multidisciplinary	outline	of	anticipated	
care,	placed	in	an	appropriate	time	frame,	to	help	a	
patient	with	a	specific	condition	or	set	of	symptoms	
move	progressively	through	a	clinical	experience	
to	positive	outcomes”66.	However,	others	consider	
this	tautologous;	all	care	pathways	are	by	definition	
integrated,	given	that	avoidance	of	fragmented	care	
processes	is	one	of	the	main	objectives63.	This	aspect	
is	highlighted	by	the	European	Pathway	Association’s	
defining	characteristics	of	a	care	pathway65:
•	 An	explicit	statement	of	the	goals	and	key	elements	
of	care	based	on	evidence,	best	practice	and	
patient	expectations
•	 The	facilitations	of	the	communication	and	
coordination	of	roles,	and	sequencing	the	activities	
of	the	multidisciplinary	care	team,	patients	and	
their	relatives
•	 The	documentation,	monitoring,	and	evaluation	of	
variances	and	outcomes
•	 The	identification	of	relevant	resources
A	care	pathway	approach	to	continuing	care	
comprises63:	
1.			a	care	plan	for	each	individual	patient	(patient	
planning	and	protocol);	
2.			the	planning	of	care	in	care	pathways	(patient	group	
planning	and	control);	
3.			the	capacity	planning	of	professionals,	equipment	
and	space	(resource	planning	and	control);	
4.			the	planning	of	the	number	of	patients	to	be	treated	
and	care	activities	to	be	carried	out	(patient	volume	
planning	and	control),	and	
5.			the	long-term	policy	of	the	institution	(strategic	
planning).
Not	all	healthcare	activities	lend	themselves	to	a	care	
pathway	approach,	since	not	all	care	is	provided	for	a	
“well-defined	patient	group”	and	a	“well-defined	period	
of	time”.	There	is	clearly	a	world	of	difference,	in	this	
respect,	between	inpatient	surgery	for	inguinal	hernia,	
and	dementia	care.	For	continuing	care	of	chronic	
conditions,	care	plans	may	need	to	be	drawn	up	and	
delivered	flexibly,	contingent	upon	differing	needs,	
clinical	trajectories	and	responses	to	intervention.	A	
‘stepped	care’	approach	is	often	used,	whereby	a	
patient	first	receives	the	most	effective,	least	invasive,	
least	expensive	and	shortest	form	of	assessment	
or	intervention,	given	the	nature	and	severity	of	
the	problem.	Following	review	assessment	and/or	
intervention	can	be	escalated	to	the	next	level	where	
necessary.	
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How might a care pathway approach be 
applicable to dementia care?
Dementia	care	would	seem,	at	first	pass,	an	
unpromising	candidate	for	application	of	the	care	
pathway	approach67.	Patients	present	and	are	
diagnosed	at	different	stages	in	the	disease	process.	
The	course	of	the	condition	can	be	highly	variable,	
in	terms	of	deterioration	in	cognitive	and	functional	
abilities,	and	onset	of	behavioural	and	psychological	
symptoms.	The	impact	on	the	individual	and	their	
family,	and	the	consequent	need	for	additional	care	
and	support,	will	be	highly	context	dependent.	
Services	strive	to	deliver	person-centred	care	
throughout,	emphasising	the	need	to	elicit,	understand	
and	respond	to	changing	needs	in	the	context	of	
values	and	preferences.	Far	from	a	‘well-defined	time	
period’,	the	need	for	care	starts	with	help-seeking	prior	
to	diagnosis,	and	extends	across	the	disease	course,	
to	death	and	beyond.	And	yet,	within	limits,	there	
are	aspects	of	the	evolution	of	the	condition,	and	the	
needs	for	evidence-based	intervention	and	support	at	
particular	phases	of	the	process	that	are	predictable.	
The	course	of	dementia	tends,	by	definition,	to	be	
progressive,	although	there	may	be	‘plateau’	periods.	
For	dementia,	monitoring,	care	and	support	needs	
to	be	continuous,	but	particular	activities	may	be	
indicated	at	particular	phases	of	the	condition.	Recent	
developments	to	the	care	pathway	approach	include	
a	distinction	between	highly	structured	fixed	time	care	
pathways	(e.g.	inguinal	hernia	surgery)	and	non-fixed	
time	but	phase-oriented	care	pathways63,	which	would	
be	more	applicable	for	dementia	care.
The	overall	objective	of	a	care	pathway	would	be	to	
provide	seamless	high	quality	care	that	is	responsive,	
flexible	and	continuing,	with	the	aim	of	maximising	
independence	and	participation,	and	optimising	health	
and	quality	of	life	for	patient	and	carers	throughout.		
Phase-orientated care for people with dementia
People	with	dementia	have	a	right	to	a	timely	diagnosis,	
well	made68.	The	concept	of	a	timely	diagnosis	was	
advanced	by	the	INTERDEM	group,	conducting	an	
analysis	of	‘The	primary	care	diagnosis	of	dementia	
in	Europe’	using	multidisciplinary,	multinational	expert	
groups,	to	establish	the	potential	for	a	consensus	
guideline69.	
“Timely	diagnosis	is	defined	as	the	time	when	the	
patient	or	caregiver	and	the	primary	care	physician	
recognize	that	a	dementia	syndrome	may	be	
developing.	The	preference	for	timely	diagnosis	
implies	that	methodologies	should	concentrate	not	
on	population	screening,	but	on	a	speedy	response	
to	the	first	reported	signs	of	changed	behaviour	and	
functioning	in	the	patient.”69
Among	the	proposed	benefits	of	a	timely	diagnosis	
is	the	relief	gained	from	better	understanding	of	
symptoms	that	have	led	to	concern68.	A	diagnosis	
is	well	made	when	the	process	of	diagnosis	and	
diagnostic	disclosure	is	perceived	and	experienced	
as	positive	and	helpful	by	patient	and	family.	This	may	
take	time,	since	acceptance	may	be	preceded	by	
denial,	anger,	and	grief.	Good	practice	for	disclosing	
dementia	diagnosis	should	include:	preparation;	
integrating	family	members;	exploring	the	patient’s	
perspective;	disclosing	the	diagnosis;	responding	to	
patient	reactions;	focusing	on	quality	of	life	and	well-
being;	planning	for	the	future;	and	communicating	
effectively70.	Other	benefits	of	a	timely	diagnosis	
are	the	opportunities	to	engage	in	health	promotion,	
optimise	current	medical	management,	maximise	
decision	making	autonomy,	plan	for	the	future,	and	
obtain	information	about	available	support	services68.	
This	implies	the	need	for	a	physical	health	and	
medication	review,	a	capacity	assessment	where	
indicated,	initiation	of	advanced	care	planning,	and	
signposting	to	community	care	services.	There	is	
evidence	to	support	the	effectiveness	of	certain	
interventions	early	in	the	disease	course	–	these	
include	carer	education,	training	and	support,	the	
prescription	of	acetylcholinesterase	inhibitors	for	those	
who	meet	criteria,	peer	support	groups	for	people	
with	dementia,	behavioural	activation	for	depressive	
reactions,	and,	possibly,	cognitive	stimulation	therapy.	
The	Scottish	Government	has	made	a	commitment	
to	delivering	a	minimum	of	one	year	post-diagnostic	
support,	informed	by	the	Alzheimer	Scotland	5	Pillars	
Model71	(understanding	the	illness	and	managing	
symptoms;	planning	for	future	decision	making;	
supporting	community	connections;	peer	support;	and	
planning	for	future	care),	and	co-ordinated	by	a	Link	
Worker.
Since	the	course	of	the	condition,	and	the	emergence	
of	complications,	is	not	easy	to	predict,	all	people	living	
with	dementia,	and	their	family	carers	need	regular	
reviews,	to	monitor	changes	in	cognitive	and	functional	
ability,	to	optimise	mental	and	physical	health	and	
wellbeing	through	health	promotion	and	managing	
comorbidity,	to	attend	to	nutrition	and	hydration,	
to	identify,	assess	and	manage	the	emergence	of	
behavioural	and	psychological	symptoms,	and	to	
reassess	unmet	needs	for	care	and	support.	The	care	
inputs	over	this	period	of	continuing	care	will	depend	
upon	the	results	of	these	reviews,	but	there	should	
also	be	facilitated	access	to	needs-driven	advice,	
support	and	reassessment	in	the	intervals	between	
assessments.	
Dementia	is	an	incurable	and	life-limiting	illness,	and	
the	World	Health	Organization	states	that	‘every	person	
with	a	progressive	illness	has	a	right	to	palliative	
care’72.	Yet	people	living	with	dementia	are	particularly	
unlikely	to	have	access	to	palliative	care	services	at	
the	end	of	life1.	Palliative	care	affirms	life	and	regards	
dying	as	a	normal	process;	intends	neither	to	hasten	
nor	postpone	death;	provides	relief	from	pain	and	other	
13ImprovIng healthcare for people lIvIng wIth dementIa
alzheImer’s dIsease InternatIonal: world alzheImer report 2016
distressing	symptoms;	offers	a	support	system	to	help	
patients	live	as	actively	as	possible	until	death,	and	to	
help	the	family	cope	during	the	patient’s	illness	and	in	
their	own	bereavement73.	Evidence	suggests	that	while	
carers	can	be	resilient	in	the	face	of	bereavement,	
intervention	and	support	services	are	needed	most	in	
the	period	before	the	patient’s	death74.	Nevertheless,	a	
palliative	care	approach	may	be	appropriate	across	the	
illness	course,	with	early	advanced	care	planning,	and	
continuing	review	of	care	preferences.
Benefits and risks of a care pathway approach
There	are	multiple	potential	benefits	associated	with	
the	introduction	of	care	pathways:
1.   An increase in the coherence and consistency of 
care between and among services, using evidence-
based guidelines
2.   Improvements in the quality of care, through the 
application and monitoring of quality standards and 
outcomes
3.   Improvements in the responsiveness of care, 
through better resource planning and allocation, 
and identification and removal of bottlenecks in the 
system
4.   The efficiency of care (and costs), through precise 
and optimal role definition, better coordination, and 
avoidance of duplication
There	is	empirical	evidence	to	support	these	benefits.	
In	Belgium,	309	healthcare	workers	reported	on	103	
care	processes	for	different	health	conditions	in	49	
hospitals,	using	the	Care	Process	Self	Evaluation	
Tool	(CPSET)	to	rate	care	processes	according	to	
their	degree	of	organisation75.	Care	processes	that	
were	supported	by	formal	care	pathways	were	8.9	
times	more	likely	to	rate	highly	on	the	coordination	of	
care,	6.7	times	more	likely	to	rate	highly	on	follow-up/
continuity	of	care,	and	4.3	times	more	likely	to	rate	
highly	for	overall	care	process	quality.	
On	the	other	hand,	there	are	legitimate	concerns	
that	an	over-concrete	application	of	a	care	pathway	
approach	may	lead	to	the	mechanisation	and	
dehumanisation	of	care,	removal	of	personal	choice	
and	abandoning	of	an	aspiration	for	a	person-centred	
approach,	and	the	rationing	of	access	to	care.	Samsi	
and	Manthorpe67,	in	reviewing	the	applicability	of	care	
pathways	to	dementia	care	highlighted	the	multiple	
possible	meanings	that	might	be	attached	to	the	
concept	by	service	providers	and	service	users;	a	
mechanism	for	the	management	and	containment	of	
uncertainty	and	confusion,	useful	for	the	professional	
as	well	as	the	person	with	dementia;	a	manual	for	
sequencing	care	activities;	a	guide	to	consumers,	
indicating	eligibility	for	care	activities,	or	a	guide	to	
self-management	for	dementia	dyads,	indicating	the	
appropriateness	of	care	activities;	and	a	manual	for	
“walking	with”	the	person	with	dementia.	
Examples of care pathways for dementia
While	there	are	many	examples	of	dementia	care	
service	guidelines,	few	of	these	would	qualify	as	
meeting	the	defining	characteristics	of	a	care	pathway.	
We	have	identified	three	examples,	which,	at	least	in	
part	fulfil	these	criteria.
1.   The Queensland University of Technology 
Clinical Practice Guidelines and Care Pathways 
for People with Dementia Living in the 
Community76
This	care	pathway	was	developed	in	collaboration	with	
State	Government	(Queensland	Health).	Caveats	are	
emphasised	in	a	set	of	fundamental	principles	that	
include	recognition	that	people	with	dementia,	their	
carers	and	families	are	central	to	making	choices	about	
care,	and	that	service	responses	need	to	recognise	
people’s	individual	care	journeys.	It	is	acknowledged	
that	the	guidelines	and	pathways	do	not	encompass	
all	care	scenarios,	and	should	be	used	flexibly.	The	
pathways	focus	on	non-pharmacological	care	only.	
The	pathways	are	strongly	evidence-based	with	a	
systematic	review	of	existing	guidelines,	and	formal	
evidence	quality	assessment.	‘Practice	tips’	are	also	
provided,	which	constitute	advice	on	good	clinical	
practice	based	upon	multidisciplinary	expert	opinion	
from	the	guideline	development	group.	Assessment	
tools	are	suggested	to	facilitate	and	monitor	the	
delivery	of	an	effective	continuum	of	care.	
This	care	pathway	is	‘phase-orientated’	with	three	
phases	identified:	
a. Recognition,	Assessment	and	Diagnosis	Phase	
b.	 	Post	Diagnosis,	Monitoring,	Management	and	Care	
Phase
c.	 The	Advanced Phase
For	each	phase	separate	but	interactive	pathways	
are	provided	for	the	general	practitioner	(primary	
care	physician),	the	health	professional	(specialist),	
and	the	care	worker	(social	care	professional).	
The	recommended	management	strategies	at	
each	phase	are	summarised	in	Table	1.1.	The	full	
pathway	document76	includes	comprehensive	clinical	
algorithms,	in	the	form	of	flow	charts	signifying	
the	assessments,	management	decisions	and	
management	actions	(including	explicit	referral	
protocols)	that	need	to	be	taken	at	each	stage.	
2.   Quality Improvement in Neurology – Dementia 
Measures Work Group Measurement Set for 
Dementia Management (copyrighted by the 
American Medical Association)19
The	Advisory	Council	for	Alzheimer’s	Research,	Care	
and	Dementia,	established	after	the	passage	of	the	
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USA	National	Alzheimer’s	Project	Act,	recommended	
quality	measures	suitable	for	evaluating	and	tracking	
dementia	care	in	clinical	settings.	An	interdisciplinary	
Dementia	Measures	Work	Group	has	developed	
a	measurement	set	applying	to	continuing	care	
after	dementia	has	been	diagnosed19.	The	premise	
for	this	work	was	that;	“health	care	for	persons	
with	dementia	is	inconsistent,	often	suboptimal,	
and	largely	unplanned;	ethnic	and	socioeconomic	
disparities	are	important	influences	on	the	quality	
of	dementia	care;	partnership	with	caregivers	is	
integral	to	improving	care;	and	that	the	well-being	
and	behavioural	stability	of	patients	with	dementia	
is	strongly	influenced	by	the	well-being	of	their	
caregivers;	and	comprehensive	integrated	care	and	
quality	improvement	initiatives	must	be	explicit	and	
practical”19.	It	includes	all	stages	of	dementia	in	a	
single	measure	set,	but	calls	for	functional	staging	
(mild,	moderate	or	severe	dementia)	in	planning	
care.	It	highlights	the	importance	of	palliative	care	
concepts	to	guide	care	prior	to	the	advanced	stages	
of	illness.	The	measurement	set	specifies	annual	
reassessment	and	updating	of	interventions	and	
care	plans	for	dementia-related	problems	that	affect	
carers	as	well	as	people	with	dementia.	For	most	
measures,	care	quality	is	indicated	by	the	proportion	
of	eligible	patients	whose	documented	care	meets	the	
identified	goal.	The	Work	Group	considered	that	while	
patient-reported	outcomes	were	a	desirable	feature	of	
quality	performance	assessment,	the	heterogeneity	
of	the	condition	and	its	management	precluded	
their	adoption19.	The	focus	on	process	measures	
alone	might	be	considered	to	be	a	weakness,	but,	
as	such,	the	measure	set	does	provide	the	outline	
of	a	prototypical	structured	care	pathway.	While	this	
is	not	an	explicitly	phase-orientated	pathway,	the	
indicators	fall	into	five	categories	of	decision	making	
(Table	1.2):	1)	assessment	of	the	person	with	dementia	
postdiagnosis	(measures	1–4	and	6),	2)	management	
of	neuropsychiatric	symptoms	(measure	5),	3)	patient	
safety	(measures	7	and	8),	4)	palliative	care	and	end-
of-life	issues	(measure	9),	and	5)	caregiver	issues	
(measure	10).	
3.   The World Health Organization Mental Health 
Gap Action Programme (mhGAP) evidence 
based guidelines and intervention guide77
The	WHO	mhGAP	guidelines	address	nine	priority	
mental,	neurological	and	substance	use	disorders;	
dementia,	depression,	psychosis,	bipolar	disorders,	
epilepsy,	alcohol	use	disorders,	drug	use	disorders,	
self-harm/suicide,	developmental	and	behavioural	
disorders,	and	other	significant	emotional	or	medically	
unexplained	complaints.	They	have	been	developed	
specifically	for	use	by	health-care	providers	working	
in	non-specialised	healthcare	settings	after	adaptation	
for	national	and	local	needs.	The	explicit	purpose	is	
to	reduce	the	treatment	gap	for	these	conditions.	The	
guidelines	comprise	an	expert	consensus	(from	the	
international	Guideline	Development	Group)	of	those	
elements	of	a	package	of	care	that	are	both	evidence-
based	and	feasible,	in	principle,	of	being	delivered	by	
non-specialists	healthworkers	in	this	context35,36,78.	
The	guidelines	are	transparently	and	strongly	based	
on	evidence	from	systematic	reviews	of	the	literature.	
Extensive	supporting	resources	are	provided	on	the	
Table 1.1  
Queensland University of Technology Clinical Practice Guidelines and Care Pathways for People with Dementia Living in the 
Community76
Phase Management Strategies for Persons 
with Dementia
Strategies for Carer support
Recognition, assessment and diagnosis 
phase
Detection
Assessment
Investigation of comorbidities
Functional assessment
Differential diagnosis
Informing the patient and carer
Postdiagnosis, monitoring, management 
and care phase
Treatment of co-morbidities
Behavioural management
Maintenance of function
Legal issues/ Decision making capacity
Service provision
Interventions to support the carer
Impact of caring on sexual relationships
Respite care
Abuse and neglect
Financial assistance
Advanced phase A palliative approach
Hydration and nutrition
Fever and infection
Symptom management
Transition to residential care
Decision making/advanced directives
Grief and loss
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WHO	mhGAP	website	(http://www.who.int/mental_
health/mhgap/en/)
The	accompanying	mhGAP	Intervention	Guide	
(mhGAP-IG),	also	developed	through	a	systematic	
review	of	evidence	followed	by	an	international	
consultative	and	participatory	process,	is	a	technical	
tool	developed	by	WHO	to	assist	in	implementation	
of	mhGAP.	Its	purpose	is	described	as	“integrated	
management	of	priority	conditions	using	protocols	
for	clinical	decision-making”,	and	as	such	essentially	
constitutes	a	care	pathway,	structured	around	an	
assess	>	decide	>	manage	structure.	For	dementia,	
the	Intervention	Guide	provides	an	initial	assessment	
and	management	guide	(does	the	person	have	
dementia/another	priority	mental	disorder/BPSD?	Are	
cardiovascular	disease	and	risk	factors	present?	Does	
the	person	suffer	from	other	physical	conditions?	Is	the	
caregiver	experiencing	strain	or	in	need	of	support?	
‘Red	flags’	are	indicated	for	the	need	for	immediate	
referral	to	specialist	services,	where	available	(unusual	
presentations,	suspicion	of	delirium).	Detailed	
guidance	is	then	provided	for	the	process	of	identifying	
dementia,	providing	psychosocial	interventions	
(managing	BPSD,	and	interventions	for	carers),	and	
pharmacological	interventions.	There	is	also	a	detailed	
plan	for	routine	follow-up	reviews.	The	intervention	
guide	(http://www.who.int/mental_health/publications/
mhGAP_intervention_guide/en/)	is	currently	available	
in	Arabic,	English,	French,	Japanese,	Persian,	
Portuguese,	and	Spanish.	
The	Dementia	Measures	Work	Group	concluded:
“The	emphasis	on	dementia	management	in	this	
measurement	set	recognizes	the	enormous	challenge	
dementia	presents	to	individual	patients	and	their	
caregivers,	health	care	providers,	public	health,	and	
government	and	private	insurers.	While	patients,	
Table 1.2  
Measure title and description of the final 10 dementia measures (measures copyrighted by the American Medical Association)
Measure title Description
1. Staging of dementia Percentage of patients, regardless of age, with a diagnosis of dementia, whose severity of 
dementia was classified as mild, moderate or severe at least once during the 12 month period
2. Cognitive assessment Percentage of patients, regardless of age, with a diagnosis of dementia, for whom an assessment 
of cognition is performed and the results are reviewed at least once within a 12 month period
3. Functional status assessment Percentage of patients, regardless of age, with a diagnosis of dementia, for whom an assessment 
of functional status is performed and the results are reviewed at least once within a 12 month 
period
4. Neuropsychiatric symptom 
assessment
Percentage of patients, regardless of age, with a diagnosis of dementia, for whom an assessment 
of neuropsychiatric symptoms is performed and the results are reviewed at least once within a 12 
month period
5. Management of neuropsychiatric 
symptoms
Percentage of patients, regardless of age, who have one or more neuropsychiatric symptoms who 
received or were recommended to receive an intervention for neuropsychiatric symptoms within a 
12 month period
6. Screening for depressive symptoms Percentage of patients, regardless of age, with a diagnosis of dementia, who were screened for 
depressive symptoms within a 12 month period
7. Counseling regarding safety 
concerns
Percentage of patients, regardless of age, with a diagnosis of dementia, or their caregiver(s), who 
were counselled regarding safety concerns within a 12 month period
8. Counseling regarding risks of driving Percentage of patients, regardless of age, with a diagnosis of dementia, or their caregiver(s), who 
were counselled regarding the risks of driving and the alternatives to driving at least once within a 
12 month period
9. Palliative care counseling and 
advance care planning
Percentage of patients, regardless of age, with a diagnosis of dementia, or their caregiver(s), who 
1) received comprehensive counselling regarding ongoing palliation and symptom management 
and end of life decisions and 2) have an advance care plan or surrogate decision-maker in the 
medical record or documentation in the medical record that the patient did not wish or was not 
able to name a surrogate decision-maker or provide an advanced care plan within 2 years of initial 
diagnosis or assumption of care
10. Caregiver education and support Percentage of patients, regardless of age, with a diagnosis of dementia, whose caregiver(s) were 
provided with education on dementia disease management and health behaviour changes and 
were referred to additional resources for support within a 12-month period
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caregivers,	and	health	professionals	await	more	
effective	disease-modifying	treatments	for	patients	
with	dementia,	adherence	to	the	measures	outlined	
here	will	improve	the	quality	of	life	for	patients	and	
caregivers	with	dementing	illnesses.”	19
There	are	additional	potential	benefits.	If	standard	
evidence	and	guideline-based	care	pathways	are	
adopted	within	a	healthcare	system,	it	become	
possible	to	monitor	the	treatment	gap	(the	inverse	of	
treatment	coverage	–	see	Figure	1).	This	is	a	critical	
issue.	Most	health	systems	have	been	focusing	on	
diagnostic	coverage,	which	is,	currently,	easier	to	
measure.	However,	diagnosis	without	a	pathway	
leading	to	assured	and	effective	treatment	and	care	
is,	at	best,	a	wasted	effort.	If	routine	assessment	of	
suitable	outcome	measures	is	introduced	into	the	care	
pathway,	then	it	also	becomes	possible	to	measure	
effective	coverage,	which	is	the	ultimate	goal	for	any	
healthcare	system.		
1.8 Conclusion
This	introductory	overview	of	healthcare	systems	
for	people	living	with	dementia	has	identified	the	
importance	of	healthcare	in	general,	and	of	primary	
healthcare	in	particular	to	the	maintenance	of	health	
and	wellbeing,	and	achievement	of	the	best	quality	of	
life	for	people	with	dementia	and	their	carers.	There	
are,	however,	many	problems	with	dementia	healthcare	
systems	as	currently	constituted.	The	first	is	that	they	
are	not	yet	capable	of	delivering	adequate	coverage	
of	basic	healthcare	services	for	people	with	dementia.	
This	is	true	for	diagnosis,	but	there	are	also	challenges	
in	delivering	care	that	is	responsive,	continuous	and	
of	appropriate	quality	(meeting	guidelines	and	service	
standards).	We	have	seen	that	task-shifting	and	task-
sharing,	including	but	not	limited	to	increasing	the	
role	and	competencies	of	primary	healthcare	services	
within	the	system,	is	likely	to	be	a	core	strategy	
for	increasing	diagnostic	and	treatment	coverage.	
Case	management	may	be	an	important	strategy	for	
improving	integration	and	coordination	of	care,	and	
increasing	treatment	coverage.	The	introduction	of	
evidence-based	care	pathways,	linked	to	process	and	
outcome	indicators,	should	help	to	improve	adherence	
to	healthcare	quality	standards,	and	allow	transparent	
monitoring	of	treatment	coverage	and	effective	
treatment	coverage.		
This	overview	defines	the	agenda	for	this	World	
Alzheimer	Report:	
We	will
1	 	conduct	a	scoping	review	of	recent	research	
evidence	on	the	role	of	primary	care	within	the	
dementia	healthcare	system.	This	will	include	
evidence	regarding	the	effectiveness	of	primary	care	
services	in	the	detection	and	diagnosis	of	dementia,	
and	in	the	provision	of	continuing	care.	We	will	also	
assess	evidence	on	strategies	and	interventions	
to	enhance	the	quality	of	care	provided	by	primary	
healthcare	services.	Finally,	we	shall	seek	to	identify	
any	studies	that	compare	aspects	of	the	quality	of	
care	provided	by	non-specialist	versus	specialist	
services,	against	the	criterion	of	‘non-inferiority’,	
that	is	that	the	processes	and	outcomes	achieved	
should	be	at	least	no	worse	than	those	achieved	by	
specialist	services	–	a	critical	justification	for	task-
shifted	care.
2	 	conduct	a	scoping	review	of	recent	research	
evidence	regarding	the	effectiveness	of	case	
management,	wherever	it	is	located	within	the	health	
and	social	care	system,	with	respect	to	outcomes	
for	people	with	dementia	and	their	carers,	and	
evidence	for	improved	efficiency	of	delivery	of	health	
and	social	care.	
3	 	conduct	a	scoping	review	of	hospitalisation	
of	people	with	dementia	seeking	to	clarify	the	
extent	of	and	reasons	for	hospitalisation,	the	
associated	harms,	the	excess	healthcare	costs,	the	
effectiveness	of	approaches	to	avoid	hospitalisation,	
and	reduce	harm	and	improve	outcomes	for	those	
who	are	admitted.	
4	 	review	the	latest	evidence	on	palliative	and	end-of-
life	care	for	people	living	with	dementia,	updating	
the	review	that	we	conducted	for	the	2013	World	
Alzheimer	Report1.
5  define outline healthcare pathways for people living 
with dementia for relatively well-resourced HIC, and 
less well-resourced LMIC settings. For selected 
HIC (Canada, South Korea, Switzerland) we will 
propose and compare two model pathways, one 
based on a specialist model of care, and one on a 
more task-shifted/task-shared counterfactual, with 
more roles performed by non-specialists, estimating 
the increasing costs of care from 2015 to 2031, 
accounting for projected increased in the numbers 
of people living with dementia, and a projected 
increase in diagnostic coverage from 50% to 75%. 
For selected LMIC (China, Indonesia, Mexico, South 
Africa), we shall assume that, currently, dementia 
healthcare is provided for only a small proportion 
of people, using a HIC model of specialist care. We 
will then estimate the increasing costs from 2015 to 
2031, assuming that the increased coverage (from 
5% in low income countries and 10% in middle 
income countries, to 50%) is achieved through 
implementation of task-shifted care pathways, as 
recommended by the World Health Organization 
Mental Health Gap Action Plan (mhGAP). 
This	agenda	is,	we	believe,	highly	relevant	to	the	future	
of	dementia	healthcare,	worldwide.	
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Health	and	social	care	systems	around	the	world	share	
three	key	challenges
•	 Improving the coverage of care
•	 Improving the quality of care
•	 Achieving the first two objectives, while limiting, 
and rendering affordable, the costs of health and 
social care in the context of population ageing
These	challenges	can	only	be	met	by	increasing	
the	cost	efficiency	with	which	care	is	delivered,	and	
developing	future-proof,	sustainable	financing	models.	
Coverage	and	equity	of	access	should	be	important	
considerations	throughout.	Policy	decisions	regarding	
the	scope	and	ambition,	and	the	design	and	delivery	of	
services	for	people	with	dementia,	should	be	evidence-
based.	Economic	models	need	to	be	developed	to	
guide	policy	decisions,	indicating	the	incremental	costs	
of	scaling	up	different	service	models.	These	will	vary	
between	settings,	depending	upon	the	cost	of	the	
service	(driven	mainly	by	staff	costs),	existing	coverage	
levels,	and	the	nature	of	cost	savings	where	these	are	
to	be	anticipated.	
The	multidisciplinary	work	group	established	by	
the	Alzheimer’s	Foundation	of	America	and	the	
Alzheimer’s	Drug	Discovery	Foundation	to	review	
evidence	for	screening	implementation	and	to	evaluate	
the	implications	of	routine	dementia	detection	for	
healthcare	redesign	called	for	an	effort	to	“Define	
‘ownership’	of	dementia	in	the	layout	of	health	care”.	In	
their	view	
“From	the	standpoint	of	health	care	delivery,	initial	
screening	for	cognitive	impairment	is	most	practical	
in	the	primary	care	setting...	The	best	setting	for	
further	diagnostic	evaluation	and	comprehensive	
management	is	unclear,	however...	The	workgroup	
encourages	systematic	consideration	of	the	
respective	roles	of	primary	and	specialty	care	in	the	
long-range	management	of	dementia	patients,	as	
part	of	the	work	of	the	National	Alzheimer’s	Project	
Act	implementation	plan.	The	discussion	should	
include	consideration	of	primary	care–specialty	
care	partnerships,	specialized	chronic	care	
manager	roles	within	primary	care,	and	research	
on	identifying	specific	subgroups	of	patients	
and	families	who	require	ongoing	complex	or	
specialized	management.”
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chapter 2
the role of primary care in the 
dementia healthcare system
2.1 Objectives and search strategy
We carried out a systematic scoping review to identify 
research relevant to the diagnosis and management 
of dementia in primary care, with the additional aims 
of comparing the quality of care and its outcomes 
between primary care and specialist secondary care 
services, and identifying promising strategies for the 
enhancement of the quality and outcomes of primary 
healthcare. We were interested in all types of relevant 
research, including observational and descriptive 
studies, qualitative research, service descriptions, 
intervention development and intervention or service 
evaluation, whether using randomised, controlled or 
non-controlled designs. 
We contacted a scoping review to map the existing 
literature, using the following search strategy. 
We used the search terms “((dementia OR Alzheimer*) 
AND (primary care))” seeking publications since 1980. 
We searched Ovid Medline, PubMed, PsycINFO and 
Cochrane databases. Following this, we conducted 
a search with Google Scholar to find ‘grey’ literature 
and articles in other databases than those mentioned 
above (reports and policy papers). We also checked 
the annual World Alzheimer Reports for any relevant 
publications. 
Inclusion criteria
•	 Studies conducted in primary care, or with a clear 
focus or relevance to primary care assessment, 
detection, diagnosis or management of dementia 
•	 A clear focus on people with dementia, Alzheimer’s 
disease, or cognitive impairment. Some 
publications referring to the management of frail 
or dependent older people were included when 
people with dementia or cognitive impairment were 
referred to specifically in stratified analyses. 
•	 English language resources
Exclusion criteria
•	 A focus on older people, generically, rather than on 
people with dementia in primary care
2.2 Search results, and characteristics 
of the eligible studies
The search retrieved 10,454 abstracts. In the first 
phase we excluded 5,838 publications after review of 
titles and abstracts, on the basis of obvious irrelevance 
or duplication. The remaining 4,616 abstracts were 
double screened by MK and MP for relevance. After 
reviewing titles and abstracts, and hard copies where 
relevant, these were limited to 234 relevant papers. 
Of these 37 (16%) were reviews, and 10 (4%) provided 
evidence-based guidance, the remaining 187 (80%) 
describing primary research. Primary research studies 
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were largely (79%) carried out in five countries; the USA 
(60 studies, 32%), the UK (39 studies, 21%), Germany 
(21 studies, 11%), the Netherlands (15 studies, 8%) and 
Canada (13 studies, 7%). Although 23 countries were 
represented, all bar six (three from Thailand, and one 
each from Malaysia, China and India), were conducted 
in high income countries. Regionally, 99 studies were 
conducted in Europe, 73 in North America, 16 in Asia 
(including 5 from Australia), and none in Latin America 
or Africa. Ten studies were carried out prior to 2000, 25 
studies from 2000-2004, 40 studies from 2005-2009, 
and 112 studies from 2010 onwards.
The distribution of this literature is summarised in Table 
2.1 below.
The	quantitative	descriptive	studies	comprised	mainly	
studies	of	recognition	and/or	recording	of	diagnosis	
in	primary	care	(14	studies),	surveys	of	general	
practitioners	or	other	primary	care	providers	to	assess	
attitudes,	knowledge	or	practice	regarding	diagnosis	
and/or	management	of	dementia	(14	studies),	aspects	
of	the	quality	of	care	provided,	and	how	it	may	be	
benchmarked	(8	studies),	prescribing	patterns	(six	
studies),	and	the	prediction/identification	of	dementia	
cases	using	health	information	system	data	(three	
studies).	Eight	of	the	qualitative	studies	examined	
attitudes,	beliefs	and	experiences	relating	to	diagnosis	
from	the	service	user	or	provider	perspective,	while	the	
remainder	explored	different	aspects	of	dementia	care	
and	management.	
Evaluative	studies	were	dominated	by	studies	of	the	
effectiveness	or	relative	effectiveness	of	different	
screening	tools	for	dementia	applied	in	primary	care	
settings.	This	was	also	the	topic	of	seven	reviews1–7.	
Most	of	the	published	evaluations	of	interventions	
or	services	(40	studies)	used	non-randomised	
designs.	We	identified	26	publications	referring	to	17	
randomised	controlled	trials,	the	design	features	and	
main	findings	of	which	are	summarised	in	Table	2.2	
below.	The	findings	of	the	more	important	trials	are	
presented	and	discussed	in	more	detail	in	the	later	
sections	of	this	chapter.
The	randomised	controlled	trials	can	be	divided	into	
three	broad	groups,	with	some	overlap	given	the	
complexity	of	some	of	the	interventions.	These	trials	
evaluated	the	effectiveness	of	
1.			practice-based	educational	interventions	on	
detection,	diagnosis	and/or	management	of	
dementia	(five	trials8,10–13),	
2.			additional	dedicated	practitioner	time,	best	
understood	as	case	management	(but	variously	
described	as	case	management,	collaborative	
care,	care	consultation,	or	comprehensive	geriatric	
assessment	and	management)	more	or	less	
integrated	into	primary	care	services,	on	service	
utilisation,	care	quality	and	outcomes	for	the	person	
with	dementia	and	carer	(five	trials14–20),	and	
3.			psychosocial	interventions	(counselling	and	
support),	provided	in	the	context	of	primary	care	on	
outcomes	for	the	person	with	dementia	and	carer	
(four	trials21–27).
Table 2.1  
Eligible studies by study design
Type of study Number of 
publications
Percentage 
of total
Descriptive studies
Intervention development 2 1.1%
Service description 6 3.2%
Qualitative or mixed methods 16 8.5%
Quantitative 62 33.2%
Evaluative studies
Screening tool 26 13.9%
Intervention evaluation 25 13.4%
Service evaluation 16 8.6%
RCT protocol 9 4.8%
RCT 25 13.4%
Total 181 100.0%
Abbreviations:
AChEIs: Acetylcholinesterase Inhibitors
AD: Alzheimer’s disease
ADL: Activities of Daily Living
AOR: Adjusted Odds Ratio
BPSD: Behavioural and Psychological 
Symptoms of Dementia
CG: Control Group
GP: General Practitioner
HR: Hazard Ratio
IG: Intervention Group
IRR: Incidence Rate Ratio
MCI: Mild Cognitive Impairment
MMSE: Mini-Mental State Examination
MoCA: Montreal Cognitive Assessment
NH: Nursing Home
PHC: Primary Healthcare
PHP: Primary Healthcare Physician
PN: Practice Nurse
PPV: Positive Predictive Value
PWD: People With Dementia
QoL: Quality of Life
RCT: Randomised Controlled Trial
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Table 2.2a 
Randomised controlled trials relevant to the detection, diagnosis or management of dementia in primary care
Education or training
Trial title Author, Year Intervention Results
Effectiveness 
of education 
interventions in 
improving detection 
and management of 
dementia in primary 
care, UK
Downs, 20068 Education interventions 
to improve detection and 
management of dementia 
in PHC. Electronic tutorial vs 
decision support software 
(DSS) vs practice-based 
workshops (PBW) vs control
DSS and PBW IGs both 
showed increased rates of 
detection compared with CG. 
No effect of any intervention 
on concordance with 
guidelines
Cluster RCT, 36 general 
practices
IDA, Germany Vollmar, 20079 Effectiveness of three hours 
training in dementia diagnosis 
+/- 2 hours additional training 
on dementia treatment/
management, based on an 
evidence-based guideline 
on GP knowledge regarding 
diagnosis and treatment
There was a significant pre-
post increase in knowledge 
scores, greater for those 
receiving the augmented 
training
137 GPs, 90 of whom 
received the additional 
training on dementia therapy
Vollmar, 201010 Online blended learning with 
quality clusters vs QCs alone 
on knowledge gain
Blended learning not 
superior to QCs alone, but 
those using online material 
had gain in knowledge
Cluster RCT. 166 GPs. 
General practice-
based intervention 
for suspecting and 
detecting dementia, 
France
Rondeau, 
200811
Effect of a two hour group 
educational meeting 
conducted by specialists 
focussing on the use of 
a battery of four brief 
neuropsychological tests vs 
‘usual practice’ on suspicion 
of dementia, and diagnostic 
accuracy
Suspicion of dementia higher 
in IG (36.4% vs. 26.8%, p < 
0.0001). PPV of suspected 
dementia was similar in IG 
(60.9%) and CG (64.4%). No 
increase in overall diagnostic 
yield following referral.
Cluster RCT, 684 PCPs.353 
IG, 331 CG All of the GPs 
were then asked to recruit 
the next five patients aged 
75 or over presenting with 
a spontaneous memory 
complaint, or who were 
reported to have this 
problem by an informant.
EVIDEM-ED Wilcock, 201312 Effect of tailored educational 
intervention based upon 
educational needs assessment 
on detection and management
No effects on documented 
evidence-based 
management (two or more 
reviews – AOR 0.94, 95% CI: 
0.33-2.62) or case detection 
rates (IRR 1.03, 95% CI: 
0.57-1.86)
23 practices, (Cluster 
randomised) 1072 PWD. 12 
months.
Case Finding of MCI 
and Dementia and 
Subsequent Care, NL
Van den 
Dungen, 201613
Effect of two evening 
postgraduate training 
sessions for PCPs on 
detection, diagnosis and 
early management of MCI 
and dementia. IG received 
additional screening and 
referral by PNs in Phase 2. 
Phase 2 outcomes were 
mental health effects of case 
finding and subsequent care. 
Non-significant increase in 
detection of dementia or 
MCI (RR 1.51, 95% CI: 0.60-
3.76). Increased detection 
apparent for MCI (RR 1.61, 
95% CI: 1.21-2.13), but not 
dementia (RR 1.04, 95% 
CI: 0.68-1.57). Differences 
in mental health outcomes 
following additional Phase 2 
screening and care, but only 
32% of patients participated 
in this phase.
Cluster RCT. 15 PHCs. 7PHCs 
and 326 patients IG, 8 PHCs 
321 patients CG. 12 months 
endpoint for detection.
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Table 2.2b 
Randomised controlled trials relevant to the detection, diagnosis or management of dementia in primary care
Case management
Trial title Author, Year Intervention Results
Cleveland 
Alzheimer’s 
Managed Care 
Intervention, USA
Bass, 200314 Effect of Alzheimer’s 
Association care consultation 
linked to managed care health 
services on service utilisation, 
satisfaction with managed 
care, carer depression and 
strain 
IG had fewer Kaiser Permanente 
case management consultations. No 
effect on physician visits, ED visits, or 
hospitalisation
IG had higher satisfaction with quality 
of health plan services, type of services, 
and information received – particularly 
those who had not received a dementia 
diagnosis
IG carers had greater reduction in 
depression, and non-spouse carers had 
greater reduction in strain 
157 PWD and their 
primary family 
carers, 12 months 
endpoint
Dementia In 
Primary Care, USA
Callahan, 
200615
Collaborative care. Advanced 
practice nurse integrated in 
PHC vs enhanced usual care
Lower BPSD in IG. Lower carer strain. No 
effect on carer depression. More AChEIs 
and antidepressants prescribed to IG. No 
effect of intervention on PWD cognition, 
depression, ADL, hospitalisation, NH 
placement, or death
153 older adults with 
AD. 12 and 18 month 
endpoints
ACCESS-Trial, USA Vickrey, 
200616
Effect of disease-based 
management program by 
case managers on quality 
of care and outcomes. Case 
management vs usual care
% of guideline recommendations. met 
was higher for IG, with higher care quality 
on 21/23 guidelines . Higher proportion of 
IG received assistance from community 
agencies. PWD QoL, caregiving quality, 
and social support were higher for IG, and 
unmet caregiving assistance needs lower. 
No effect on carer QoL.
Cluster RCT. 18 
PHCs and 408 PWD 
and their carers. 12 
month endpoint
Chodosh, 
200617
Effect of a comprehensive 
dementia care management 
model on PCPs knowledge, 
attitudes about dementia, 
and perception of quality of 
dementia care
IG PCPs had better knowledge about 
assessing decision-making capacity than 
CG PCPs. IG PCPs viewed PWD as more 
difficult to manage in primary care than 
CG PCPs. There were no other differences 
in knowledge, attitudes, or care quality 
perceptions.
232 PCPs, 129 from 
9 IG clinics; 103 from 
9 CG clinics. 9 month 
endpoint 
Chodosh, 
201218
Secondary analysis of IG to 
determine factors associated 
with improved care quality
Case management uptake was 
associated with higher care quality. 
Additional coordinated interactions with 
PHC and community agency staff yielded 
even higher quality
Dutch EASYcare 
study, NL
Perry, 200819 Effect of home-based 
comprehensive geriatric 
assessment (CGA) and 
management on dementia 
diagnosis
Secondary analysis. Increased rate of 
new detections in intervention arm 19/66 
vs 4/47 (RR 3.38, 95% CI: 1.23-9.30)
151 vulnerable older 
adults. 6 months 
follow up
Alzheimer’s 
Association 
Collaborative Care, 
USA
Fortinsky, 
200920
Effect of ‘dementia care 
consultants’ provided by 
local Alzheimer’s Association 
chapters on nursing home 
placement, and carer 
outcomes
Less likely to have NH placement (AOR 
0.40, 95% CI: 0.14-1.18). No effect on 
carer self-efficacy, carer depression or 
strain
84 family carers. 
Cluster RCT. 
12 months. 
Implementation 
problems – high 
turnover, and care 
plans not discussed 
with physicians
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Table 2.2c 
Randomised controlled trials relevant to the detection, diagnosis or management of dementia in primary care
Caregiver psychosocial interventions
Trial title Author, Year Intervention Results
REACH, USA Burns, 200321 Effect of patient behaviour 
management only vs patient 
behaviour management 
plus caregiver stress-coping 
management on caregiver outcomes
Caregivers who received the 
patient behaviour management 
component only had significantly 
worse outcomes for general 
well-being and a trend toward 
increased risk of depression. Both 
arms showed reduced impact 
from care recipient behaviours
RCT. 167 caregiver/
care recipient dyads. 
24 months
IDA, Germany Donath, 201022 Training of GPs and 
recommendation of carer 
counselling and support groups. 3 
arms, A. diagnostic training only, B 
and C. Diagnostic and treatment/
management training with 
instruction to refer to carer support 
groups and counselling immediately 
or after 1 year. Effectiveness on 
care process variables (adherence 
to treatment guidelines, and carer 
access to counselling and support).
High adherence to diagnostic 
and therapeutic guidelines in all 
three intervention arms. 4-5 fold 
higher access to support groups 
and counselling in groups B and 
C. Low use of other community 
support services with no between 
group differences
Cluster RCT. 129 GPs 
and 390 PWD. 2 year 
endpoint
Menn, 201223 Effectiveness on nursing home 
placement, and outcomes for the 
carer and person with dementia
No difference in nursing home 
placement, mortality, cognition, 
ADL, carer burden, or HRQOL. 
Service use and costs similar 
between all three groups
As above, two year 
endpoint for nursing 
home placement, and 
four year endpoint 
for cost and other 
outcomes
DAISY, Denmark Waldorff, 201224 Effect of early psychosocial 
counselling and support provided 
to people with very mild dementia 
in the post-diagnostic period on 
person with dementia cognition, 
depression and QoL, and carer 
depression and QoL. Control support 
or support + DAISY intervention 
(multi-faceted and semi-tailored 
counselling education and support) 
No differences on any primary or 
secondary outcomes
330 PWD and their 
main caregivers. 12 
month endpoint
Phung, 201325 As above No differences on any primary or 
secondary outcomes
As above. 36 month 
endpoint
Sogaard, 201426 Early psychosocial intervention 
(psychosocial counselling and 
support) on costs from a societal 
perspective
Not cost-effective. None of the 
cost or QOL outcomes differed 
between the two arms.
As above. 36 month 
endpoint. 
Effects of a 
psychological 
intervention in a 
primary health 
care center 
for caregivers 
of dependent 
relatives, Spain
Rodriguez-
Sanchez, 201327
Effect of group cognitive behavioural 
therapy (CBT), administered in PHC 
by a psychologist with PCP or PN 
co-therapists vs treatment as usual 
on caregiver mood, dysfunctional 
thoughts, quality of life and strain 
IG had lower psychological 
morbidity and dysfunctional 
thoughts. No significant between 
group differences in caregiver 
strain or quality of life
RCT. 125 caregivers 
(83 randomised to IG, 
42 to CG). 9-11 week 
endpoint
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Table 2.2d 
Randomised controlled trials relevant to the detection, diagnosis or management of dementia in primary care
Task-shifting (non-specialist vs specialist care)
Trial title Author, Year Intervention Results
AD-Euro, NL Meeuwsen, 
201228
Usual care provided by 
multidisciplinary memory 
clinic or PHC GP. Effect on 
carer QoL and caregiver 
sense of competence
QoL was non-significantly higher 
and burden non-significantly 
lower in memory clinic
175 patients with 
a new diagnosis 
of mild/moderate 
dementia living 
in community. 12 
months endpoint.
Meeuwsen, 
201329
Comparing cost 
effectiveness
Costs were non-significantly 
cheaper, and quality of life 
years lost marginally greater 
in the memory clinic arm. No 
evidence was found that memory 
clinics were more cost-effective 
compared to general practitioners 
with regard to post-diagnosis 
treatment and coordination of 
care of patients with dementia in 
the first year after diagnosis.
As above
Meeuwsen, 
201430
Comparing content of 
dementia care
PWD attending memory clinics 
were more likely to be prescribed 
cognitive enhancer medication, 
more likely to receive information 
about their condition, and more 
likely to be advised to attend 
Alzheimer cafes
As above
Other interventions
Trial title Author, Year Intervention Results
Video decision support 
tool for advance care 
planning in dementia, USA
Volandes, 200931 Effect of video decision 
support tool vs. narrative 
alone on advanced care 
planning of older people 
in the event of developing 
severe dementia
IG more likely to opt for palliative 
care (86% vs 64%) and less likely 
to opt for life prolonging care 
(4% vs 14%) (AOR for palliative 
care 3.9, 95% CI: 1.8-8.6). IG 
were more likely to maintain their 
preferences when reinterviewed 
six weeks later
200 older 
people with PHC 
appointments at 
4 PHC. Pre-and 
post-intervention, 
with further 6 week 
reassessment of 
preferences
Comparing the mini 
mental state examination 
and the Montreal 
cognitive assessment 
to screen for cognitive 
impairment in older 
patients at cardiovascular 
risk, France
Golstein, 201532 Effectiveness of MMSE 
vs MoCA in detecting 
cognitive impairment in 
older outpatients with high 
cardiovascular risk
Compared with physician 
judgement, MMSE detected 
cognitive impairment with 97% 
sensitivity and 9% sensitivity and 
MoCA 94% specificity and 9% 
sensitivity
111 patients aged 
65 and over at high 
cardiovascular risk 
and prescribed 
cardiovascular 
prevention in 
primary care
preDIVA, NL Van Charante, 
201633
Effects of practice-based 
nurse led cardiovascular 
intervention on the 
incidence of dementia, and 
disability score
No effect on the incidence of 
dementia (HR 0.92, 95% CI: 
0.71-1.19) or disability scores. 
Neither was there any effect 
of the intervention on incident 
cardiovascular disease (HR 95% 
CI: 1.06, 0.86-1.31)
Cluster RCT. 116 
general practices 
with 3526 
participants aged 
70-78 years
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2.3 Framework for presentation of 
research findings on the role of primary 
care in dementia healthcare
To	present	the	key	findings	of	this	large	and	complex	
literature	in	the	most	informative	way,	we	have	divided	
the	healthcare	provided	for	people	with	dementia	and	
their	carers	into	three	phases:
1.		Detection	and	diagnosis
2.		Early	post-diagnostic	care	and	support
3.		Continuing	care
For	each	phase	we	describe	studies	that
a)			assess	the	quality	of	care	provided	by	non-specialist	
health	workers	in	primary	care	services,	and	
its	outcomes.	These	are	mainly	cross-sectional	
quantitative	descriptive	studies.
b)			compare	the	quality	of	care	delivered	by	non-
specialists	in	primary	care,	and	its	outcomes,	with	
that	provided	by	specialists	in	secondary	or	tertiary	
care.	These	are	mainly	non-randomised	quantitative	
comparisons	of	patient	groups	first	diagnosed,	and/
or	managed	by	PCPs	versus	specialist	clinicians	
(geriatricians,	psychiatrist	or	neurologists).	We	only	
identified	one	randomised	controlled	trial	in	this	
category.
c)			describe,	and/or	evaluate	the	effectiveness	of	
system	or	service	level	innovations	designed	to	
enhance	the	quality	of	healthcare	provided	for	
people	with	dementia	in	primary	care.	These	
comprised	randomised	controlled	trials,	controlled	
trials,	pre-	and	post-implementation	evaluations,	
and	service	descriptions.	
2.4 Detection and diagnosis
Studies of the quality of dementia diagnosis 
processes and outcomes in primary care
Recognition	of	dementia	in	primary	care	has	been	
confirmed	to	be	low	in	many	studies	conducted	in	high	
income	countries.	The	typical	design	of	such	studies	
is	that	older	patients	seen	in	primary	care	are	given	
a	research	diagnostic	assessment,	and	this	is	then	
compared	with	the	PCPs	contemporaneous	clinical	
judgment,	and/or	recording	of	information	suggesting	
a	clinical	diagnosis	in	primary	care	medical	records.	
In	a	systematic	review	of	15	such	studies	conducted	
mainly	in	Europe	and	North	America,	the	pooled	
proportion	of	dementia	cases	identified	by	PCPs	
was	73.4%	(95%	CI:	62.6-82.9%)34.	Moderate	to	
severe	dementia	(81.2%)	was	more	likely	to	have	been	
detected	than	mild	dementia	(45.1%).	Diagnoses	were	
even	less	likely	to	have	been	recorded	in	the	patient	
notes	(37.9%,	95%	CI:	26.8-49.6%).	It	should	be	noted	
(despite	the	title	of	the	review)	that	these	were	not	
studies	of	diagnostic	accuracy	per	se,	since	there	was	
no	requirement	that	the	GP	should	have	carried	out	a	
formal	diagnostic	assessment.	Indeed,	the	lack	of	such	
an	assessment	may	be	one	explanation	for	modest	
recognition	rates.	Another	limitation	that	is	rarely	
discussed	in	these	studies	relates	to	the	concept	of	
an	external	‘gold	standard’	–	even	specialists	working	
in	memory	clinics	sometimes	show	surprisingly	low	
levels	of	diagnostic	agreement	with	each	other35.	Some	
of	the	cases	identified	by	the	research	diagnostic	
assessment	may	not	have	been	considered	by	the	
PCPs	to	have	warranted	a	‘timely’	diagnosis.	These	
were	also	studies	of	‘unassisted’	PCP	diagnosis,	
meaning	that	no	structured	diagnostic	program	was	in	
place,	and	no	training	was	offered.	Findings	of	these	
studies	therefore	reflect	a	likely	ceiling	on	levels	of	
recognition	with	routine,	unmodified	primary	care	for	
older	persons.	
Cognitive	testing	may	play	an	important	part	in	
refining	the	accuracy	of	GP	assessments.	In	a	survey	
conducted	of	GP	referrals	to	a	UK	specialist	memory	
service,	in	only	20%	was	there	evidence	of	cognitive	
testing	having	been	performed	at	primary	care	prior	to	
referral36.	Overall	37%	of	PCP	referrals	were	diagnosed	
with	dementia,	but	this	was	56%	for	those	that	had	
been	cognitively	tested	by	the	PCP	and	32%	for	those	
that	had	not.	A	further	audit	from	the	same	specialist	
memory	service	studied	the	impact	of	National	Institute	
for	Health	and	Clinical	Excellence/Social	Care	Institute	
for	Excellence	(NICE/SCIE)	guidelines	(2006)	and	the	
National	Dementia	Strategy	(2009)	on	PCP	referral	
behaviour37.	While	over	the	two	year	period	from	2008	
to	2010	PCP	referrals	had	increased,	the	proportion	
diagnosed	with	dementia	fell,	and	there	was	no	
increase	in	the	use	of	cognitive	testing.
Studies comparing the quality and outcomes 
of non-specialist and specialist dementia 
diagnosis
Two	non-randomised	studies	compared	aspects	of	the	
quality	of	the	diagnostic	process	and/or	its	outcomes	
for	groups	of	people	first	diagnosed	by	non-specialist	
primary	care	doctors,	compared	to	those	managed	by	
specialist	geriatricians,	neurologists	and	psychiatrists.	
These	indicate	some	potential	concerns	regarding	
diagnostic	process	in	primary	care.	The	largest	of	
these	was	a	secondary	analysis	of	US	Medicare	data	
using	a	5%	random	sample	of	patients	with	two	or	
more	claims	for	Alzheimer’s	disease	and	a	diagnosis	
of	cognitive	decline	in	the	previous	three	years	
made	either	by	specialists	(neurologist,	psychiatrist,	
or	geriatrician	-	n	=	2593)	or	non-specialists	(n	=	
13,961)38.	Patients	first	diagnosed	with	cognitive	
decline	by	specialists	had	a	significantly	shorter	time	to	
Alzheimer’s	diagnosis,	after	matching	for	age,	gender,	
comorbidity	and	baseline	service	costs	(mean:	3.5	
versus	4.6	months,	p	<	0.0001).	All	cause	medical	care	
costs	peaked	in	the	year	after	diagnosis,	and	in	the	
year	before	death.	After	matching,	patients	diagnosed	
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by	specialists	had	significantly	lower	average	total	all-
cause	medical	costs	in	the	first	12	months	after	their	
cognitive	decline	diagnosis	($19,824	versus	$25,863,	p	
<	0.0001).	
The	quality	of	the	dementia	diagnostic	process	for	
those	managed	by	non-specialist	services	is	also	
called	into	question	by	a	study	of	the	use	of	a	non-
specific	‘dementia	not	otherwise	specified’	(DNOS)	
diagnostic	category	in	the	New	England	Veterans	
Affairs	Health	Care	System39.	Aside	from	valid	
uncertainty,	this	coding	may	reflect	an	inadequate	
assessment,	with	adverse	consequences	for	access	to	
dementia	subtype-specific	treatment	and	advice.	The	
DNOS	coding	was	applied	as	a	final	diagnosis	by	41%	
of	primary	care	physicians	versus	27%	of	neurologists.	
Conversely,	30%	who	saw	a	non-specialist	first,	48%	
who	saw	a	psychiatrist	first,	and	63%	who	saw	a	
neurologist	first	were	given	a	diagnosis	of	Alzheimer’s	
disease.	When	100	randomly	selected	DNOS	case	
records	were	examined	in	detail,	the	initial	diagnosis	
was	made	by	a	non-specialist	in	74%,	and	of	these	
cases	cognitive	testing	was	carried	out	in	only	12%	
of	first	visits	and	2%	of	follow-ups.	While,	overall,	it	
was	adjudged	that	subtype-specific	diagnoses	could	
have	been	provided	for	48%	of	DNOS	diagnoses,	
this	was	the	case	for	only	7%	at	initial	non-specialist	
assessment,	due	to	inadequate	information	in	the	case	
record.	
Studies evaluating the effectiveness of 
system or service level innovations to 
enhance the quality of dementia detection 
and diagnosis in primary care, and its 
outcomes
Screening
The	use	of	routine	screening	in	primary	care,	to	
boost	detection,	remains	highly	controversial4,40,41.	
Several	brief	cognitive	tests	have	been	proposed	
as	feasible	for	use	in	primary	care,	with	reasonable	
evidence	for	their	validity4–7.	However,	there	are	
concerns	regarding	their	suitability	for	use	in	
LMIC,	where	low	education	and	illiteracy	may	be	
obstacles	to	successful	administration42,43.	In	2013,	
the	US	Preventive	Services	Task	Force	updated	its	
previous	2003	guidance	on	screening	for	cognitive	
impairment	in	older	adults,	based	upon	an	extensive	
and	fully	systematic	evidence	review4.	Screening	
programmes	must	be	shown	to	deliver	net	benefit	for	
those	screened;	however,	the	Task	Force	found	no	
studies	that	directly	addressed	the	possible	adverse	
psychological	effects	of	screening	(as	opposed	to	
attitudes	towards	screening),	or	adverse	effects	from	
false-positive	or	false-negative	testing.	Screening	
programmes	should	also	demonstrate	beneficial	
impact	on	clinical	decision-making	and	behaviour;	
however,	the	Task	Force	also	identified	no	trials	that	
examined	the	direct	effect	of	screening	on	patient,	
caregiver,	and	clinician	decision-making	outcomes.	
(There	is,	however,	some	evidence	that	PCPs	are	much	
less	likely	to	act	upon	screening	evidence	of	cognitive	
impairment,	compared	with	other	impairments	such	
as	falls	risk,	hearing,	urinary	incontinence	and	low	
mood44.)	The	current	recommendation	therefore	is	
against	routine	screening	on	the	grounds	that	the	
benefits	of	earlier	diagnosis	may	be	modest,	that	
there	has	been	no	adequate	or	systematic	study	of	
the	possible	harms	associated	with	screening	and	
diagnosis,	and	that	the	cost-effectiveness	of	the	
process	has	not	been	established.	The	last	two	of	
these	concerns	are	well-founded,	based	on	absence	of	
evidence.	The	first	is	more	contested.	The	Task	Force	
took	the	view	that	while	AChEIs,	memantine,	complex	
caregiver	interventions,	and	cognitive	stimulation	all	
have	evidence	to	support	their	use	in	mild	to	moderate	
dementia,	the	clinical	importance	of	their	benefit	is	
unclear.	Alongside	the	clinical	benefits	from	early	
intervention,	a	wider	perspective	of	the	benefits	of	
earlier	diagnosis	should	also	take	into	account	the	right	
to	a	diagnosis,	the	potential	for	advanced	care	and	
financial	planning	while	the	person	with	dementia	still	
has	capacity	to	decide	these	matters,	the	opportunity	
to	optimise	medical	care	including	attention	to	physical	
comorbidities,	better	knowledge	of	available	services,	
and	the	more	timely	delivery	of	additional	support	and	
care	when	the	need	should	arise41,42.
Two	published	audits	of	the	results	of	screening	
programs	illustrate	some	of	the	problems	with	
efficiency	and	cost-effectiveness.	In	the	USA,	patients	
attending	routine	primary	care	through	Veterans	
Affairs	(VA)	services	were	offered	screening	using	the	
Mini-Cog45.	97%	agreed	to	be	screened,	and	26%	
were	screen	positive.	Of	these,	only	28%	agreed	
to	further	detailed	evaluation.	A	high	proportion	of	
these	were	then	diagnosed	with	dementia	(75%)	or	
cognitive	impairment	(19%).	From	8,342	veterans	
offered	the	screening,	432	new	cases	of	dementia	
(5%)	were	identified.	In	the	UK,	a	different	approach	
was	used	in	a	case-finding	program	introduced	in	
33	primary	healthcare	centres	in	Surrey	Downs.	
Registered	patients	were	invited	specifically	for	
screening	on	the	basis	of	elevated	risk	defined	as	age	
over	65,	with	a	diagnosis	of	diabetes,	hypertension,	
heart	disease,	Parkinson’s	disease,	stroke	or	TIA46.	
Screening	was	carried	out	using	the	Mini-Cog	and	a	
functional	assessment	questionnaire,	with	abnormal	
scores	on	both	being	considered	positive	screening	
outcomes.	12%	of	the	practice	population	were	
identified	as	at	risk,	and	sent	invitation	letters.	Of	
these,	only	30%	attended	the	screening,	among	
whom	18%	were	screen	positive.	These	were	reviewed	
by	GPs	who	concluded	that	57%	were	suitable	for	
referral	to	memory	clinic	services	for	a	diagnostic	
assessment.	80%	accepted	this	assessment.	Again	
the	overwhelming	majority	were	diagnosed	with	
either	dementia	(62%)	or	MCI	(33%).	From	the	6657	
28
registered	patients,	101	new	cases	of	dementia	were	
identified	(1.5%).	
In	both	studies,	the	screening	process	was	deemed	
acceptable	to	patients	who	participated,	with	no	
obvious	evidence	of	harms,	although	these	were	not	
systematically	ascertained45,46.	Of	note,	in	the	USA	
VA	program,	118	veterans	who	passed	the	screening	
examination	still	requested	a	further	evaluation,	and	of	
these	70%	were	diagnosed	with	dementia	and	18%	
with	cognitive	impairment45.	The	screening	process	
was	considered	to	be	worthwhile	by	primary	care	
staff,	and	to	be	feasible	with	little	additional	workload;	
however,	additional	resources	were	provided	for	the	
screening45,46.	Results	of	the	two	audits	suggest	
that,	while	routine	screening	of	attendees	at	primary	
care	has	a	much	higher	uptake	than	a	targeted	
invitation	to	screening	of	registered	patients,	those	
who	respond	with	interest	to	an	invitation	are	more	
likely	to	take	up	an	offer	of	more	detailed	assessment,	
if	screen	positive.	In	both	examples,	though,	there	
was	considerable	attrition	through	the	various	
stages,	and	the	clinical	status	of	those	who	declined	
screening	or	diagnostic	assessment	is	unknown45,46.	
The	positive	predictive	value	for	the	group	finally	
attending	diagnostic	evaluation	is	very	high.	However,	
the	additional	yield	may	be	modest;	in	the	UK	Surrey	
Downs	example	it	was	estimated	that	the	additional	
101	cases	identified	increased	the	proportion	of	
dementia	cases	diagnosed	in	the	district	from	49	to	
52%,	with	an	incremental	cost	per	patient	diagnosed	
of	£2,465	(US$	3,211)	per	case46.	Set	against	this,	both	
audits	reported	a	substantial	‘ripple	effect’	with	a	large	
increase	in	referrals	to	dementia	diagnostic	services	
by	primary	care	practitioners,	outside	of	the	screening	
program45,46.	
There	are	relatively	few	empirical	studies	of	the	
predictors	of	refusal	of	cognitive	screening.	In	one	
US	study47,	554	participants	of	whom	10.3%	refused	
screening,	had	previously	been	administered	the	
Perceptions	Regarding	Investigational	Screening	
for	Memory	in	Primary	Care	Questionnaire	(PRISM-
PC).	Older	age,	scepticism	regarding	the	benefits	
of	dementia	screening,	scepticism	regarding	the	
benefits	of	other	forms	of	screening	(colon	cancer	and	
depression),	and	belief	that	there	were	no	effective	
treatments	for	Alzheimer’s	disease	were	associated	
with	refusal.	There	was	no	association	with	PRISM-
PC	scores	on	concerns	regarding	stigma,	loss	of	
independence,	or	suffering	arising	from	dementia	
screening	and	its	results.	
There	is	currently	interest	in	the	feasibility	of	using	
routine	health	information	and	demographic	data	to	
stratify	primary	care	patient	populations	according	
to	their	risk	for	dementia,	such	that	costly	screening	
activities	can	be	targeted	more	appropriately.	Only	one	
of	the	several	studies	that	we	identified	used	a	robust	
screening	efficiency	analysis48.	In	377	UK	general	
practices	with	930,395	patients	aged	60–95	years	
without	a	recording	of	dementia,	cognitive	impairment	
or	memory	symptoms	at	baseline,	risk	algorithms	were	
developed	to	predict	the	incidence	of	dementia	over	
5	years	for	two	age	groups	(60–79	and	80–95	years).	
The	model	was	then	validated	on	a	separate	cohort	of	
264,224	patients	from	practices	that	did	not	contribute	
to	the	development	cohort.	Potential	predictors	
included	sociodemographic,	cardiovascular,	lifestyle	
and	mental	health	variables.	Discrimination	was	good	
for	those	aged	60–79;	predictors	included	age,	sex,	
social	deprivation,	smoking,	BMI,	heavy	alcohol	use,	
anti-hypertensive	drugs,	diabetes,	stroke/TIA,	atrial	
fibrillation,	aspirin	use,	and	depression.	The	algorithm	
had	a	high	negative	predictive	value,	but	lower	positive	
predictive	value,	hence	would	be	mostly	applicable	for	
‘ruling	out’	those	at	very	low	risk	from	further	testing	or	
intensive	preventative	activities	at	most	risk	thresholds.	
Discrimination	was	poor	for	the	80–95	years	model.	
The	conclusions	of	the	US	Task	Force	seem	
reasonable.	Routine	screening	should	not	be	carried	
out,	other	than	for	the	purpose	of	carefully	controlled	
and	informative	research.	Definitive	evidence,	sufficient	
to	influence	policy	and	practice	will	come	from	well-
designed	randomised	controlled	trials.	In	this	respect,	
we	identified	one	relevant	protocol	for	a	randomised	
controlled	trial.	The	objective	of	the	CHOICE	trial	
is	to	determine	the	cost-effectiveness	of	dementia	
screening	in	primary	care	and	its	impacts	on	mental	
health	and	quality	of	life49.	4,000	people	aged	65	
and	over	will	be	randomised	to	receive	telephone	
cognitive	screening	(with	referral	to	a	memory	clinic	for	
diagnostic	assessment,	as	indicated),	or	no	screening,	
and	followed	up	over	12	months.
Education and training
All	but	two	of	the	five	trials	of	educational	interventions	
had	already	been	included	in	a	systematic	review	from	
201150,	and	were	discussed	in	the	World	Alzheimer	
Report	2011	that	focused	on	the	case	for	earlier	
diagnosis42.	The	main	conclusion	of	these	reviews	was	
that	educational	and	training	interventions	targeting	
primary	care	practitioners	may	have	a	modest	impact	
on	detection8,11,	particularly	when	they	include	an	
active	and	continuing	practice-based	component	(e.g.	
practice-based	workshops	or	decision	support	tools	
-	see	Box	2.1	for	an	example)	as	opposed	to	standard	
continuing	medical	education.	This	conclusion	is	to	
some	extent	contradicted	by	the	null	results	of	the	
more	recently	published	large	cluster	randomised	
controlled	trial	of	the	flexible	and	multi-faceted	
EVIDEM-ED	intervention	in	the	UK12.	Another	recent	
cluster	randomised	controlled	trial	of	a	continuing	
medical	education	intervention	in	the	Netherlands	
failed	to	show	any	significant	impact	on	diagnosis	rates	
for	MCI	and	dementia	overall,	with	the	trend	towards	
improvement	accounted	for	by	increased	diagnosis	of	
MCI	rather	than	dementia13.
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Further	developments	to	enhance	recognition	and	
diagnosis	of	dementia	in	primary	care	need	to	be	
based	upon	a	clear	understanding	of	underlying	
barriers,	which	are	complex	and	multifactorial.	We	
identified	two	recent	systematic	reviews	on	this	
topic52,53.	Both	reviews	highlighted	the	importance	
of	patient	factors,	PCP	factors	and	system	
characteristics,	alongside	the	intrinsically	complex	
biomedical,	psychosocial,	and	ethical	nature	of	the	
condition52,53.	Key	themes,	common	to	both	reviews	
included	a	lack	of	PCP	confidence	in	their	ability	to	
diagnose	and	manage	the	condition	(see	also	Box	
2.2),	time	constraints,	discomfort	with	disclosing	
the	diagnosis,	concerns	regarding	stigma	and	other	
potential	adverse	effects	of	a	diagnosis,	therapeutic	
nihilism,	lack	of	post-diagnostic	support	systems	for	
the	person	with	dementia	and/or	carer,	and	lack	of	
support	for	the	PCP	in	managing	the	condition	(see	
Table	2.2a).	
The	first	conclusion	of	the	reviews	was	that	education	
and	training	needed	to	focus	more	on	PCP	perceptions	
and	attitudes	that	impact	directly	on	their	motivation	to	
make	a	diagnosis,	given	that	technical	abilities	may	not	
be	the	critical	limiting	issue:	
“it	is	easy	to	imagine	how	uncertainty	amongst	
clinicians	who	do	not	deal	with	it	regularly	might	
arise.	This,	dovetailed	with	the	inherent	stigma	and	
apprehension	about	making	a	wrong	diagnosis	and	
disclosing	the	diagnosis	with	aptitude	and	empathy,	
seems	to	be	the	font	of	insecurities	that	make	PCPs	
reluctant	or	unable	at	times	to	recognise	dementia	
earlier.	So,	rather	than	simply	augmenting	clinical	
knowledge,	educational	interventions	should	ideally	
be	more	attitudinal,	focusing	on	enhancing	PCPs’	
perceptions	of	their	suitability	and	ability	to	make	
the	diagnosis,	and	the	value	of	doing	so	in	a	timely	
manner”.52
Second,	there	was	a	concern	that	most	efforts	to	
improve	recognition	in	primary	care	have	been	isolated,	
and	limited	in	scope,	duration	and	intensity53.	One-
off	educational	and	training	efforts	are	unlikely	to	be	
impactful,	and	because,	on	average,	each	PCP	will	
encounter	only	a	small	number	of	patients	with	recent	
onset	and	undiagnosed	dementia	each	year,	‘learning	
from	experience’	cannot	be	relied	upon52.	Interventions	
tend	to	target	only	a	subset	of	barriers,	and	often	with	
only	modest	intensity	and	very	limited	coordination.	
System	barriers	were	alluded	to	commonly	by	PCPs	in	
studies	in	varied	European	as	well	as	North	American	
health	systems52,53.	While	some	of	these	arose	within	
Box 2.1
An example of active and 
continuing practice based 
development. The Canadian Mild 
Dementia Knowledge Transfer 
Toolkit
In	Canada,	a	Mild	Dementia	Knowledge	Transfer	
Toolkit	has	been	developed	to	improve	PCPs’	
knowledge	and	skills	in	the	assessment,	
diagnosis	and	initial	management	of	mild	
dementia51.	The	toolkit	includes	assessment	
tools,	a	data	gathering	form,	and	relevant	
Canadian	Dementia	Guidelines.	The	toolkit	
is	introduced	by	memory	clinic	specialists	
in	the	primary	care	centres.	PCPs	are	then	
encouraged	to	put	it	into	use.	A	memory	clinic	
assistant	demonstrated	use	of	the	toolkit	on	
the	first	patients.	Later	assessments	were	
conducted	jointly	and	then	independently	by	
the	non-specialists.	Assessments,	diagnoses	
and	management	plans	were	then	reviewed	with	
the	specialists.	This	performance-orientated,	
context-relevant	aspect	of	the	learning	
experience	was	highly	rated	by	participants.	
Box 2.2
Californian primary care 
practitioners attitude to diagnosing 
and managing dementia, 
compared with other chronic 
conditions 
In	three	California	healthcare	organisations,	164	
PCPs’	views	about	primary	care	for	dementia	
were	analysed	and	compared	with	views	about	
care	for	heart	disease	and	diabetes	mellitus54.	
PCPs	considered	patients	with	dementia	more	
difficult	to	manage,	were	less	likely	to	believe	
that	their	organisation	had	expertise	or	referral	
pathways	to	manage	dementia,	and	could	
provide	care	coordination,	and	were	markedly	
less	confident	that	they	could	improve	the	
quality	of	life	of	patients	with	dementia.	They	
were	more	sceptical	of	the	value	of	routine	
screening	for	dementia,	but	were	more	likely	to	
see	opportunities	for	improvement	in	their	ability	
to	manage	dementia	than	other	conditions.	
Improving	primary	care	management	of	dementia	
should	directly	address	PCP	concerns	about	
expertise	and	referral	resources,	difficulty	of	care	
provision,	and	PCP	views	about	prospects	for	
patient	improvement.
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primary	care,	more	often	they	referred	to	difficulties	in	
accessing	or	communicating	with	specialist	dementia	
diagnostic	and	support	services.	Detection	and	
diagnosis	pathways	that	rely	upon	PCPs	identifying	
cognitive	impairment,	and	then	referring	to	specialist	
teams	for	formal	diagnosis	and	dementia	sub-typing,	
and	care	planning,	depend	critically	upon	good	
communication	and	access	between	primary	care	
and	specialist	services.	Too	little	attention	has	been	
given	to	establishing,	resourcing	and	coordinating	the	
systems	of	care	that	people	with	a	timely	diagnosis	
could	access.	Meeting	this	challenge	will	need	
coordinated	and	sustained	action,	ideally	through	
the	framework	of	a	national	dementia	strategy	and	
plan53.	In	England	an	analysis	of	dementia	diagnoses	
recorded	on	primary	care	Quality	Outcome	framework	
registers	(from	2006/7	to	2011/12),	and	antidementia	
drug	prescription	rates	showed	that	both	increased	
significantly	from	2009,	with	a	4%	rise	in	2010	and	
a	12%	rise	in	201155.	Increases	in	antidementia	drug	
prescriptions	correlated	closely	with	increases	in	
diagnoses	at	district	(primary	care	trust)	level.	While	a	
direct	causal	effect	could	not	be	established,	there	was	
a	marked	change	in	trends	before	the	launch	of	the	
strategy55.	
Key	elements	of	a	strategic	approach	to	improving	
detection	and	diagnosis	of	dementia	in	primary	care	
would	include	locating	responsibility	for	dementia	
diagnosis,	care	planning	and	coordination	in	
primary	care,	and	supporting	their	ability	to	do	this	
through	case	management	(e.g.	specialist	memory	
nurses,	working	in	primary	care),	and/or	shared	(or	
collaborative)	care	in	which	primary	and	secondary	
care	services	work	together	in	a	closely	integrated	
way	to	deliver	services	according	to	an	agreed	
protocol,	with	clearly	defined	roles	and	responsibilities,	
consultation	and	referral	pathways.	In	the	UK,	PCPs	
were	much	more	likely	to	view	earlier	diagnosis	
more	favourably	when	there	had	been	supportive	
interactions	with	specialist	care	services52.	
Structured diagnostic services in primary care 
(primary care memory clinics)
There	are	several	documented	examples	of	dementia	
diagnostic	services	established	in	primary	care.	The	
rationale	for	this	approach	is,	first,	that	specialist	
memory	clinic	services,	although	greatly	expanded	
in	most	high	income	countries,	have	been	struggling	
to	meet	the	increased	demand	for	assessments,	
arising	from	ageing	populations	and	increasing	
awareness.	Second,	an	assessment	in	the	more	
familiar	environment	of	primary	care	(or,	sometimes,	at	
home)	may	be	more	convenient	and	less	challenging	
for	patients.	Third,	PCPs	are	usually	well	acquainted	
with	their	patients’	medical	and	personal	histories	
and	family	circumstances,	facilitating	assessment	of	
cognitive	decline	and	its	impacts.	Finally,	in	principle,	
equivalent	diagnostic	assessments	conducted	by	
non-specialists	should	be	cheaper	than	those	carried	
out	by	specialists,	and	hence	more	cost-effective,	
assuming	similar	levels	of	effectiveness.	Two	types	
of	model	have	been	demonstrated,	a	task-shifted	
model,	in	which	PCPs	are	responsible	for	making	the	
diagnosis,	and	task-shifted	models	in	which	this	and	
related	activities	are	shared	to	some	extent	between	
PCPs	and	specialists.
Task-shifted	primary	care	memory	clinic	models	
have	several	common	elements62.	The	assessment	
is	carried	out	in	the	primary	care	facility,	or	at	home.	
The	PCP	is	responsible	for	allocating	the	diagnosis,	
but	is	supported	by	a	nurse	practitioner,	who	may	be	
a	primary	care	practice	nurse,	or	a	specialist	‘memory	
nurse’	recruited	or	seconded	from	the	specialist	sector.	
Their	role	is,	typically,	to	coordinate	the	assessment	
process,	engage	with	the	patient	and	family,	and	to	
conduct	cognitive	and	other	evaluations.	In	effect,	their	
role	is	one	of	case	management	for	the	diagnostic	
process,	ensuring	that	the	PCP’s	time	is	used	
efficiently.	There	is	an	implicit	stepped	care	element	
to	all	of	the	services;	for	complex	cases,	specialist	
services	are	always	available	to	provide	advice	to	the	
PCP,	or	to	accept	referrals.	
Beyond	these	generic	elements,	there	are	important	
differences	between	the	service	models.	In	Ontario,	
the	Canadian	Centre	for	Family	Medicine	Family	Health	
Team	has	established	a	primary	care	memory	clinic	
essentially	along	specialist	memory	clinic	lines63.	
Referrals	to	the	clinic	are	made	by	PCPs.	There	is	
multidisciplinary	input	(PCP,	nurse,	social	worker	and	
pharmacist),	and	detailed	neuropsychological	and	
social	care	needs	assessments	are	carried	out	on	all	
patients.	After	a	structured	assessment	process	lasting	
approximately	two	hours,	diagnosis	is	reached	in	a	
multidisciplinary	consensus	meeting.	All	requirements	
of	Canadian	consensus	guidelines	on	dementia	
assessment	and	management	are	met,	including	
diagnostic,	post-diagnostic	support	and	follow-up.	A	
similar	model	was	applied	in	six	practices	in	Central	
New	South	Wales,	Australia,	where	case	identification	
using	the	GPCOG	was	followed	by	an	invitation	
for	a	formal	structured	assessment	by	a	specialist	
memory	nurse	working	in	primary	care,	comprising	
the	CAMCOG	clinical	and	cognitive	test	battery	and	
assessment	of	ADL,	quality	of	life	and	mood,	and	a	
carer	assessment.	The	mean	length	of	the	assessment	
was	around	90	minutes	for	patients	and	one	hour	for	
carers64.	Multi-disciplinary	case	discussion	and	care	
planning	with	the	primary	care	team	were	then	based	
on	assessment	findings	reported	by	the	specialist	
memory	nurse.	
In	contrast,	in	Bristol	UK,	where	primary	care	led	
dementia	services	were	piloted	in	11	of	55	primary	
care	centres	between	2012	and	2013,	and	then	rolled	
out	across	the	city,	the	dementia	diagnostic	service	
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Table 2.3  
Barriers to the diagnosis of dementia in primary care52,53
Themes Patient factors Primary care physician factors System characteristics
Lack of support 
available to patient, 
carer or PCP
Lack of knowledge about community 
support services
Lack of access to community 
support services
Limited access to secondary 
care services
Absence of multidisciplinary 
teams to enhance 
management
Perceived need for dementia 
care coordinator to assist 
with this56
Therapeutic nihilism PCPs often express the view that there 
are no available treatments or benefits 
to diagnosis, which therefore could do 
more harm than good. 
Evidence that these attitudes can lead to 
delay in timely diagnosis57,58. 
In one UK survey, in 2000 only 52% 
of PCPs felt that timely diagnosis was 
worthwhile59. 
Time constraints Not enough time ring-
fenced to carry out tests, 
assessments and reviews
Financing Patients and their families may 
struggle to afford the costs 
of specialist referral in some 
healthcare systems. 
In the US Medicare system, work 
with caregivers is not reimbursed 
unless the patient is present.
Inadequate financial remuneration 
(especially in countries where PCPs are 
paid according to services they provide).
Billing and reimbursement 
systems discourage 
adherence to care quality 
standards60. 
Payment and coding 
structures need to be 
redesigned to reflect the 
work providers need to do to 
provide high quality care. 
Stigma Concerns regarding stigma may 
be one factor deterring or delaying 
help seeking
PCP concerned about ‘labelling’, and 
often assuming that a diagnosis would 
not be wanted until so severe as to be 
self-evident
Diagnostic uncertainty Intrinsic complexity. Blurring with 
normal ageing in the early stages.
Low confidence in diagnostic ability. 
Trepidation regarding the potential 
adverse consequences of misdiagnosis
Too little training in the basic 
medical training curriculum
Disclosing the 
diagnosis
PCPs often report discomfort in doing 
this. 
Euphemistic terms are often used, or 
PCPs focus on discussing management 
with no formal diagnosis communicated. 
Diagnosis is more likely to be 
communicated to carer than patient. 
More training in this area seen by PCPs 
as a high priority61 
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is	provided	fully	integrated	within	the	normal	primary	
care	clinics,	and	diagnosis	is	reached	by	the	GP,	with	
no	multidisciplinary	input	(other	than	that	of	a	specialist	
memory	nurse)	after	an	average	of	around	four	10	
minute	appointments	with	patients	and	carers65.
Preparation,	training	and	support	to	establish	the	
services	also	differed.	In	Canada	this	comprised	a	five	
day	intensive	training	and	mentoring	program	(see	Box	
2.3).	In	Bristol	PCPs	attended	an	introductory	three	
hour	training	workshop.	Ongoing	training	and	support,	
particularly	peer	to	peer	workshops	led	by	GPs	with	a	
special	interest	were	seen	as	valuable.	
The	evaluation	of	these	three	models	has	been	
minimal,	comprising	mainly	limited	process	data	
and	qualitative	and/or	quantitative	assessment	of	
service	satisfaction	in	small	samples	of	patients	and	
their	carers63–65.	A	common	finding	across	all	three	
programs	was	that	the	primary	care	service	seemed	
acceptable	to	patients	and	carers,	and,	in	Bristol65,	
as	acceptable	as	that	provided	by	specialist	services.	
In	Ontario,	non-urgent	referrals	were	seen	within	at	
most	two	to	three	months	from	referral,	compared	
with	the	four	to	six	month	wait	time	for	a	non-urgent	
consultation	with	a	geriatrician	in	the	region63.	
Subjective	experiences	were	generally	positive;	in	
Australia,	for	example,	85%	or	more	of	patients	gave	
positive	ratings	for	the	length	of	the	examination,	
the	usefulness	of	the	assessment,	the	experience	of	
assessment,	and	their	willingness	to	recommend	the	
process	to	others64.	The	work	of	the	memory	nurse	
was	generally	highly	valued	by	patients,	carers	and	
PCPs.	In	Bristol,	both	PCPs	and	specialist	memory	
clinic	providers	raised	concerns	about	the	possibility	
of	misdiagnosis	in	primary	care,	given	the	much	more	
cursory	assessment	than	that	carried	out	by	specialist	
services,	but	this	was	not	formally	evaluated65.	In	
Ontario,	geriatricians	reviewed	assessments	of	30	
patients,	and	were	in	almost	complete	concordance	
with	diagnoses	and	management	plans63.	
The	Gnosall	Surgery	primary	care	memory	clinic	in	
the	UK	is	perhaps	the	best	documented	example	of	
a	task-shared/collaborative	care	model	for	dementia	
diagnosis67.	The	monthly	primary	care	memory	clinic	
is	supported	by	a	practice-based	nurse	case	manager	
(‘eldercare	facilitator’),	and	a	specialist	psychiatrist.	
The	PCP	reviews	initial	memory	complaints,	takes	
the	decision	to	refer	to	the	case	manager	for	further	
assessment	and	subsequently	to	refer	to	the	memory	
clinic,	reviews	the	memory	clinic	assessment	and	
agrees	a	shared	care	plan	with	the	psychiatrist.	
The	case	manager	conducts	initial	assessments,	
coordinates	the	memory	clinic,	and	is	responsible	for	
coordinating	delivery	of	the	care	plan,	liaising	with	
patient	and	family	throughout.	The	visiting	psychiatrist	
conducts	the	memory	clinic	assessment,	and	agrees	a	
shared	care	plan	with	the	PCP.	
The	main	benefits	claimed	for	this	model	were	that	
assessment	delays	are	minimised	and	attendance	
rates	are	nearly	100%68.	The	case	manager	develops	
expertise	on	the	range	of	local	services	and	how	to	
access	them.	The	surgery	has	identified	100%	of	the	
predicted	dementia	prevalence	for	the	population.	
Service	users	report	high	levels	of	satisfaction.	
Managing	the	service	in	the	familiar	environment	of	the	
GP	Health	Centre	helps	reduce	the	fear	and	stigma	
that	might	be	associated	with	attending	a	psychiatric	
clinic.	Gnosall	Surgery’s	use	of	all	secondary	
healthcare	for	all	older	patients	is	substantially	less	
than	predicted,	and	older	people	who	were	admitted	
had	shorter	lengths	of	stay.	
Box 2.3
Taking innovation to scale – the 
Canadian Centre for Family 
Medicine Family Health Team 
(CCFM-FHT) Ontario memory clinic
The	CCFM	memory	clinic	has	developed,	
implemented	and	evaluated	a	5-day	training	
program	to	assist	other	FHTs	to	implement	their	
own	primary	care	memory	clinics66.	This	targets	
the	multidisciplinary	FHT	team,	and	comprises	
a	2-day	workshop	aimed	to	increase	knowledge	
and	skill	related	to	the	assessment	and	
management	of	cognitive	impairment,	followed	
by	a	3-day	mentorship	program.	Aside	from	
didactic	training,	each	team	works	through	eight	
case	studies	of	increasing	complexity	over	the	
2-day	workshop.	Facility-specific	implementation	
issues	are	discussed,	based	upon	a	pre-
completed	online	needs	assessment	survey.	The	
mentorship	program	comprises	an	observership	
session	at	the	CCFM	memory	clinic	with	remote	
video	access	to	assessments,	and	participation	
in	the	consensus	discussions.	A	few	weeks	later,	
the	multidisciplinary	team	in	each	new	memory	
clinic	is	mentored	by	the	CCFM	team	as	they	
conduct	patient	assessments	during	the	first	
two	days	of	their	memory	clinic.	On	this	visit	a	
presentation	is	made	to	the	other	members	of	the	
FHT	explaining	the	role	of	the	new	memory	clinic	
to	encourage	“buy-in”.
Ongoing	mentorship	support	is	provided	to	
each	new	clinic	as	they	begin	to	apply	their	new	
knowledge	and	skills	to	their	practice	setting.	A	
‘community	of	practice’	has	been	established	
allowing	primary	care	memory	clinic	providers	
to	meet,	share	experiences,	problem-solve,	and	
receive	one-day	booster	sessions.	
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NHS	England	commissioned	a	review	of	three	
contrasting	diagnostic	service	models	and	their	costs,	
comparing	the	Gnossal	Surgery	model	with	a	specialist	
care	led	service	with	limited	input	from	PCPs	with	a	
‘special	interest’,	and	a	traditional	specialist	memory	
clinic68.	The	Gnosall	Surgery	model	at	an	estimated	
cost	per	patient	of	£396	was	no	more	expensive,	and	
possibly	cheaper	than	the	alternatives,	£877	and	£491	
respectively.	Following	the	success	of	the	Gnosall	
Memory	Clinic	model,	it	is	being	rolled	out	throughout	
the	district	for	163	PCPs	in	41	practices,	with	a	total	
population	of	approximately	360,000.	The	scaled	up	
service	will	require	six	case	managers,	and	a	total	
annual	budget	of	approximately	£865,00068.
Use of videoconferencing technology 
(telemedicine) for dementia diagnosis
A	randomised	controlled	trial	was	conducted	in	
Australia	to	assess	the	validity	of	diagnoses	made	
by	specialists,	remotely,	using	video	conferencing	
technology	to	interview	patients	and	carers35.	After	
receiving	a	diagnosis	based	on	face	to	face	interview,	
205	patients	referred	by	their	PCPs	to	a	memory	clinic	
were	randomised	to	receive	an	additional	consultation,	
either	face	to	face	or	by	videoconference.	Each	
specialist	physician	had	access	to	the	patient	chart	
and	the	results	of	a	battery	of	standardised	cognitive	
assessments	administered	face	to	face	by	the	clinic	
nurse.	Levels	of	agreement	for	the	videoconference	
group	(Percentage	agreement=	0.71;	weighted	Kappa	
=	0.52;	P	<	.0001)	and	for	the	face	to	face	interview	
(Percentage	agreement=	0.70;	weighted	Kappa	=	0.50;	
P	<	.0001)	were	both	statistically	significant,	and	did	
not	differ	significantly	from	each	other	(P	=	0.84).	The	
conclusion,	therefore,	was	that	the	videoconference	
diagnosis	was	not	inferior	to	face	to	face	assessment.	
Previous	studies	have	shown	that	preliminary	
standardised	cognitive	and	functional	assessment	
tools	can	also	be	reliably	administered	and	scored	via	
videoconferencing.	Remote	specialist	assessment	by	
videoconferencing	is	therefore	a	promising	technology,	
with	a	variety	of	applications,	most	particularly	to	
provide	specialist	inputs	into	primary	care	diagnostic	
services,	including	those	in	rural	and	remote	areas.	
2.5 Post-diagnostic care and support
Evidence for the quality of post-diagnostic 
care in primary care
The	importance	of	post-diagnostic	support	as	part	of	
the	continuum	of	care	has	only	recently	begun	to	be	
highlighted.	Alzheimer	Scotland’s	influential	5	Pillars	
Model69	defines	the	key	elements	as	understanding	
the	illness	and	managing	symptoms;	planning	for	
future	decision	making;	supporting	community	
connections;	peer	support;	and	planning	for	future	
care.	The	Scottish	Government’s	commitment	to	
delivering	a	minimum	of	one	year	post-diagnostic	
support,	informed	by	this	model,	does	not	appear	to	
have	led,	as	yet,	to	any	published	evaluations	of	the	
effectiveness	and	impact	of	this	complex	intervention.	
Post-diagnostic	support	requires	coordinated	input	
from	health	and	social	care	professionals,	and	it	is	
unclear	as	yet	where	in	the	system	such	services	
should	be	located.	
In	the	evaluation	of	the	Bristol	primary	care	memory	
clinics	(see	also	section	2.4	above)	there	was	evidence	
from	some	carer	and	patient	narratives	that	less	time	
was	spent	on	disclosing,	clarifying	and	discussing	
the	diagnosis	in	the	primary	care	service,	and	hence	
that	the	process	of	supporting	patients	through	the	
assessment	was	more	thorough	in	secondary	than	
in	primary	care65.	However,	post-diagnostic	support	
was	lacking	across	both	primary	and	specialist	care	
service	models,	other	than	some	signposting	to	
community	agencies,	and	advanced	care	planning65.	
Where	provided,	this	came	from	the	memory	nurses.	
No	carers	or	patients	reported	receiving	support	from	
their	GP.	There	was	a	strong	sense,	from	professionals	
as	well	as	patients	and	carers	that	the	service	was	
focused	upon	diagnosis,	with	little	structured	aftercare	
or	support.	Only	those	with	a	diagnosis	of	Alzheimer’s	
disease	were	offered	follow-up,	to	review	cognitive	
enhancer	medication.		
Evidence for the relative quality and 
outcomes of post-diagnostic care provided 
by primary care and specialist dementia care 
services
We	identified	one	randomised	controlled	trial	of	the	
relative	effectiveness	of	primary	and	specialist	care	
during	the	early	post-diagnostic	period,	the	AD-Euro	
trial	conducted	in	the	Netherlands70.	Two	hundred	and	
twenty	people	with	mild	to	moderate	dementia,	newly	
diagnosed	in	a	memory	clinic,	were	to	be	randomised	
to	receive	routine	follow-up	care	by	their	primary	care	
provider,	or	their	local	specialist	memory	clinic	service.	
This	was	a	completely	pragmatic	trial;	no	training	was	
provided	to	primary	care	providers,	and	there	were	
no	trial	protocols	to	guide	management	in	either	arm.	
However,	memory	clinic	care	in	the	Netherlands	is	
based	on	the	specialist	Dutch	Dementia	guideline	
of	the	Dutch	Institute	for	Healthcare	Improvement.	
Outcome	assessments	were	carried	out	at	6	and	12	
months;	the	main	outcomes	were	the	quality	of	life	of	
the	person	with	dementia,	measured	using	the	QoL-
AD	and	self-perceived	carer	strain	measured	using	
the	Sense	of	Competence	Questionnaire	(SCQ).	To	
establish	cost-effectiveness	a	cost-utility	analysis	was	
carried	out	using	utilities	generated	by	the	EuroQol	
instrument	(EQ-5D),	from	a	societal	perspective,	that	
is	taking	into	account	health	service	and	formal	care	
service	utilisation,	and	the	costs	of	unpaid	informal	
care.	
175	people	with	dementia	and	their	primary	carers	
were	included	in	the	trial.	Most	(84%)	of	the	trial	
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participants	had	mild	or	very	mild	dementia.	There	
were	no	significant	differences	in	the	primary	outcomes	
between	primary	care	and	memory	clinic	groups28.	
The	quality	of	life	of	the	people	with	dementia	in	the	
memory	clinic	group	was	higher	(+0.5	points,	95%	CI:	
-0.7	to	+1.6)	and	carer	strain	lower	(-2.4	points,	95%	CI:	
-5.8	to	+1.0)	than	in	the	primary	care	group.	There	were	
small	but	statistically	significant	differences	in	carer	
depression,	state	and	trait	anxiety	levels	at	12	months	
favouring	the	primary	care	group.	However,	these	
were	unlikely	to	be	clinically	significant,	and	may	have	
been	accounted	for	by	differential	loss	to	follow-up.	
No	other	secondary	outcomes	(behavioural	symptoms	
and	depression	in	the	person	with	dementia,	and	the	
quality	of	life	of	the	carer)	differed	between	the	two	
arms	of	the	trial	at	six	or	12	months	follow-up.	
In	a	subsequent	publication	the	care	inputs	were	
compared	between	the	two	arms	of	the	trial30.	This	
revealed	that,	compared	with	those	in	the	primary	care	
arm,	those	in	the	memory	clinic	arm	were	more	likely	
to	have	used	cognitive	enhancer	medication	during	
the	follow-up	period	(RR	1.56,	95%	CI:	1.18-2.07),	to	
have	information	and	explanations	provided	to	their	
carer	(RR	1.53,	95%	CI:	1.04-2.25),	and	to	have	visited	
an	Alzheimer	Café	(RR	3.10,	95%	CI:	0.96-10.09).	
There	were	no	significant	differences	in	use	of	home	
care,	day	care,	physiotherapy	or	occupational	therapy.	
Similar	proportions	in	each	arm	were	admitted	to	
nursing	home	or	residential	care.
From	a	societal	perspective,	compared	to	general	
practitioners’	care,	treatment	by	the	memory	clinics	
was	on	average	marginally	and	non-significantly	
cheaper	(-1024,	95%	CI:	-7723	to	+5674)29.	However,	
when	assessed	using	the	EQ-5D,	quality	adjusted	
life	years	were	non-significantly	lower	for	memory	
clinic	care	(-0.025	points,	95%	CI:	-0.114	to	+0.064).	
The	incremental	cost-effectiveness	point	estimate	
from	the	bootstrap	simulation	was	euro	41,442	per	
QALY	(quality-adjusted	life	year)	lost	if	one	would	use	
memory	clinic	care	instead	of	general	practitioner	care.	
The	only	cost	components	that	differed	significantly	
between	the	two	groups	were	hospital	inpatient	
admissions	and	memory	clinic	visits	(substantially	
higher	in	the	memory	clinic	arm),	and	primary	care	
visits	(higher	in	the	primary	care	arm).	However,	any	
healthcare	cost	savings	were	more	than	offset	by	
the	non-significantly	higher	cost	of	informal	care	and	
nursing	home	care	in	the	primary	care	arm.
There	are	some	weaknesses.	Although	this	was	not	
highlighted	in	the	publications,	the	trial	seems	to	have	
under-recruited,	with	175	rather	than	the	targeted	220	
patient	and	carer	dyads	included.	However,	loss	to	
follow-up	was	only	9%	against	the	projected	30%	
allowed	for	in	the	sample	size	calculations,	so	loss	of	
power	to	detect	clinically	significant	differences	should	
not	have	been	critical.	The	study	only	recruited	people	
with	dementia	diagnosed	in	memory	clinics,	with	a	
full	work	up	reported	back	to	primary	care,	which	
may	have	enhanced	the	quality	of	care	provided	by	
GPs	compared	with	those	clients	they	had	diagnosed	
themselves	without	referral	to	a	memory	clinic.	
Evaluations of interventions designed to 
enhance the quality of post-diagnostic 
support in primary care
Psychosocial interventions
We	identified	two	trials	of	psychosocial	carer	
interventions	provided	through	primary	care	services	
in	the	early	post-diagnostic	phase.	Neither	trial	showed	
evidence	of	any	benefit	for	people	with	dementia	or	
their	carers,	for	any	relevant	outcomes.	The	German	
IDA	trial	was	entirely	pragmatic,	and	although	the	
training	of	GPs	in	the	two	intervention	arms	resulted	
in	an	impressive	uptake	of	carer	counselling	and	
support22,	this	was	generally	for	only	one	or	two	
sessions,	perhaps	accounting	for	the	lack	of	evidence	
of	effectiveness23.	The	Danish	DAISY	trial	examined	the	
effect	of	multifaceted	and	semi-tailored	psychosocial	
support	for	the	person	with	dementia	and	their	
carer	for	one	year	in	the	immediate	post-diagnostic	
period.	Although	the	authors	refer	to	implementation	
problems	a	high	proportion	of	dyads	completed	the	
full	intervention	program24.	Failure	to	select	for	those	
with	unmet	needs	for	support	may	have	contributed	to	
the	clear	lack	of	clinical	and	cost-effectiveness	of	this	
intervention25,26.	
Video decision support tools for advanced care 
planning
Advanced	care	planning,	and	advanced	directives	
regarding	care	are	complicated	by	the	difficulty	that	
many	may	experience	in	comprehending	the	lived	
experience	of	late	stage	dementia.	In	the	USA,	a	
randomised	controlled	trial	was	conducted	of	the	effect	
of	adding	a	video	of	a	person	with	late	stage	dementia	
to	a	structured	narrative	describing	some	of	the	typical	
features	of	late	stage	dementia31.	The	video	depicted	a	
person	with	advanced	dementia,	living	in	a	care	home,	
who	had	lost	the	ability	to	speak	and	mobilise,	and	
needed	feeding	assistance.	After	viewing	the	video	
and	hearing	the	narrative	(intervention	group,	n=94),	
or	hearing	the	narrative	only	(control	group,	n=106),	
the	participants,	who	were	attendees	at	primary	
care	centres	aged	65	and	over,	without	moderate	or	
severe	cognitive	impairment,	were	asked	to	state	their	
preferences	for	goals	of	care	in	the	event	of	developing	
advanced	dementia.	The	options	were:	life	prolonging	
care,	limited	care,	and	comfort	care.	Life	prolonging	
care,	was	described	as	aiming	to	prolong	life	at	any	
cost.	Limited	care	was	described	as	aiming	to	maintain	
physical	functioning,	and	included	treatments	such	
as	admission	to	hospital,	intravenous	fluids,	and	
antibiotics	but	not	resuscitation	or	treatment	in	the	
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intensive	care	unit.	The	third	option,	comfort	care,	was	
described	as	aiming	to	maximise	comfort	and	to	relieve	
pain	only.	Participants	randomised	to	the	video	arm	
were	more	likely	to	select	comfort	care	(86%	vs	64%	
in	the	control	group),	and	less	likely	to	choose	either	
limited	care	(9%	vs	19%),	or	life	prolonging	care	(4%	
vs	14%).	Six	weeks	later,	decisions	made	by	the	video	
group	were	found	to	be	more	stable	than	those	made	
by	the	control	group.	Knowledge	about	advanced	
dementia,	which	was	low	at	baseline,	increased	to	a	
greater	extent	in	the	video	group	than	in	the	control	
group.	
The	study	has	limitations.	The	authors	acknowledge	
that	the	content	of	the	video	is	likely	to	impact	on	
decision	making.	The	depiction	of	only	one	example	
cannot	convey	the	range	of	living	circumstances	
and	quality	of	life	experiences	of	people	living	with	
advanced	dementia.	The	video	was	prepared	with	
an	expert	steering	group	of	medical	professionals,	
which	did	not	include	people	with	dementia	or	their	
carers.	Finally,	only	9%	of	participants	had	received	
a	diagnosis	of	dementia,	whereas,	in	clinical	practice,	
this	would	be	the	context	(post-diagnosis)	in	which	
advanced	care	planning	would	be	most	likely	to	take	
place.	Nevertheless,	the	structured	and	standardised	
manner	in	which	the	information	is	conveyed	would	
be	likely	to	have	a	useful	application	in	the	delivery	of	
contextual	information,	by	non-specialists	in	primary	
care.
2.6 Continuing care
Evidence for the quality of continuing care in 
primary care
In	the	UK	National	Health	Service,	an	annual	dementia	
review	was	introduced	into	Quality	and	Outcomes	
Framework	(QOF)	guidelines	for	primary	care,	with	
a	pay-for-performance	link	to	remuneration.	The	
review	should	comprise	an	appropriate	physical	and	
mental	health	review,	coordination	with	secondary	
care	if	appropriate,	and	an	assessment	of	impact	on	
carers,	and	carer’s	needs	for	information.	A	survey	
was	conducted	of	52	practices	in	7	primary	care	
trusts	in	Greater	Manchester.	Case-notes	of	911	
people	with	dementia,	of	whom	745	were	at	least	15	
months	post-diagnosis	and	hence	eligible	for	a	review,	
were	scrutinised	for	evidence	of	adherence	to	QOF	
guidelines71.	While	80%	of	eligible	patients	had	had	
an	annual	review,	only	51%	had	a	social	care	review,	
and	61%	a	discussion	with	carers.	Despite	a	high	
prevalence	of	vascular	comorbidity,	over	a	quarter	of	
patients	were	prescribed	antipsychotic	medication,	
usually	for	unclear	indications,	and	only	57%	of	these	
had	had	a	medication	review	in	the	past	6	months.	
Adherence	to	depression	guidelines	was	particularly	
weak.	Thus,	although	a	high	proportion	of	patients	
received	reviews,	the	quality	of	those	reviews	was	
suboptimal71.	Case	reviews	were	less	likely	to	be	
carried	out,	and	overall	quality	of	care	was	lower	
for	patients	with	vascular	dementia	as	opposed	to	
Alzheimer’s	disease,	and	for	those	registered	with	
single-handed	practices.	
In	another	publication,	the	same	research	group	
assessed	the	quality	of	primary	care	management	
of	cardiovascular	comorbidity	in	the	subset	of	700	
people	with	dementia	with	one	or	more	diagnosed	
vascular	disease	or	risk	factor72.	Quality	of	care	was	
measured	on	30	indicators	from	the	UK	Quality	and	
Outcomes	Frameworks	(QOFs)	for	hypertension,	
coronary	heart	disease,	stroke,	diabetes	mellitus,	atrial	
fibrillation,	heart	failure,	and	smoking.	These	included	
monitoring	and	control	of	risk	factors,	checking	for	
complications,	and	provision	of	evidence-based	
treatments.	Level	of	care	received	by	people	with	
dementia	was	significantly	lower	compared	with	those	
without	dementia	for	22	of	30	indicators;	most	notably	
for	measurement	processes.	Overall	quality	of	vascular	
care	was	lower	for	those	in	care	homes,	and	those	
with	fewer	comorbid	physical	conditions.	There	is	
also	evidence	from	a	smaller	and	weaker	study	in	the	
USA	that	access	to	lipid	lowering	drugs	may	be	lower	
for	people	with	dementia	than	others73.	Those	with	
dementia	had	a	much	lower	likelihood	of	taking	lipid	
lowering	drugs	in	the	previous	year	(AOR	0.39,	95%	
CI:	0.16-0.95)	after	adjusting	for	age,	sex,	education,	
visit	with	PCP	within	the	past	year,	and	clinical	and	
lifestyle	variables	that	might	be	proxies	for	need	of	
lipid	lowering	(self-reported	heart	disease,	stroke	or	
transient	ischemic	attacks,	hypertension,	smoking,	
and	alcohol	consumption).	While	this	might	reflect	a	
prescribing	bias,	the	finding	might	also	be	explained	by	
a	protective	effect	of	lipid	lowering	drugs	on	dementia	
incidence,	or	a	tendency	for	lipid	levels	to	fall	with	the	
onset	of	dementia.	
Studies comparing the quality of continuing 
care provided by non-specialist and 
specialist services 
In	Alberta,	Canada,	people	with	dementia	are	
supported	by	Primary	Care	Networks	(PCNs),	Geriatric	
Assessment	Teams	(GATs),	and	Community	Care	(CC)	
services.	Eighty-one	referrals	from	PCNs	to	a	GAT	
service	were	scrutinised	through	systematic	case	note	
reviews	for	evidence	of	adherence	to	the	guidelines	
of	the	Third	Canadian	Consensus	Conference	on	the	
Diagnosis	and	Treatment	of	Dementia74.	Sixty-nine	
of	the	patients	were	diagnosed	by	the	specialist	GAT	
service	with	dementia,	41	of	whom	had	also	had	a	
diagnosis	recorded	by	the	PCP	(sensitivity	59%).	
Compared	to	the	GAT	service,	the	PCN	service	was	
significantly	less	likely	to	have	carried	out	cognitive	
testing,	assessed	activities	of	daily	living,	assessed	
BPSD,	assessed	decision	making	capacity,	explored	
driving	status,	or	wandering,	assessed	capacity,	
explored	advanced	care	planning,	assessed	caregiver	
coping	or	strain,	or	referred	to	community	care	
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services.	Other	than	assessing	capacity	and	carer	
strain,	guideline	targets	were	met	in	nearly	all	cases	
assessed	by	specialist	GAT	services.	
In	a	recent	USA	study	of	unmet	carer	needs,	307	
patient-carer	dyads	were	surveyed	upon	referral	
to	a	dementia	care	program75.	Only	32%	of	carers	
reported	confidence	in	managing	dementia-related	
problems,	while	19%	knew	how	to	access	support	
from	community	services,	and	these	proportions	did	
not	vary	significantly	according	to	source	of	referral.	
However,	those	referred	by	geriatricians	were	more	
likely	(42%)	than	an	internist	or	family	practitioner	
(13%)	or	a	neurologist	or	psychiatrist	(16%)	to	
agree	that	their	provider	helped	them	work	through	
dementia	care	problems.	There	was	no	difference	
in	carer	strain,	carer	depression,	carer	self-efficacy	
score,	or	behavioural	and	psychological	symptoms	
according	to	type	of	referring	provider.	Compared	
with	those	managed	by	PCPs	or	geriatricians,	carers	
of	individuals	referred	by	neurologists	or	psychiatrists	
also	less	frequently	agreed	that	the	individual’s	regular	
doctor	understood	how	dementia	complicates	other	
health	conditions,	that	they	had	received	advice	about	
handling	dementia-related	problems	or	about	what	
to	expect	in	the	future,	and	that	they	were	aware	of	
services	to	help	provide	care.
Surveys	of	management	decisions	in	response	to	
vignettes	of	agitated	people	with	dementia	were	
conducted	on	small	samples	of	primary	care	
physicians,	geriatric	psychiatrists,	and	neurologists	
in	North	Carolina76,77.	This	work	was	conducted	in	
the	mid-1990s,	casting	some	doubt	on	the	current	
relevance	of	the	findings.	PCPs	were	less	likely	to	
recommend	access	to	a	dementia	support	group	and	
respite	day	care	than	others,	while	neurologists	were	
more	likely	to	recommend	nursing	home	placement	
than	all	other	groups.	All	groups	saw	neuroleptic	
medication	as	the	first	line	of	treatment	(55%),	while	
only	22%	recommended	psychosocial	interventions.	
Evaluations of innovations designed to 
enhance the quality of continuing care in 
primary care
Educational interventions
Systematic	reviews	concur	that	educational	
interventions	targeting	primary	care	providers,	on	their	
own,	generally	have	no	discernible	impact	on	guideline	
adherence	or	evidence-based	management8,12,22.	
Improvements	in	care	quality	were	only	seen	in	one	
trial,	where	primary	care	provider	education	was	
coupled	with	ongoing	case	management	support	
integrated	into	primary	care16.
Case management
We	identified	five	randomised	controlled	trials	of	case	
management	interventions	centred	around	primary	
care14–16,19,20	(see	also	Table	2.2b),	and	three	controlled	
trials	without	randomisation78–81.	See	also	Chapter	3	for	
a	broader	review	of	case	management	interventions.
Each	of	the	randomised	controlled	trials	indicated	at	
least	some	relevant	benefits.	These	included	higher	
rates	of	detection	of	dementia19,	improved	adherence	
to	management	guideline	recommendations15,16,	
(limited)	evidence	of	benefits	for	people	with	
dementia15,16,	lower	carer	depression	and/or	strain14,15	
or	unmet	needs	for	carer	support16,	and	a	lower	
rate	of	nursing	home	placement20.	Findings	were	
not,	however,	consistent	among	studies,	perhaps	
attributable	to	differences	in	the	design,	targeting	
and	degree	of	implementation	of	the	intervention.	
One	salient	issue	may	be	the	extent	to	which	the	
additional	case	management	support	is	effectively	
integrated	with	and	supportive	of	the	delivery	of	
primary	healthcare,	and	community	social	care18.	
In	one	trial,	dementia	care	consultants	provided	by	
Alzheimer’s	Association	chapters	seemed	to	have	
worked	relatively	independently,	and	care	plans	
faxed	to	PCPs	were	rarely	discussed	with	patients	or	
carers20.	Home	based	assessment	for	specific	carer	
needs	and	linkage	to	community	care	organisations	
seemed	to	be	critically	important	for	improvement	in	
carer	mastery82.	Critically,	none	of	the	trials	of	primary	
care	case	management	included	an	assessment	of	
the	cost-effectiveness	of	the	interventions	provided.	
In	the	most	comprehensive	assessment	of	service	
utilisation,	there	was	no	effect	on	utilisation	of	primary	
care	or	hospital	healthcare	services,	but	generic	
case	management	and	health	promotion	services	
provided	by	the	primary	care	provider	were	used	less	
often,	presumably	since	this	service	was	provided	
more	effectively	by	the	dementia	case	manager14.	
Reduction	in	unmet	caregiving	assistance	and	more	
assistance	from	community	agencies,	as	noted	in	the	
ACCESS-Trial	would	imply	higher	costs,	alongside	
potential	benefit16.	The	ongoing	German	DELPHi-MV	
trial	will	be	the	first	to	assess	the	cost-effectiveness,	
alongside	the	efficacy	and	efficiency	of	implementing	
a	support	system	initiated	and	coordinated	by	a	nurse	
dementia	care	manager	for	persons	with	dementia	
who	live	at	home83.	Primary	outcomes	are	quality	
of	life,	behavioural	and	psychological	symptoms	of	
dementia,	pharmacotherapy,	and	carer	strain,	and	
a	comprehensive	evaluation	of	cost-effectiveness	is	
planned.	
In	a	study	conducted	in	two	community-based	primary	
care	practices,	the	effectiveness	of	nurse-practitioner	
co-management	compared	with	management	by	
PCP	alone	was	studied,	specifically	for	patients	with	
comorbidities81.	The	care	approach	for	all	patients	
was	based	on	the	Assessing	Care	of	Vulnerable	Elders	
(ACOVE)-2	model:	case	finding,	delegation	of	data	
collection,	structured	visit	notes,	physician	and	patient	
education,	and	linkage	to	community	resources.	
458	patients	aged	75	and	older	screened	positive	
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for	at	least	one	condition:	falls,	urinary	incontinence,	
dementia,	and	depression.	Half	had	received	nurse-
practitioner	co-management.	Quality	of	care	was	
assessed	against	ACOVE-3	quality	indicators,	using	
medical	record	review.	Quality	scores	for	all	conditions	
(falls,	80%	vs	34%;	UI,	66%	vs	19%;	dementia,	59%	
vs	38%)	except	depression	(63%	vs	60%)	were	
significantly	higher	for	patients	who	were	co-managed	
by	a	nurse	practitioner.	The	program	for	people	with	
dementia	comprises	a	dementia	registry,	structured	
needs	assessments	of	individuals	in	the	registry	and	
their	caregivers,	individualised	dementia	care	plans	
that	are	monitored	and	revised,	and	open	access	for	
support	and	advice84.	For	150	people	with	dementia,	
the	most	common	recommendations	in	the	initial	care	
plans	were	referrals	to	support	groups	(73%)	and	
the	Alzheimer’s	Association	(73%),	caregiver	training	
(45%),	and	medication	adjustment	(41%).
The	US	Partners	in	Dementia	Care	(PDC)	program78,79	
involves	a	collaboration	between	Veterans	Affairs	
(VA)	Medical	Centers	and	Alzheimer’s	Association	
chapters,	to	support	veterans	with	dementia	living	
in	the	community	and	receiving	primary	care	from	
the	VA,	and	their	caregivers.	Care-coordination	
provided	by	care	coordinators	from	the	VA	health	
system	working	in	tandem	with	coordinators	from	the	
Alzheimer’s	Association	social	care	support	system.	
The	VA	Medical	Centers	had	primary	responsibility	for	
health	concerns	(medication	management,	accessing	
healthcare	services	and	using	them	effectively,	disease	
management),	whereas	the	care	coordinator	from	
the	Alzheimer’s	Association	chapter	had	primary	
responsibility	for	assisting	carers	with	social	care	
concerns	(carer	strain,	accessing	family	support	and	
information	services	and	using	them	effectively).	
The	aim	was	to	integrate	healthcare	and	community	
services	while	strengthening	the	informal	care	network	
and	providing	information,	coaching,	and	emotional	
support	to	caregivers.	The	program	targeted	both	
patients	and	carers.	PDC	was	evaluated	in	a	controlled	
trial	in	which	five	matched	communities	were	allocated	
to	PDC	(two	sites)	or	treatment	as	usual	(three	sites)	
with	outcomes	assessed	at	6	and	12	months.	The	initial	
sample	was	508	veterans	with	diagnosed	dementia,	
and	486	carers.	PDC	veterans	had	significantly	less	
adverse	outcomes	than	those	receiving	usual	care	
(including	reduced	relationship	strain,	depression	
and	unmet	needs,	and	less	embarrassment	about	
memory	problems)	particularly	for	more	impaired	
veterans	after	six	months,	with	further	improvements	
noted	to	12	months79.	Intervention	group	carers	had	
significant	improvements	in	unmet	needs,	carer	strain,	
depression,	and	support	resources	through	to	six	
months	with	more	limited	improvements	in	the	second	
six	months	of	follow-up78.	
A	pragmatic	quasi-experimental	controlled	study	of	
case	management	supplementing	care	provided	by	
PCPs	was	carried	out	in	the	Netherlands	from	2011-
201380.	In	2008,	the	Dutch	Ministry	of	Healthcare	had	
stipulated	that	case	management	had	to	be	part	of	
usual	care	for	persons	with	dementia	in	all	regions	
by	the	end	of	2011.	At	the	end	of	this	roll-out	period,	
the	investigators	compared	outcomes	for	521	people	
with	dementia	and	their	carers,	over	a	two-year	
follow-up	period,	for	regions	where	case	management	
had	still	not	yet	been	implemented	(control	group,	
n=73),	compared	with	regions	implementing	two	
different	models	of	case	management.	These	were	
intensive	case	management	(CM)	provided	by	a	single	
organisation	specialising	in	dementia	care	(n=234),	
and	linkage	case	management	where	health	and	social	
care	agencies	collaborate	to	appoint	case	managers	
authorised	to	work	across	the	entire	system	(n=214).	
Case	managers	in	the	intensive	CM	systems	generally	
worked	full-time,	whereas	those	in	the	linkage	CM	
systems	worked	part-time	integrating	this	work	
with	another	role	such	as	a	district	nurse.	Average	
caseloads	were	similar;	53.9	patients	(SD	23.3)	for	
linkage	CM	and	61.6	(SD	16.7)	for	intensive	CM.	
There	were	no	differences	among	the	three	groups	
in	behavioural	and	psychological	symptoms,	carer	
psychological	morbidity,	transition	into	a	care	home,	
or	mortality.	Carer	quality	of	life	scores	were	higher	for	
intensive	CM	than	linkage	CM	recipients.	Intensive	CM,	
but	not	linkage	CM,	was	associated	with	fewer	total	
needs,	met	and	unmet	care	needs	compared	with	the	
control	group.	
In	a	recent	systematic	review	of	case	management	
for	dementia	in	primary	care,	the	authors	identified	
likely	effective	components,	linked	to	a	concept	of	
‘high	intensity	case	management’85.	This	comprised;	
a	caseload	of	fewer	than	50	patients	per	fulltime	
equivalent	case	manager;	regular	meetings	with	the	
informal	carer	and	the	person	with	dementia,	at	least	
half	of	which	should	be	face	to	face;	education	on	
health	conditions	and	self-management;	close	contact	
with	the	PCP;	proactive	and	timely	follow-up;	and	
follow-up	with	patients	during	hospitalisations	and	
short-term	admissions	to	care	homes.
The	results	of	an	evaluation	of	an	attempt	to	integrate	
case	management	into	routine	primary	care	in	the	
UK	(the	EVIDEM	project86,87)	illustrates	the	problems	
encountered	when	case	managers’	previous	
experience	is	insufficiently	orientated	to	the	role,	
when	there	is	not	enough	protected	time	allocated	
to	the	case	management	role,	and	where	there	is	no	
clear	mandate	to	case	manage	across	all	relevant	
services.	As	the	investigators	candidly	pointed	out	
‘little	case	management	took	place’87,	with	low	levels	of	
recruitment,	few	meetings	with	people	with	dementia	
and	their	carers,	missed	opportunities	to	identify	and	
address	unmet	needs,	and	almost	no	interaction	with	
other	services86.	
38
Psychosocial interventions for carers
A	recent	systematic	review	identified	three	evaluations	
of	psychosocial	interventions	for	supporting	carers	
of	people	with	dementia,	delivered,	as	part	of	
continuing	care,	in	the	primary	care	setting88.	Two	were	
randomised	controlled	trials21,27	(see	also	Table	2.2c),	
and	one	an	uncontrolled	pre-	post-implementation	
assessment	of	a	translation	of	proven	intervention	
model	into	routine	primary	care89.	In	contrast	to	carer	
support	interventions	delivered	in	the	immediate	post-
diagnostic	phase,	these	continuing	care	interventions	
generally	show	evidence	of	benefit.	
A	small	RCT	conducted	in	two	Spanish	primary	care	
facilities	indicated	quite	impressive	effects	of	group	
cognitive	behavioural	therapy,	administered	in	primary	
care	by	a	psychologist	with	non-specialist	primary	care	
staff	co-therapists	on	carer	psychological	morbidity	
and	dysfunctional	thoughts27.	The	Resources	for	
Enhancing	Alzheimer’s	Caregiver	Health	(REACH)	trial	
conducted	in	the	Veteran’s	Administration	(VA)	health	
system	in	the	USA	demonstrated	that	supplementing	
patient	behaviour	management	training	with	carer	
stress	coping	was	associated	with	better	general	
well-being	and	a	non-significant	trend	towards	
reduced	depression	symptoms21.	The	REACH	II	
randomised	controlled	trial	later	provided	evidence	of	
efficacy	for	a	much	more	intensive	multicomponent	
behavioural	intervention	for	dementia	caregivers	using	
education,	support,	and	skills	training	to	address	
safety,	social	support,	problem	behaviours,	carer	
depression,	and	health90.	Subsequently,	in	the	REACH	
VA	study,	the	REACH	II	model	was	implemented	in	
the	primary	care	context	in	24	VA	Medical	Centers	in	
15	states89.	53	staff	members,	mainly	social	workers,	
psychologists	or	nurses	performed	the	interventions,	
with	127	carers	enrolled	at	the	24	facilities.	The	
intervention	comprised	nine	one-hour	individual	
home	sessions,	three	half-hour	individual	telephone	
sessions,	and	five	one-hour	monthly	telephone	support	
group	sessions.	From	baseline	to	six	months,	carers	
reported	significantly	decreased	burden,	depression,	
impact	of	depression	on	daily	life,	caregiving	
frustrations,	and	number	of	troubling	dementia-related	
behaviours.	However,	the	standardised	effect	sizes,	
while	statistically	significant	were	small	(0.22-0.33).	
There	were	no	statistically	significant	changes	in	carer	
general	health	or	social	support,	or	safety	for	the	
person	with	dementia.	No	information	is	provided	on	
the	uptake	of	the	intervention	or	coverage	achieved,	
and	there	was	no	cost-benefit	analysis.	The	large	
majority	of	carers	who	participated	(96%)	believed	that	
the	program	should	be	provided	by	the	VA	to	all	carers.
Use of technology
Baseline	data	from	227	people	who	had	screened	
positive	for	dementia	from	the	DELPHi-MV	intervention	
group	and	received	a	standardised	computer-assisted	
needs	assessment,	indicated	a	high	number	of	
unmet	needs	with	over	90%	having	three	or	more	
unmet	needs,	particularly	in	the	domains	of	“nursing	
treatment	and	care”	(38%),	“social	counselling	and	
legal	support”	(20%),	and	“pharmacological	treatment	
and	care”	(15%)91.	The	computer-assisted	needs	
assessment	is	linked	to	a	rule-based	decision	support	
system	that	supports	the	compilation	of	the	individual	
intervention	plan	by	suggesting	corresponding	specific	
interventions	to	the	general	practitioner.	Its	introduction	
in	the	intervention	group	was	associated	with	an	
85%	increase	in	the	number	of	specific	interventions	
recommended	to	the	GPs92.			
A	study	conducted	among	PCPs	in	Canada,	examined	
the	effect	of	a	Driving	and	Dementia	Toolkit	on	
knowledge,	confidence	and	anticipated	change	
in	patient	assessment93.	The	toolkit	comprised	
background	information	on	the	topic,	information	on	
local	resources	and	how	to	access	them,	a	guide	to	a	
screening	assessment	of	older	drivers’	safety,	and	a	list	
of	frequently	asked	questions.	The	toolkit	was	made	
available	online	and	in	printed	format.	Knowledge	
and	confidence	increased	significantly	for	most	of	the	
toolkit	content	questions.	There	was	also	a	clear	intent	
on	the	part	of	study	participants	to	begin	including	
additional	pertinent	questions	in	the	patient/carer	
interview	when	assessing	a	patient’s	fitness	to	drive.	
Satisfaction	ratings	with	the	toolkit	rated	an	average	of	
8.4/10.	
2.7 Summary and discussion
Primary	healthcare	services	have	always	played	an	
important	role	in	dementia	care,	and	will	continue	
to	do	so.	The	questions	addressed	in	this	scoping	
review	have	to	do	with	assessing	the	quality	of	the	
care	provided	across	the	care	pathway,	comparing	
care	quality	and	its	outcomes	for	non-specialist	and	
specialist	care,	and	identifying	promising	avenues	for	
enhancing	the	quality	of	care	provided	in	primary	care.	
A	secondary	set	of	questions	arise	from	the	evidence	
presented	in	this	section	of	the	report.	What	should	
be	the	role	of	primary	care?	Can	this	and	should	this	
be	made	more	explicit?	Is	there	scope	for	tasks	and	
activities	carried	out	by	specialist	services	to	be	shifted	
towards	or	shared	with	non-specialists	at	the	primary	
care	level?
It	is	important	to	note	that	the	sections	of	this	chapter	
that	address	the	quality	of	care	provided	by	primary	
care	and	compare	this	with	specialist	care	describe	
in	essence	the	status	quo,	in	which	the	roles	and	
responsibilities	of	primary	care	with	respect	to	
dementia	care	have	generally	not	been	explicitly	
defined,	where	basic	curriculum	and	in-service	training	
has	been	limited,	and	when	care	processes	are	not	
supported	by	evidence-based	clinical	guidelines	or	
care	pathways.	In	this	respect,	the	sections	of	this	
chapter	that	describe	strategies	to	enhance	the	quality	
of	care	and	its	outcomes	are	particularly	relevant.	
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There	is	no	doubt	that	dementia	is	currently	under-
detected,	under-diagnosed,	under-disclosed,	under-
treated	and	under-managed	in	primary	care53.	That	
having	been	said,	where	PCPs	do	take	responsibility	
for	dementia	care	there	is	at	least	some	evidence	to	
suggest	that	this	is	not	notably	inferior	in	its	outcomes	
to	that	provided	by	specialists,	even	though	care	
processes	may	be	less	scrupulously	adhered	to.	
There	is	evidently	much	scope	for	improvement,	with	
some	well	evaluated	examples	of	system	and	service	
level	innovations	to	support	a	more	prominent	role	of	
primary	care	services	in	diagnosis,	post-diagnostic	and	
continuing	care.		
Recognition	of	dementia	in	primary	care	can	be	
boosted	by	in-service	education	and	training,	which	
seeks	to	alter	attitudes	and	perceptions	as	well	as	
provide	technical	skills,	and	that	has	a	practice-based	
component	with	specialists	guiding	and	mentoring	
non-specialists	to	assume	the	responsibility	for	
recognition	and	diagnosis.	Indicated	screening	using	
cognitive	tests	can	support	timely	diagnosis	by	
responding	to	concerns	raised	by	patients	and	carers.	
However,	general	screening,	of	all	older	attendees	or	
all	those	registered	to	a	primary	care	service	cannot	
currently	be	recommended,	and	should	not	be	carried	
out,	in	advance	of	more	research	evidence	on	benefits,	
harms	and	cost-effectiveness.	There	are	several	
successful	examples	of	memory	clinics	established	
in	primary	care,	and	run	by	PCPs	supported	by	
nurse	practitioners.	A	key	issue	here	may	be	whether	
dementia	diagnosis	is	a	task	that	is	explicitly	
recognised	as	within	the	capacity	of	non-specialist	
services	–	a	recent	review	of	guidelines53	suggest	that	
Canada	may	be	unique	in	asserting	that	the	typical	
presentations	of	the	most	common	types	of	dementia	
can	be	accurately	diagnosed	by	PCPs,	even	in	the	
early	stages	of	the	disease,	with	clinical	evaluation,	
brief	cognitive	testing,	basic	laboratory	tests,	and	
structural	neuroimaging,	as	appropriate.	It	may	be	
for	that	reason	that	some	of	the	more	innovative	
approaches	to	scaling	up	primary	care	diagnosis	
are	currently	originating	from	that	country51,63,66,94.	
In	England,	local	commissioning	practices	have	now	
given	rise	to	some	diverse	task-shifted	and	task-shared	
diagnostic	service	models.	Of	note,	the	Gnossal	
Surgery	model,	while	primary	care-based	still	requires	
all	diagnoses	to	be	made	by	a	specialist	psychiatrist67.	
We	could	find	no	studies	that	had	explicitly	compared	
the	accuracy	of	diagnoses	made	by	non-specialists	
and	specialists.	Such	studies	should	focus	on	mild	
dementia,	where	diagnostic	uncertainty	is	greatest,	
and,	given	the	lack	of	a	gold	standard	(with	modest	
levels	of	diagnostic	agreement	between	specialists35)	
should	determine	the	predictive	validity	of	diagnoses	
made	by	specialists	and	non-specialists,	assessing	
whether	diagnosed	cases	progress	in	impairment	
and	needs	for	care95.	There	is	also	a	need	for	more	
research	to	be	carried	out	into	good	practice	for	
diagnostic	disclosure,	ensuring	a	‘diagnosis	well	
made’	with	respect	to	appropriate	information,	clearly	
delivered,	anticipating	and	addressing	negative	
impacts,	and	signposting	sources	of	support.	It	is	
unclear	whether	or	how	this	can	be	achieved	in	primary	
care.	Several	studies	indicate	underperformance,	and	
a	need	for	more	training	and	support	for	this	important	
activity.	
The	post-diagnostic	phase	is,	in	principle,	an	important	
phase	of	the	care	pathway,	bridging	from	the	‘diagnosis	
well-made’	to	a	system	of	continuing	care	and	support	
in	the	context	of	declining	cognitive	and	functional	
abilities	and	increasing	need	for	care	and	support.	This	
phase	was	the	focus	for	the	only	randomised	controlled	
trial	that	compared,	in	the	Netherlands,	post-diagnostic	
dementia	care	services	provided	by	non-specialists	
in	primary	care	with	those	provided	by	specialists	
from	memory	clinic	services70.	The	results	of	this	
‘non-inferiority’	trial	were	largely	reassuring	in	that	the	
outcomes	of	the	care	provided	by	PCPs	were	no	worse	
than	those	for	care	provided	by	specialists28,	and	
costs	were	similar29.	However,	some	care	processes	
were	more	commonly	adhered	to	by	specialists	(anti-
dementia	medication,	information	provided	to	carer,	
and	referral	to	community	support)30.	The	tentative	
conclusion	was	that	models	of	care	during	this	phase	
could	be	determined	by	the	preferences	of	people	
with	dementia	and	carers,	and	regional	and	national	
policy	priorities.	The	potential	benefits	of	the	full	range	
of	post-diagnostic	support	activities	(as	for	example	
advocated	by	Alzheimer	Scotland	in	their	‘5	pillars’	
model)	have	yet	to	be	evaluated.	However,	the	results	
of	two	large	randomised	controlled	trials	conducted	
in	Germany23	and	Denmark24	are	concerning	in	
this	regard.	In	contrast	to	a	large	body	of	evidence	
suggesting	that	psychosocial	education,	training	
and	support	interventions	are	moderately	effective	in	
improving	carer	outcomes,	no	benefits	for	either	the	
person	with	dementia	or	the	carer	could	be	identified	
from	their	implementation	in	the	early	post-diagnostic	
phase,	and	the	interventions	were	not	cost-effective.	
Post-diagnostic	support	needs	to	be	thought	
through	carefully,	since	needs	and	preferences	will	
vary	considerably	among	people	with	dementia	and	
their	carers	during	this	phase.	It	may	be	that	service	
responses	need	to	be	more	bespoke	and	targeted,	
based	upon	assessment	and	monitoring,	rather	than	
seeking	to	deliver	a	uniform	post-diagnostic	care	
pathway	for	all.	
There	is	ample	evidence	that	primary	care	services	
struggle	to	deliver	high	quality	continuing	care	for	
people	with	dementia,	even	in	systems	where	their	
role	has	been	made	more	explicit,	such	as	through	
the	UK	Quality	Outcomes	Framework71,72,	and	the	
Canadian	Consensus	Conference	on	the	Diagnosis	
and	Treatment	of	Dementia74.	It	is	also	clear	that	
educational	interventions	alone	have	no	discernible	
impact	on	guideline	adherence	and	evidence	based	
management.	Case	management	interventions	
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do,	however,	seem	to	offer	some	promise	in	that	
regard15,16.	Case	management,	when	delivered	with	
appropriate	intensity,	with	a	clear	mandate	to	work	
across	health	and	social	care	services,	and	by	case	
managers	with	appropriate	skills	and	enough	time	
to	focus	on	care	management	activities,	can	deliver	
better	outcomes	for	carers	and	(less	consistently)	
people	living	with	dementia.	In	the	primary	care	
context	case	managers	can	act	as	a	task-shifting,	
capacity	increasing	device,	freeing	up	the	PCP	from	
time-consuming	routine	assessment,	education	and	
support,	and	care	coordination	activities.	
However,	despite	much	high	quality	research	over	the	
last	15	years,	important	questions	remain	unanswered.	
1.			Is	case	management	cost-effective?	Although	an	
increase	in	the	efficiency	of	care	is	a	key	objective	
of	case	management,	the	relevant	outcomes	have	
not	been	assessed	in	most	studies.	This	would	
require	an	evaluation	of	avoidance	of	undesirable,	
unnecessary	or	potentially	harmful	patterns	of	
service	utilisation	(for	example	duplication	of	care,	
emergency	department	attendance	and	avoidable	
hospital	admissions	–	see	also	Chapter	4),	and,	
crucially,	an	economic	evaluation	of	the	cost-
effectiveness	of	the	intervention.	Most	of	the	models	
evaluated	imply	either	the	creation	of	a	new	cadre	of	
specialist	case	managers,	or	the	partial	diversion	of	
part-time	case	managers	from	their	primary	roles	in	
the	system.	There	are	therefore	cost,	resourcing	and	
service	planning	implications.	Most	of	the	models	
evaluated	are,	in	effect	demonstration	studies,	and	
we	do	not	yet	know	whether	they	could,	or	should	
be	taken	to	scale.	
2.			What	type	of	case	manager,	and	what	model	
of	case	management	works	best?	There	is	
considerable	variability	in	the	models	that	have	been	
evaluated,	and	much	uncertainty	as	to	which	would	
be	optimal.	Common	sense	would	suggest	that	
the	ability	to	focus	full-time	on	case	management	
would	limit	distractions,	and	lead	to	a	more	rapid	
acquisition	of	role	competencies,	and	there	is	some	
indirect	evidence	from	the	studies	we	reviewed	
to	support	this.	The	primary	location	of	the	case	
manager	within	the	health	system	may	be	a	critical	
factor,	and	this	varies	between	studies,	probably	
reflecting	the	prevailing	dementia	care	models	in	
the	countries	concerned.	Thus,	in	the	USA,	case	
managers	were	located	either	within	the	health	
system	(sometimes	from	specialist	services,	but	
more	usually	in	the	primary	care	sector	of	a	Health	
Maintenance	Organization),	or	a	voluntary	sector	
care	provider	(e.g.	the	Alzheimer’s	Association),	
or	both.	In	the	Netherlands,	two	models	seem	to	
have	come	about,	one	providing	intensive	case	
management	from	a	specialist	dementia	care	
service	provider,	and	the	other	case	management	
commissioned	from	a	consortium	of	health	and	
social	care	providers	including	primary	care,	but	
primarily	located	in	a	variety	of	sectors80.	In	the	UK,	
there	has	been	particularly	strong	interest	in	a	model	
of	case	management	located	in	primary	care52,86,96.	
Case	management	integrated	in	primary	care	clearly	
has	appeal	when,	as	in	England,	this	is	the	location	
of	the	register	of	all	of	the	diagnosed	cases,	and	
when	the	whole	population	is	registered	to	a	single	
primary	care	provider.	If	dementia	care	coordination	
were	to	be	a	mandated	role	for	primary	care,	then	
the	capacity	of	the	service	to	deliver	this	would	be	
greatly	increased	if	supported	by	co-management	
by	PCPs	and	case	managers.	
3.			How	can	information	technology	support	the	
implementation	of	case	management?	Health	
information	systems	to	support	effective	case	
management	are	often	alluded	to	as	challenges	
in	the	studies	described,	but	with	few	explicit	
examples	or	evaluations	of	innovations.	Such	
technologies	can	be	used	to	structure	assessments,	
support	decision-making,	facilitate	caseload	
management,	and	monitor	and	improve	adherence	
to	guidelines,	service	standards	and	care	pathways.	
A	critical	issue	in	the	coordination	of	care	across	
services	is	the	ability	to	access	and	share	
information	across	providers78,79.
4.			At	which	phase	or	phases	of	the	condition	would	
case	management	be	most	effective	and	most	
indicated,	and	would	the	model,	content	and	
delivery	of	case	management	need	to	be	modified	
for	specific	subgroups?	Most	evaluated	case	
management	programs	recruited	community-
dwelling	older	people	with	dementia,	without	
regard	to	disease	type	or	stage,	and	some	have	
excluded	those	without	an	identifiable	primary	
informal	caregiver.	None	have	stratified	their	findings	
according	to	patient	subgroups.
5.			Should	case	management	(particularly	at	the	level	of	
primary	care)	be	provided	for	frail	and/or	dependent	
older	people	in	general,	or,	in	programs	specifically	
constructed	for	people	with	dementia?	The	former	
approach	might	be	more	effective	in	promoting	the	
integrated	delivery	of	holistic	and	person-centred	
healthcare.	Dementia	and	cognitive	impairment	
are	highly	prevalent	in	this	patient	group,	and	make	
the	greatest	contribution	to	functional	impairment,	
needs	for	care,	and	complexity	in	delivering	health	
and	social	care.	Case	management	can	be	effective,	
and	cost-effective97,98.	While	such	evaluations	are	
not	usually	stratified	by	disorder,	positive	benefits	
have	been	shown	for	the	identification	of	dementia19,	
and	for	meeting	dementia	care	quality	indicators81.	
On	the	other	hand,	it	is	often	emphasised,	correctly,	
that	dementia	is	‘not	just	another	diagnosis’,	but	
one	with	particularly	profound	implications	for	the	
intensity	and	orientation	of	future	care41,99.	As	such,	
perhaps	people	with	dementia	need	access	to	case	
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management	services	with	specialist	knowledge	
and	skills,	and	adequate	resources	to	meet	their	
complex	needs.				
Throughout	the	literature	on	healthcare	management	
of	dementia,	there	is	surprisingly	little	focus	on	the	
integrated	care	of	physical,	mental	and	cognitive	
comorbidities,	with	the	effective	care	of	chronic	
physical	conditions	particularly	neglected.	This	
limitation	appears	to	be	pervasive.	There	is	clear	
evidence	for	a	high	prevalence	of	multimorbidity100,	
some	evidence	of	more	limited	access	to	treatment	
and	monitoring	for	diabetes	and	eye	care100,	and	sub-
optimal	management	in	primary	care	of	cardiovascular	
disease	and	its	risk	factors72.	However,	as	was	
noted	in	a	recent	scoping	review	on	management	of	
comorbidities	
“Less	is	known	about	service	organisation	and	
delivery	or	the	views	and	experiences	of	people	
with	dementia	and	their	family	carers…	There	
is	a	need	for	more	research	looking	at	the	ways	
in	which	having	dementia	impacts	on	clinical	
care	for	other	conditions	and	how	the	process	
of	care	and	different	services	are	adapting	to	the	
needs	of	people	with	dementia	and	comorbidity.	
People	with	dementia	should	be	included	in	the	
debate	about	the	management	of	comorbidities	
in	older	populations	and	there	needs	to	be	greater	
consideration	given	to	including	them	in	studies	
that	focus	on	age-related	healthcare	issues”100.
A	review	of	dementia	clinical	guidelines	highlights	their	
general	lack	of	applicability	to	older	patients	among	
whom	multimorbidities	are	particularly	common101.	
While	most	of	the	guidelines	considered	the	specific	
needs	of	older	persons,	only	60%	reported	evidence-
based	treatment	recommendations	for	one	or	more	
comorbidity,	and	only	32%	considered	multiple	
morbidities.	Education	and	training	programmes	
for	PCPs,	to	the	extent	to	which	they	include	
aspects	of	continuing	care,	seem	to	give	little	or	
no	attention	to	the	challenges	of	delivering	holistic,	
person-centred	care	to	people	with	dementia	and	
multimorbidities8,12,13.	Case	management	interventions	
attend,	to	varying	degrees,	to	physical	health	through	
medication	management,	promoting	self-management	
and	healthy	behaviours,	and	encouraging	efficient	use	
of	healthcare	services.	However,	the	health	outcomes	
considered	are	generally	dementia-specific.
While	the	focus	of	this	chapter	has	been	upon	the	
role	that	is,	and	could	be,	played	by	generalists	in	
primary	care,	thought	also	needs	to	be	given	to	the	
optimal	role	of	specialists	within	a	more	task-shifted	
and	task-shared	model	of	care	provision.	Neurologists,	
psychiatrists	and	geriatricians	play	an	important	part,	
to	varying	degrees	in	different	health	systems,	in	
delivering	diagnostic,	post-diagnostic	and	continuing	
care	services.	Dementia	care	is	a	sub-speciality	
area	for	all	three	of	these	medical	disciplines,	and	
not	all	such	specialist	clinicians	will	have	the	relevant	
experience,	knowledge	and	skills.	This	may	be	
particularly	true	for	low	and	middle	income	countries	
with	less	well	developed	specialist	dementia	care	
systems102.	
For	those	that	have	developed	these	skills	(which	are	
not	formally	accredited	in	most	systems),	there	is	often	
a	tacit	assumption	that	neurologists,	psychiatrists	and	
geriatricians	have	equivalent	competencies	across	the	
comprehensive	range	of	assessment	and	management	
activities	that	might	be	required.	This	seems	
improbable,	and	some	of	the	studies	identified	in	this	
review	highlight	differences	in	management	styles	and	
care	quality	between	the	three	groups.	Geriatricians	
might	be	expected	to	be	particularly	competent	at	
assessing	and	managing	complex	multimorbidities;	
psychiatrists	at	assessing	and	managing	behavioural	
and	psychological	symptoms,	and	neurologists	at	
making	difficult	diagnoses,	identifying	rare	neurological	
disorders,	and	distinguishing	other	forms	of	primary	
brain	disease.	Of	course,	there	are	also	likely	to	be	high	
levels	of	generic	skills	shared	among	all	three	groups.	
Within	a	more	task-shifted	model	of	dementia	
healthcare,	it	would	make	sense	for	much	of	the	
activity	where	specialist	expertise	is	generic	among	
the	three	disciplines	to	be	taken	on	by	non-specialists	
in	primary	care,	while	ensuring	that	the	relevant	
specialist	expertise	is	sought	for	particular	assessment	
and	management	problems.	Task-shifted	models	of	
care	require	specialist	support,	both	while	they	are	
being	established	(design,	training	and,	in	effect,	
handing	over	the	task),	and	continuously	thereafter	
(referral,	supervision,	mentoring	and	support).	
Within	a	resource-limited	system,	this	requires	some	
modification	of	specialist	roles	and	responsibilities,	
away	from	frontline	patient	care,	and	towards	capacity-
building	activities.	In	low	and	middle	income	countries,	
where	specialist	care	is	underdeveloped,	and	the	
diagnosis	and	treatment	gap	is	most	pronounced,	
the	specialist	care	sector	workforce	will	need	to	
be	strengthened,	numerically	and	in	terms	of	skills	
development	to	take	on	this	role.	In	HIC,	there	may	
be	potential,	over	time,	to	decommission	and/or	
reorientate	some	components	of	specialist	care	
services,	to	the	extent	that	task-shifted	primary	care-
based	services	are	proven	to	provide	cost-effective	
care	of	equivalent	quality.	This	is	not	yet	a	relevant	
consideration	for	most	LMIC.	At	the	same	time,	
policymakers	in	these	settings	should	treat	calls	for	
investment	in	western	models	of	specialist	orientated	
care103,104	with	due	caution.	The	belief	reported	by	
one	specialist	in	an	article	in	The	Hindu	newspaper	
in	India,	that	dementia	management	“…	is	done	best	
by	qualified	professionals	(including	neurologists	and	
psychiatrists	trained	in	dementia	care)	in	memory	
clinics”104	requires	careful	and	critical	examination,	
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particularly	with	respect	to	the	need	to	scale	up	access	
to	these	services.	
In	Chapter	7	we	present	the	results	of	a	cost-modelling	
exercise	comparing,	in	HIC,	the	cost	implications	of	
scaling	up	dementia	healthcare	services	for	people	
with	dementia	in	HIC	for	more	and	less-task	shifted	
systems	of	service	delivery,	and	for	LMIC	assessing	
the	costs	of	scaling	up	task-shifted	systems	of	care.	
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chapter 3 
care coordination and case management 
for people with dementia
Care coordination, through case management, has 
been presented as a means of improving care and 
reducing costs. The Case Management Society of 
America (CMSA) describes case management as 
“a collaborative process of assessment, planning, 
facilitation and advocacy for options to meet an 
individual’s health need through communication and 
available resources to promote quality cost-effective 
outcomes”1. 
Case management has numerous potential benefits 
for people with dementia: reducing the burden of the 
disease; managing the evolution of needs over the 
disease course; facilitating access to services; and 
providing advice (including decision-making regarding 
end of life). Over the last decades, research on case 
management has been conducted within primary care 
and specialist care settings, and in the community, 
studying its effect on outcomes for people with 
dementia, their carers, and service utilisation. Case 
management for people with dementia and their carers 
has been advocated in dementia care strategies 
or national Alzheimer’s Plans in several countries 
including Australia2, England3, France4, Denmark5 or 
Mexico6 (see http://www.alz.co.uk/alzheimer-plans for 
the full list). 
3.1 Objectives and search strategy
We carried out a review of recent research evidence 
regarding the effectiveness of case management, 
wherever it is located within the health and social 
care system, with respect to outcomes for people 
with dementia and their carers, and evidence for 
improved efficiency of delivery of health and social 
care. We were interested in a wide range of outcomes, 
including, for the person with dementia (quality of 
life, behaviour, mortality), the carer (quality of life, 
strain, mood), and for service use (hospitalisation, 
transfer into a care home, and overall costs). All 
types of relevant research were of interest, especially 
systematic reviews and randomised controlled trials 
(RCTs). 
We conducted a scoping review in order to map the 
existing literature, using the following search strategy. 
We used the search terms ‘dementia OR 
Alzheimer’s disease’ AND ‘case management OR 
care management OR care coordination’, seeking 
papers published from 1980 onwards. We searched 
Ovid Medline, PubMed, PsycINFO and Cochrane 
databases. Following this, a search with the use of 
Google Scholar was conducted to find ‘grey’ literature 
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and articles in other databases than those mentioned 
above (reports and policy papers).
Inclusion criteria
•	 Studies	with	a	clear	focus	or	relevance	to	case	
management	and	care	coordination
•	 A	clear	focus	on	older	people	with	dementia,	
Alzheimer’s	disease,	or	cognitive	impairment
•	 English	language	resources
Exclusion criteria
•	 A	focus	on	older	people	rather	than	on	people	with	
dementia	
•	 Editorials,	Opinion	pieces	
3.2 Search results, and characteristics 
of the eligible studies
Overall, the search retrieved 5,007 abstracts. First, 
we excluded 3,048 publications after review of titles 
and abstracts, which were duplicates, conference 
abstracts and other non-relevant abstracts. The 
remaining 1,959 abstracts were double screened 
by MK and MG for relevance. After reviewing titles 
and abstracts, and hard copies if necessary, 90 
publications were identified as meeting our inclusion 
criteria.  
Among	those	publications,	17	were	reviews	
(qualitative,	quantitative,	or	mixed),	16	described	
case	management	approaches,	32	described	RCTs	
of	the	effectiveness	of	case	management,	and	25	
provided	other	relevant	evidence	on	implementation	of	
case	management	programmes	using	study	designs	
other	than	RCTs.	Randomised	controlled	trials	were	
mainly	conducted	in	High	Income	Countries	(n=26,	
including	the	United	States	of	America,	Canada,	the	
United	Kingdom,	Finland,	and	the	Netherlands)	and	
most	of	the	case	management	interventions	included	
care	coordination	as	well	as	support	programmes,	
counselling	or	education	(n=25).	
3.3 What is the evidence to 
support case management (cost-) 
effectiveness?
The number of reviews on case management is 
now substantial. In addition to the two reviews7,8 
described in previous World Alzheimer Reports9,10, we 
identified four more recent reviews from the current 
search11-15. Although overlapping in terms of the 
individual studies included, these reviews have come 
to differing conclusions about the effectiveness of 
case management. 
Following the CMSA definition of case management, 
Pimouguet et al.7 reviewed a total of 12 trials 
focussing on the efficacy of case management for 
community dwelling people with dementia and their 
carers in terms of healthcare costs, institutionalisation 
and hospitalisation. Among those, only four reported 
a positive impact of case management on time to 
transfer into a care home, duration of care home 
admission, or care home admission rate. The evidence 
was considered too weak to allow any conclusion 
regarding the efficacy of case management for people 
with dementia and their carers on costs and resource 
utilisation. Somme et al.8 conducted a more restricted 
review on the impact of case management programs, 
that include case identification, standardised 
multidimensional assessment, and the development, 
implementation, and monitoring and reassessment 
of an individualised care plan, on clinical outcomes 
and utilisation of resources by people with dementia. 
Only six RCTs (also identified in the first review7) were 
included, of which four reported moderately significant 
effects on clinical outcomes or resource utilisation. 
The authors highlighted that the degree of integration 
between health and social service organisations and 
the intensity of case management appeared to be 
related to greater efficacy. Each of these reviews7,8 
were descriptive and did not perform any meta-
analyses. 
After systematic review, a meta-analysis conducted 
by Tam-Tham et al.13 pooled the effects of 17 RCTs 
to evaluate the effectiveness of dementia case 
management compared with usual care on reducing 
long-term care placement, hospitalisation, and 
emergency department visits, and on delaying time 
to long-term care placement and hospitalisation. The 
overall pooled relative risk (RR) of long-term care 
placement estimated was not significant (RR=0.94, 
95% CI: 0.85-1.03, p=0.227) for dementia case 
management compared to usual care. However, when 
follow-up duration was below 18 months, a significant 
reduction in risk of long-term care placement was 
found (RR=0.61, 95% CI: 0.41-0.91, p=0.015). No 
significant effect of dementia case management was 
found on hospitalisation and emergency department 
visits. It was therefore concluded that dementia case 
management showed only a short-term positive effect 
on long-term care placement among older people with 
dementia living in the community and that other types 
of resource utilisation needed further investigation.
More recently, Reilly et al.15 in a Cochrane review 
on case management approaches to home support 
for people with dementia highlighted that ‘case 
management’ is often used fairly approximately in the 
literature and is usually defined in a multifaceted way. 
Their review was therefore guided by the definition 
of case management as ‘any intervention delivered 
in the community (not in hospital or residential care 
settings) predominantly focused on the planning 
and co-ordination of care required to meet the 
identified needs of the person with dementia’. The 
primary objective was to evaluate the effectiveness 
of case management approaches to home support 
47ImprovIng healthcare for people lIvIng wIth dementIa
alzheImer’s dIsease InternatIonal: world alzheImer report 2016
Country
UK (London)
Author
Hinchliffe31
Year
1995 (Year of publication 
not year of study)
Intervention
Individualised care 
package for the carer and 
the person with dementia, 
including medication, 
psychological technique, 
and social measures.
Care management 
tasks: assessment, care 
planning, implementation/
management of care 
plan, arranging/allocating 
services, case closure 
(discharged back to the 
GP)
Care manager: planning 
by multidisciplinary 
team, implementation by 
psychiatrist
Duration: 4 months. N=22
Control
Waiting list, received 
a delayed intervention 
package at 16 weeks.
Follow-up
4 and 8 months
Participant Outcomes
Neuropsychiatric 
symptoms.
Carer Outcomes
General Health, Change in 
mental health.
Main Results 
Improvement in 
behavioural difficulties 
of the participant and 
improvement in carer’s 
mental health after 
intervention.
Study, Country
Medicare Alzheimer’s Disease Demonstration, USA
Author
Newcomer, Yordi, Shelton & Miller18-20, 32-34
Year
1997-2001 (Years of publication)
Intervention
Two case-management models:
- Model A (low reimbursement – high caseload) – sites 
operated with a target case-manager-to-client ratio of 1:100 
and had a monthly community service reimbursement limit or 
cap from USD290 through USD489 per month per participant
- Model B (high reimbursement – low caseload) – sites 
operated with a target case-manager-to-client ratio of 1:30 
and a slightly higher reimbursement limit of from USD430 
through USD699 per month per participant
Care management tasks: assessment, care planning, 
implementation/management of care plan, arranging/
allocating services, case budget management/budget holding, 
monitoring the implementation of the care plan. Large 
orientation to assessment, client monitoring, care planning 
and situational problem-solving.
Care manager: nurses, social workers, mental health 
professionals, gerontology specialists
Duration: Unclear – Demonstration operational December 
1989 -November 1994. N=4151
Control
Usual care. N=3944
Follow-up
6, 12, 18, 24 and 36 months
Participant Outcomes
Mortality, Home entry rates, Use of home care services, Day 
care use, Assisted living housing use, Annual mean number of 
emergency department visits, Medicare expenditures.
Carer Outcomes
Burden, Depression, Annual mean number of hospital 
admissions, Annual mean length of hospital stay.
Main Results 
Greater likelihood of community service use.
Small reduction in caregiver burden and depression over 36 
months after intervention for some sites.
No effect on nursing home entry rates for treatments overall.
Lower likelihood of any hospitalisation during the study 
period for caregivers in the intervention. For those who 
were hospitalised, no significant differences in the number 
of caregivers’ hospitalisations, hospital length of stay, or 
Medicare payments.  
Country
Canada
Author
Chu29
Year
2000 (Year of publication)
Intervention
Early Home Care Program - 
includes case management, 
occupational therapy physical 
therapy social work, nursing, 
respiratory therapy in-home 
respite, and out-of-home 
respite, homemaking, 
personal care assistance, 
volunteer service and 
psychiatric consultation
Care management tasks: care 
planning, implementation/
management of care 
plan, arranging/allocating 
services, monitoring the 
implementation of the care 
plan
Care manager: social worker, 
occupational therapist, nurse
Duration: 18 months. N=37
Control
Information package on 
community resources. N=38
Follow-up
3, 6, 10, 14 and 18 months
Participant Outcomes
Well-being, Cognition, 
Activities of Daily Living, 
Neuropsychiatric Symptoms, 
Number using services, 
Length of time participants 
remained in the community.
Carer Outcomes
Well-being.
Main Results 
Caregivers in the treatment 
group felt less burdened at 
six months, Institutionalisation 
was delayed for patients (with 
mild to moderate impairment) 
in the treatment group
Table 3.1  
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Study, Country
Effects of supporting community-
living demented patients and their 
caregivers, Finland
Author
Eloniemi-Sulkava22
Year 
2001
Intervention
Programme of systematic, 
comprehensive support by 
a dementia family care co-
ordinator who had access to the 
physician and co-ordinated the 
care, services and support of the 
families.
Care management tasks: 
assessment, care planning, 
implementation/management of 
care plan, arranging/allocating 
services
Care manager: registered nurse 
with public health background and 
extensive training
Duration: 2 years. N=53
Control
Usual services (community care 
by municipal social and healthcare 
system or private). N=47
Follow-up
1 and 2 years
Participant Outcomes
Cognition (MMSE), Death at 
home, Placement in long-
term institutions, Time to 
institutionalisation / maintenance 
of community residence.
Carer Outcomes
Burden.
Main Results 
Rate of institutionalisation 
was significantly lower in the 
intervention group during the first 
months.
Benefit of the intervention 
decreased with time.
Study, Country
Cleveland Alzheimer’s managed care 
demonstration, USA (Ohio)
Author
Bass, Clark & Judge16, 35, 36
Year
2003 (Year of publication)
Intervention
Telephone-based care consultation 
delivered within a partnership between 
a managed care health system and an 
Alzheimer’s Association
Case management tasks: assessment, 
care planning, implementation and 
monitoring of care plan.
Care manager: care consultants/
assistants
Duration: 12 months. N=94
Control
Usual managed care services. N=63
Follow-up
12 months
Participant Outcomes
Depression, Cognition, Satisfaction 
with services, Use of services, Hospital 
admissions, Physician visits, Emergency 
department visits.
Carer Outcomes
Strain and depression, satisfaction with 
types of services.
Main Results 
Decrease in selected but not all, service 
utilisation, and decrease in caregiver 
depression.
Effects of the intervention intensified for 
satisfaction outcomes and care-related 
strain outcomes.
Reduced feeling of embarrassment and 
isolation for intervention participants.
Fewer physician visits, less emergency 
department visits or hospital admissions, 
higher satisfaction with managed care 
services, and decreased depression and 
strain for intervention participants.
Study, Country
Dementia Care Management Programme, 
Hong Kong SAR China
Author
Chien27
Year
2005-2006
Intervention
Dementia care management programme 
(educational and supportive group for 
carers)
Care management tasks: Assessment, 
care planning, implementation and 
monitoring of care plan
Care manager: case manager (who 
received 32 hours of formal training) with 
a nurse
Duration: 6 months. N=44
Control
Standard care with 6 months educational 
sessions. N=44 
Follow-up
6 months
Participant Outcomes
Cognition (MMSE), Neuropsychiatric 
symptoms, Length of institutionalisation 
over past 6 months to a residential 
care home or hospital unit at 6 and 12 
months, Length of institutionalisation to a 
residential care home or hospital unit, Use 
of services, Institutionalisation over past 
6 months.
Carer Outcomes
Quality of Life, Burden, Social support.
Main Results 
Over the 12-month follow-up period:
Participants in the dementia care 
program showed significantly greater 
improvements in symptoms and 
institutionalization rates,
Caregivers reported significantly greater 
improvements in quality of life and 
burden.
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Study, Country
Care Management for Patients With 
Alzheimer Disease and Their Family 
Caregivers, USA (Indianapolis)
Author
Callahan17
Year
2006
Intervention
Collaborative care management
Case management tasks: case finding, 
assessment, financial assessment, care 
planning, implementation and monitoring 
of care plan, arranging/allocation of 
services, review, case closure.
Care manager: geriatric nurse practitioner
Duration: 12 months. N=84
Control
Augmented usual care. N=69
Follow-up
6, 12 and 18 months
Participant Outcomes
Cognitive functioning, Neuropsychiatric 
symptoms, Depression, Activities of Daily 
Living, Cholinesterase inhibitor use, 
Healthcare use (physician or nurse visits), 
Numbers died, Number of admissions 
to hospital, to nursing home, Length of 
hospital stay.
Carer Outcomes
Mood, Satisfaction of Primary Care.
Main Results 
Intervention patients were more likely 
to receive cholinesterase inhibitors and 
antidepressants, and had significantly 
fewer behavioural and psychological 
symptoms of dementia.
Intervention caregivers reported 
significant improvements in distress and 
showed improvement in depression.
No group differences were found for 
depression, cognition, activities of daily 
living, or on rates of hospitalisation, 
nursing home placement, or death.
Study, Country
ACCESS-Trial, USA (California)
Author
Vickrey, Duru & Chodosh21, 37, 38
Year
2006 (Year of publication)
Intervention
Chronic care model and linkages with community resources 
and multi-agency co-ordination, including dementia care 
managers, formal procedures for communication within and 
between organisations and agencies, included adherence to 
23 dementia guideline recommendations, Internet-based care 
management, collaborative care planning with carers, carer 
self-management support, on-going follow-up and provider 
education.
Care management tasks: case finding/screening, assessment, 
care planning, implementation/management of care plan.
Care manager: social workers who received formal training
Duration: 18 months or until case closed or no longer enrolled 
in programme. N=238
Control
Usual care. N=170
Follow-up
12, 18 months
Participant Outcomes
Cognition (MMSE), Behaviour, Quality of life, Cholinesterase 
inhibitor use, Service use at 18 months, Institutionalisation/
nursing home stays, Hospital admissions/inpatient utilisation, 
Emergency department visits, Use of one or more community 
services.
Carer Outcomes
Quality of life, Social support, Number of participants in 
carer support group, Informal caregiving hours per month, 
Healthcare in the home per month, Confidence in care-giving, 
Mastery, Satisfaction, Adherence to guidelines, Knowledge 
about dementia.
Main Results 
Patient health-related quality of life, overall quality of patient 
care, caregiving quality, social support, and level of unmet 
caregiving assistance needs were better for participants in the 
intervention group. Caregiver health-related quality of life did 
not differ between the 2 groups.
No significant differences in the mean monthly cost of 
healthcare and caregiving services for intervention versus 
usual care patients.
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Study, Country
Dementia Family Care 
Programme, Hong Kong SAR 
China
Author
Chien26
Year
2007-2009
Intervention
Case manager assigned 
to families – home visits, 
health and educational needs 
assessment, education about 
dementia, support programme 
for effective dementia care
Case management tasks: 
assessment, care planning, 
implementation and monitoring 
of care plan
Care manager: nurse
Duration : 6 months. N=46
Control
Routine care. N=46
Follow-up
1 week, 12 and 18 months
Participant Outcomes
Cognition (MMSE), 
Neuropsychiatric symptoms, 
Family Caregiving Burden, Social 
support, Utilisation of services, 
Length of institutionalisation to a 
residential care home or hospital 
unit.
Carer Outcomes
Quality of Life.
Main Results 
Participants in the intervention 
group reported significantly 
greater improvements in 
clients’ symptoms and 
institutionalisation rates, and 
caregivers’ quality of life and 
burden, at 18-month follow-up.
Country
India (Goa)
Author
Dias30
Year
2008 (Year of publication)
Intervention
Stepped-care model aiming at 
improving awareness an knowledge 
of carers regarding dementia, 
providing emotional support to 
carers, to maximise their care-
giving resources and improve care-
giving skills
Care management tasks: case 
finding, implementation and 
monitoring of care plan
Care manager: Healthcare assistant 
(trained for a week), supervised by 
psychiatrists and counsellor
Duration: 6 months minimum. N=41
Control
Only education and information 
regarding dementia. Placed on 
waiting list to receive intervention 
after 6 months.
Follow-up
3 and 6 months
Participant Outcomes
Functional ability, Neuropsychiatric 
symptoms.
Carer Outcomes
Mental health, Burden
Main Results 
Significant reduction of mental 
health and neuropsychiatric 
symptoms in the intervention group.
Non-significant reductions in the 
burden, functional ability and 
neuropsychiatric symptoms. Non-
significant reduction in the total 
number of deaths in people with 
dementia in the intervention arm.
Study, Country
Multicomponent Support Program for Elderly 
Couples with Dementia, Finland
Author
Eloniemi-Sulkava23
Year
2009
Intervention
Family care co-ordinator, geriatrician’s medical 
investigations and treatments, goal-oriented 
support group meetings for spouse carers and 
individual tailored services.
Care management tasks: case finding/screening, 
assessment, care planning, implementation/
management of care plan, arranging/allocating 
services.
Care manager: trained public health registered 
nurse with extensive training
Duration: maximum 24 months. N=63
Control
Usual services (community care by municipal 
social and healthcare system or private). N=62
Follow-up
6, 12 and 24 months
Participant Outcomes
Functional ability (12 months), Neuropsychiatric 
symptoms (12 months), Numbers and % of deaths 
of people with dementia, number and % of people 
institutionalised, Costs of municipal healthcare 
and social care services (total Euros per year), 
Time to institutionalisation, Use and cost of 
services from intervention budget.
Carer Outcomes
Burden, Number of deaths
Main Results 
At 1.6 years, a larger proportion in the control 
group than in the intervention group was in long-
term institutional care.
At 2 years, the difference was no longer 
statistically significant. Intervention led to 
reduction in use of community services and 
expenditures. When the intervention costs were 
included, the differences between the groups 
were not significant.
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Study, Country
MIND (Maximising Independence at 
Home) Pilot, USA (Baltimore)
Author
Samus & Tanner39, 40
Year
2008-2010
The MIND study was ‘awaiting 
classification’ in the Cochrane review15
Intervention
Care coordination – individualised care 
planning, referral and linkage to services, 
provision of dementia education and skill 
building strategies, care monitoring by an 
interdisciplinary team.
Care management tasks: case finding/
screening, assessment, care planning, 
implementation/management of care 
plan.
Care manager: non-clinical community 
workers
Duration: 18 months. N=74
Control
Augmented usual care. N=114
Follow-up
4.5, 9, 14.5 and 18 months
Participant Outcomes
Neuropsychiatric symptoms, Depression, 
Quality of life, Time to transfer from home, 
Unmet care needs.
Carer Outcomes
Burden, Depression, Carer unmet needs, 
Quality of life.
Main Results 
Significant delay in time to transition from 
home in the intervention group.
Significant reductions in the proportions of 
unmet needs and significant improvement 
in quality of life in the intervention group.
No difference in the percentage of 
caregiver unmet needs, nor caregiver 
depression, burden or quality of life.
Study, Country
Effectiveness of case management 
among older adults with early symptoms 
of dementia and their primary informal 
caregivers, Netherlands
Author
Jansen25
Year
2011 (Year of publication)
Intervention
Case management delivered by district 
nurses who had a co-ordinating function 
consisting of assessment, giving advice 
and information, planning, co-ordination, 
organising collaboration and monitoring 
of care.
Care management tasks: assessment, 
care planning, implementation/
management of care, arranging/allocating 
services, monitoring the implementation 
of the care plan.
Care manager: district nurse
Duration: 12 months. N=54
Control
Usual care. N=45
Follow-up
6 and 12 months
Participant Outcomes
Quality of life, Number institutionalised, 
Number died, Mean number of days in 
hospital per month, Use of primary care, 
Use of services.
Carer Outcomes
Quality of life, Psychological well-being, 
Burden, Sense of competence.
Main Results 
No statistically significant and clinically 
relevant differences over time between 
the two groups.
Table 3.1 (continued)  
Randomised controlled trials relevant to care coordination/case management approaches for people with dementia living at home
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for people with dementia from the perspective of 
the patients, carers and staff compared with other 
forms of treatments (including treatment as usual, 
standard community treatment and other non-case 
management interventions). All relevant RCTs and 
economic evaluations including both people with all 
types of dementia and their carers were included. 
A total of 13 randomised studies including 9615 
participants were eligible for inclusion, four from the 
US16-21, four in Europe22-25, three in Hong Kong26-
28, one in Canada29 and one in India 30. Most of the 
studies 16-23, 25, 26, 28, 29 had a duration of 12 months or 
more while the longest lasted three years18-20. Case 
managers were employed from various professional 
groups. Three studies were based in primary care 
centres 17, 21, 25 and case managers were based 
in dementia resource centres in two studies26,27. 
Almost all trials included face-to-face visits or home 
visits22-27,30; only one reported solely telephone-based 
case management delivered within a partnership 
between a managed care system and an Alzheimer’s 
Association16. See Table 3.1 for the full description 
of those studies (intervention, control group, care 
management tasks, and outcomes). After assessment 
of the risk of bias, it was concluded that all were 
subject to performance bias as in any psychosocial 
intervention with non-blinded participants or case 
managers. However, the overall risk of detection bias 
(blinding of outcome assessors) was low. 
The	main	results	of	the	meta-analyses	are	summarised	
below.	
•	 People	in	the	case	management	group	were	
significantly	less	likely	to	be	institutionalised	at	
6	months	(OR	0.82,	95%	CI:	0.69-0.98)	and	18	
months	(OR	0.25,	95%	CI:	0.10-0.61).	The	effects	
at	10-12	months	(OR	0.95,	95%	CI:	0.83-1.08)	or	
24	months	(OR	1.03,	95%	CI:	0.52-2.03)	were	not	
significant.
•	 One	trial27	showed	a	significant	reduction	in	the	
number	of	days	per	months	in	a	residential	home	or	
hospital	unit	in	the	case	management	group	at	six	
months	(mean	difference	-5.80,	95%	CI:	-7.93	to	
-3.67),	12	months	(mean	difference	-7.70,	95%	CI:	
-9.38	to	-6.02)	but	not	18	months	(mean	difference	
0.17,	95%	CI:	-0.92	to	+1.26).	However,	another	
trial23	reported	no	significant	difference	between	
the	two	groups	regarding	time	to	transition	into	a	
care	home	(HR	0.66,	95%	CI:	0.38-1.14).
•	 No	difference	was	found	in	the	odds	of	
hospitalisation	at	six	months	(OR	1.06,	95%	CI:	
0.61-1.84),	12	months	(OR	0.87,	95%	CI:	0.59-1.30)	
or	18	months	(OR	0.76,	95%	CI:	0.53-1.10).
•	 No	significant	effects	were	found	on	mortality	
among	people	with	dementia	at	4-6,	12,	18-24	or	
36	months.
•	 No	significant	effects	were	found	on	the	quality	of	
life	of	the	person	with	dementia	or	carer	at	4-6,	12,	
18-24	or	36	months.
•	 Some	evidence	of	benefit	for	carer	strain	was	
found	at	six	months	(standardised	mean	difference	
-0.07,	95%	CI:	-0.12	to	-0.01)	but	this	would	not	
be	considered	clinically	significant,	and	there	was	
no	evidence	of	longer	term	benefit.	Additionally,	
case	management	was	found	effective	at	reducing	
behaviour	disturbances	at	18	months	in	two	trials	
(standardised	mean	difference	-0.35,	95%	CI:	
-0.63	to	-0.07,	p=0.01).
•	 A	greater	improvement	in	carer	depression/
mood	measures	at	18	months	(standardised	
mean	difference	-0.08,	95%	CI:	-0.16	to	-0.01,	
p=0.03)	was	found	in	the	case	management	group.	
However,	this	effect	is	small	and	unlikely	to	be	of	
clinical	significance.	
•	 Some	evidence	was	found	regarding	reduced	
cost	of	services	at	12	months	(standardised	mean	
difference	-0.07,	95%	CI:	-0.12	to	-0.01)	in	two	
trials	and	incurred	lower	dollar	expenditure	for	the	
total	three	years	(mean	difference	-705.00,	95%	CI:	
-1170.31	to	-239.69,	p=0.003)	in	one	trial.	
The overall conclusions of this review were that there 
is some evidence that case management is beneficial 
for both the person with dementia and their carer 
at improving some outcomes at certain time points. 
However, the heterogeneity between interventions, 
outcomes measures and length of follow-up across 
the 13 included RCTs was important. 
Two additional studies39-41 were identified by Reilly 
et al. during their systematic review. One study 
was ongoing in the UK41 at the time and showed 
that the model of case management evaluated was 
unlikely to be sustainable in general practice under 
current conditions. A definitive trial was therefore not 
recommended. The second study, the Maximising 
Independence at Home (MIND) pilot randomised 
trail39,40 assessed whether dementia care coordination 
delays time to transition from home, reduces unmet 
needs in older people with memory disorders and 
reduces caregiving burden in informal carers. Details 
of the study are included in Table 3.1. The study 
included around 300 community-living older people 
and their carers in Baltimore, who were followed 
for 18 months. Participants randomised to case 
management had significant delay in time to all-cause 
transition from home, and the adjusted risk of leaving 
home was decreased by 37% compared to the control 
group (HR 0.63, 95% CI: 0.42 to 0.94). Significant 
reductions in the proportions of unmet needs in safety 
and legal/advance care domains were also found in 
the intervention group. However, unmet carer needs 
declined in both groups, and there was no statistically 
significant difference between groups. Improvement 
in quality of life for intervention participants was 
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reported39. No difference was found in most carer 
burden measures, depression or quality of life. Only a 
modest clinically-meaningful impact on informal carer 
time spent with the care recipient was found40. 
Further evidence on the effectiveness of case 
management in primary care has been provided by 
controlled trials without randomisation42-45  and one 
RCT focusing on carer outcomes only46, as described 
in the case management section of Chapter 2 (see 
section 2.6). Whether the intervention was comprised 
of care management by a nurse-practitioner45, a 
collaboration between Veterans Affairs Medical 
Centers and Alzheimer’s associations42,43  or case 
management supplementing usual care44, all of these 
studies showed a positive effect on at least some 
relevant outcomes, including comorbidities, adverse 
events, unmet needs, carer strain, depression, 
behavioural and psychological symptoms, transition 
into care homes, and mortality. The RCT reporting 
on the efficacy of an individualised dementia care 
consultation intervention for family carers of people 
with dementia living in the community46 also showed 
positive effects on nursing home admission and carer 
outcomes. 
Case management is only one model of support for 
people living with dementia and their carers. Earlier 
this year, Goeman et al.14 conducted a systematic 
review on the effectiveness of a support worker 
role for people with dementia and their carers. This 
review covered all the of the models of support 
for community-dwelling people with dementia and 
their carers including case managers, care workers, 
counselling support and multi-team integrated care. 
36 studies were included and carefully described. 
The heterogeneity of the studies and high risk of bias 
impeded meta-analyses. The essential components 
shared by support models with a positive effect 
on carer strain and quality of life were: long term 
interventions, face to face contact, individualised 
education and support based on needs, multi-
disciplinary teams, health service/clinical background 
of support workers, ongoing follow-up and inter-
professional and inter-sectoral collaborations. A lack 
of cost-effectiveness studies was highlighted by the 
authors.
If positive effects on participant’s and carer’s 
outcomes have been demonstrated in some trials 
(controlled or not) and meta-analyses, the evidence 
on the cost-effectiveness of case management 
interventions for people with dementia and their carers 
remains very weak because of lack of evidence. In 
Reilly et al.’s review15, only three studies reported 
data on healthcare costs18, 21, 23 . Another systematic 
review from Knapp and colleagues47 on dementia care 
costs and outcomes found little economic evidence 
on the cost-effectiveness of non-pharmacological 
interventions for people with dementia, especially 
strategies focussing on care organisation and support 
such as direct payments or case management. 
Long term studies of cost-effectiveness of case 
management interventions were suggested. Recently, 
new evidence from the ‘Partners in Dementia 
Care’ (PDC) intervention (a telephone-based care 
coordination and support service delivered through 
partnerships between Veterans Health Administration 
medical centers and local Alzheimer’s Association 
chapters) in the United States was published48. This 
cost analysis of the PDC intervention in a 30-month 
trial involving five VHA medical centers aimed at 
examining whether PDC reduced direct Veterans 
Health Administration (VHA) healthcare costs 
compared with usual care. A total of 434 veterans 
aged 50 and older with dementia and their carers 
and 165 controls were included. During the study, 
intervention participants showed higher VHA costs 
than usual-care participants both before and after 
the intervention but they did not differ significantly 
regarding change in costs from pre- to post-baseline 
periods. The conclusion was that PDC met veterans’ 
needs without significantly increasing VHA healthcare 
costs. 
3.4 Implementation of case 
management 
Case management has been designed to increase the 
capacity of Primary Healthcare (PHC) to cope with the 
complex needs of people with dementia, to improve 
the quality of dementia care, and to develop cost-
effective and efficient ways to coordinate services1. 
Although effectiveness has been demonstrated in 
some studies, implementation of case management 
programmes can be challenging49. A mixed-methods 
review from Khassanov et al.50 sought to identify the 
conditions limiting and facilitating successful case 
management implementation in PHC. As already 
reported in Chapter 2 (see section 2.6), low intensity, 
large caseload and approach have impeded the 
implementation of case management interventions. 
Two recent qualitative studies provide further insight 
into the facilitators and barriers to the delivery of 
case management for people with dementia51,52. In 
the UK, the CAREDEM feasibility study assessed 
the introduction of a successful United States’ 
case management model to primary care17,53. The 
intervention was delivered by a social worker and 
nurses, and comprised needs assessment of the 
person with dementia and their carers, creation 
of a personal care or support plan, prioritisation 
and initiation of actions to provide support, and 
a systematic follow-up of the plan and actions. 
Interviews were carried out with case managers, 
people who had dementia, carers and health and 
social care professionals before, during and after 
introduction of case management. A lack of clarity 
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over the nature and scope of case management from 
case managers and practices and a lack of resources, 
skills and training to deliver the intervention, variable 
investment in the intervention and limited reflection 
and feedback on the case manager role were 
identified as key barriers to implementation52. Case 
managers had difficulties identifying and acting on 
unmet needs of people with dementia and their 
carers, with limited training and supervision to remedy 
this skills gap. Most stakeholders considered case 
management worthwhile but all expressed a lack 
of clarity over the remit of case managers and their 
overlap with existing roles. Primary care teams were 
not engaged and case managers provided little 
feedback on the approach to members of the primary 
care team52. 
In the Netherlands, a qualitative evaluation was 
conducted of the implementation of two different 
case management models; the linkage model 
(a network in which multiple case management 
providers are active and the case manager acts 
as a mediator between the client and the multiple 
care agencies) and the combined intensive case 
management/joint agency model (a network in which 
case management and care services are nested in 
one independent organisation)51. Semi-structured 
interviews were performed with case managers, 
project leaders, health insurers and municipalities. 
Implementation was facilitated in the intensive model 
by the independence of the case management 
organisation while the presence of multiple competing 
case management providers in the linkage model 
impeded the implementation. Impeding factors were 
more prominent in the linkage model, related to the 
organisational structure of the dementia care network 
and how partners collaborated with each other. As a 
result the intensive case management model seemed 
easier to implement as case managers were more 
able to provide quality of care, were less constrained 
by competitiveness of other care organisations and 
worked more closely with the expert team than in the 
linkage model.
Essential components and preconditions of case 
management for people with dementia were 
investigated by Verkade et al.54 using a different 
methodology: a Delphi consensus survey. A list of 
components was selected through a literature review 
and a focus group, before being validated by 35 
experts. After three rounds, a consensus was found 
on 61 (of 75 statements). Information, support and 
counselling, coordination of the care provided and, to 
a lesser extent, practical help were identified as the 
essential components of case management for people 
with dementia. Vision, care relationship, structured 
methodology, integration of case management into 
the healthcare chain, and the case manager’s level of 
training and expertise were essential preconditions 
to case management. One of the key aspects of 
providing case management services was a patient-
centred approach. 
3.5 Summary and discussion
In absence of a disease course modifying treatment 
for dementia, and considering the increasing number 
of people with dementia globally55, interventions and 
strategies aiming at improving the efficiency and 
effectiveness of care for people with dementia are 
much needed. Although case management has been 
implemented in some countries as part of national 
strategies or Alzheimer’s plans over the last decade, 
the evidence for effectiveness is modest. Positive 
effects in terms of reduced or delayed transition into 
care homes and reduced unmet needs were found 
in some studies, while the effects on hospitalisation 
and mortality were generally not significant. The 
evidence on the benefits on carer strain and 
psychological morbidity, and the quality of life of the 
person with dementia and their carer seem weak. 
While a few studies indicated a modest reduction in 
healthcare costs in the medium term, the lack of cost-
effectiveness studies is striking. 
Inconsistencies or weaknesses in the evidence 
on the effectiveness of case management can 
probably be partly explained by the considerable 
heterogeneity among trials in the interventions 
studied, outcomes measured and duration of follow-
up. The application of the term case management 
itself can be, as highlighted by Reilly et al.15, fairly 
loose. Case management models ranged from 
interventions focusing on support and education for 
carers of people with dementia7,56 to a much more 
comprehensive approach providing support and 
education alongside the development and monitoring 
of a care plan by a multidisciplinary team8,15. As the 
nature of case management interventions also seem 
to impact the implementation and effectiveness of 
these programmes, it might be timely to ‘reframe’ 
the concept of case management in more functional 
terms, as suggested by Bamford et al., as a ‘dynamic, 
collective activity that involves numerous inter-related 
people and agencies and an ongoing shaping of social 
processes’ 52 for which the multilevel coordination 
of care would be an essential component. More 
research needs to be undertaken to clarify the 
effective components of case management, and its 
delivery. Evidence to date suggest that these are 
likely to include; a manageable caseload for delivering 
interventions with the required intensity; clear role 
definition with adequate preparation and training; and 
empowerment of the case manager to access and 
coordinate care across providers and sectors. These 
factors should be borne in mind when developing new 
services. Most importantly, no opportunity should be 
lost for rigorous evaluation of this promising service 
innovation, whether as part of a research experiment 
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(a randomised controlled trial), or a roll out into 
routine care. Arguably, the necessary level of system 
integration and support may be hard to achieve 
in the experimental context, so non-randomised 
evaluations of ‘real world’ scale up may have much to 
offer. Studies need to include a comprehensive set of 
process and outcome measures, which should include 
service utilisation and cost, in addition to clinical and 
quality of life outcomes for the person with dementia 
and their carer. Increased consistency in outcome 
measures would support future evidence synthesis 
through meta-analysis. 
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chapter 4 
acute general hospital care for people 
with dementia
4.1 Background
With demographic ageing, older people account for 
an increasing proportion of acute general hospital 
admissions, amounting in higher income countries 
to up to two-thirds of the inpatient population. Acute 
care is frequently delivered to frail older people, with 
chronic multimorbidities and complex needs for care. 
People with dementia are over-represented in this older 
inpatient population, for complex reasons. This is a 
matter of concern because of the many complications 
and generally adverse outcomes for acute admissions 
of people with dementia, and the higher than average 
costs arising from their longer than average length 
of stay in hospital. Clearly, unnecessary admissions 
should be avoided; at the same time, not all hospital 
admissions are avoidable, and people with dementia 
have the right to acute care that will improve their 
quality of life, when the need arises. It is therefore also 
necessary to attend to the quality of care that people 
with dementia receive in hospital.
In this section of the review, we sought to 
answer five questions:
•	 How often are people with dementia admitted to 
hospital, and what proportion of older general 
hospital inpatients are affected by the condition? 
What are the main reasons for admission?
•	 Are older people with dementia at increased risk 
of harm when admitted, and what are the likely 
mechanisms?
•	 What are the excess healthcare costs associated 
with acute hospital care for people with dementia, 
and what are the principal drivers of these high 
costs?
•	 How might admissions to hospital be avoided?
•	 For those people with dementia who are admitted 
to hospital, which interventions and systems of 
care might reduce harm, and improve outcomes, 
including the quality of life and satisfaction of 
people with dementia and their carers? Is there 
also evidence that interventions can reduce length 
of stay and costs?
4.2 How often are people with 
dementia admitted to hospital, and 
what proportion of older general 
hospital inpatients are affected by the 
condition? What are the main reasons 
for admission?
Since	many	people	with	dementia	are	frail	and	
have	complex	medical	comorbidities,	their	hospital	
admission	rate	is	higher	than	for	similarly	aged	people	
without	dementia,	both	for	all	cause	and	‘potentially	
avoidable’	admissions1–5.	In	a	recent	US	cohort	study,	
covering	the	period	1994-2007,	hospital	admission	
rates	were	419	per	1000	person	years	for	people	with	
dementia,	compared	to	200	per	1000	person	years	for	
similarly	aged	controls3.	Most	studies	control	for	age,	
sex	and	indicators	of	general	health	status	that	may	
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predict	admission	(comorbidity	indices	and	propensity	
scores);	after	adjusting	for	such	factors,	it	seems	
that	people	with	dementia	are	still	around	one	and	a	
half	times	more	likely	to	be	admitted2–4.	There	is	also	
some	evidence	from	the	USA	that	hospital	admission	
rates	among	people	with	dementia	have	been	rising	
over	time6.	There	are	few	published	data	from	low	and	
middle	income	countries.	Analysis	of	health	service	
utilisation	data	from	the	10/66	Dementia	Research	
Group	prevalence	studies7,	carried	out	for	this	review,	
reveals	that,	while	admission	rates	are	lower	than	in	
high	income	countries,	older	people	with	dementia	
are	generally	at	greater	risk	than	others	of	hospital	
admission.	Other	than	in	Beijing,	China	there	was	no	
clear	evidence	that	they	experienced	longer	length	of	
stay	(see	Table	4.1).
The	prevalence	of	dementia	among	general	hospital	
inpatients	has	been	surprisingly	little	studied,	and	
estimates	vary	greatly	depending	upon	the	type	
of	inpatient	setting	studied	and	the	screening	and	
diagnostic	methodology8.	Nevertheless,	it	seems	likely	
that	older	people	with	dementia	are	over-represented	
among	hospital	inpatients	compared	with	the	general	
population;	in	one	of	the	larger	studies,	from	the	UK,	
age-specific	prevalence	was	16.4%	for	men	and	29.6%	
for	women	aged	70-79,	rising	to	48.8%	and	75.0%	for	
90	years	or	older9.	
A	recent	systematic	review	identified	seven	studies	that	
had	compared	identified	causes	of	admission	among	
inpatients	of	general	hospitals	with	dementia,	and	
similarly	aged	inpatients	without	dementia10.	Three	of	
the	studies	were	from	the	USA,	two	from	France	and	
two	from	the	UK.	There	was	reasonably	consistent	
evidence	across	studies	that	orthopaedic	crises	
(falls	and	fractures),	respiratory	crises	(particularly	
infection),	and	urological	factors	(particularly	infection)	
were	over-represented	among	admissions	of	people	
with	dementia.	There	was	some	evidence	that	acute	
cardiac	syndrome	and	admissions	for	cardiovascular	
indications	in	general	were	under-represented	among	
people	with	dementia.	The	largest	study	by	far	used	
French	primary	care	and	national	medical	insurance	
databases	to	compare	admission	rates	and	cause	
of	admission	for	258,809	people	with	a	diagnosis	of	
dementia	and	88,296	controls2.	Admissions	were	
more	common	for	people	with	dementia	linked	to	the	
following	diagnostic	groups;	nervous	system,	urology,	
orthopaedics,	respiratory	medicine,	cardiology,	
endocrinology	and	infectious	disease.	Drilling	down	
into	these	diagnostic	groups	revealed	a	pattern	of	lower	
admission	rates	for	elective	intervention	procedures	
including	cardiac	and	vascular	catheterisation	(RR	0.5),	
cataracts	(RR	0.7),	hernias	(RR	0.8),	cholecystectomy	
(RR	0.7),	and	radiotherapy	(RR	0.5)	or	chemotherapy	
(RR	0.6)	for	cancer.	There	were	particularly	high	
Table 4.1  
Admission rates, average lengths of stay and relative risk of admission for people with dementia in low and middle income 
countries (unpublished data from 10/66 Dementia Research Group population based surveys)
Setting Admission rates per 1000 
person years
Adjusted* RR of admission 
(people with dementia vs 
others)
Mean difference in length of stay 
in days (people with dementia 
vs others)
Cuba 48 0.42 (0.16-1.15) +6.0 (-2.3 to +14.4)
Dominican Republic 164 1.51 (0.78-2.94) -2.5 (-8.6 to +3.6) 
Puerto Rico 396 1.66 (1.01-2.71) -1.3 (-5.4 to +2.9)
Peru (urban) 92 0.97 (0.27-3.42) -2.2 (-12.9 to +8.5)
Peru (rural) 0 - -
Venezuela 272 1.51 (0.73-3.11) +4.0 (-2.7 to +10.6)
Mexico (urban) 44 0.56 (0.07-4.71) -9.2 (-25.0 to +13.9)
Mexico (rural) 92 1.90 (0.39-9.32) +2.8 (-4.6 to +10.3)
China (urban) 284 2.25 (0.90-5.62) +33.0 (+9.6 to +56.4)
China (rural) 0 - -
India (urban) 108 3.19 (0.64-15.95) +9.6 (-3.2 to +22.4)
India (rural) 148 1.75 (0.55-5.52) -1.0 (-4.1 to +2.0)
Pooled estimates Median 26%, IQR 15-62% 1.46 (1.10-1.93)
I2=6.0%
+0.2 (-1.7 to +2.1)
I2=44.2%
*Adjusted for age, sex and number of limiting long-term conditions
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rates	of	admission	for	head	injury	(RR	3.0),	fractures	
and	sprains	(RR	2.2),	bowel	obstruction	(RR	2.2),	
respiratory	infection	(RR	2.9),	urinary	tract	infection	
(RR	2.0),	and	nutritional	and	metabolic	disorders	
(RR	2.5).	In	a	similar	data	linkage	study	from	the	UK,	
using	Hospital	Episode	Statistics,	the	most	common	
clinical	classifications	for	inpatients	with	dementia	
were	urinary	tract	infection,	pneumonia,	chronic	renal	
failure,	fractured	neck	of	femur,	syncope,	superficial	
injury,	acute	bronchitis,	acute	cerebrovascular	disease,	
and	non-specific	chest	pain.	Among	these	conditions,	
urinary	tract	infections	made	a	particularly	notable	
contribution	to	excess	length	of	stay	and	falls,	while	
bronchitis	and	cerebrovascular	disease	had	the	most	
marked	effect	on	excess	mortality.
Two	other	studies	from	the	USA	focused	upon	causes	
of	potentially	avoidable	hospitalisation	(PAH),	with	
divergent	findings3,11.	In	a	cohort	study	of	3019	older	
people	enrolled	into	an	integrated	care	plan	the	
association	between	dementia	and	PAH	(1.78,	95%	
CI:	1.38-2.31)	was	even	stronger	than	that	for	all	cause	
admissions	(1.41,	95%	CI:	1.23-1.61).	Among	the	
causes	of	PAH,	admissions	for	bacterial	pneumonia,	
congestive	heart	failure,	dehydration,	duodenal	ulcer,	
and	urinary	tract	infection,	were	significantly	higher	
among	those	with	dementia.	In	a	cross-sectional	
comparison	of	Medicare	claims	data	for	195,024	
beneficiaries	with	dementia,	and	the	same	number	
of	controls,	those	with	dementia	were	significantly	
more	likely	to	have	admissions	for	diabetes	short-term	
complications	(OR	1.43,	95%	CI:	1.31-1.57),	diabetes	
long-term	complications	(OR	1.08,	95%	CI:	1.02-1.14),	
and	hypertension	(OR	1.22,	95%	CI:	1.08-1.38),	but	
less	likely	to	have	potentially	avoidable	hospitalisations	
for	chronic	obstructive	pulmonary	disease	(COPD)/
asthma	(OR	0.85,	95%	CI:	0.82-0.87)	and	heart	failure	
(OR	0.89,	95%	CI:	0.86-0.92)11.	Risks	of	PAH	increased	
significantly	with	comorbidity	burden,	suggesting	that	
these	chronic	conditions	become	harder	to	manage	
and	control	effectively	in	the	context	of	multiple	other	
conditions.
The	overall	picture	is	one	in	which	people	with	
dementia	are	more	likely	to	be	admitted	as	inpatients	
to	general	hospital	than	people	of	similar	age	and	
medical	infirmity,	particularly	for	accidents	and	injuries	
arising	from	falls,	for	urinary	tract	and	respiratory	
infections,	and	for	chronic	disease	complications	that	
might	have	been	averted	with	better	management	
in	the	community.	Infections,	which	predispose	to	
delirium	and	falls,	have	a	particular	impact	on	length	of	
stay.	On	the	other	hand,	people	with	dementia	are	less	
likely	to	be	admitted	for	interventional	procedures	that	
have	the	capacity	to	enhance	quality	of	life,	including	
cataract	surgery,	vascular	catheterisation	and	stenting,	
cholecystectomy,	and	cancer	care.	This	would	be	
justified	were	these	interventions	to	be	much	less	
feasible	(for	example	because	of	impaired	capacity,	
problems	with	consent,	lack	of	cooperation,	and	poor	
adherence),	were	adverse	events	to	be	more	frequent,	
and/or	outcomes	to	be	sub-optimal	for	people	living	
with	dementia.	While	such	beliefs	may	influence	
treatment	decisions,	we	could	find	no	hard	evidence	
from	published	studies	to	support	this.		
4.3 Are older people with dementia at 
increased risk of harm during a hospital 
admission, and what are the likely 
mechanisms?
Delirium is one of the key adverse and potentially 
avoidable events experienced at much higher 
rates by people with dementia during their hospital 
admissions12,13. This may be in part because of the 
reasons for admission for people with dementia, and 
their high rates of multimorbidity and polypharmacy. 
However, people with dementia are more vulnerable 
to delirium for any given type or degree of physical 
morbidity. Delirium, and its mental and behavioural 
consequences, may be an important driver of 
increased length of stay12,14. Both delirium and 
dementia (by dint of cognitive impairment, hypoactive 
states, and behavioural and psychological symptoms) 
can reduce capacity for informed consent, and 
impair motivation and compliance with investigations, 
procedures, treatments and rehabilitation. Confinement 
to bed, whether due to restraint, sedation or hypoactive 
states, increases the risk of pneumonia and bedsores. 
Urinary incontinence can lead to bedsores or urinary 
tract infections from catheterisation. Agitation is 
recognised as a cause of post-operative surgical 
complications. Hospital inpatients with dementia are 
around three times more likely to experience a fall 
during their admission, and when this occurs, lengths 
of stay are more than doubled from around 13 to 
around 30 days15. 
Mortality	rates	are	exceptionally	high	during	
admission9,15	and	somewhat	higher	after	discharge16.	
However,	a	causal	link	between	the	admission	and	
death	is	hard	to	establish.	The	very	high	mortality	
rates	during	admission	may	reflect,	in	part,	a	tendency	
to	admit	people	with	dementia	at	the	very	end	stage	
of	the	disease	process.	Thus,	the	impending	death	
may	have	precipitated	the	admission,	rather	than	the	
admission	contributing	to	the	death.	There	have	been	
relatively	few	studies	of	place	of	death	for	people	
with	dementia.	A	systematic	review	published	in	2014	
identified	that	16	to	51%	died	in	hospital	in	studies	
conducted	in	UK,	US	and	various	European	countries,	
with	deaths	in	care	homes	being	the	most	frequent	
outcome17.	A	more	recent	and	extensive	study	from	
the	UK	indicated	a	reversal	in	a	previous	trend	for	
an	increasing	proportion	of	deaths	in	hospital,	from	
2006	onwards,	with	around	40%	of	deaths	occurring	
in	hospital	by	201118.	Again	the	commonest	place	of	
death	was	a	care	home,	and	deaths	at	home	were	
unusual.	There	are	no	published	data	from	low	or	
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middle	income	countries.	Analysis	of	verbal	autopsies	
conducted	for	the	10/66	Dementia	Research	Group	
population-based	cohort	studies	in	Latin	America,	
India	and	China19,	carried	out	for	this	review,	indicate	
that	deaths	in	hospital	are	at	least	as	common	
as	in	high	income	countries	(Table	4.2).	However,	
deaths	at	home	were	the	mode	in	most	sites,	with	
almost	no	deaths	in	care	home	settings.	People	with	
dementia	were	less	likely	to	die	in	hospital	than	others	
(surprisingly	no	similar	comparisons	seem	to	have	
been	carried	out	in	high	income	countries).	The	notable	
exception	was	Beijing,	China,	where	most	deaths	
occurred	in	hospital,	and	this	outcome	was	more	likely	
for	people	with	dementia.
When	discharged	from	hospital,	people	with	dementia	
are	more	likely	to	suffer	a	critical	loss	of	independence,	
and	increased	needs	for	care.	This	includes	a	near	
fourfold	risk	of	requiring	high	levels	of	homecare13,	and	
at	least	a	twofold	increased	risk	of	being	discharged	
to	nursing	home	or	residential	care20,21.	These	studies	
are	more	than	30	years	old;	more	recent	estimates	
from	the	UK	using	Hospital	Episode	Statistics,	
controlling	carefully	for	clinical	status,	suggest	a	more	
modest	1.4	times	increased	risk15.	Data	from	the	same	
study	suggested	that	failed	discharges	(defined	as	
readmission	within	30	days)	are	also	more	common	
for	people	with	dementia	both	for	elective	admissions	
(8.2	vs	3.8%)	and	for	non-elective	admissions	(25.0	vs	
17.0%)15.	
4.4 What are the excess healthcare 
costs associated with acute hospital 
care for people with dementia, and 
what are the principal drivers?
It	is	clear	from	analyses	of	comprehensive	US	
Medicare	data	that	the	costs	of	healthcare	in	general	
are	substantially	higher	for	people	with	dementia	
than	age-matched	controls1,4,5,	and	that	a	substantial	
proportion	of	these	costs	arise	from	hospitalisation1.	
In	the	first	study,	using	data	from	1999,	total	mean	
annual	beneficiary	payments	were	3.3	times	higher	
for	people	with	dementia	compared	to	those	without	
dementia	(US$9,922	vs	US$2,995)	adjusting	for	age,	
gender,	ethnicity	and	comorbidity1.	While	dementia	
was	associated	with	higher	payments	for	all	types	of	
expenditure,	mean	adjusted	inpatient	hospitalisation	
expenditures	were	3.5	times	higher	for	people	with	
dementia	(US$5,335	vs	US$1,523),	accounting	for	
55%	of	the	total	excess	expenditure.	The	second	
study,	covering	the	period	2009-2014,	stratified	the	
costs	with	respect	to	timing	of	dementia	diagnosis5.	
The	increased	utilisation	and	costs	(both	for	all	
healthcare	services	and	for	inpatient	admissions)	
is	apparent	for	at	least	the	year	prior	to	diagnosis,	
reaches	a	peak	in	the	year	after	diagnosis,	and	then	
declines	but	still	to	an	elevated	level	compared	with	
matched	controls5.	Total	healthcare	costs	were	1.4	
times	higher	in	the	year	prior	to	diagnosis	(US$15,091	
vs	US$10,662),	2.9	times	higher	in	the	year	after	
diagnosis	(US$27,126	vs	US$9,274)	and	1.8	times	
higher	one	to	two	years	after	diagnosis	(US$17,527	vs	
US$9,930).	Inpatient	admission	costs	were	1.7	times	
higher	in	the	year	prior	to	diagnosis	(US$7,243	vs	
US$4,320),	3.4	times	higher	in	the	year	after	diagnosis	
Table 4.2  
Proportion of deaths among people with dementia occurring in hospital, and relative risk of this event, from low and middle 
income countries. Unpublished data from the 10/66 Dementia Research Group surveys
Setting Proportion of deaths among people with 
dementia, occurring in hospital
RR of death in hospital (dementia vs 
others)
Cuba 41.4% 0.88 (0.80-0.97)
Dominican Republic 29.1% 0.89 (0.81-0.97)
Peru (urban) 31.0% 0.66 (0.44-0.98)
Peru (rural) 83.3% 0.96 (0.70-1.32)
Venezuela 16.2% 0.83 (0.71-0.97)
Mexico (urban) 31.3% 0.86 (0.66-1.12)
Mexico (rural) 23.1% 0.90 (0.72-1.12)
China (urban) 86.0% 1.21 (1.07-1.38)
China (rural) 2.7% 0.90 (0.82-1.00)
India (urban) 13.4% 0.99 (0.79-1.25)
Pooled estimates Median 26%, IQR 15-62% 0.92 (0.88-0.96)
I2=63.1%
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(US$11,540	vs	US$3,391)	and	1.8	times	higher	one	to	
two	years	after	diagnosis	(US$6,699	vs	US$3,682).
The	process	of	hospital	care	is	more	complicated	
for	people	with	dementia,	with	significant	cost	
implications8.	They	experience	substantially	longer	
hospital	stays4,13,	20–22,	and	require	more	nursing	
resources	than	others13,22.	Impact	of	dementia	on	
length	of	stay	was	most	extensively	demonstrated	in	a	
recent	analysis	of	Hospital	Episode	Statistics	from	the	
UK	National	Health	Service15;	adjusting	for	age,	gender	
and	clinical	status,	mean	lengths	of	stay	were	27%	
longer	for	inpatients	with	dementia	(13.6	vs	10.7	days),	
but	with	substantial	national	variation.	The	excess	
length	of	stay	was	as	high	as	85%	in	some	regions15.	
The	authors	of	the	UK	report	attempted	to	calculate	the	
annual	cost	to	the	National	Health	Service,	taking	into	
account	costs	incurred	from	excess	lengths	of	stay,	
excess	readmissions,	and	the	impact	of	excess	falls.	
In	this	context,	‘excess’	referred	to	the	incremental	
adverse	outcome	for	a	person	with	dementia	
compared	with	a	person	without	dementia	of	the	
same	age,	sex	and	clinical	status.	For	2010	the	costs	
for	excess	lengths	of	stay	were	£117.3	million,	those	
for	excess	readmissions	£122.5	million,	and	those	
for	excess	falls	£25.0	million,	amounting	to	£264.8	
million	overall.	On	the	one	hand,	these	almost	certainly	
represent	an	underestimation	of	the	incremental	costs	
given	the	likely	under-detection	and	under-recording	
of	dementia	during	hospital	admissions15.	On	the	
other	hand,	while	the	authors	of	the	report	refer	to	
‘the	excess	costs	incurred	by	the	NHS	occasioned	by	
differences	in	the	way	dementia	patients	are	treated’15,	
one	should	be	cautious	in	equating	‘excess’	with	
‘avoidable’.	While	it	is	appropriate	to	aim	to	eliminate	
the	differential,	at	least	some	of	the	incremental	
costs	may	be	intrinsic	to	the	complexities	of	inpatient	
dementia	care.	
4.5 How might admissions to hospital 
be avoided?
Hospital admissions might, in theory, be avoided in at 
least four ways:
1.   Deterioration in health, such as would necessitate an 
admission, might be averted by better management 
in the community. Ambulatory care sensitive 
conditions (ACSCs) are chronic conditions for which 
it may be possible to prevent acute exacerbations 
and reduce the need for hospital admission. 
An emergency admission for an ACSC is often 
considered to be an indicator of poor quality primary 
and community care. Examples of ACSCs relevant 
to the care of older people with dementia include; 
dehydration, urinary tract infection (UTI), bacterial 
bronchopneumonia, exacerbation of Chronic 
Obstructive Pulmonary Disease (COPD), congestive 
heart failure, hypertension, and uncontrolled 
diabetes and diabetes complications.
2.   Even where a clinical indication for acute admission 
may be present, it may not be in the interests of 
the person with dementia given the substantial 
associated risks. Alternative options would be 
to provide equivalent or near equivalent care at 
home (‘hospital at home’), or to pursue a more 
palliative course of management. This would require 
a holistic, person-centred assessment, and the 
consent of the person with dementia, or an advance 
care plan, or a judgment of their best interests 
supported by assent from next-of-kin or other legally 
constituted authority. 
3.   A high proportion of people with dementia die in 
hospital (see previous section). Holistic, palliative, 
end-of-life care is less available for people with 
dementia than for older people with more obviously 
terminal conditions, and the end-of-life is too 
infrequently acknowledged, discussed, and planned 
for. The high mortality rate for admissions of people 
with dementia is likely to reflect, in part, admissions 
of those near the end of their lives that might, 
with more planning and support have better been 
managed in the community (see section on end-of-
life care for further information). 
4.   Although widely acknowledged and discussed, 
the extent of ‘social admissions’ to acute inpatient 
care is hard to estimate. Home care arrangements 
can break down suddenly through changes in 
carer circumstances, or care demands exceeding 
available resources. Residential and nursing care 
homes can trigger hospital accident and emergency 
visits and admissions for similar reasons. While it 
might be tempting to blame such occurrences on 
a deficit of supplementary social care and support 
in the community, often anxieties over changes 
in health status play a part, and the effective and 
seamless integration of community health and social 
care is most likely to reduce the incidence of such 
admissions.
A recent systematic review of interventions to prevent 
hospitalisations of older people with dementia 
identified only 10 studies, despite applying quite 
broad inclusion criteria23. All but one were randomised 
controlled trials, and of small size. Interventions that 
were applied were heterogeneous, but mainly fell into 
two groups – case management/care coordination 
(four trials) and multidisciplinary assessment and 
management in the community (four trials). The other 
two trials were of home based occupation therapy and 
group support for carers. In only half of the trials was 
hospitalisation a primary outcome, indicating that the 
intervention was not specifically targeted at this effect. 
In none of the trials was a reduction in the incidence 
of hospitalisation convincingly demonstrated. Effects 
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were most favourable for multidisciplinary assessment 
and management, where two trials showed a non-
significant trend in the direction of lower hospitalisation 
rates24,25, and in one other those randomised to the 
intervention experienced fewer days in hospital over 
the two year follow-up period26. In the discussion of 
the largely null findings from this body of research, 
the review authors noted that insufficient research 
attention had been accorded to an issue that was now 
a major policy priority. The interventions tended not 
to have a clinical medical focus, and did not target 
the common reasons for admission for people with 
dementia namely, optimising control of pre-existing 
chronic conditions, and prevention of unintentional 
injuries, acute infections and dehydration. Future 
research needs to have an explicit focus on ‘keeping 
persons with dementia out of hospital, whenever 
possible’23. It was also noted that most of the quite 
intensive interventions that had been trialled relied 
upon specialist secondary care providers with little 
interaction or integration with primary care. It may 
be that task-shifted and collaborative care models, 
with a prominent role for primary care, may be at 
least as effective, while ensuring greater coverage 
and continuity of care. In an interesting analysis of 
Medicare data for patients newly diagnosed with 
a geriatric condition there was an inverse dose 
response relationship between geriatric care outpatient 
consultations and emergency department visits. 
However, geriatric consultation in primary care, where 
most care was delivered by family medicine was as 
effective as geriatric specialist care27. In England, an 
ecological correlational study indicated a small but 
statistically significant inverse correlation between 
the success of primary care centres in implementing 
the Quality and Outcomes Framework for dementia 
recognition and care, and the rate of emergency 
admissions for dementia, and ambulatory care 
sensitive conditions28.
Emergency Departments (EDs) are often the portal 
of entry for hospitalisation of people with dementia, 
and represent, in effect, a last chance to divert an 
admission that may not be necessary. Assessment 
in EDs is complicated by multiple factors29. The staff 
may lack expertise in comprehensive multidimensional 
geriatric assessment, detection of dementia and 
delirium. The person with dementia may be unable 
to communicate accurate and comprehensive 
information, and key informants may or may not 
be available. Their cognitive impairment may be 
exacerbated by symptoms of physical ill health, 
particularly pain, and by the unfamiliar, noisy and 
busy environment29. A recent systematic review into 
best practice for the management of ED patients with 
cognitive impairment identified 12 studies, most of 
which had focused upon the detection of cognitive 
impairment dementia, and delirium29. Detection can 
be boosted by the use of structured brief screening 
assessments, such as the Orientation Memory 
Concentration test and the Confusion Assessment 
Method for delirium. However, screening and detection 
are worthless if they do not then influence subsequent 
behaviour and outcomes. Worryingly, there is evidence 
from one study that recognition would not have altered 
ED management decisions or disposition plans for any 
of the majority of patients whose cognitive impairment 
and/or delirium had been missed30. Another study 
identified that information regarding screening findings 
in the ED relayed to general practitioners did not lead 
to any appropriate follow-up action31. It does not 
seem that the focus of this otherwise comprehensive 
review was upon the avoidance of hospital admission, 
perhaps because there appeared to be no trials that 
are directly relevant to this question; however, several 
evaluations of pertinent interventions for frail older 
people attending ED are mentioned in the discussion29. 
One describes a sociomedical geriatric assessment 
team working in the ED at Brest University Hospital. 
Admissions are claimed to be reduced on the basis 
that such attendances ‘usually’ result in admission, 
but the admission rate was only 49% for those 
assessed by the team32. The other trials focused 
upon frail older people who were already planned 
to be discharged from hospital. The feasibility of 
implementing a comprehensive geriatric assessment 
in ED, with rapid referral to community agencies had 
been demonstrated33. Such interventions seem to have 
some benefits over the months following discharge, 
in terms of lowering nursing home admissions and 
improving satisfaction with post-discharge care34, 
and reducing functional decline and death35. They 
did not however have any effect on subsequent 
healthcare utilisation, hospital admission, or costs34,35. 
One carefully matched pre- and post-cohort study, 
published since the systematic review, evaluated 
the impact of the TREAT service (Triage and Rapid 
Elderly Assessment Team) based in the ED at the 
Royal Free Hospital in the UK36. The service was 
specifically orientated to the avoidance of admission, 
and appeared to be achieving this objective, with a 
substantial increase in the same day discharge rate, 
and a reduction in the length of stay for those who 
were admitted36. 
‘Hospital at home’ refers to in reach services provided 
by health professionals in the patient’s own home, 
in situations when inpatient hospitalisation would 
otherwise be necessary. This could include intensive 
nursing, and therapies, for example intravenous 
antibiotics and/or fluids, oxygen, and attention to pain 
control. Conditions addressed in this way include 
pneumonia, exacerbations of chronic obstructive 
pulmonary disease, deep vein thrombosis, cellulitis 
and end-of-life care. Procedurally, the patient would 
be considered to be admitted to hospital, and would 
remain under the governance of the hospital services. 
As with a hospital admission, the treatment is intended 
to be of limited duration. Hospital at home is delivered 
under two sets of circumstances; to avoid admission, 
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and to provide early, supported discharge from 
hospital. While there are several descriptions of such 
services on the internet37,38, focused on providing a 
service for people with dementia, we could find no 
published formal evaluation. In general, the results 
of hospital at home services seem very favourable, 
for medical, surgical, rehabilitation and psychiatric 
interventions, with reduced mortality, readmission rates 
and costs, and higher patient and carer satisfaction39. 
The feasibility and effectiveness of delivering 
hospital at home care for older people with particular 
conditions has also been demonstrated40, with some 
marginal cost benefits41. There is clearly a need for an 
evaluation of this type of service, specifically for people 
with dementia; a large randomised controlled trial is 
currently being conducted in the Netherlands, with 
results expected in 201842.
There is clearly a need for much more research into 
interventions at the service and system level to avoid 
hospitalisations, specifically of people with dementia. 
As so succinctly stated in Phelan et al’s review
“We support the prevailing belief among many 
in the field that dementia is not ‘just another 
diagnosis’ on a patient’s problem list. Dementia 
impairs an individual’s ability to manage his/
her other chronic conditions, to recognize and 
articulate the onset of new physical or emotional 
symptoms, and to seek assistance/care in the face 
of alterations in one’s overall condition. Dementia 
implies that self-management support must be 
available. Thus, a diagnosis of dementia should 
shape the focus and approach to management 
of all other health issues in the context of routine 
outpatient care”.23
While the costs of hospital admission are high 
and concentrated, it is already apparent that the 
community-based and/or outreach services required 
to prevent this outcome are likely to be intensive 
and maintained over relatively long periods of time. 
Therefore, while it may be possible, desirable and 
beneficial to reduce the extent of acute admissions of 
people with dementia, the potential for cost-savings, 
which seem to be an important driver of policy focus 
on this issue at present, may well be illusory. Costs 
would, however, be shifted from acute hospital to 
community health and social care, which would require 
adjustments to budgets and resource allocation. 
Another important concern is that elective admissions 
for planned procedures such as cataract surgery 
may not be being offered to people with dementia 
as often as they should. It may be that consideration 
of the needs for such elective procedures should be 
incorporated into post-diagnostic counselling and 
advanced care planning, since at that stage, assuming 
a timely diagnosis, the person with dementia would 
retain capacity to make an informed decision, and 
outcomes from the procedure would be likely to be 
better.
4.6 For those people with dementia 
who are admitted to hospital, which 
interventions and systems of care might 
reduce harm, and improve outcomes, 
including the quality of life and 
satisfaction of people with dementia 
and their carers?
In a recent review of the current state of care for people 
with dementia in general hospital inpatient settings43, 
the fundamental problems were identified as:
a)   a tension between prioritisation of task-centred 
acute care for the indication for admission, and the 
acknowledged need to provide person-centred 
dementia care,
b)   an insufficient understanding of what constitutes 
person-centred care, 
c)  a general lack of requisite knowledge and skills.
Advocated actions were mainly at the systems level, 
focusing on managerial and workforce development; 
providing an appropriate care environment; fostering 
a positive care culture; changing attitudes; and 
cultivating a better understanding of the challenges for 
the person with dementia, for carers, and for inpatient 
healthcare staff43. The aspiration would be to effect a 
transformation such that ‘(the) cultures of care… are 
person-centred and where people with dementia are 
respected, valued and treated with dignity and receive 
high quality treatment for their medical needs, and do 
not negatively impact on the dementia’43.
An alternative and complementary analysis44 focused 
more upon the workforce attitudes, behaviours and 
competencies that needed to be targeted to effect 
change; detection of dementia and delirium, needs 
assessment, reduction of external stressors, capacity 
for effective and focused communication, and 
productive engagement with family carers. There has 
been almost no attention paid to the critical issue of 
patient safety in communication in handovers between 
healthcare settings (focusing in particular upon 
medication review, the information needs of everyone 
involved in the handover, and involvement of carers)45. 
Transfers between inpatient units are common for 
inpatients with dementia, and should be minimised, 
but when necessary all relevant information must be 
communicated effectively in the handover of care.
A striking finding from the published literature was the 
almost complete absence of the voice of the person 
with dementia, whose experiences, perceptions 
and views seem not to have been systematically 
studied43. Given the general acknowledgment of 
carers’ negative experiences of hospital admission, 
there have also been surprisingly few studies of 
this phenomenon, and its origins. In a qualitative 
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study of 35 carers of 34 patients aged 70 and over, 
most with dementia, admitted to geriatric, medical 
or orthopaedic wards at an English NHS acute 
care hospital, detailed post-discharge open-ended 
interviews were accompanied by non-participant 
observation of events and interactions on the ward46. 
This supported the conclusion of recent reviews - 
“Family carers expected a personalised style of care 
in hospital, which contrasted with the busy experience 
of an acute hospital ward”. Carers did not experience 
the hospital admission as ‘respite’; rather it was seen 
as a stressful crisis, regardless of the perceived quality 
of inpatient care, with much disruption in established 
care routines. While experiences were variable, a 
common set of themes emerged, constituting a 
‘cycle of discontent’, arising when concerns over care 
quality occurred in the context of a sense of loss of 
control. When expectations did not match perception 
of care, often triggered by key events, this led to 
suspicion and loss of confidence, followed by hyper-
vigilant monitoring, and a breakdown in relationships, 
with challenges, expression of anger, conflict and 
withdrawal. Aside from medical care, carers judged 
overall quality of care with respect to nutrition and 
hydration, maintaining safety, approaches to caring for 
a confused person, and showing warmth. Competence 
was judged by the ability to manage agitation and 
control pain. Expectations that the ward would be 
a place of safety, and that staff would demonstrate 
appropriate knowledge and skills in communicating 
with the person with dementia, and in managing 
confusion and disturbed behaviour, were often not 
met. Carers who wished to be involved in care were 
sometimes prevented from being so, and complained 
of being ignored, patronised, or treated inflexibly. 
Communication was perceived as inadequate, and 
orientated more towards discharge planning rather 
than care during the admission. 
The care environment
In contrast with many modern long-term care facilities, 
acute care hospital settings have generally not been 
designed with the needs of people with dementia 
uppermost in mind. There is nothing ‘homely’ about 
the environment, little to orientate inpatients to time, 
place and person, and much distracting noise and 
activity, day and night. For these reasons, among 
others, hospitalisation can be a difficult experience 
for those with normal cognitive function – all the more 
so then for those with dementia and/or delirium. 
There have been various attempts to create more 
‘dementia-friendly’ ward spaces. A redesign carried 
out for one orthopaedic ward and a healthcare for 
the elderly ward at the Bradford Royal Infirmary, UK, 
has been carefully documented47, and presented in 
the context of learning from 23 similar programmes 
funded under a UK Government initiative through the 
King’s Fund ‘Enhancing the Healing Environment’ 
initiative. A design assessment tool generated from 
this programme (http://www.kingsfund.org.uk/projects/
enhancing-healing-environment/ehe-design-dementia) 
focuses on whether the ward environment promotes; 
meaningful interaction between patients, their families 
and staff; well-being; eating and drinking; mobility; 
continence and personal hygiene; orientation; calm, 
safety and security. 
Key	features	of	completed	projects	include:	
•	 projects were co-designed and developed by staff, 
patients and carers
•	 ‘de-cluttering’ by removing unnecessary equipment 
and furniture to simplify the environment
•	 improved and flexible lighting schemes, to ensure 
that all areas are evenly lit, mimicking natural 
daylight in daytime, and promoting a sleep/wake 
cycle
•	 attention to flooring, ensuring that floors are matt 
and non-slip, and do not create (through light and 
shade or patterning) artificial visual barriers to 
those with perceptual disturbances
•	 ‘deinstitutionalising’ colour schemes, and using 
colour accents to demarcate different ward areas 
and bays. 
•	 Individual bed spaces are personalised, for 
example with facilities to exhibit family pictures 
through a television screen, and a memory box 
with personal artefacts and possessions.
•	 dividing up common areas into smaller social 
spaces, for example sections of corridor with 
seating and reminiscence activities, and a small 
café for patients and carers. 
•	 Providing points of interest with photographs, and 
tactile artwork
Of course, a well-designed physical environment does 
not guarantee good quality care, and psychosocial 
factors, particularly the presence and visibility of staff, 
and their meaningful engagement with patients and 
carers are complementary43. 
Special units provide specialised care for people 
with dementia and/or delirium in a custom designed 
setting. They can in principle have a dual function, 
providing care for patients presenting with the most 
difficult management problems, while also conducting 
training, modelling and disseminating good practice 
in dementia care throughout the hospital workforce48. 
There have been some limited small-scale evaluations 
of such units based on a comparison with ‘normal 
care’ on general wards within the same hospital49–51. 
These suggest that there may be some benefits with 
respect to staff knowledge and skills, carer satisfaction 
with the ward environment and care provided, 
and, possibly, for the person with dementia, with 
improvements in nutrition, reductions in behaviour 
disturbance, and increased mobility with no increase 
in the incidence of falls. Strikingly, however, there 
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was no evidence for reduced length of stay, or lower 
rates of discharge to a care home49–51. Indeed, all of 
the evaluations mentioned delayed discharge due to 
problems finding a placement as a significant reason 
for the lack of reduction in length of stay. One of the 
more detailed evaluations came from a project at New 
Cross Hospital, Wolverhampton, UK, which highlighted 
the need for substantial organisational change to make 
the unit an effective component of the system, and 
maximise its impact51. Hence, in addition to creating 
a dementia-friendly ward providing person-centred 
care, a hospital wide dementia training program was 
instigated with the trainer based in the dementia unit, 
outreach was provided to other wards, and there was 
increased dedicated social work time for discharge 
planning. Some cost savings were made, mainly 
through improvements in staff satisfaction, reduction in 
turnover and sickness absences, and hence a reduced 
need for temporary agency staff. There were also no 
formal complaints relating to dementia care on the 
special unit, which are costly to handle. 
Hospital staff
Staff attitudes and actions (reflecting values and 
beliefs) are closely related to knowledge and skills, 
and the need for education and training to develop 
workforce capacity for dementia care. Care provided 
by nurses is clearly a crucial element. Nurses too often 
lack the confidence and competence to assess and 
manage their patient’s special needs. A belief that 
decline is inevitable will be associated with a failure 
to identify and diagnose the causes of confusion 
(dementia versus delirium) and a sense that such 
individuals are misplaced in ‘curative’ acute care 
settings. Disruptive behaviour can impact on nurses’ 
time management and ward routines in a highly task-
orientated system, and hence be a source of irritation. 
In contrast, a ‘healthful’ perspective identifies cognitive 
decline (whether acute, acute on chronic or chronic) as 
pathological, and seeks an underlying cause for acute 
confusion, considering chronic confusion only when 
other causes were ruled out. Whether in dementia or 
delirium, disturbed behaviour is too often interpreted 
as a nuisance to be controlled through supervision 
or medication, rather than a valid form of non-verbal 
communication of unmet needs that need to be 
ascertained and addressed – for pain control, nutrition, 
rest, social interaction or reassurance. In short, the 
person, not the environment is held to blame, a classic 
category error first described by Kitwood in 199352. At 
the same time, it should be acknowledged that such 
behaviour can be stressful for nurses, other patients 
and families, particularly when it involves interference 
with other patients’ privacy, possessions and clinical 
care48. The need for attitudinal change, to avoid 
labelling and blame, therefore extends well beyond the 
ward staff. 
Communication skills are at the heart of person-
centred care. In mechanical terms, this should involve 
a set of basic skills; approaching in a calm, gentle and 
relaxed fashion using the person’s preferred form of 
address; speaking directly even if unable to respond; 
remaining calm if the person appears agitated; 
communicating in a quiet setting, minimising external 
distractions, and avoiding moving around; using short 
simple sentences, and limiting choices44. Person-
centred care involves much more than this; getting to 
know the individual, their life history, interests, desires, 
and values; always being compassionate, respectful, 
and thinking about things from the person’s point of 
view when delivering care that is individually tailored 
to their needs. For people with dementia, this will 
almost always require close interaction with carers. 
Most reviews point to the contrast between task-
orientated systems of acute inpatient care that seek to 
maintain patient safety and limit length of stay through 
rigorous check list protocols, and the more flexible, 
and potentially more time-consuming demands of 
patient-centred care43,44,53. An alternative view is that 
investment in person-centred care is, in the long-run, 
time saving; this is plausible, but thinly evidenced43.
Recent reviews agree that there is a need for more 
intensive education and training across the health 
system to change attitudes and address the deficit in 
knowledge and skills43,44,53. While in service training 
is necessary and important, a higher profile for and 
greater commitment towards dementia care in the 
basic curriculum, reflecting changing patterns of 
morbidity, would arguably deliver greater and more 
sustainable benefits, and a workforce fit for purpose. 
In service training programs are not usually evaluated 
or published, with a lack of evidence of sustainability 
of knowledge and competence, leading to a lack of 
evidence base to inform generalisable good practice43. 
Experiential methods of teaching, involving contact 
with people with dementia outside of the hospital 
setting has been advocated54. Such ‘active learning’ 
initiatives focus on the engagement of staff at an 
emotional level with the experiences of patients.
Systems and models of care
Specialist mental health liaison teams
Specialist mental health liaison teams are a relatively 
common service in some high income countries, and 
in England the Department of Health has issued a 
commissioning call for them to be provided for all acute 
care hospitals. It is important to note that such services 
are not restricted to dementia assessment and care, 
but cover the full range of mental and cognitive 
comorbidities, with the commonest conditions among 
the case mix being dementia, depression, delirium and 
adjustment disorders55. There are different models of 
provision. Some services, providing inreach to make 
assessments and give advice on management, could 
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more properly be termed ‘consultation’ services. True 
liaison models should ideally be based on site, and 
involve a greater degree of day to day interaction and 
functional integration between the liaison services and 
the teams providing inpatient care55,56. Such teams 
may comprise specialist nurses, psychiatrists, or be of 
a multidisciplinary nature55. True liaison services confer 
several potential benefits55. They do not rely entirely 
upon general hospital staff detecting and referring 
cases for further assessment. The service is generally 
more responsive, and feedback on assessments 
is more direct, and continuous. Such services can 
potentially provide resources and leadership for 
training and education in the acute hospital setting 
and promote changes in the structure and culture of 
care48. Direct patient care activities include diagnostic 
assessment, advice on behavioural management, 
assessment of capacity, and discharge planning. 
The evidence base for the effectiveness and cost-
effectiveness of liaison services for older people is 
weak, and studies are generally of poor quality. There 
are few randomised controlled trials, all of which have 
design flaws55. All bar one fail to show any significant 
benefits in terms of key clinical outcomes or length of 
stay. The exception is the trial conducted by Slaets 
et al in the mid-1990s in the Netherlands57 where the 
delivery of a mental health liaison service integrated 
with geriatric medicine, compared with usual care, was 
associated with improved physical functioning, a five 
day shorter length of stay, fewer readmissions, and 
fewer discharges to nursing homes. Findings from non-
randomised pre-post evaluations with historic controls 
are generally more favourable, indicating potential for 
improved clinical outcomes and reductions in length of 
stay55, with some relatively well-designed evaluations 
providing quite persuasive evidence58,59. 
Dementia specialist nurses
A recent review of the potential role of a dementia 
specialist nurse highlighted the ways in which their 
set of competencies; advanced assessment skills, 
sharing information, ethical person centred care, 
carrying out therapeutic interventions, preventative 
and health promotion, balancing the needs of the 
person with dementia and carer; might help to fill gaps 
in knowledge and skills53. Specialist dementia nurses 
can, in principle, provide comprehensive assessment 
including dementia specific factors that may increase 
risk of adverse events, care coordination, oversee all 
aspects of inpatient care, support carers and engage 
in discharge planning. There is, however, a tension 
between the feasibility of providing this focused 
attention for a potentially very large number of clients, 
and time spent on advising and training non-specialist 
staff, raising awareness and changing the culture of 
care across the hospital as a whole. There is a danger, 
if the nurse takes on too much frontline care, that other 
staff may become deskilled53. There appears to have 
been only one evaluation of this type of service, in 
which one nurse saw approximately 30 new referral 
patients per month (of whom only a small proportion 
were diagnosed with dementia), with additional follow 
up reassessments60. A reduction in average length 
of stay from 11 to nine days was claimed, but the 
methodology for the comparison was not described60.
Systems level interventions for the primary 
prevention of delirium 
The Hospital Elder Life Programme (HELP) was devised 
specifically to prevent delirium in frail older inpatients 
with specific risk factors (defined as those with one 
or more of cognitive impairment, visual or hearing 
impairment, reduced mobility, sleep disturbance or 
dehydration). The intervention is a complex package 
of enhanced care delivered collaboratively by the 
healthcare team and the HELP staff members, 
comprising a nurse specialist, a geriatrician, and 
trained volunteers. Interventions included a daily 
visitor program for orientation and social support, 
exercise for early mobilisation, massage and music to 
promote sleep, mealtime assistance for feeding and 
hydration, education for staff and family members, and 
support for discharge. The effectiveness of the HELP 
program was demonstrated in a non-randomised 
controlled trial, in which the incidence of delirium was 
reduced by 40% overall (OR, 0.60; 95% CI: 0.39-
0.92)61. Sustained effectiveness has been confirmed 
following implementation at scale62,63. A recent 
Cochrane systematic review confirmed the quite strong 
evidence for the effectiveness of such multicomponent 
interventions (RR 0.69, 95% CI: 0.59-0.81), while also 
highlighting the much more limited evidence, from one 
small trial, of effectiveness among those with dementia 
(RR 0.90, 95% CI: 0.59-1.36)64. In the original HELP 
trial61, those with severe dementia were excluded, and 
59% of participants had MMSE scores of 25 or over. 
There is, as yet, no evidence that such interventions 
reduce length of stay, although this seems quite 
possible given the effects on delirium prevention. A 
large trial, including this outcome, with a more rigorous 
cost-effectiveness evaluation is currently underway 
in the Netherlands65. The HELP intervention has been 
extensively disseminated, and resource, training and 
support materials are available online66. Despite this, 
uptake has been surprisingly low outside of North 
America66. In the UK, the National Institute for Health 
and Clinical Excellence (NICE) has collaborated with 
HELP to produce a harmonised and updated set of 
evidence-based guidelines67. 
Concern is expressed in all recent reviews at the lack 
of rigorous evaluation of services that commissioners 
are advocating and providers are implementing. 
Well-conducted large scale randomised controlled 
trials, providing clear evidence of cost-effectiveness 
are largely lacking. There is a body of evidence that 
quality of care can be improved, with enhanced 
staff and service-user satisfaction, but evidence on 
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the tractability of the key health system economic 
indicators (length of stay and readmission rates) 
is much weaker. While there are examples of 
implementation and innovation in care, this is patchy 
and piecemeal, with minimal coverage of basic 
enhancements to the quality of care provided to 
people with dementia. As noted by Dewing and Dijk, 
“Currently there seems to be little to celebrate in the 
way of excellence in dementia care in the general 
hospital”43. There may be an emerging consensus 
on the key components of good quality care, but no 
real evidence on the optimal resources, systems and 
structures to deliver this at scale, and in a sustainable 
way. Again, most reviews and reports emphasise that 
simply introducing a mental health liaison service, or 
a dementia specialist nurse, or a special dementia 
care unit is not enough. Indeed, if these are not 
properly integrated into the wider hospital and health 
service management structure, with clear ownership, 
they will struggle to function properly43,53,55. What is 
needed is a wholescale restructuring of the culture 
of care, which, first and foremost, accords adequate 
priority, in resources and planning, to the needs of 
people with dementia. Hence, governance at senior 
management level is essential, with monitoring of key 
performance indicators. Careful consideration should 
be given to every stage of the care pathway, to all of 
the staff that have contact with patients and carers, 
and all of the environments and systems that they are 
likely to encounter during their stay. Education and 
training of hospital staff to achieve clearly defined 
competencies appropriate to role needs to be carried 
out as part of in-service training. However, sustainable 
changes in culture and practice will only be achieved 
once this training is a prominent part of the core 
undergraduate and postgraduate medical and nursing 
curriculum. Priority should be given, in particular, to a 
person-centred approach to care, and respectful and 
productive interaction with carers at all stages of the 
admission.   
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chapter 5 
Palliative care
5.1 Introduction
There are currently no disease modifying treatments 
for dementia, which is a life-limiting illness, and 
deaths with dementia are increasingly common. In 
the World Alzheimer Report 2013 ‘Journey of Caring’1, 
we reviewed the literature on end-of-life care for 
people with dementia (section 4.2), and considered 
separately the applicability and use of advanced care 
planning (section 5.2). These two issues are closely 
related, since advanced care planning allows people 
with dementia to think through, and state preferences 
for future care options. Many important decisions 
along the dementia journey will need to be taken at 
a time when the capacity of people with dementia to 
contribute to them may be significantly compromised2. 
However, these are just two elements of what, in recent 
reviews and expert consensus exercises has been 
described as a ‘palliative care approach’ to dementia 
care extending across the disease course, from 
diagnosis to death, and beyond2–4. 
The interest in a palliative care approach to dementia 
care has been motivated by concerns that those 
dying with advanced dementia are often not seen 
as having a terminal condition, and are much less 
likely than others to be managed palliatively. Thus, 
US nursing home residents with dementia were eight 
times less likely than those with cancer to have do-
not-resuscitate orders and three times less likely to 
have do-not-hospitalize orders, and were much more 
likely to experience burdensome interventions such 
as tube feeding, laboratory tests and restraints5. 
There have also been problems with lack of access 
to specialist palliative care, which, historically, has 
been closely linked to cancer care. In one UK study, 
only 9% of people with dementia at the end of life 
on acute medical wards were referred to palliative 
care specialists, compared to 25% of people without 
cognitive problems6.
Our purpose in this chapter is to update and integrate 
the sections of the World Alzheimer Report 2013, 
in the context of the emerging consensus around 
the ‘palliative care approach’ to dementia care. We 
conducted a scoping review of the literature (2013-
2016) using the search terms “dementia AND (end of 
life care OR palliative care)” and “Alzheimer’s AND 
(end of life care OR palliative care)”. After excluding 
duplicates, we identified 2108 unique publications. 
Review of titles, abstracts and hard copies limited 
this to 100 relevant publications. Of these, 46 focused 
on end of life, and/or dying with dementia, 21 had a 
specific focus on palliative care in advanced dementia, 
and 18 described research conducted in care homes. 
Sixty-three publications (63%) focused on one or other 
of these themes, reflecting a persistent orientation to 
the later stages of dementia care. Sixteen studies (16%) 
addressed advanced care planning. Strikingly, there 
were no experimental studies, either using randomised 
controlled, controlled or quasi-experimental designs 
to evaluate innovations relating to palliative care in 
dementia. 
5.2 What is palliative care?
According to the World Health Organization’s 
definition7, palliative care:
•	 provides	relief	from	pain	and	other	distressing	
symptoms;
•	 affirms	life	and	regards	dying	as	a	normal	process;
•	 intends	to	neither	hasten	nor	postpone	death;
70
•	 integrates	the	psychological	and	spiritual	aspects	
of	patient	care;
•	 offers	a	support	system	to	help	patients	live	as	
actively	as	possible	until	death;
•	 offers	a	support	system	to	help	the	family	cope	
during	the	patient’s	illness	and	in	their	own	
bereavement;
•	 uses	a	team	approach	to	address	the	needs	of	
patients	and	their	families,	including	bereavement	
counselling,	if	indicated;
•	 will	enhance	quality	of	life,	and	may	also	positively	
influence	the	course	of	illness.
5.3 How, and when, is palliative care 
applicable to dementia care?
The World Health Organization has stated that ‘every 
person with a progressive illness has a right to 
palliative care’8. 
Kydd and Sharp4, in a systematic review of policy 
formulations with respect to the palliative care 
approach in dementia care, identified, in effect, four 
main areas of relevance:
1.   The WHO definition of palliative care has much in 
common with fundamental principles of dementia 
care, including the need for care to become more 
person-centred and relationship focused, while 
involving family and carers and attending to their 
needs.
2.   The palliative care approach acknowledges explicitly 
that dementia is a life-limiting illness, which, if 
adopted early may help to promote advanced care 
planning. 
3.   A palliative care focus encourages more nuanced 
management of complex physical comorbidity 
in advanced dementia, avoiding burdensome or 
futile clinical investigations and interventions, and 
unnecessary and distressing transitions in the care 
system. 
4.   It may secure for people with dementia better 
access to the expertise of specialist palliative care 
services in addressing, for example, complex ethical 
dilemmas, and managing physical complications 
and distress at the end of life. 
However, as subsequent sections of this chapter 
make clear, we are some way from a general or even 
widespread acceptance, let alone adoption, of a 
broadly defined palliative care approach to dementia 
care. Among dementia care practitioners and 
researchers, palliative care is often considered to be 
synonymous with end-of-life care, and relevant only to 
the advanced phase of the condition9. Palliative care 
practitioners have a much broader view of their roles 
and functions, and as the WHO definition specifies, 
palliative care is 
“applicable early in the course of illness, in 
conjunction with other therapies that are intended 
to prolong life, and includes investigations needed 
to better understand and manage distressing 
clinical complications” 8. 
Palliative care should, therefore, be about living well 
as well as dying well with dementia4. Kydd and Sharp 
neatly observe that good dementia care already 
implicitly reflects a palliative care approach, posing 
the question “Does reluctance to use the language 
of palliation reflect a conflict with the message of 
rehabilitative potential to live well—or is [it] that the 
language itself is unhelpful because it is poorly 
understood and can be quite terrifying?”4.
A qualitative study of the views of professionals 
working in long-term care facilities in six European 
countries sought to clarify the stage in the disease 
trajectory when people with dementia might be 
considered to be eligible for palliative care10. Three 
different time points were commonly identified; early 
in the disease trajectory; when signs and symptoms of 
advanced dementia are present; and from the time that 
curative treatment of co-morbidities is futile. However, 
there was no consensus within countries, professional 
disciplines, or even among staff within the same 
facility. 
A recent Delphi expert consensus, convened by the 
European Association for Palliative Care (EAPC), on 
optimal palliative care in older people with dementia, 
made 57 recommendations within 11 domains 
(applicability of palliative care; person-centred 
care, communication and shared decision making; 
setting care goals and advance planning; continuity 
of care; prognostication and timely recognition of 
dying; avoiding overly aggressive, burdensome or 
futile treatment; optimal treatment of symptoms 
and providing comfort; psychosocial and spiritual 
support; family care and involvement; education of 
the healthcare team; societal and ethical issues)3. 
With respect to the applicability of palliative care the 
consensus was clear – the recommendation being that 
the palliative care approach should be applied across 
the disease course (see Box 5.1)
In making these recommendations the EAPC experts 
also argued for a modification of the traditional 
palliative care model, which dichotomises curative 
(disease-modifying) and palliative (symptom 
management) goals, and sees these as representing 
distinct phases of care11. Instead, they propose 
three goals for dementia care; prolongation of life, 
maintenance of function, and comfort; the relative 
emphasis of which tends to change over the disease 
course3. 
The main arguments for implementing a palliative care 
approach early in the disease course include:
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1.   Respect for autonomy is a fundamental principle 
of human bioethics, as laid down in the Nuremberg 
Code, requiring that participation in research 
(and by extension medical care) is on the basis of 
voluntary, informed consent. The Code carries the 
qualification that ‘the person involved should have 
the legal capacity to give consent’. Decision-making 
capacity is a critical issue in dementia care, given 
progressive cognitive decline. People with dementia 
are more likely to retain decision-making capacity in 
the early stages, so advanced care planning, if it is 
to prioritise the views of the person with dementia, 
needs, ideally, to feature in the early post-diagnostic 
phase of care. 
2.   Advanced care planning has its origins in decision-
making for end-of-life care12. However, it has a much 
broader application for people with dementia, for 
whom many important decisions may need to be 
made after decision-making capacity has been lost, 
but some time before death.
3.   Even if one accepts the particular salience of 
palliative care to end-of-life care, it is probable that 
most people with dementia die before reaching 
the advanced stage of the disease. Survival times 
from diagnosis range from 2.9 to 7.0 years for mild 
dementia, 1.5 to 3.0 years for moderate dementia 
and 1.4-2.4 years for severe dementia13, and 
mortality rates increase with severity14. However, 
at any one time, in a given population, there are 
many more people with milder as compared with 
advanced dementia. Given the apparent lack of 
other direct evidence, for the purposes of this 
report, we conducted an additional analysis on 
patterns of mortality in the 10/66 population-based 
cohort studies in Latin America, India and China15. 
Of 485 deaths among people with dementia, 384 
occurred among people with mild dementia at 
baseline (58%), 134 among those with moderate 
dementia (28%), and only 67 (14%) among those 
with severe dementia.  
5.4 Advanced care planning
What is advanced care planning (ACP)?
Advanced care planning is defined by the World Health 
Organization as ‘a process to make clear a person’s 
wishes and that will usually take place in anticipation 
of future deterioration of an individual’s condition, 
with loss of capacity to make decisions and/or ability 
to communicate wishes to others’. In principle, ACP 
provides an opportunity to anticipate future decisions 
relating to health and social care needs, allowing the 
person with dementia to make choices and feel in 
control, and provides an opportunity to initiate timely 
palliative care. Consistent with a person-centred 
approach to care, advanced care planning should elicit 
personal values, beliefs, and preferences about current 
and future care. 
Advanced care planning in practice
ACP can take different forms and lead to different 
outcomes. Discussions can result in a statement of 
preferences or wishes (an Advanced Statement or 
Directive), the appointment of a Lasting Power of 
Attorney (LPA), or an Advance Decision to Refuse 
Treatment (ADRT), in specific future circumstances16. 
All of these legal instruments require that at the time of 
the provision being made, the person retains capacity 
to make the provision. The instrument would only take 
effect if the person had subsequently lost decision-
making capacity (see Box 5.2), and hence could no 
longer be consulted directly.
An advanced statement or directive is a written or oral 
statement to communicate to others preferences or 
wishes related to future care or personal preferences. 
For example, a person with dementia might express 
a preference not to be admitted to hospital from their 
care home, even if that might shorten their life, as long 
as their comfort could be assured. Preferences cannot 
be made for acts that may be illegal, such as assisted 
suicide.
A Lasting Power of Attorney is a nomination in a 
prescribed form of a person responsible for taking 
decisions on the behalf of an individual on economic, 
health or personal matters, in the event of loss of 
capacity. For example, a person with dementia might 
appoint their daughter to give or withhold consent 
for all healthcare investigations and treatments. Any 
Box 5.1
European Association for 
Palliative Care White Paper – 
recommendations for applicability 
of palliative care for people with 
dementia3 
1.1   Dementia can realistically be regarded 
as a terminal condition. It can also be 
characterized as a chronic disease or, in 
connection with particular aspects, as a 
geriatric problem. However, recognizing 
its eventual terminal nature is the basis for 
anticipating future problems and an impetus 
to the provision of adequate palliative care.
1.2   Improving quality of life, maintaining function 
and maximizing comfort, which are also 
goals of palliative care, can be considered 
appropriate in dementia throughout the 
disease trajectory, with the emphasis on 
particular goals changing over time.
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decisions taken by the appointed person should be 
made in the person with dementia’s best interests, with 
the assumption that they would be familiar with their 
previously stated values and preferences. 
An Advance Decision to Refuse Treatment is a 
decision to refuse certain types of treatment, in certain 
specified health states, should loss of capacity ensue. 
For example, a person with dementia might decide 
to refuse tube feeding, should they lose the ability 
to swallow, at the end of life. This decision should 
be made under the supervision of someone who 
understand the intricacies of the process, and by 
someone who has mental capacity at the time of the 
decision. 
How widespread is advanced care planning?
The use of ACP among people with dementia is on 
the increase in many countries. In a recent study of 
just over 1000 people with dementia in Belgium, 52% 
had made some form of advance care planning (just 
6% initiated by the individual concerned, most having 
been prompted by a clinician, and only 9% had a legal 
representative)18. In a survey conducted in 2005 in 
the USA, 65% of older people attending a memory 
service with cognitive impairment or dementia had a 
durable power of attorney and 56% a living will19. This 
was a sizeable increase from a US study of nursing 
home residents in 1996, in which it was reported that 
only 21% had a living will, 40% a ‘do-not resuscitate 
order’ and only 6% a treatment restriction relating to 
medication, feeding or other interventions20. These 
surveys were conducted in countries with policies in 
place to encourage ACP, underpinned by legislation. 
Internationally, there is little available evidence on its 
use, but this is likely to be highly variable, and much 
lower in those countries where awareness of dementia 
is limited, where ACP is not discussed, and where 
advanced directives may not carry legal force. In 
dementia care as for other clinical contexts, the use of 
ACP is much more common among those with better 
education, and in the USA among white compared with 
black Americans19. 
How effective is advanced care planning?
There is no direct evidence from randomised controlled 
trials for the effectiveness of advance care planning 
for people with dementia. A recent systematic review 
of the effectiveness of ACP for people with cognitive 
impairment and dementia identified four relevant 
studies, which did not, in fact, select specifically for 
people with dementia or cognitive impairment, and 
did not report any subgroup analyses21. Findings are 
nevertheless of interest, and of tangential relevance. 
In two studies, use of ACP was associated with a 
reduction of unnecessary hospital admissions22,23, and 
in one study there was a significant increase in hospice 
use in the group with ACP in place24. Another study 
conducted among older medical inpatients showed 
that advance care planning resulted in having end-of-
life wishes more likely to be followed, and in particular 
that ACP was associated with an improvement in 
carers’ stress, anxiety and depression25. A large 
Box 5.2
Decision-making capacity 
For a person to have decision-making capacity, 
they should 
1.   Understand the information relevant to making 
the decision. This could include, the nature of 
their health condition, the proposed treatment, 
its potential risks and benefits
2.   Retain the information long enough to make a 
stable and consistent decision
3.   Demonstrate that they have weighed up the 
information to make their choice, consistent 
with their values and preferences, and free of 
any outside influence or coercion
4.  Be able to communicate their decision
This is a functional assessment17, which needs 
to be carried out separately for each important 
decision. A person with dementia may lack 
capacity to manage their finances, while still 
be able to decide that they would not wish to 
be resuscitated in the event of a cardiac arrest. 
Evidently there should be no blanket assumption 
that people with advanced dementia in general, 
or a particular person with dementia, lacks 
capacity to make any decision; this would imply 
a total loss of autonomy, the avoidance of which 
should be a key objective of dementia care. 
While the clinical judgment of capacity is 
dichotomous, i.e. that capacity is retained or not 
retained, in practice patients often have more 
or less capacity along a continuum, and the 
ultimate judgement, as to whether the patient has 
enough capacity to make the decision is often 
finely balanced, and open to contention, which 
sometimes has to be resolved through a legal 
process. People with dementia can be supported 
to exercise their autonomy by ensuring that every 
effort is made to enhance their understanding 
of the information relevant to the choice, and by 
assisting them with the decision-making process. 
Decision-making capacity may wax and wane. 
If a decision can be delayed, until, for example, 
recovery from an intercurrent illness, then the 
capacity assessment should be repeated at a 
more favourable time. 
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study, linked to the US Health and Retirement Survey 
indicated that participants who had made an advanced 
directive, and lacked capacity, were highly likely to 
receive care consistent with their stated preferences26. 
Studies assessing how ACP can improve outcomes 
in vulnerable older people are still few, and of limited 
quality27, compared to other clinical populations with 
life-limiting conditions where the effectiveness of these 
directives has been studied in more detail. There is 
an urgent need for high quality trials to be conducted 
of the effectiveness and cost-effectiveness of ACP 
in dementia, including the longer term benefits and 
harms associated with ACP in the early post-diagnostic 
phase. 
Issues in implementing advance care 
planning
Optimal timing
As with issues around the optimal timing for 
introducing the palliative care approach, there 
are controversies regarding the best timing for 
discussions regarding advanced care planning. In 
principle, ACP should be undertaken with the person 
who has dementia early in the disease to ensure 
that their wishes are represented and responded to 
appropriately. However, such discussion could distress 
some people, especially if the health or social care 
professionals do not have the appropriate training or 
interpersonal skills.
In the wider context of decision-making for end-of-
life care older people have expressed worries and 
difficulties related to; thinking about and discussing 
death and dying; a perceived link between advance 
care statements and euthanasia; and the possibility 
that anticipated preferences might not reflect a 
readiness to ‘disengage’ from their lives when the 
time came12. There is also evidence that frail older 
people may be reluctant to address what they see as 
hypothetical questions regarding possible scenarios 
arising in the context of chronic disease care, some of 
which may be depressing to contemplate28. They are, 
somewhat paradoxically, more willing to confront the 
more concrete realities of treatment decisions in end-
of-life care and dispositions to be made after death28. 
There is limited direct evidence for the acceptability 
and feasibility of ACP conducted early in the disease 
course. A pilot study conducted in a UK memory clinic 
was accompanied by a small qualitative evaluation29. 
All but three of 12 patients considered ACP to be a 
positive and helpful experience. Perceived benefits 
included having time to think about the future, 
feeling relieved and less worried having discussed 
their preferences and shared them with family and 
professionals, and reassured about future support. 
Two patients found discussing the future dispiriting, 
while another found the exercise too hypothetical. 
There was a consensus among patients, carers and 
staff that ACP should be discussed sooner rather 
than later. For staff, this should be after the patients 
had time to think about the diagnosis, but when they 
were still in contact with the service, and still had 
the capacity to make decisions about future care. In 
Ireland, a survey of 133 primary care practitioners 
(PCPs) revealed that 96% considered dementia to 
be a terminal condition, and 61% thought that early 
discussions would assist decision-making during 
the advanced stages30. However, respondents were 
evenly divided on whether ACP should be initiated 
at the time of diagnoses. While most PCPs felt that 
their service should be taking the lead in introducing 
and promoting ACP, they also identified needs for 
training and support, and a standard format for ACP 
documentation. 
Capacity
Two studies from the UK attempted to calibrate 
decision-making capacity for advanced care planning 
against disease stage as indexed by Mini-Mental 
State Examination score, with convergent findings 
that MMSE thresholds of 18-20 best discriminated 
between those who could and could not engage 
meaningfully in advanced care planning31,32. However, 
other studies have raised concerns regarding ability 
to participate for those with even mild or very mild 
dementia. In a German Memory Clinic, objective tests 
of decision-making capacity revealed significant 
problems even among patients with mild cognitive 
impairment (MCI) and mild dementia, and those with 
more impaired decision-making capacity generally 
had a less pronounced desire to participate in 
decision-making33. In another study conducted in a UK 
memory clinic service, it was noted that participants 
with mild dementia (mean MMSE score 24) found it 
difficult to consider preferences and wishes about 
the end of their lives, with little sense of the potential 
value of ACP, or how expressing preferences and 
wishes now could influence care later34. People 
with dementia had difficulty considering their future 
selves, tending instead to express preferences relating 
to their current status and care needs. The EAPC 
consensus acknowledges some of these problems, 
recommending (3.4) that ‘In mild dementia, people 
need support in planning for the future’3.
Carer and family involvement
Carers may be involved in advanced care planning 
in two contexts. First, whether or not the person with 
dementia retains decision-making capacity, good 
practice guidance stresses the importance of involving 
significant others, in particular carers, in the process. 
Thus the EAPC recommends3, inter alia, that
2.2   Shared decision making includes the patient and 
family caregiver as partners and is an appealing 
model that should be aimed for.
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2.3   The healthcare team should ask for and address 
families’ and patients’ information needs on the 
course of the dementia trajectory, palliative care 
and involvement in care.
2.5   Current or previously expressed preferences with 
regard to place of care should be honoured as 
a principle, but best interest, safety and family 
caregiver burden issues should also be given 
weight in decisions on place of care.
2.6   Within the multidisciplinary team, patient and 
family issues should be discussed on a regular 
basis.
3.6   Advance care planning is a process, and plans 
should be revisited with patient and family on a 
regular basis and following any significant change 
in health condition.
When the person with dementia has lost capacity to 
make a decision, then the carer may act as a proxy 
decision maker, either informally or legally empowered 
through a lasting power of attorney. Under such 
circumstances, they are enjoined to consider the 
person with dementia’s best interests; in essence 
what they would have wanted had they retained the 
capacity to decide for themselves. However, there 
is growing evidence that the views of people with 
dementia and carers may differ, regarding the locus 
of decision-making, values and priorities, and patient 
preferences33–35. In the German Memory Clinic 
Study, people with mild cognitive impairment or mild 
dementia, and their relatives were asked to rank who 
should have the greatest say in medical and social care 
decisions, including stopping driving and relocation to 
a care home33. For medical care decisions, patients 
wanted to be guided by their physicians. For social 
care decisions they wanted physicians to have very 
little influence. For decisions in general they wished 
their relatives and carers to have little influence, 
compared to their own wish to participate in the 
process. The converse was true for relatives. In the 
UK, Dening et al conducted a qualitative study of 
generation and prioritisation of preferences for end-
of-life care by people with dementia alone, carers 
alone and dyads of people with dementia and their 
carers34. Quality of care, family contact, dignity and 
respect were ranked as significant themes by all 
groups. However, for people with dementia the ranking 
of priorities was: to maintain family links, to maintain 
independence, to feel safe, not to be a burden, to 
be treated with respect and dignity, to choose their 
place of care, to have pleasurable activities, person-
centred care, and to be in touch with the world and 
have a comfortable environment. For carers the order 
of priorities was: for them to be in control, for the 
person with dementia to have a good quality of life, to 
have good quality care, to have a comfortable death, 
to be treated with respect and dignity and for the 
carer to be supported. An important theme was the 
contrast between the prioritisation, by the persons with 
dementia, of maintaining independence, and, by the 
carer, of the need to be in control. In the dyad group, it 
was noted that carers tended to speak on behalf of the 
person with dementia, thus influencing the consensus. 
Several carers expressed concerns that an ACP would 
lead to loss of control at critical junctures, and would 
be open to misinterpretation by professionals. 
Two quantitative studies compared directly the end-
of-life care preferences of people with dementia 
(with decision making capacity) with their carers’ 
perceptions of what the person with dementia would 
prefer. In the UK, researchers compared 60 people 
with dementia and their carers’ preferences regarding 
three treatment options (antibiotics, cardiopulmonary 
resuscitation, tube-feeding) in three hypothetical 
illness scenarios (the ‘here and now’, severe stroke 
with coma and terminal cancer) using the Life Support 
preferences Questionnaire (LPSQ)35. Other than for the 
‘here and now’, both people with dementia and carers 
were uncertain about their treatment preferences, 
and agreement between person with dementia and 
carer was low to moderate. Carers tended to over-
estimate the person with dementia’s preference for 
life-prolonging intervention in the context of severe 
stroke. Relationship quality, carer distress and burden 
had no influence on levels of agreement. Conversely, 
in a similar study conducted in Israel, of people with 
MCI and mild dementia, spouse preferences for end-
of-life care correlated moderately well with patient 
preferences36.
Several studies have identified family and carer issues 
as potential barriers to the effective implementation 
of ACP for dementia. This was a frequently 
occurring theme according to the perceptions of 
healthcare professionals, who cited the occasional 
unwillingness of families to engage in ACP, and 
their unpreparedness for the task. This could be 
compounded by dysfunctional family dynamics and 
disagreements between family members37. The need 
for multidisciplinary input was cited, including social 
work, to better engage families in the process30,37. This 
finding gels with findings from a review of family carer 
perspectives38, which indicated a limited readiness 
among many to contemplate their relative’s death and 
the process of dying. Nonetheless, in a qualitative 
study of advanced care planning focused on end-of-
life care for nursing home residents with advanced 
dementia, carers generally understood the relevance 
and timeliness of discussing options for end-of-life 
care, and appreciated the opportunity to do so, while 
also experiencing some discomfort and distress39. 
Preparation for ACP in this context should include an 
assessment of the carer’s readiness to engage, which 
may be facilitated by a better understanding of the 
limited life expectancy, and hence the relevance of the 
discussion39. Practitioners should also be sensitive 
to grief reactions linked to the separation process, 
in advance of death, following admission to a care 
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home. A review has recommended more research 
to understand the thought processes and emotions 
of carers, and to enhance understanding of how to 
engage them with ACP38. It also counsels that ‘ACP 
may not be for everyone’ and therefore approaching 
ACP should be carefully considered by professionals 
before engaging with families and people with 
dementia.
EAPC guidelines3 recommend that; families need 
education regarding the progressive course of the 
dementia and (palliative care) treatment options; 
this should be a continuous process addressing 
specific needs in different stages, examining family 
receptiveness (recommendation 9.3) and that; families 
need support in their new role as (future) proxy 
decision maker (9.5).
Healthcare professionals
A review of the literature on healthcare professionals’ 
perceptions of ACP identified several important issues 
to be addressed in the early integration and planning 
for palliative care in dementia37. The first of these 
was a lack of awareness among many healthcare 
professionals of dementia as a life limiting condition, 
inhibiting discussion of end-of-life care and ACP. 
The UK health system Gold Standard Framework 
prognostic indicator has been recommended as a 
practical and easy to use tool to identify those that 
may be nearing the end of life40. However, a recent 
systematic review of prognostic indicators suggests 
some difficulty in reliably predicting six month mortality 
among people with advanced dementia; undernutrition 
and underhydration, comorbidity and dementia severity 
were the most reliable predictors41. The second issue 
was ethical and moral concerns voiced by some 
healthcare professionals. These included a hesitancy 
to discuss death, and a fear of upsetting the people 
in their care, compounded by moral dilemmas around 
discussing future goals of care focused on a palliative 
as opposed to a curative approach. Communication 
challenges when interacting with people with dementia 
and their families were also highlighted. Some staff in 
some studies viewed their role as preserving life, even 
if this was against the expressed wishes of the patient 
and their family. There were also concerns expressed 
that ACP might turn out to be a ‘false promise’ if 
there were later problems with implementation, either 
because they were no longer considered consistent 
with the patient’s current best interests, or because 
of resource limitations. The review concluded that 
despite evidence that healthcare professionals 
recognise the potential benefits of ACP, they struggle 
with its implementation. There was a great need for 
education and training of health professionals to 
improve consistency in practice; regarding dementia 
as a condition, the illness trajectory, and the concept 
and process of ACP itself. The need for a structured 
approach to ACP has also been highlighted, both 
for recording the outcomes of the process, and the 
potential utility of ACP toolkits42. 
The EAPC guidelines3 recommend that; the healthcare 
team in its entirety, including allied health professionals 
and volunteers, needs to have adequate skills in 
applying a palliative care approach to dementia 
(recommendation 10.1); core competencies should be 
available within a healthcare team, and all individual 
members should be able to provide at least a baseline 
palliative care approach (10.2) and that; care plans 
should be documented and stored in a way that 
permits access to all disciplines involved in any stage 
and through transfers of care (3.7).
5.5 End-of-life care
Access to palliative care at end-of-life
As previously noted, it has been stated that those 
dying with advanced dementia are often not seen as 
having a terminal condition, and are much less likely 
than others to be managed palliatively. Some research 
from the early 2000s supported that conclusion5,6. 
Recently published evidence provides a more nuanced 
picture regarding progress towards access to palliative 
care for people with dementia. For example, in the 
USA, nursing homes appear to be moving towards 
providing a more palliative approach to end-of-life care 
for residents with a diagnosis of dementia. Trends in 
the use of hospice care in the last 100 days of life were 
compared for over a million deaths of US nursing home 
residents occurring between 2003 and 200743. Over the 
five years, hospice use for people dying with dementia 
increased from 25.1% to 36.5%, and from 26.5% to 
34.4% for other deaths. The rate of in-hospital deaths 
remained virtually unchanged. By 2007, people dying 
with dementia were significantly more likely than 
others to use hospice care services (OR 1.07, 95% CI: 
1.04-1.11) and much less likely to die in a hospital (OR 
0.76, 95% CI: 0.74-0.78). In another recent US study, 
for those admitted to hospice care, the quality of care 
for those with a diagnosis of dementia did not seem 
to differ from others, other than with respect to an 
excess use of tube-feeding44. The Dutch End of Life in 
Dementia study showed widespread use of appropriate 
palliative care measures in nursing homes the last 
week of life. Opioid medication was prescribed to 
73% of those in pain. Shortness of breath was treated 
with opioids in 71% of cases, with 74% receiving 
oxygen. Bronchodilators and diuretics were used for 
symptomatic relief. For agitation, nonpharmacological 
interventions were provided for 62% of those affected, 
often combined with anxiolytic or sedative medication. 
Pain and shortness of breath were mostly treated with 
opioids and agitation mainly with anxiolytics. At the 
day of death, 77% received opioids, and 21% received 
palliative sedation45.
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Quality of end-of-life care
Two recent studies of the quality of end-of-life hospital 
care for people with dementia in Ireland and Germany 
reveal significant persisting problems46,47. In Ireland, 
a National Audit of hospital care for people with 
dementia revealed that many assessments essential to 
dementia palliative care were not performed46. Of the 
total sample, 76 patients died, were documented to 
be receiving end-of-life care, and/or were referred for 
specialist palliative care, and for this group even less 
symptom assessment was recorded; 27% received 
no pain assessment, 68% no delirium screening, and 
93% no assessment of mood or behavioural and 
psychological symptoms of dementia. In all, 37% had 
antipsychotic drugs during their admission and 71% 
of these received a new prescription in hospital, most 
commonly for agitation. In a German study the opinion 
of carers was sought regarding end-of-life care for 
1241 recently deceased older people, of whom 310 
had a diagnosis of dementia47. 42% of the people 
with dementia (compared with 36% of others) died at 
home, which was the preferred outcome for 95% of 
patients and 78% of relatives. People with dementia 
were also less likely to die in a hospital ward (20% vs 
27%), an intensive care unit (6% vs 16%) or a hospice 
(3% vs 10%). According to information supplied by the 
relatives, most of the people with dementia suffered in 
the days before death from symptoms that could have 
been alleviated; disorientation and confusion (86.9%); 
anxiety (61.0%); tension (59.9%); shortness of breath 
(56.7%), and pain (52.5%). While pain was actually a 
less common experience for people with dementia 
than others, 36% of people with dementia vs 27% 
of others died with a pressure sore. For people with 
dementia, end-of-life care at home and in care homes 
was rated as of significantly better quality than hospital 
care. Relatives were critical of the quality of care on 
hospital wards, citing the limited availability of staff and 
emotional support47. 
Box 5.3
eapc guidelines3 relevant to end-of-life care for people with dementia
Domain 6. Avoiding overly aggressive, 
burdensome or futile treatment
6.1   Transfer to the hospital and the associated risks 
and benefits should be considered prudently 
in relation to the care goals and taking into 
account also the stage of the dementia.
6.2   Medication for chronic conditions and 
comorbid diseases should be reviewed 
regularly in light of care goals, estimated life 
expectancy, and the effects and side effects of 
treatment.
6.3   Restraints should be avoided whenever 
possible.
6.4   Hydration, preferably subcutaneous, may be 
provided if appropriate, such as in case of 
infection; it is inappropriate in the dying phase 
(only moderate consensus).
6.5   Permanent enteral tube nutrition may not be 
beneficial and should as a rule be avoided in 
dementia; skillful hand feeding is preferred (only 
moderate consensus).
6.6   Antibiotics may be appropriate in treating 
infections with the goal of increasing comfort 
by alleviating the symptoms of infection. Life-
prolonging effects need to be considered, 
especially in case of treatment decisions 
around pneumonia.
Domain 7. Optimal treatment of symptoms 
and providing comfort
7.1    A holistic approach to treatment of symptoms 
is paramount because symptoms occur 
frequently and may be interrelated, or 
expressed differently (e.g., when pain is 
expressed as agitation).
7.2    Distinguishing between sources of discomfort 
(e.g., pain or being cold) in severe dementia 
is facilitated by integrating views of more 
caregivers.
7.3   Tools to assess pain, discomfort and 
behaviour should be used for screening and 
monitoring of patients with moderate and 
severe dementia, evaluating effectiveness of 
interventions.
7.4    Both non-pharmacological and 
pharmacological treatment of physical 
symptoms, challenging behaviour or discomfort 
should be pursued as needed.
7.5    Nursing care is very important to ensure 
comfort in patients near death.
7.6    Specialist palliative care teams may support 
staff in long-term care settings in dealing with 
specific symptoms, while maintaining continuity 
of care. In managing behavioural symptoms, 
however, palliative care teams may need 
additional dementia care specialist expertise.
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Good practice guidance on end-of life care 
for people with dementia
In the World Alzheimer Report 2013, we highlighted the 
Alzheimer Europe 2008 position paper and guidelines 
on end-of-life care48. This has now been updated to 
2013. In 2014 the European Association for Palliative 
Care published their White Paper defining optimal 
palliative care in older people with dementia, which 
includes recommendations for end-of-life care3.
Principles of end-of-life care
The key objectives of end-of-life care are articulated 
in the Alzheimer Europe guidelines as maintaining 
the dignity, personhood and quality of life of the 
person with dementia, while attending also to carers’ 
needs48. Alzheimer Europe also focuses on the need 
for good communication throughout, and attending 
to spiritual needs. Their guidelines provide relevant, 
practical and helpful guidance on pain management; 
feeding and swallowing problems; constipation, 
diarrhoea and incontinence; pneumonia and infections; 
dehydration and mouth care; skin care; maintaining 
body temperature; use of sedation; restraint, and falls; 
breathing difficulties; and the moments preceding 
and following death48. The principles of end-of-life 
care are summarised in the EAPC guidelines3 under 
Domain 6 (avoiding overly aggressive, burdensome or 
futile treatment), and Domain 7 (optimal treatment of 
symptoms and providing comfort) (see Box 5.3). 
Box 5.4
principles of comfort care. core statements in canadian comfort care Booklet49
Advanced dementia is a terminal condition
1.   Advanced dementia should be considered a 
terminal condition with most patients dying 
from nutrition/hydration or infection problems, 
especially pneumonia.
Hydration and nutrition issues
2.   Feeding tubes are not recommended only to 
prolong life at this stage of dementia.
3.   Fluids given intravenously or subcutaneously 
may help some patients but can also contribute 
to discomfort (increasing bronchial secretions, 
delaying pain-free coma state) and prolong the 
dying process.
4.   Withholding or withdrawing artificial nutrition/
hydration is an acceptable option in advanced 
dementia, when swallowing difficulties are 
irreversible.
5.   Withholding or withdrawing artificial nutrition/
hydration is generally not associated with 
discomfort, with adequate mouth care.
Antibiotics for end-stage pneumonia
6.  When ‘comfort care without life prolongation’ 
is the goal, antibiotics can be withheld and 
treatment will then aim at symptom control
7.  Even when pneumonia is treated with antibiotics, 
clinicians should pay attention to symptom 
control (e.g. prescribing opioids despite risk of 
respiratory depression) because pneumonia 
usually causes significant discomfort.
Use of opioids and sedation
8.  Prescribing opioids may be necessary to control 
pain or breathing difficulties and is acceptable 
if the intention is to relieve the patient and not to 
hasten death.
9.   Sedation is useful for some anxious patients and 
the advantages of less sedation may be less 
relevant in the context of severe dementia.
Cardiopulmonary resuscitation
10.  Cardiopulmonary resuscitation is not 
recommended in advanced dementia because it 
can harm the patient and has very little chance 
of success.
Hospital transfer
11.  Hospital transfer of the patient with advanced 
dementia should be exceptional, only to provide 
comfort by technical means not available in the 
nursing home.
Medical decision process
12.  In decisions regarding whether or not to use life-
prolonging treatment, the ideal decision-making 
process is to reach a consensus between 
the physician, the substitute decision maker 
and other significant relatives or friends of the 
patient.
13.  The substitute decision maker does not make 
decisions; his or her role is to give or withhold 
consent to medical options with regard to the 
patient’s best interests (according to patient 
values and any written or verbal advanced 
directives).
14.  The doctor does not have the power to impose a 
management plan on the family. If the substitute 
decision maker and the physician disagree, they 
should seek compromise.
Euthanasia
15.  Active life termination (hastening death) is not an 
acceptable option for advanced dementia.
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These are articulated in a slightly different form, and 
with more focus on the avoidance of burdensome or 
futile treatment in the Canadian Comfort Care Booklet 
(see Box 5.4) designed for use by staff in care homes49. 
This has also been evaluated for its cultural relevance 
and acceptability in Japan and France.  
Components of good quality end-of-life care
It is clear from existing guidelines that good quality 
end-of-life care, is, to an important extent, about 
attention to symptom burden. Achieving comfort 
may involve quite intensive medical management and 
pharmacological as well as non-pharmacological 
intervention, alongside avoiding futile and burdensome 
investigation and management. However dignity, 
quality of life, and spiritual well-being will be achieved 
through attention to the overall quality of person-
centred care, communication, and the environment in 
which end-of-life care is provided.
Attention to symptom burden 
Symptom burden for people with dementia is a 
common problem towards end of life. The most 
commonly experienced symptoms are pain, pressure 
sores, shortness of breath, eating and swallowing 
problems, infections, agitation and other psychological 
symptoms (Box 5.5). In the Dutch End of Life in 
Dementia study (2007-2011) the most common 
symptoms in the last week of life for 330 nursing home 
residents were pain (52%), followed by agitation (35%) 
and shortness of breath (35%)45. Pain and agitation 
were particularly strongly associated with low quality of 
life at the end-of-life. Death from respiratory infection 
was associated with the largest symptom burden. 
Some of the symptoms, in particular pain, are under-
detected in patients with dementia50. This is likely to 
result from communication difficulties in advanced 
dementia, combined with lack of good assessment 
skills by some health professionals50. Under-detection 
can lead to under treatment of symptoms, and this has 
been reported as a concern in some studies51. On the 
other hand, over-treatment with burdensome and futile 
interventions, such as tube-feeding and antibiotics, 
in the period leading to end of life should also be 
avoided51. 
Supporting carers and families
It has been reported from the USA that while end-
of-life care for people with dementia was extremely 
demanding of family carers, they often showed 
considerable resilience in the face of bereavement; 
intervention and support services were needed most 
before the patient’s death58. Support for carers needs 
to be culturally sensitive and take into account ethnic 
differences in caregiving experiences, attitudes to end-
of-life care and bereavement reactions59. 
Box 5.5
Symptom burden at the end of life
•	 Pain:	Depending	on	the	setting,	the	stage	of	
dementia,	and	the	method	of	ascertainment,	
between	20%	and	50%	of	people	with	
dementia	report	some	form	of	pain	in	the	
course	of	their	illness	progression52,	with	
higher	proportions	affected	towards	the	end	
of	life47,51,53.	One	study	found	that	people	
with	dementia	are	more	likely	to	experience	
pain	in	the	last	six	months	of	life,	compared	
to	cancer	patients	(75%	vs	60%)54.	
•	 Pressure	sores:	several	studies	have	
recorded	the	prevalence	of	pressure	ulcers	
towards	the	end	of	life,	varying	from	17%	in	
a	study	of	terminal	dementia5	to	47%	in	a	
study	of	older	adults	with	advanced	dementia	
living	in	seven	Italian	long-term	institutions55.	
Pressure	sores	should	be	avoidable	with	
good	nursing	care,	and	are	a	key	indicator	of	
care	quality.
•	 Shortness	of	breath:	a	recent	review	of	the	
literature	identified	that	shortness	of	breath	is	
a	common	symptom	in	about	half	to	three-
quarters	of	people	with	dementia51,	and	
increases	closer	to	death53.
•	 Eating	and	swallowing	problems:	Problems	
with	swallowing	are	common	in	advanced	
dementia.	However,	the	use	of	feeding	tubes,	
while	widespread,	is	controversial,	and	needs	
to	be	evaluated	carefully	with	respect	to	the	
preferences	of	the	person	with	dementia	and	
carer,	and	the	balance	of	risks	and	benefits	
for	individual	patients.	A	Cochrane	systematic	
review	suggests	that	tube	feeding	in	people	
with	dementia	does	not	confer	any	benefit	
for	nutritional	status,	reduction	of	pressure	
sores,	or	survival	time56.	
•	 Infections:	Pneumonia	and	other	infections	
are	often	the	direct	cause	of	death	for	people	
with	dementia.	Up	to	71%	of	dementia	
deaths	are	directly	linked	to	pneumonia57,	a	
condition	which	can	cause	much	discomfort,	
but	which	can	be	alleviated	through	effective	
palliative	care.	
•	 Agitation	and	other	psychological	symptoms:	
It	has	been	estimated	that	90%	of	people	
with	dementia	will	develop	some	form	of	
behavioural	and	psychological	symptoms	of	
dementia	(depression,	anxiety,	hallucinations,	
delusions,	wandering,	agitation,	aggression),	
and	that	over	half	of	people	with	dementia	
remain	agitated	and	distressed	towards	the	
end	of	life50.
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A consistent theme to emerge from a synthesis of 
qualitative research into caregivers’ perceptions of 
end-of-life care, was the importance of relationships 
with professionals as a core component of care 
quality38. Key elements included frequency of contact, 
provision of information, and support and reassurance 
for the carers. These seemed to be important issues, 
regardless of the context of end-of-life care; at home, 
at a care home, or in hospital. As previously noted, 
in one German study of end-of-life care, the carers 
of people with dementia were particularly critical of 
the quality of care on hospital wards, highlighting the 
limited availability of staff and of emotional support47. 
Alzheimer Europe guidelines highlight the concern 
that carers’ commonly feel when part or all of the 
care of the person with dementia is taken over by 
professionals - that they may be excluded, and that the 
person with dementia is not being cared for properly48. 
This scenario is played out with more intensity in 
the end-of-life phase, as more medical and nursing 
support is required, again, regardless of care setting. 
Carers naturally feel that they are best placed to 
understand the needs and wishes of the person with 
dementia, and want to share this with the healthcare 
professionals. Alzheimer Europe recommends that 
a good relationship and an atmosphere of trust is 
established when carers feel that their views are 
properly considered, that they can ask questions, that 
their concerns and criticisms are dealt with in a positive 
manner and that they are given every opportunity to 
participate in the care of the person with dementia48. 
When end-of-life care is provided at hospital or in 
a care home, carers may want to be permanently 
present, and this need should be met including the 
possibility to sleep at the facility. For those dying at 
home, flexible respite care may allow carers to get 
some rest with the reassurance that they will be with 
the person with dementia at the time of death48.
The EAPC guidelines3 recommend that; families may 
need support throughout the trajectory, but especially 
with institutionalisation, with a major decline in health 
and when death is near (recommendation 9.2); family 
involvement may be encouraged; many families may 
wish to be involved in care even when the person is 
admitted to a care home (9.4); and that professional 
caregivers should have an understanding of families’ 
needs related to suffering from chronic or prolonged 
grief through the various stages, and when decline is 
evident (9.6).
Professional staff training and development
Communication and shared decision-making are key 
factors in end of life care. Having trust in doctors and 
surrounding staff is an essential factor for patients 
and caregivers during palliative care60. However, 
many nurses and care home staff do not feel well 
prepared to deal with issues related to end-of-life and 
dying with dementia, and there is a need to improve 
training for nursing home and specialist palliative care 
staff to deal with advanced dementia, and to achieve 
best practice for people with dementia at the end of 
life61. Symptom management, focusing on pain and 
behavioural and psychological symptoms, and also 
ways of approaching and dealing with patients and 
their families, are two areas that have been highlighted 
as requiring improvement. 
Effectiveness of palliative care approaches 
in end-of-life care
There is very little direct evidence regarding the 
effectiveness of palliative approaches to end-of-
life care, and no randomised controlled trials have 
been carried out to test its effectiveness or cost-
effectiveness. The lack of relevant evidence in this area 
is striking.
In a observational cohort study involving 28 care 
homes (the Dutch End of Life in Dementia study), data 
was analysed for 148 residents who died after follow-
up. Care plans made at the time of admission were 
assessed to determine if a palliative ‘comfort goal’ 
was agreed at the time. The main outcomes were 
family satisfaction with care, and the quality of dying. 
Families were more satisfied with end-of-life care when 
a comfort goal was established shortly after admission, 
but only for those residents who died within six months 
of admission. No association was found between 
‘comfort goal’ care plans and quality of dying62.
Other studies have focused on service utilisation and 
cost outcomes. In the UK the effect of an Appreciative 
Inquiry intervention, designed to improve end-of-life 
care for people with dementia living in care homes, 
on service and hospital care costs was assessed for 
three care homes before and after implementation 
of the six month intervention63. The intervention 
aimed to change how care home staff, primary care 
practitioners and district nurses worked together to 
address difficulties and uncertainties of providing end-
of-life care to people with dementia. It was perceived 
as having a positive impact on working relationships. 
Following the intervention total service costs fell 
by 43%, and hospital care costs by a remarkable 
88%. In New York, pharmacy costs were compared 
before and after a palliative care consultation for 60 
hospital inpatients with advanced dementia64. There 
was a significant average decrease in overall average 
daily pharmacy cost from US$31.16 to $20.83. There 
was also a significant increase in the proportion of 
participants taking analgesics, from 55% to 73%, and 
a proportionate rise in daily analgesic cost. 
5.6 Summary and conclusion
This scoping review of the recent literature on palliative 
care for people with dementia reveals a significant 
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upswing in research activity, coupled with increasing 
advocacy for, and awareness of, the relevance of 
palliative care principles to dementia care. Much of 
the research that we have highlighted in this review 
comprises studies of process, and implementation, 
that is the extent to which palliative care approaches 
are being applied in practice, and difficulties, obstacles 
and barriers to their more widespread uptake and 
implementation. Much less research relates to the 
outcomes achieved by palliative care, and how these 
can be optimised. The lack of any experimental studies 
(randomised controlled trials) of the effectiveness of 
advanced care planning, or the implementation of a 
palliative care approach at any stage of care is very 
striking. It seems that current guidelines on good 
practice are almost entirely based upon expert opinion 
and consensus, rather than evidence3,48. 
The reasons for this state of affairs are hard to 
determine. Within the palliative care field in general 
the evidence-base on palliative care approaches for 
progressive chronic diseases other than cancer has 
been slow to develop65. As several commentators 
have highlighted, there are still conceptual issues to be 
resolved. The concept of advanced dementia is unclear 
and open to varying definitions and interpretations9. 
The transition into ‘end-of-life’ phase is also not clearly 
demarcated2,9. The application of a ‘palliative care 
approach’ to these phases, and/or its potential wider 
application across the disease course continues 
to be debated. Nevertheless the improvement of 
palliative care services for people with dementia is an 
acknowledged policy priority for governments across 
Europe66. 
Investigators for the European IMPACT project 
have called for a systematisation of palliative care 
for people with dementia2, with structured care 
pathways and good practice supported by evidence, 
and identification of appropriate outcomes to allow 
the effects of interventions to be measured. The 
investigators identified five key areas where more 
clarity was required; the division of responsibilities 
amongst practitioners of different health and social 
care disciplines; the structure and function of 
advanced care planning; the management of rising 
risk and increasing complexity; boundaries between 
disease-modifying treatment and palliative care 
and between palliative and end-of-life care; and the 
process of bereavement2. Support for this call for 
a more structured approach to policy and planning 
for the continuum of care for people with dementia, 
and the place of palliative care within it, comes from 
a recent review of national dementia strategies67. 
The reviewers examined six transitions covering the 
dementia journey from symptom recognition to end-
of-life care and critically evaluated whether and how 
the national dementia strategies of Australia, England, 
France, the Netherlands, Norway, Scotland, and the 
United States addressed each transition. They found 
that most adequately address earlier transitions in 
the journey, but fewer strategies address the later 
transitions. In essence, the focus is upon living well 
with dementia, with relatively less attention to the 
complex medical, social and ethical management of 
the complex physical, cognitive and functional declines 
that culminate in death.
The EAPC consensus guidelines3 also recognise the 
need for system level initiatives to promote access 
to better palliative care including; more collaboration 
between dementia care and palliative care services 
(recommendation 11.3); economic and system 
incentives to encourage excellent end-of-life care for 
patients with dementia (11.6); and national strategies for 
dementia, for palliative care, end-of-life care, and for 
long-term care to include palliative care for dementia 
patients (11.8).
Most would agree that people with dementia should be 
encouraged and enabled to exercise their autonomy 
regarding options for future care, consistent with their 
values and preferences. Early discussions with family 
carers that acknowledge the likely loss of decision-
making capacity and their increasing role as proxy 
decision-makers would be likely to assist carers in 
assuming this role, and enhance their ability to judge 
what might be in the person with dementia’s best 
interests. The empowerment of people with dementia 
needs to be stressed, to emphasise that the palliative 
care agenda is focused, first and foremost, upon 
their choices, and their quality of life, rather than cost 
savings. There is evidence of undermanagement of 
chronic comorbid physical health conditions, with 
missed opportunities to improve function and avoid 
acute crises leading to hospitalisation68,69. Palliative 
care, informed always by patient preferences, avoids 
futile and burdensome interventions, while ensuring 
that everything possible is done to maintain comfort. 
At the level of costs, one would want to avoid ‘bad 
costs’ (arising from healthcare that is futile, ineffective 
and does not improve quality of life), while reinvesting 
in ‘good costs’ (that enhance comfort and quality 
of life). A good example is an overall reduction of 
pharmacy costs based upon reducing polypharmacy 
at the end-of-life, but which included a net increase in 
costs of analgesic medication64. Given that there are 
no curative or disease-modifying treatments available 
for dementia, it is important to focus upon the specific 
goals of dementia care, which can include, at various 
phases and to different degrees, prolongation of life, 
improvement of function, and comfort3. While several 
studies and reviews have addressed the optimal time 
for a more palliative approach, none have done so from 
the perspective of the person with dementia, whose 
views on these matters should be paramount.
Comprehensive dementia care cannot, and should not 
be subsumed into a palliative care approach, across 
the disease course. Nevertheless, palliative care 
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principles are applicable at every stage of the journey 
of care, and much can be learnt from the achievements 
of the discipline in other progressive chronic disease 
areas. There is an urgent need for more research, 
specific to the dementia field, regarding; preferences of 
people with dementia, and how these can be elicited; 
the implementation, benefits and harms of advance 
care planning; and the relative costs and benefits of 
palliative care assessments and services in the more 
advanced phases of the condition. Another major 
gap in the research literature is that of palliative care 
services and end-of-life issues for people with young 
onset dementia, who have a higher absolute and 
relative loss of life years, and, in all likelihood, specific 
needs70. 
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chapter 6 
dementia care in canada, china, 
Indonesia, Mexico, south africa, 
south Korea and switzerland 
6.1 Introduction
In	this	chapter	we	explore	the	context	for	the	
implementation	of	the	proposed	dementia	healthcare	
pathways	in	Canada,	China,	Indonesia,	Mexico,	South	
Africa,	South	Korea	and	Switzerland,	the	countries	
for	which	we	will	investigate	the	cost	implications	of	
implementing	the	dementia	healthcare	pathways.	For	
each	country	we	consider,	briefly,	key	demographic	
and	socioeconomic	characteristics,	the	prevalence	
of	dementia	and	estimated	numbers	of	people	with	
dementia	in	2015	and	2030,	the	current	dementia	
and	healthcare	policy	context,	other	sources	of	
care	and	support	to	people	with	dementia	and	the	
main	challenges	that	need	addressing	in	each	of	the	
dementia	care	systems.
These	descriptions	of	the	dementia	care	systems	
have	been	produced	through	a	scoping	review	of	both	
academic	and	grey	literature.	Each	country	description	
has	been	revised	by	academics,	officials	or	members	
of	national	Alzheimer’s	associations.	We	have	also	
benefitted	from	research	assistance	and	support	
from	researchers	from	most	of	the	countries	covered,	
who	have	enabled	us	to	access	information	written	in	
languages	not	spoken	by	the	authors.
The	amount	of	information	available	for	the	different	
countries	varied	considerably,	with,	predictably,	
much	more	from	HIC	than	for	LMIC.	Also,	in	countries	
where	the	health	and	social	care	systems	are	highly	
decentralised,	such	as	Canada,	China	and	Switzerland,	
there	is	very	limited	national	level	data,	or	even	
comparable	data	for	the	different	regions,	between	
which	there	may	be	significant	variation.
6.2 Dementia care in Canada
Canada,	in	North	America,	is	the	world’s	second	
largest	country	in	land	mass,	and	the	38th	in	terms	of	
population.	Most	of	the	population	is	concentrated	in	
urban	centres	in	the	south	of	the	country.	The	majority	
of	the	country’s	aboriginal	population	lives	on	rural	
reserves,	land	claim	regions	in	the	Arctic	or	in	poor	city	
neighbourhoods	(Marchildon,	2013).
Canada	is	a	high-income	country,	with	an	advanced	
industrial	economy.	It	has	a	federal	government	
structure,	with	two	levels	of	government	of	equal	
constitutional	importance:	the	federal	(or	central)	level	
and	the	ten	provincial	governments.	Three	Northern	
territories	also	have	some	autonomy,	but	not	to	the	
same	degree	as	the	provinces.
Prevalence of dementia
Following	a	systematic	review	and	consultation	with	a	
panel	of	national	and	international	experts	convened	by	
the	Alzheimer	Society	of	Canada,	there	is	consensus	
that	“the	Canadian	Study	of	Health	and	Aging	(1994)	
remains	the	best	and	most	reliable	population	data	
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source	to	use	as	a	basis	to	build	present	and	future	
prevalence	estimates”	(Alzheimer	Society	of	Canada,	
2016).	These	are	also	the	same	prevalence	estimates	
reported	in	the	World	Alzheimer	Report	2015	(Prince	et	
al.,	2015).	
Based	on	these	prevalence	rates,	the	World	Alzheimer	
Report	2015	estimated	that	in	2015	there	were	just	over	
556,000	people	with	dementia	in	Canada,	of	these,	
65%	were	women	and	nearly	half	were	aged	85	or	
more.	By	2030	the	number	of	people	is	expected	to	
rise	to	886,000	(see	Figure	6.1).	
Policy landscape and healthcare system context
Canada	does	not	currently	have	a	national	dementia	
strategy,	although	in	2014	the	Health	Minister	
announced	plans	to	develop	one.	However,	many	
of	Canada’s	provinces	have	historically	developed	
provincial	plans	(Rosow	et	al.,	2011).	The	Alzheimer	
Society	of	Canada	and	the	Canadian	Medical	
Association	have	both	been	pushing	for	a	national	
strategy	as	the	prevalence	of	dementia	is	rising	and	
with	that	the	economic	impact	on	Canada’s	already	
strained	health	and	social	care	systems.
In	part	reflecting	the	lack	of	a	national	policy	for	
dementia	care	and	support	in	Canada,	there	is	very	
little	data	available	on	dementia	at	national	level.	
While	there	is	good	information	at	provincial	level,	the	
information	collected	is	mostly	not	comparable,	making	
it	difficult	to	bring	it	together	and	to	provide	a	national 
picture	of	the	state	of	dementia	care	in	Canada.
Studies	of	the	costs	of	dementia	in	Canada	have	
reported	widely	differing	estimates,	ranging	from	
$910	million	to	$33	billion.	An	expert	panel	facilitated	
by	the	Alzheimer	Society	of	Canada	examined	the	
methods	and	data	used	in	the	different	studies.	The	
panel	agreed	that	ideally	costs	of	illness	studies	
should	take	a	societal	perspective	when	estimating	
the	consequences	of	dementia,	that	the	scope	should	
include	direct	and	indirect	service-related	costs,	as	
well	as	informal	and	intangible	costs,	and	that	these	
costs	should	be	compared	between	populations	
living	with	dementia	and	those	without	the	condition.	
Based	on	those	criteria,	the	panel	recommended	the	
estimates	of	the	National	Population	Health	Study	of	
Neurological	Conditions	(Alzheimer	Society	of	Canada,	
2016).
According	to	this	study,	the	costs	of	dementia	in	
Canada,	including	the	costs	of	unpaid	care,	were	
($CAD)	10.4	billion	in	2016	and	projected	to	rise	to	
16.6	billion	by	2031	(Public	Health	Agency	of	Canada,	
2014).	The	study	also	reported	that	costs	for	people	
with	dementia	are	estimated	to	be	five-and-half	
times	greater	than	for	older	people	who	do	not	have	
dementia.	Home	care	and	long-term	care	are	the	
largest	contributors	to	direct	costs.	In	2011,	family	
caregivers	provided	19.2	million	unpaid	hours	of	care.	
The	main	responsibility	for	healthcare	is	with	the	
provinces	and	in	practice	each	of	them	has	its	own	
healthcare	system.	However,	the	federal	government	
retains	some	responsibilities,	for	example	by	
guaranteeing	universal	access	to	healthcare	services,	
some	aspects	of	health	and	pharmaceutical	regulation	
(Medicare)	and	the	financing	and	administration	of	
health	benefits	and	services	for	specific	populations	
(primary	care	to	aboriginal	communities,	and	some	
services	delivered	to	the	Royal	Canadian	Mounted	
Police,	Correctional	Services,	the	Armed	Forces	and	
veterans).
The	healthcare	system	in	Canada	is	predominantly	
publicly	financed	(70%),	through	a	mixture	of	federal,	
provincial	and	territorial	taxes	(Marchildon,	2013).	All	
provinces	have	a	model	consisting	of	a	single-payer	
hospital	and	medical	care	service	with	a	centralised	
payment	system.	Medically	necessary	hospital	
and	physician	services	are	free	at	the	point	of	use	
(Medicare).	The	provincial	and	territorial	governments	
provide	or	subsidise	prescription	drugs,	long-term	care	
and	home	care;	these	programmes	usually	require	user	
fees,	except	for	some	exempted	populations	(mostly	
the	older	population	and	the	very	poor).	There	is	
virtually	no	public	coverage	for	dental	care	and	vision.	
There	is	pressure	on	health	financing	in	Canada	
as	a	result	of	tax	cuts	by	the	federal	and	provincial	
governments	and	continued	increases	in	expenditure.	
While	the	outcomes	of	the	Canadian	healthcare	
system	compare	favourably	to	those	of	other	high-
Figure 6.1 
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income	countries	(Marchildon,	2013),	there	is	public	
dissatisfaction	with	long	waiting	times	and	shortages	
of	services,	which,	particularly	for	long-term	care,	have	
led	to	increasing	pressures	on	family	caregivers	and	on	
other	parts	of	the	healthcare	system	(The	Conference	
Board	of	Canada,	2015).
Current diagnostic and healthcare pathways
In	Canada	the	typical	healthcare	pathway	starts	with	
a	visit	to	a	family	physician	(who	may	be	either	in	a	
traditional	single	practice	or	in	an	inter-professional	
primary	care	team).	The	family	physician	acts	as	the	
gatekeeper	and	requests	diagnostic	tests,	prescribes	
drug	therapies	and	refers	to	medical	specialists	as	
needed.	The	model	of	primary	care	is	changing,	
with	less	single-doctor	practices	and	more	inter-
professional	primary	care	teams,	as	a	result	of	the	
10-year	plan	of	2004,	which	contained	a	commitment	
that	at	least	50%	of	all	residents	should	have	access	
to	primary	care	24	hours	a	day,	7	days	a	week.	Most	
hospitals	in	Canada	are	public	or	non-profit,	although	
there	are	some	private	for-profit	specialised	ambulatory	
and	advanced	diagnostic	services.	Hospitals	provide	
some	ambulatory	care,	however	this	is	increasingly	
being	provided	in	primary	care	or	specialised	
ambulatory	services	(Marchildon,	2013).
Although	Canada	has	distinct	healthcare	systems	in	
each	of	the	provinces,	clinical	practice	in	dementia	
diagnosis	and	treatment	is	guided	by	evidence-based	
national	clinical	standards,	approved	by	consensus	
by	the	academic	and	clinical	community.	The	current	
clinical	standards	for	the	diagnosis	and	treatment	
of	dementia	were	approved	in	2012,	at	the	“Fourth	
Canadian	Consensus	Conference	on	the	Diagnosis	
and	Treatment	of	Dementia	(CCCDTD4)”	(Gauthier	et	
al,	2012).
As	discussed	in	chapter	2	and	Aminzadeh	et	al	(2012),	
in	Canada	the	national	clinical	standards	argue	that	
most	types	of	dementia	can	be	diagnosed	in	primary	
care,	and,	in	line	with	the	previous	versions,	the	
fourth	version	emphasises	that	the	diagnosis	and	
management	of	dementia	should	primarily	be	a	primary	
care	responsibility	(Moore	et	al,	2014).	Despite	this,	
there	is	some	evidence	from	Alberta	that,	in	practice	
and,	in	comparison	with	the	guidelines	and	with	more	
specialised	diagnostic	settings	such	as	the	Geriatric	
Assessment	Team,	primary	care	practitioners	are	
underutilising	diagnostic	and	functional	assessment	
tools,	not	giving	sufficient	attention	to	caregiver	issues,	
and	underusing	community	supports	(Parmar,	2014).	
The	study	also	highlights	the	poor	level	of	coordination	
between	primary	care	and	specialist	services,	resulting	
in	unnecessary	duplication	of	assessments.
Variations	in	practice,	also	with	respect	to	the	national	
clinical	standards,	have	also	been	observed	across	
different	areas.	A	study	comparing	the	provision	
of	dementia	healthcare	in	three	areas	of	Canada	
found	variability,	which	was	particularly	marked	
for	the	provision	of	advance	care	planning	and	day	
programme	services.	Variation	was	found	both	
between	and	within	provinces	(Tam-Tham	et	al,	2016).	
Due	to	its	geography,	providing	care	to	people	in	
rural	and	remote	communities	is	challenging	in	
Canada.	A	study	that	involved	surveying	local	home	
care	assessors	about	availability	of	dementia	care	
services	in	Saskatchewan	found	a	significant	lack	of	
availability	of	diagnostic	services	such	as	dementia	
screening,	multidisciplinary	team	assessments	and	
post-diagnostic	support	(counselling,	registers	for	
individuals	and	caregivers,	caregiver	support	groups)	
(Morgan	et	al.,	2015).	There	is	growing	research	on	
the	use	of	telehealth	to	deliver	care	and	support	to	
people	with	dementia	and	caregivers	in	rural	areas	(for	
example	Conn	et	al,	2013	and	O’Connell	et	al,	2014).
There	are	also	differences	in	the	treatment	and	care	
of	people	living	in	residential	care	homes,	who	are	
being	diagnosed	at	a	later	stage	than	those	living	in	
the	community.	A	study	in	Ontario	found	that	people	
in	residential	care	were	four	times	more	likely	to	be	
diagnosed	with	dementia	at	a	later	stage	than	those	
who	receive	home	care	(Bartfay	et	al,	2016).	
Other care and support for people with 
dementia and their families
Rehabilitation	and	long-term	care	policies	and	
services,	including	home	and	community	care,	
palliative	care	and	support	for	informal	carers,	vary	
considerably	among	provinces	and	territories,	as	does	
the	provision	of	long-term	care	in	residential	homes	
and	assisted	chronic	care	facilities	(Marchildon,	2013).
The	support	for	family	caregivers	is	a	provincial	
responsibility.	Each	province	and	territory	has	its	
own	priorities,	generally	set	out	as	part	of	a	package	
of	home	care	services.	Since	2002,	the	federal	
government	has	provided	tax	credits	for	eligible	
caregivers.	Employed	caregivers	also	have	a	right	to	26	
weeks	of	paid	leave	as	part	of	the	Compassionate	Care	
Benefit	part	of	the	Employment	Insurance	Programme.
Challenges that need to be addressed
A	national	dementia	strategy	for	Canada	would	create	
better	opportunities	to	coordinate	the	provincial	efforts	
in	dementia	research	and	in	the	improvement	of	clinical	
and	community-based	programmes.	Alzheimer	Society	
of	Canada	argues	that	this	is	particularly	important	
in	the	light	of	the	projected	increases	in	the	numbers	
of	people	living	with	dementia	in	Canada	(Alzheimer	
Society	of	Canada,	2015)	and	proposes	the	creation	
of	a	Canadian	Alzheimer’s	Disease	and	Dementia	
Partnership	with	research,	prevention	and	living	well	
with	dementia	as	its	strategic	objectives.
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While	Canada	has	established	healthcare	pathways	to	
deliver	care	to	people	with	dementia,	there	is	evidence	
that	some	sectors	of	the	population	have	difficulties	
accessing	care,	including	those	living	in	rural	and	
remote	locations,	the	aboriginal	communities,	and	
people	living	in	long-term	care	accommodation.
6.3 Dementia care in China
China	is	the	country	experiencing	the	greatest	overall	
increase	in	numbers	of	older	people	in	the	world,	with	
the	population	aged	60	or	above	projected	to	increase	
from	around	200	million	in	2015	to	490	million	by	2050.	
The	number	of	people	aged	80	or	above	is	projected	to	
grow	by	over	439%	in	the	same	period,	from	22	to	121	
million	(United	Nations,	2016).
Mainland	China	(which	this	section	describes)	is	
classified	as	an	upper-middle	income	economy	by	the	
World	Bank.	Its	economy	has	expanded	rapidly	since	
the	start	of	market	reforms	in	1978,	which	have	lifted	
more	than	800	million	people	out	of	poverty	(World	
Bank,	2015).	Since	the	global	financial	crisis,	annual	
economic	growth	has	slowed,	from	14%	in	2007	to	
6.5%	in	2015.	
Prevalence of dementia
The	World	Alzheimer	Report	2015	estimated	that	there	
were	just	over	9.5	million	people	with	dementia	in	
China,	which	was	20%	of	the	total	number	of	people	
in	the	world	with	dementia.	By	2030,	the	number	of	
people	living	with	dementia	in	China	is	expected	to	rise	
to	over	16	million	(see	Figure	6.2).	
Policy landscape and healthcare system context
Meeting	the	needs	of	very	large	numbers	of	people	
living	with	dementia	and	other	age-related	conditions	
is	challenging	for	China,	not	just	because	of	the	
scale,	but	also	because	of	the	speed	of	demographic	
change.	It	has	been	estimated	that,	at	the	current	rate,	
China	will	experience	in	26	years	the	same	change	in	
population	that	took	115	years	in	France	(China	Joint	
Study	Partnership,	2016).
The	Chinese	government	has	embarked	on	
major	health	policy	reforms,	which	resulted	in	the	
achievement	of	near-universal	healthcare	coverage	for	
its	entire	population	by	2011.	Coverage	grew	from	less	
than	50%	of	the	population	in	2005,	to	95%	in	2011	
(Yu,	2015).	This	required	a	very	substantial	funding	
commitment,	with	public	expenditure	on	health	more	
than	doubling	between	2009	and	2013	(Meng	et	al,	
2015).	China	has	joined	Japan	and	the	Republic	of	
Korea	in	achieving	universal	health	coverage	before	
becoming	a	high-income	country	(Yu,	2015).
Having	successfully	extended	the	breadth	of	health	
coverage	(in	terms	of	the	numbers	of	people	covered),	
the	major	challenges	now	are	to	increase	its	scope	
(in	terms	of	the	comprehensiveness	and	quality	
of	services)	and	its	depth	(the	degree	of	financial	
protection),	which	remain	insufficient	(Liang	and	
Langenbrunner,	2013).	This	new	phase	of	reforms	
happens	in	a	context	of	slower	economic	growth	
which,	coupled	with	demographic	and	epidemiological	
pressures,	means	that	serious	consideration	needs	to	
be	given	to	economic	sustainability	(China	Joint	Study	
Partnership,	2016).
Improving the delivery of healthcare
The	market-oriented	healthcare	reforms	of	the	1980s	
included	the	introduction	of	competition	between	the	
three	tiers	of	the	healthcare	system	(primary	care,	
secondary	and	tertiary	hospitals),	and	the	introduction	
of	direct	out-of-pocket	payments	directly	to	healthcare	
providers.	This	took	the	traditional	gatekeeping	role	
away	from	primary	care	doctors	(Xu	et	al,	2010).
Despite	the	launch	of	reforms	that	prioritised	a	primary	
care	practitioner	system	in	2009,	much	of	the	recent	
growth	in	healthcare	facilities	and	utilisation	in	China	
has	been	concentrated	in	the	hospital	sector.	Between	
2002	and	2013,	the	number	of	tertiary	and	secondary	
hospitals	increased	by	82%	and	29%	respectively.	
At	the	same	time	there	was	a	small	decline	(6%)	in	
the	number	of	primary	care	providers.	Between	2010	
and	2014,	the	percentage	of	healthcare	provision	
that	took	place	in	hospitals	increased	from	34.9	to	
39.1%,	whereas	the	proportion	of	activity	in	primary	
care	dropped	from	61.9	to	57.4%	(China	Joint	Study	
Partnership,	2016).	The	system	has	been	described	
as	“hospital-centric”,	fragmented	and	volume-driven,	
and	China	now	has	more	hospital	beds	per	1,000	
Figure 6.2 
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population	than	either	Canada,	UK,	US	or	Spain	(China	
Joint	Study	Partnership,	2016).
The	lack	of	success	of	primary	care	in	China	can	be	
attributed	to	the	lack	of	a	gatekeeping	role	by	primary	
care	practitioners	(PCPs),	an	ineffective	referral	
system	between	the	three	tiers	of	healthcare	provision,	
little	public	trust	in	the	quality	of	care	provided	in	
primary	care	and	the	restricted	list	of	drugs	that	can	
be	prescribed	(Zou	et	al,	2015,	Mash	et	al,	2015,	Wu	
and	Lam,	2016).	People	can	bypass	the	primary	care	
system	and	access	the	same	care	directly	at	a	hospital	
(although	at	a	higher	cost,	and	usually	further	away).	
While	the	current	lack	of	gatekeeping	role	by	PCPs	can	
be	addressed	by	further	reforms	to	the	reimbursement	
systems,	the	perceived	lack	of	quality	of	primary	care	
reflects	important	differences	in	the	qualifications	
and	pay	of	PCPs	compared	to	doctors	working	in	
hospitals	(Wang	et	al,	2012).	The	majority	of	primary	
care	health	workers	only	have	post-school	training	
(China	Joint	Study	Partnership,	2016).	In	contrast,	for	
doctors	to	practice	in	secondary	(or	township	health	
centres)	and	tertiary	hospitals,	they	must	pass	the	
national	Licensed	Doctors	Examination	or	the	Licensed	
Assistant	Doctors	Examination	after	at	least	three	
years’	medical	education	at	a	medical	college	(Xu	et	
al.,	2014).	Currently,	only	38%	of	licensed	doctors	and	
21%	of	registered	nurses	are	working	in	primary	care	
(Wu	and	Lam,	2016).
Primary	care	in	China	is	gradually	evolving	from	the	
“barefoot	doctors”	provision	developed	across	the	
whole	country	in	the	1950s	and	which	had	a	huge	
impact	on	population	health.	These	“barefoot	doctors”	
were	usually	farmers	who	received	3	to	6	months	
training	by	urban	doctors	to	enable	them	to	practice	
medicine	in	rural	areas	(Wu	and	Lam,	2016).	In	the	
1980s	an	exam	was	introduced;	those	who	passed	
could	continue	to	practice	as	“village	doctors”	and	
those	who	didn’t	became	health	workers	(Weiyuan,	
2008).
There	are	concerns	that	the	“village	doctors”	are	
ageing	and	that	it	will	be	difficult	to	replace	them	
without	substantial	investment	and	changes	in	their	
working	conditions,	income	and	pension	entitlements.	
Moreover,	since	2006	the	government	has	prioritised	
medical	education	to	international	standards	and	there	
has	been	less	emphasis	on	training	village	doctors	(Xu	
et	al.,	2014).	Primary	care	is	a	relatively	new	discipline	
in	standard	medical	schools,	is	often	taught	by	public	
health	specialists	and	is	seen	as	low	status,	thus	not	
attracting	many	students	(Mash	et	al,	2015).	
A	national	directive	in	2011	set	a	target	of	2	to	3	
licensed	primary	care	doctors	(GPs)	per	10,000	
people.	The	average	number	in	2013	was	1.07,	but	the	
ratio	was	below	1	in	poorer	parts	of	China.	To	meet	the	
target,	an	additional	130,000	GPs	would	be	needed	
(Wu	and	Lam,	2016).
Improving financial protection
China	has	made	big	improvements	in	protecting	the	
population	from	the	risk	of	very	high	out-of-pocket	
healthcare	costs.	The	share	of	out-of-pocket	payments	
has	decreased	compared	to	total	health	expenditure,	
from	a	high	point	of	60%	in	2001	to	32%	in	2014,	
which	is	just	under	the	average	for	other	upper-
middle	income	countries	(33%),	although	still	above	
WHO’s	recommended	level	of	20%	for	reducing	the	
risk	of	impoverishment	as	a	result	of	disease	(Liang	
and	Langenbrunner,	2013	and	China	Joint	Study	
Partnership,	2016).		
There	are,	however,	important	differences	in	the	degree	
of	coverage	afforded	by	the	three	insurance	schemes	
available	in	China:	an	urban	scheme	for	those	in	formal	
employment,	another	urban	scheme	for	those	who	are	
not	employed	or	in	informal	employment,	and	a	rural	
scheme.	Because	reimbursement	levels	and	service	
coverage	are	much	lower	in	the	rural	than	in	the	urban	
insurance	schemes,	rural	populations	have	more	
restricted	access	to	healthcare	(Meng	et	al,	2015).	
Those	who	cannot	afford	health	insurance	premiums	
and	out-of-pocket	medical	bills	are	also	covered	by	
the	Medical	Assistance	Program	(MA)	(Liang	and	
Langenbrunner,	2013).	
One	of	the	main	health	policy	goals	for	the	government	
is	to	establish	a	consolidated	health	insurance	system	
by	2020.	A	consolidated	system	would	not	only	be	
able	to	improve	some	of	the	inequity	and	portability	
difficulties	related	to	the	current	fragmented	system,	
but	the	examples	of	Taiwan	and	South	Korea	suggest	
that	it	could	also	reduce	administration	costs	
(Meng	et	al,	2015),	thereby	contributing	to	efficiency	
improvement.	The	consolidation	of	the	health	insurance	
scheme	could	also	provide	an	opportunity	for	
designing	new	service	packages	and	reimbursement	
schemes	that	favour	cost-effective	services,	and	for	
using	alternative	payment	services	to	the	current	fee-
for-service	approach	(Meng	et	al,	2015).
Next reform steps
It	is	expected	that	the	next	(13th)	Five-year	
Development	Plan	2016-2020	will	seek	to	address	
many	of	the	issues	outlined	above	in	the	so	called	
“deep	water”	phase	of	health	reform	(China	Joint	
Study	Partnership,	2016);	in	particular,	“strengthening	
the	three-tiered	system,	including	primary	care	
and	community-based	services,	human	resources	
reform,	optimising	use	of	social	insurance,	and	
encouraging	private	investment	(“social	capital”)	to	
sponsor	healthcare.	Policies	also	support	“people	first	
principles”	such	as	building	harmonious	relationships	
with	patients,	promoting	greater	care	integration	
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between	hospitals	and	primary	care	facilities	through	
tiered	service	delivery	and	use	of	multidisciplinary	
teams	and	facility	networks,	shifting	resources	towards	
the	primary	level,	linking	curative	and	preventive	care”	
(China	Joint	Study	Partnership,	2016,	p.	xvii).
China’s national policy on dementia
There	is	no	specific	National	Dementia	Plan	in	China,	
but	dementia	has	been	prioritised	(together	with	
autism,	schizophrenia	and	depression)	in	the	National	
Five-year	plan	for	Mental	Health	(2015-2020).	The	
main	objectives	of	this	plan	include	the	development	
of	integrated	services,	training	of	mental	health	
specialists,	improvement	of	rehabilitation	services	
and	community-	and	family-based	supports,	and	the	
promotion	of	social	awareness	and	mitigation	of	social	
stigma	(The	State	Council	of	the	PRC,	2015).
The costs of dementia in China
Although	national	data	on	the	costs	of	dementia	care	
and	support	in	China	is	not	yet	readily	available,	there	
are	some	studies	that	give	an	indication	of	the	health	
and	care	costs	of	dementia	in	China.	As	with	many	
other	countries,	the	studies	are	difficult	to	compare,	as	
they	take	different	perspectives	(e.g.	some	include	only	
health	costs,	some	include	societal	costs)	and	refer	
to	different	populations	(people	accessing	hospitals,	
compared	to	general	population).	
In	one	national	hospital-based	survey	in	2009,	the	total	
out-of-pocket	(OOP)	monthly	cost	per	person	with	
dementia	averaged	US$487.	Of	this,	US$56	was	spent	
on	doctor	visits,	US$137	on	drug	therapy,	US$139	on	
hospital	visits,	and	US$155	on	housekeeping	services.	
The	costs	of	providing	care	by	family	members,	in	
terms	of	reported	forgone	employment,	ranged	from	
US$88	to	US$614	(Mould-Quevedo,	et	al.,	2013).	
The	total	cost	of	healthcare	far	exceeded	average	per	
capita	disposable	income	(US$210	for	urban	dwellers	
and	US$63	for	rural	dwellers)	(National	Bureau	of	
Statistics	of	China,	2010).	It	should	be	noted	that,	
because	these	estimates	are	based	on	a	survey	of	
people	attending	tertiary	hospitals	(which	involve	
large	out-of-pocket	payments),	and	who	have	been	
diagnosed	with	dementia,	it	is	likely	that	the	sample	is	
of	higher	socio-economic	status	than	average	and	not	
fully	representative	of	the	costs	experienced	by	other	
people	living	with	dementia.
Using	the	cost	estimates	from	Mould-Quevedo	et	
al	(2013),	another	study	modelled	the	impact	on	the	
Chinese	economy	of	care	provision	(in	both	the	formal	
and	informal	sectors)	to	people	with	Alzheimer’s	
disease.	This	study	estimated	that	the	impact	on	
the	economy	will	exceed	US$1	trillion	in	2050	(at	
2011	prices),	and	notably,	62%	of	the	total	cost	was	
attributable	to	the	loss	of	formal	labour	from	unpaid	
family	caregivers	(Keogh-Brown,	et	al.,	2016).
While	the	studies	above	were	based	on	a	sample	of	
people	using	hospital	services,	there	are	also	cost	
estimates	from	a	geographically	defined	population	
from	the	10/66	study,	covering	all	of	the	population	
aged	65	or	above	in	a	defined	urban	population	
(Xicheng,	Beijing),	and	a	rural	population	(Dixang).	
From	this	base,	Liu	(2013)	estimated	the	attributable	
costs	of	dementia	in	China	in	2008	international	dollars	
and	from	a	public	sector	perspective	as	$8,687	per	
person	per	year.	Of	this	total,	$148	was	for	medical	
care,	$1,195	for	paid	social	care	and	$7,344	for	unpaid	
family	care.	The	study	also	investigated	the	total	cost	of	
services	used	and	found	that	the	total	costs	of	medical	
care	(including	public	and	out-of-pocket	payments)	
were	$5,243	per	year	for	people	with	dementia	living	in	
the	urban	area,	compared	to	$313	for	people	living	in	
the	rural	area	(Liu,	2013).
There	is	little	information	available	on	the	unit	costs	
of	care	for	people	with	dementia	in	China.	A	Delphi	
panel	study	by	Yu	et	al	(2015)	gathered	consensus	on	
the	unit	costs	for	people	with	dementia	living	in	urban	
areas.	Unit	costs,	in	RMB,	included	figures	of	30,000	
per	month	for	hospital	inpatient	stays,	1,600	for	a	
“diagnosis	hospitalisation”,	500	for	biological	analysis,	
1,050	for	an	MRI	scan	and	100	for	the	cognitive	
assessment	scale.	The	cost	of	a	caregiver	or	a	nursing	
home	place	was	6,000	per	month.
Current diagnostic and healthcare pathways
People	with	dementia	in	China	are	underdiagnosed	and	
undertreated.	Access	to	care	by	people	with	dementia,	
as	in	many	other	countries,	is	hampered	by	beliefs	that	
it	is	a	natural	part	of	the	ageing	process	(Patel	et	al,	
2016).	Stigma	may	also	play	a	role:	a	qualitative	study	
in	both	rural	and	urban	China	found	that	stigma	around	
dementia	was	characterised	by	fear,	reluctance	and	
avoidance	to	engage	with	people	with	dementia.	The	
study	also	revealed	low	awareness	about	dementia	
among	family	caregivers	and	the	assumption	that	
declining	cognitive	functioning	is	a	normal	part	of	
ageing	(Hsiao	et	al,	2015).
A	population-based	caregiver	survey	in	four	Chinese	
cities	found	that	only	26.9%	of	people	with	dementia	
had	received	a	diagnosis.	Only	21.3%	reported	
receiving	a	recommendation	for	their	family	member	
with	dementia	to	take	medication	and	only	2%	used	
any	medication	(Chen	et	al,	2013).	A	Delphi	panel	of	
doctors	in	urban	China	considered	that	only	10%	of	
people	with	dementia	were	diagnosed	and,	of	those,	
only	21%	used	any	medication	(Yu	et	al.,	2015).
Primary	care	doctors	are	often	inadequately	trained	
and	may	be	reluctant	or	unable	to	detect,	diagnose	
or	manage	dementia	(Patel	et	al,	2016).	A	qualitative	
study	by	Wu	et	al	in	Lanxi	reported	that	the	three	rural	
physicians	they	interviewed	(who	were	all	older	than	
60)	had	only	received	short-term	training	in	basic	
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healthcare	to	become	village	doctors.	They	appeared	
to	have	poor	knowledge	of	dementia	and	did	not	use	
any	formal	screening	instruments	for	diagnosis.	They	
considered	ageing	to	be	the	cause	of	dementia	and	
were	not	aware	of	any	treatments.	According	to	one	of	
the	doctors	interviewed:	“In	the	countryside,	there	is	a	
common	notion	that	going	to	the	doctor	for	this	kind	of	
illness	[dementia]	is	a	waste	of	money	since	it	cannot	
be	cured”	(Wu	et	al.,	2016	p.162).
Lack	of	training	in	dementia	diagnosis	and	care	is	also	
a	problem	in	highly	specialised	tertiary	hospitals.	Jia	
et	al	(2015)	implemented	a	training	intervention	in	36	
tertiary	hospitals	in	China.	At	baseline	they	found	that	
only	6	of	the	36	hospitals	had	a	memory	clinic,	and	
only	47	doctors	(out	of	1,361	working	in	neurology)	
had	been	trained	in	the	dementia	area.	Only	0.1%	of	
outpatients	visiting	the	hospitals	received	a	diagnosis	
of	dementia	and,	of	those	who	did	have	a	diagnosis,	
only	23.6%	received	anti-dementia	medication.	
After	the	intervention,	205	doctors	had	been	trained	
in	dementia	care	and	all	36	hospitals	had	memory	
clinic	services.	The	diagnosis	rate	increased	four-fold	
(to	0.41%)	and	67.5%	of	those	diagnosed	received	
medication.
The	Delphi	panel	study	by	Yu	et	al.	(2015)	suggests	
that	people	with	dementia	with	neuropsychiatric	
symptoms	were	more	likely	to	be	diagnosed	and	
treated	by	psychiatric	departments,	and	more	likely	to	
be	hospitalised.
Other care and support for people with 
dementia and their families
The	care	and	support	of	people	with	dementia	is,	
both	by	culture	and	law,	a	family	responsibility.	The	
involvement	of	the	government	in	long-term	care	is	
relatively	recent,	other	than	the	provision	of	institutional	
care	to	people	without	family	or	resources	(the	“Three	
No’s:	no	children,	no	income	and	no	relatives”).	The	
use	of	institutional	care	has	therefore	been	associated	
with	stigma	(Feng	et	al,	2012,	Wu	et	al,	2016).	
However,	demographic	and	socio-economic	changes	
have	made	it	impossible	to	continue	to	rely	almost	
exclusively	on	family	care,	and	the	fulfilment	of	family	
obligations	through	the	purchase	of	care	is	increasingly	
considered	to	be	acceptable.
The	government	aims	to	establish	three	tiers	of	
services	for	people	who	need	care:	(i)	home	care	as	
the	basis;	(ii)	community-based	services	as	support;	
and	(iii)	institutional	care	as	the	last	resort.	In	practice,	
the	availability	of	home	and	community-based	support	
is	limited	and	the	government	policy	efforts	have	
focussed	on	increasing	the	availability	of	institutional	
care	(Wu	et	al,	2016).
A	survey	by	Wu	et	al	(2016)	in	the	Lanxi	county	
found	that	available	day	care	services	were	targeted	
at	healthy	older	people	and	were	not	used	by	any	
individuals	with	dementia.	Specialist	community-based	
dementia-specific	services	such	as	day	care,	respite,	
caregiver	support	and	case	management	only	exist	in	a	
few	major	urban	centres.
Home	care	tends	to	be	provided	by	informal	workers,	
with	low	qualifications	and	who	have	usually	migrated	
from	rural	areas.	As	there	are	no	subsidies	or	public	
support	for	home	care	in	most	regions,	this	kind	of	
service	tends	only	to	be	used	by	those	who	are	better	
off.	The	use	of	paid	care	at	home	by	people	with	
dementia	is	much	higher	in	the	wealthier	urban	areas.	A	
survey	by	Li	et	al	(2013)	in	the	Zheijiang	province	found	
that,	of	people	in	need	of	care,	5.9%	used	paid	care	
in	rural	areas,	compared	to	36.9%	in	urban	areas.	The	
study	also	found	that	support	from	children	was	the	
most	important	source	of	income	in	rural	areas	among	
those	who	paid	for	care,	whereas	in	urban	areas	older	
people	(or	their	spouses)	were	more	likely	to	be	able	to	
pay	for	their	own	care.
The	10/66	study	found	slightly	bigger	differences	in	
their	survey	of	older	people	in	an	urban	population	
(Xicheng,	Beijing)	and	a	rural	one	(Dixang).	Only	2%	
of	people	in	need	of	care	in	the	rural	area	used	paid	
care,	compared	to	45%	in	the	urban	area.	The	study	
also	gives	an	indication	of	the	impact	of	unpaid	care	
provision	on	the	family’s	economic	situation:	while	only	
4%	of	urban	family	carers	reported	having	cut	back	
on	work	to	provide	care,	the	figure	was	48%	for	rural	
carers	(Liu	et	al,	2009).
As	a	result	of	the	government’s	focus	on	institutional	
care,	provision	of	this	service	has	grown	enormously.	
In	1980	there	were	only	4	facilities	(all	government-
run)	in	Tianjin,	but	numbers	increased	to	13	by	1990,	
68	by	2000	and	157	by	2010.	Of	these	157,	20	were	
government-run	and	137	private.	There	have	been	
similar	rates	of	growth	in	other	areas	such	as	Nanjing	
and	Beijing	(Feng	et	al,	2012).	
In	2010	there	were	an	estimated	40,000	institutional	
care	facilities	(with	3.15	million	beds)	in	the	whole	of	
China,	which	amounted	to	about	half	as	many	long-
term	care	beds	per	1,000	of	older	people	as	in	most	
developed	countries.	The	12th	Five-Year	Plan	set	out	
plans	to	double	the	number	of	beds	by	2015	to	reach	
a	ratio	of	30	beds	per	1,000	older	people	(Feng	et	al,	
2012).
For	people	with	dementia	the	evidence	so	far	
suggests	that	the	quality	of	care	in	many	institutions	
is	problematic.	In	fact,	many	institutions	refuse	to	
admit	people	with	dementia	(Yu	et	al,	2015;	Wu	et	
al.,	2016),	partly	because	staff	are	not	adequately	
trained	to	manage	the	behavioural	and	psychological	
symptoms.	Even	in	care	homes	that	in	principle	do	not	
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admit	people	with	dementia,	there	are	nevertheless	
residents	with	dementia,	as	the	symptoms	can	develop	
after	admission.	A	systematic	review	of	staff	and	
care	in	long-term	care	institutions	in	China	found	that	
the	reported	percentage	of	residents	with	cognitive	
impairment	ranged	from	13%	to	66%	(Song	et	al,	
2014).	
In	their	qualitative	study	in	Lanxi,	Wu	et	al.	(2016)	
found	that	none	of	the	residents	with	dementia	in	
nursing	homes	were	receiving	any	dementia-related	
medication	and	that,	despite	having	higher	charges	
for	people	with	dementia,	none	of	them	provided	
medical,	psychological	or	rehabilitative	support	for	the	
condition.
An	important	development	that	is	likely	to	have	a	
positive	impact	on	the	ability	of	older	people	to	afford	
care	and	support	has	been	the	launch	of	the	rural	
pensioners’	pension	scheme	in	2009	and	the	merger	
of	the	rural	and	urban	pension	schemes	in	2014.	These	
developments	have	resulted	in	a	trebling	of	the	number	
of	people	covered	by	the	old	age	pension	system.	By	
the	end	of	2013,	approximately	80%	of	the	population	
of	working	age	and	above	were	covered	by	a	pension	
system	(MOHRSS,	2013	and	ILO,	2014).
Challenges that need to be addressed
While	China	has	made	big	improvements	in	the	
coverage	of	healthcare,	access	to	care,	treatment	and	
support	by	people	with	dementia	is	very	limited.	The	
literature	suggests	that	the	following	issues	should	be	
addressed	to	improve	the	current	situation:
•	 Lack	of	awareness	about	the	fact	that	dementia	
is	not	a	natural	part	of	ageing,	accompanied	
by	stigma,	may	be	a	major	reason	why	people	
with	dementia	have	relatively	low	contact	with	
healthcare	services.	Where	they	do	access	
services,	this	tends	to	be	via	psychiatric	care	and	
as	a	result	of	behavioural	symptoms	(Wu	et	al.,	
2016).
•	 Very	limited	training	about	dementia	for	healthcare	
professional	at	all	levels,	particularly	with	regards	
to	standard	diagnostic	procedures,	medication	and	
non-pharmacological	interventions.
•	 The	current	lack	of	a	gatekeeping	role	for	primary	
care	doctors	means	that	people	can	access	
specialist	hospital	services	directly	if	they	wish.	
The	perceived	low	quality	of	primary	care	(and	low	
professional	qualifications	of	village	doctors)	is	a	
major	reason	why	people	prefer	to	use	hospital	
care	despite	higher	out-of-pocket	payments	and	
having	to	travel	longer	distances.
•	 The	affordability	of	healthcare	remains	a	very	
important	problem,	particularly	for	people	in	rural	
areas,	as	out-of-pocket	payments	are	relatively	
high.	The	consolidation	of	the	three	health	
insurance	schemes	may	help	reduce	inequalities	
in	affordability	of	healthcare	between	the	rural	and	
urban	areas.
•	 Despite	a	stated	policy	that	people	should	be	able	
to	remain	at	home	for	as	long	as	possible,	most	of	
the	expansion	in	long-term	care	services	has	been	
in	institutional	care.	There	are	concerns	about	the	
ability	of	nursing	home	staff	to	care	adequately	for	
people	with	dementia,	mostly	as	a	result	of	lack	of	
training.	
•	 In	families	with	low	incomes	in	rural	areas	the	
provision	of	unpaid	care	can	contribute	to	further	
impoverishment,	as	family	carers	may	have	to	
give	up	work	to	support	their	relatives	(Liu	et	al,	
2009).	Families	with	higher	incomes	can	more	
easily	afford	to	pay	for	private	care	at	home	or	
nursing	home	fees,	and	very	poor	people	without	
family	support	can	access	free	care	through	social	
assistance.	The	expansion	of	the	social	insurance	
system	to	cover	long-term	care	could	help	reduce	
the	financial	risks	associated	with	dementia,	as	
demonstrated	by	pilot	schemes	in	various	cities	
such	as	Qingdao	(Yang	et	al.,	2016).
6.4 Dementia care in Indonesia
Indonesia,	in	South	East	Asia,	is	formed	by	over	14,000	
islands	and	is	home	to	more	than	300	ethnic	groups.	
More	than	half	of	the	population	lives	on	the	island	of	
Java.	
In	economic	terms,	Indonesia	has	been	classified	by	
the	World	Bank	as	a	“low-middle	income	economy”.	
It	has	experienced	a	period	of	sustained	economic	
growth	since	2009,	and	has	made	great	progress	
in	the	reduction	of	poverty,	from	about	half	of	the	
population	in	1999	to	11%	in	2015	(World	Bank,	
2015).	While	services	and	industry	contribute	most	
to	gross	domestic	product,	agriculture	remains	the	
largest	sector	in	terms	of	employment.	Insufficient	
infrastructure	development	poses	a	challenge	to	
continued	economic	growth,	and	the	country’s	food	
security	weaknesses	were	recently	exposed	by	an	
extended	drought	in	2015.	There	is	a	large	gap	in	
resources	and	prosperity	between	urban	and	rural	
areas,	which	affects	the	availability	of	care	for	people	
with	dementia	and	the	support	available	to	their	
families.
Prevalence of dementia
Indonesia	is	the	world’s	fourth	most	populated	country.	
Its	large	population	(over	257	million	people	in	2015)	
is	relatively	young	compared	to	other	countries	in	
South	East	Asia.	However,	even	with	the	relatively	
low	proportion	of	older	people	compared	to	other	
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countries,	Indonesia	is	still	ranked	eighth	in	the	world	in	
terms	of	the	overall	number	of	older	people.
There	are	no	locally	generated	estimates	of	the	
prevalence	of	dementia	in	Indonesia	so	far.	Using	
data	from	comparable	countries,	the	World	Alzheimer	
Report	2015	estimated	that	in	2015	there	were	just	over	
556,000	people	with	dementia	in	Indonesia.	By	2030	
the	number	of	people	is	expected	to	rise	to	nearly	2.3	
million	(see	Figure	6.3).	
A	local	study	of	the	prevalence	of	dementia	in	
Yogyakarta	found	a	very	high	prevalence	of	dementia	
among	older	people,	and	also	of	risk	factors	for	
dementia	(Alzheimer’s	Indonesia,	2016).	It	will	be	
important	to	understand	how	social	and	economic	
changes	are	affecting	risk	factors	for	dementia	and	
consider	those	in	public	health	policy.	
Education,	for	example,	which	is	(inversely)	linked	to	
dementia	risk,	has	changed	dramatically	in	the	last	few	
decades.	While	half	of	the	population	currently	aged	
over	70	years	are	literate,	literacy	rates	among	the	
younger	generation	(18-34)	are	close	to	100%	(Priebe	
and	Howell,	2014).
Policy landscape
Despite	the	increasing	importance	of	dementia,	and	
its	growing	impact	on	society,	dementia	has	been	
a	low	priority	health	issue	in	Indonesia.	However,	
the	Indonesian	Ministry	of	Health	launched	the	first	
National	Dementia	Plan	in	March	2016,	accompanied	
by	a	pledge	of	$105,000	to	support	its	implementation.	
The	Indonesian	National	Dementia	Plan	focuses	on	
improving	the	quality	of	life	of	people	with	dementia	
and	their	caregivers,	raising	awareness,	reducing	
stigma	and	minimising	the	risk	of	dementia.	In	
particular,	the	plan	includes:
•	 Awareness,	risk	reduction,	promotion	of	healthy	
lifestyles
•	 Advocacy	–	human	rights	for	people	living	with	
dementia	and	their	family	carers
•	 Access	to	information	and	quality	services
•	 Early	detection,	diagnosis,	holistic	management	of	
cognitive	problems
•	 Strengthening	human	resources	and	the	overall	
system	infrastructure
•	 Promoting	a	life-course	approach	
•	 Supporting	research	on	cognition	and	dementia
Another	important	development	was	the	launch,	in	
2014,	of	Indonesia’s	universal	healthcare	programme,	
Jaminan	Kesehatan	Nasional	(JKN),	with	the	aim	of	
providing	health	insurance	to	the	entire	population	by	
2019.	The	JKN	brings	together	various	state-owned	
health	insurance	schemes	that	previously	covered	
parts	of	the	population.	It	is	funded	by	contributions	
from	those	in	employment	and	a	government	subsidy	
to	cover	those	without	employment	and	resources	
(Mboi,	2015).	There	is	a	strong	policy	impetus	to	
improve	access	to	and	quality	of	healthcare	in	
Indonesia,	although	the	starting	point	is	one	of	wide	
differences	between	different	regions,	and	between	
urban	and	rural	areas.	
Current diagnostic and healthcare pathways
There	is	almost	no	data	available	on	Indonesia’s	health	
and	social	care	services	for	people	with	dementia,	
which	reflects	the	low	profile	of	dementia	in	Indonesia	
until	very	recently.	Alzheimer’s	Indonesia	(ALZI)	and	
others	have	helped	us	gather	some	information	which	
we	have	used	to	provide	a	picture	of	the	current	
situation.
While	there	are	some	specialist	dementia	healthcare	
services	in	Indonesia,	these	are	currently	available	
to	very	few	people;	for	example,	there	are	specialist	
dementia	services	in	eight	public	hospitals	and	ten	
private	hospitals,	and	there	are	five	memory	clinics	
(four	public	and	one	private).
The	community-based	primary	care	centres	
(Pukesmas)	in	principle	provide	diagnostic	and	
continuing	care	through	general	practitioners.	
However,	of	nearly	9,000	Pukesmas,	only	42%	provide	
general	healthcare	services	for	older	people,	and	
many	GPs	are	unable	to	provide	diagnostic	services	
for	dementia	due	to	lack	of	training.	The	quality	and	
range	of	services	available	is	very	different	between	
urban	and	rural	areas:	many	Pukesmas	in	rural	areas	
are	only	able	to	provide	very	basic	care.	In	many	cases,	
the	local	health	workers	consider	dementia	symptoms	
a	normal	part	of	ageing	and	do	not	diagnose	or	refer	
people	presenting	those	symptoms.
Access	to	dementia	diagnosis	and	care	is	also	
hampered	by	a	prevalent	belief	in	families	that	
dementia	is	a	normal	part	of	ageing	and	lack	of	
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knowledge	about	the	existence	of	treatments	for	some	
of	the	symptoms	of	dementia.
Where	specialist	dementia	services	are	provided,	
these	appear	to	be	of	very	high	quality	and	reflect	
international	practice.	For	example,	an	anecdotal	
report	by	Nicole	Batsch	(2015)	describes	a	memory	
clinic	in	Yogyakarta:
“I	visited	the	clinic	in	Yogyakarta	which	was	
established	when	the	hospital	built	a	new	building	
three	years	ago.	Dr.	Astuti	and	her	team	offer	
diagnostic	support	and	behavioral	interventions	and	
see	about	three	new	patients	each	day.	Patients	
and	families	often	seek	treatment	after	struggling	
at	home	with	behavioral	challenges	many	years	
after	symptoms	first	emerge.	A	formal	diagnosis	
takes	about	three	days	to	complete	and	includes	
brain	scans,	neuropsychological	testing	and	other	
tests	to	look	for	acute	causes.	The	clinic	uses	
some	Western	instruments	such	as	the	Mini-Mental	
Status	Exam	(MMSE)	that	have	been	validated	
in	Bahasa	Indonesia	(the	national	Indonesian	
language)	and	other	cultural	adaptations.	For	
example,	one	test	uses	pictures	of	elephants	and	
camels.”
The	team	also	offers	Cognitive	Stimulation	Therapy	
and	patients	visit	the	clinic	on	a	regular	basis	to	take	
part	in	this	evidence-based	intervention	that	has	
been	translated	into	Bahasa	Indonesian,	as	well	as	
participate	in	other	activities.”	
The	Ministry	of	Health,	in	collaboration	with	
Alzheimer’s	Indonesia	and	medical	professionals,	is	
developing	a	Guideline	for	Dementia	Risk	Reduction	
and	Management	in	Primary	Care	Centres	which	is	
expected	to	be	launched	towards	the	end	of	2016.	
Other care and support for people with 
dementia and their families
In	Indonesia	there	is	a	strong	sense	of	filial	obligation,	
and	families	of	people	with	dementia	are	the	main	
providers	of	care.	
There	are	a	few	examples	of	community-based	care	
and	support	for	people	with	dementia	in	the	formal	
sector,	for	example	there	are	only	three	day	centres	
in	urban	areas	in	Jakarta	and	East-Java,	and	two	
of	them	are	private	and	too	expensive	for	people	
with	limited	resources	to	access.	Until	recently	there	
has	been	relatively	little	involvement	by	NGOs,	but	
Alzheimer’s	Indonesia,	created	three	years	ago,	is	now	
running	caregiver	support	groups	in	Jakarta,	West	
Java,	Central	Java,	East	Java	and	Yogyakarta.	These	
caregiver	support	groups	are	mainly	in	urban	areas	
and	provide	information	about	caring	for	people	with	
dementia	and	promote	peer	support	and	networking.
There	are	also	a	few	examples	of	institutional	care,	but	
these	are	rare	and	target	the	very	wealthy.	While	some	
wealthier	families	are	in	a	position	to	pay	others	to	
provide	care,	there	is	a	very	strong	cultural	preference	
for	that	care	to	be	provided	in	the	family	setting.	The	
care	is	provided	by	informal	paid	workers,	who	usually	
live	with	the	families.	Sometimes	these	paid	helpers	are	
integrated	into	the	family	structure	as	adopted	children	
or	nieces	(Schröder-Butterfill	and	Fithry,	2014).	It	is	
expected	that,	as	the	size	of	the	middle	class	rises,	as	
well	as	migration,	the	number	of	these	“paid	informal	
carers”	will	increase.	It	will	be	important	to	include	
the	training	of	these	paid	informal	carers	in	dementia	
policy.
As	part	of	the	Jakarta	Smart	City	Initiative,	the	
Jakarta	Government	and	Alzheimer’s	Indonesia	are	
collaborating	to	help	make	Jakarta	more	dementia-
friendly.	The	Jakarta	Government	has	developed	
an	app,	called	Qlue,	which,	among	other	features,	
includes	reports	of	missing	people.	When	people	are	
found	wandering,	a	trained	team	of	social	workers	will	
screen	them	for	dementia	and	other	health	conditions,	
while	the	family	are	located.	Under	this	initiative	
Alzheimer’s	Indonesia	is	providing	dementia	training	
to	staff	from	Jakarta’s	Health	and	Social	Departments,	
primary	care	doctors	and	their	teams,	social	workers	
and	other	civil	servants.	
Challenges that need to be addressed
There	are	very	low	levels	of	awareness	of	dementia	
among	healthcare	staff,	particularly	in	primary	care	
health	services	and	in	rural	areas,	which	limits	their	
ability	to	diagnose	and	care	for	people	affected	by	
dementia.	Training	health	professionals	on	dementia	
is	needed,	as	is	funding	the	development	of	dementia	
services.
Lack	of	understanding	of	the	difference	between	
normal	ageing	and	dementia	means	that	most	people	
do	not	seek	help,	and	therefore	miss	opportunities	
to	have	some	of	their	symptoms	treated	or	to	obtain	
support.
The	availability	of	family	care	is	expected	to	change	
in	the	next	few	decades	due	to	declines	in	fertility,	
increased	migration,	and	increased	labour	force	
participation	by	women.	Also,	there	are	very	high	rates	
of	widowhood	for	women,	in	part	due	to	the	tradition	
for	women	to	marry	older	men,	and	in	part	because	
of	other	social	and	cultural	factors,	such	as	women	
not	being	able	to	remarry	in	some	ethnic	groups.	
Childlessness	is	also	relatively	high	among	the	older	
population	(Schröder-Butterfill	and	Fithry,	2014).
While	Indonesia	has	achieved	important	reductions	in	
poverty,	it	affects	older	people	disproportionately,	in	
part	because	older	people	are	more	likely	to	remain	
in	the	informal	economy	in	rural	areas,	and	in	part	
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because	pension	coverage	remains	very	low	(only	8%	
of	older	people	have	a	formal	pension).	Older	people	
also	have	much	lower	literacy	rates	than	younger	
generations.	Poorer	older	people,	given	the	same	
health	conditions	as	their	wealthier	counterparts,	are	
much	less	likely	to	use	healthcare	services,	particularly	
in	rural	areas	and	particularly	women	(Priebe	and	
Howell,	2014).
6.5 Dementia care in Mexico
Mexico	is	the	third	largest	territory	in	Latin	America	
and	its	population	of	around	120	million	people	in	
2015	makes	it	the	second	most	populated	in	the	
continent	(INEGI	2015).	Close	to	80%	of	the	population	
live	in	urban	areas.	There	are	marked	inequalities	
in	Mexico,	the	most	disadvantaged	groups	are	
people	in	the	southern	states,	women,	children	and	
indigenous	groups.	Despite	major	reforms	aiming	to	
reduce	poverty	and	inequality,	just	under	10%	of	the	
population	live	in	extreme	poverty.	A	high	share	(60%)	
of	employment	in	Mexico	is	in	the	informal	sector,	
which	affects	the	revenues	available	for	publicly	funded	
healthcare	and	other	social	protection	programmes,	
given	their	links	to	taxation	(OECD,	2016).	Mexico’s	
indigenous	groups	represent	about	16%	of	the	
population	and,	despite	recent	policy	efforts,	continue	
to	face	major	difficulties	accessing	healthcare,	
education	and	employment	(Servan-Mori	et	al.,	2014).	
Demographic and prevalence data
There	are	estimates	of	the	prevalence	and	incidence	
rates	of	dementia	in	Mexico	from	two	nationally	
representative	surveys,	the	Mexican	Health	and	Aging	
Study	(MHAS)	and	the	National	Health	and	Nutrition	
Survey	2012	(ENSANUT),	and	also	data	from	the	10/66	
study.
Data	from	the	MHAS,	a	prospective	panel	study	of	
ageing	and	health	in	Mexico,	found	that	prevalence	of	
dementia	was	6.1	percent	in	the	population	aged	60	
years	and	above,	with	estimated	incidence	rate	of	27.3	
per	1,000	person-years	for	dementia	(Mejia-Arango	
&	Gutierrez	Robledo	2011).	This	study	also	found	that	
prevalence	rates	of	dementia	decreased	with	higher	
educational	level	and	that	hypertension,	diabetes	and	
depression	were	risk	factors	for	dementia.	Estimates	
from	the	ENSANUT	2012	survey	showed	a	prevalence	
of	dementia	of	7.9	percent	(Manriquez	et	al.,	2013).	
The	10/66	study	estimated	a	prevalence	of	dementia	
of	7.4	percent	in	urban	areas	and	7.3	percent	in	
rural	areas	(Llibre-Rodríguez	et	al,	2008),	similar	to	
estimates	from	ENSANUT	2012,	and	an	incidence	of	
30.4	per	1,000	person-years	(Prince	et	al,	2012).
The	World	Alzheimer	Report	2015	estimated	that	
in	2015	there	were	just	over	800,000	people	with	
dementia	in	Mexico,	and	of	these	64%	were	women.	
By	2030	the	number	of	people	is	expected	to	rise	to	
just	over	1.5	million.	
With	regard	to	risk	factors	for	dementia,	Mexico	has	
particularly	high	rates	of	obesity:	between	2000	and	
2012	the	rates	of	people	considered	to	be	overweight	
or	obese	increased	from	62.3%	to	71.3%	of	the	adult	
population,	and	one	in	three	children	is	overweight	or	
obese.	Diabetes	is	also	increasing	rapidly,	affecting	
15.9%	of	adults,	more	than	double	the	OECD	average	
of	6.9%	(OECD,	2016).
Policy landscape
In	2014	the	National	Institute	of	Geriatrics,	in	
collaboration	with	the	National	Neurology	and	
Neurosurgery	Institute,	the	National	Public	Health	
Institute,	the	Mexican	AD	Federation	and	the	National	
Institute	for	Older	Adults	(INAPAM)	published	the	
Alzheimer’s	Plan	of	Action	(APA).	The	Plan	is	in	line	with	
Federal	health	legislation	regarding	development	and	
health	of	the	populations.	
The	main	objective	of	the	Plan	is	to	promote	the	
wellbeing	of	people	with	dementia	and	their	families	
through	strengthening	the	response	of	the	Mexican	
Health	System	and	ensure	equal	access	to	adequate	
services	(Gutierrez-Robledo	and	Arrieta-Cruz,	2015).
The	Plan’s	aims	are:
•	 Increasing	awareness	and	eliminating	stigma	and	
negative	stereotypes.
•	 Increasing	access	to	sound	and	current	information	
for	health	professionals,	people	with	dementia	and	
their	caregivers.
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•	 Developing	a	comprehensive	care	model	in	line	
with	the	needs	and	characteristics	of	the	country.
•	 Supporting	the	development	of	multidisciplinary	
research	in	order	to	better	understand	the	process	
of	Alzheimer’s	disease	and	other	dementias.
•	 Increasing	the	training	of	all	health	professionals	
and	caregivers	so	they	can	better	manage	their	
care	provision.
•	 Strengthening	prevention	strategies	and	
programmes	to	combat	chronic	diseases	as	
risk	factors	for	Alzheimer’s	disease	and	other	
dementias	and	curtail	their	incidence,	as	well	as	
providing	timely	diagnosis	and	treatment.
In	terms	of	implementation	of	the	Plan,	most	
progress	has	been	achieved	in	the	training	of	health	
professionals	and	in	raising	awareness	among	the	
general	public.	In	line	with	the	National	and	the	
Regional	Plan	on	Alzheimer’s	disease,	the	National	
Institute	of	Geriatrics	generated	three	training	
strategies.	First,	a	Diploma	in	Alzheimer’s	disease	and	
other	dementias,	a	160-hour	course	designed	with	a	
multidisciplinary	perspective	and	guided	by	experts	
in	the	topic.	The	other	strategies	include	an	online	
course	‘Principles	of	the	person-centred	care	model	
for	people	with	dementia’	for	health	professionals,	and	
an	open	online	course	titled	‘What	we	need	to	know’	
and	offered	through	the	Tele-education	platform	of	
the	Ministry	of	Education.	By	mid-2016,	200	health	
professionals	had	completed	the	person-centred	care	
course,	while	close	to	5,000	people	had	registered	for	
the	online	open	course.	This	high	response	is	seen	as	
an	important	way	to	work	towards	reducing	general	
beliefs	in	society	that	memory	loss	is	a	normal	and	
unavoidable	part	of	the	ageing	process,	as	well	as	on	
increasing	knowledge	on	risk	factors	and	prevention	
strategies.
Health system context
Healthcare	services	in	Mexico	are	provided	through	a	
variety	of	insurance	systems,	each	with	its	own	staff,	
clinics	and	hospitals.	The	insurance	systems	offer	
different	levels	of	care	to	different	groups	and	with	
different	outcomes,	thereby	entrenching	inequality	in	
access	to	healthcare	among	different	sectors	of	the	
population.	The	largest	insurance	systems	are	the	
Instituto	Mexicano	del	Seguro	Social	(IMSS),	which	
covers	people	in	salaried	formal	employment,	and	
the	Instituto	de	Seguridad	y	Servicios	Sociales	de	
los	Trabajadores	del	Estado	(ISSSTE),	which	covers	
federal	and	state	level	government	employees.	There	
is	also	a	network	of	Servicios	Estatales	de	Salud,	or	
government-funded	State	Health	Services	(SHS),	for	
those	without	employment-linked	insurance.	In	2004,	
with	the	aim	of	achieving	universal	health	coverage,	
the	government	introduced	the	Seguro	Popular	(SP),	
which	extended	publicly-funded	health	insurance	to	
50	million	Mexicans	who	were	previously	uninsured.	
Prior	to	Seguro	Popular,	these	individuals	would	have	
had	access	to	SHS	but	been	liable	to	pay	a	user	fee.	
The	package	of	services	covered	by	Seguro	Popular	
has	been	continuously	expanded,	now	covering	95%	
of	presentations	to	clinics	and	hospitals.	However,	
access,	quality	and	use	of	services	vary	by	region,	
ethnicity,	and	socio-economic	characteristics	(Angel	et	
al.,	2016).
Mexico	has	lower	availability	of	healthcare	services	
than	most	OECD	countries.	In	2013	it	had	2.2	
practising	doctors,	2.6	practising	nurses	and	1.6	
hospital	beds	per	1,000	population	(compared	to	
the	OECD	averages	of	3.3,	9.1	and	4.8	respectively)	
(OECD,	2016).	The	number	of	doctor	consultations	per	
capita	in	the	public	system	is	also	very	low:	2.8	per	
capita	compared	to	the	OECD	average	of	6.6.	These	
low	rates	may	reflect	unmet	healthcare	needs	among	
those	with	fewer	resources,	and	also	that	those	who	
are	better	off	opt	to	use	private	healthcare	instead,	due	
to	dissatisfaction	with	the	quality	or	accessibility	of	
services	provided	by	the	health	insurance	institutions.	
Out-of-pocket	payments	represent	45%	of	health	
system	revenue	and	4.0%	of	household	expenditure	
(OECD,	2016).	
The	OECD’s	assessment	of	the	Mexican	health	care	
system	highlights	that	as	well	as	being	unequal,	the	
lack	of	coordination	between	the	different	insurance	
schemes	results	in	huge	inefficiencies,	with	10%	of	the	
national	health	budget	being	spent	on	administration.	
Millions	of	people	belong	to	more	than	one	insurance	
scheme,	and	millions	more	are	not	aware	of	belonging	
to	any	scheme	(OECD,	2016).
The	OECD	also	highlights	that	primary	care	is	not	as	
developed	as	it	should	be,	with	people	not	registered	
with	a	named	primary	care	doctor	and	opening	hours	
restricted.	Instead,	people	often	seek	care	from	
hospital	emergency	departments	and	from	pharmacies	
that	offer	consultations	with	a	physician.	This	reduces	
the	opportunities	for	prevention	and	care	coordination	
(OECD,	2016).
An	important	strength	of	the	Mexican	health	care	
system	has	been	the	adoption	of	a	consolidated	
drug	purchasing	mechanism	at	the	federal	level.	
The Comisión Coordinadora para la Negociación de 
Precios de Medicamentos y otros Insumos para la 
Salud (CCNPMIS,	Coordinating	Commission	for	the	
Negotiation	of	Prices	of	Pharmaceuticals	and	other	
Health	Inputs)	was	set	up	in	2008	and	it	coordinates	
an	annual	negotiation	process	with	pharmaceutical	
companies	for	the	products	included	in	the	Mexican	
national	formulary.	This	strategy	seems	to	have	been	
successful	in	reducing	drug	prices	in	Mexico	(OECD,	
2016).
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Current diagnostic and healthcare pathways
As	in	most	middle-	and	low-income	countries,	some	
specialist	dementia	healthcare	services	are	available	
in	Mexico,	but	are	available	to	very	few	people;	those	
in	Mexico	City	or	other	large	cities,	or	those	who	
can	access	the	private	health	sector.	As	with	other	
health	problems,	there	is	high	inequality	in	dementia	
diagnosis	and	treatment,	as	those	few	with	enough	
financial	resources	who	access	private	services	get	
timely	and	accurate	diagnosis	and	quality	treatment	
practices	and	recommendations	for	caregivers,	while	
the	majority	of	older	adults	have	no	access	to	such	
care.
In	public	health	institutions	older	adults’	first	contact	
is	with	family	doctors	or	general	practitioners	who	are	
not	only	untrained	to	provide	an	accurate	diagnosis	
of	dementia,	but	have	no	accurate	knowledge	of	the	
disease	or	its	progress,	and	still	very	often	think	that	
memory	loss	and	changes	in	behaviour	are	normal	
consequences	of	ageing.	Therefore,	even	where	some	
services	are	available	at	the	second	or	tertiary	care	
levels,	few	people	may	be	referred	for	specialist	care	
(Lopez-Ortega,	2016).
A	qualitative	study	of	the	experiences	of	families	of	
people	with	dementia	reported	that	most	general	
practitioners	were	not	equipped	to	recognize	early	
signs	of	cognitive	impairment	and	as	a	result	did	
not	feel	prepared	to	offer	treatment.	This	resulted	in	
caregivers	looking	to	the	private	sector	for	support,	but	
this	was	often	out	of	financial	reach	(Juarez-Cedillo	et	
al.,	2014).	
The	cost	of	anti-dementia	drugs	in	Mexico	is	much	
lower	than	in	other	LMIC,	reflecting	the	early	availability	
of	locally	produced	generics	(Suh	et	al,	2009)	and	the	
role	of	the	consolidated	drug	purchasing	system.
Other care and support for people with 
dementia and their families
Mexico	lacks	national	long-term	care	policies	and	
services.	Most	care	for	people	with	dementia	is	
provided	by	family	members	within	the	household	who	
have	little	or	no	training	or	knowledge	of	Alzheimer’s	
disease	and	other	dementias.	In	addition,	given	
there	are	no	special	benefits	such	as	tax	incentives,	
monetary	support	or	respite	care	to	support	family	
caregivers.
While	some	public	day-care	services	are	available	for	
older	adults,	most	are	for	functional	and	independent	
older	adults	while	just	a	few	cater	for	people	with	
dementia.
In	some	states	there	is	support	from	voluntary	non-
governmental	organisations,	mainly	through	the	
provision	of	training,	group	support	and	some	day-care	
services.	FEDMA,	the	Mexican	Alzheimer’s	Federation,	
was	created	in	2002	and	is	currently	the	largest	
association	with	21	registered	state-level	organisations	
and	46	support	groups.	As	part	of	their	work,	they	
organise	national	meetings	that	include	activities	and	
talks	for	people	with	dementia,	their	family	members	
and	caregivers.	They	have	also	been	fundamental	in	
the	consolidation	of	a	movement	to	improve	the	lives	
of	people	affected	by	dementia	in	the	country	(Torres	
Castro,	Martinez	Ruiz	and	Arrieta	Cruz,	2015).	
Challenges that need to be addressed
In	2016,	the	national	Alzheimer’s	Plan	of	Action	is	
still	at	the	beginning	of	its	implementation.	While	
there	has	been	important	progress	in	the	training	of	
professionals	and	efforts	to	improve	awareness	and	
knowledge	about	dementia,	achieving	the	Plan’s	
aims	of	improving	the	treatment,	care	and	support	of	
people	with	dementia	will	also	require	a	wider	reform	
of	the	healthcare	system.	In	particular,	the	current	
fragmentation	and	unequal	coverage	of	the	different	
insurance	schemes	and	the	lack	of	a	strong	primary	
care	system	need	to	be	addressed	in	order	to	deliver	
adequate	care	and	support	to	people	with	dementia	
and	other	chronic	health	conditions.
In	addition,	there	is	a	need	to	consider	the	creation	
of	personal	and	social	care	public	strategies	to	
support	caregivers,	ensure	that	the	costs	of	providing	
unpaid	care	are	not	excessive	and	detrimental	to	their	
quality	of	life,	and	at	the	same	time	guaranteeing	care	
that	enables	people	with	dementia	to	live	well.	The	
government	will	also	need	to	consider	the	sustainability	
of	the	current	degree	of	reliance	on	family	care:	smaller	
family	sizes,	internal	and	international	migration	rates,	
and	women’s	increasing	participation	in	the	labour	
force	and	activities	outside	the	home,	pose	future	
challenges	to	the	availability	of	family	care	and	support	
for	older	adults	(Gutierrez	Robledo,	Lopez-Ortega,	
Arango	Lopera,	2012).	
6.6 Dementia care in South Africa
South	Africa	is	classified	as	an	upper-middle	income	
country	by	the	World	Bank	(2015),	with	an	abundant	
supply	of	natural	resources,	well-developed	financial,	
legal,	communications,	energy	and	transport	sectors.	
South	Africa	experienced	average	annual	economic	
growth	of	approximately	5%	in	real	terms	between	
2004	and	2007,	but	this	has	since	slowed,	largely	as	a	
result	of	the	global	economic	recession,	and	from	2008	
to	2012,	growth	was	just	above	2%	(Statistics	South	
Africa,	2016).	
South	Africa’s	population	reached	nearly	55	million	in	
2015.	It	is	experiencing	rapid	growth	in	the	number	of	
older	adults	and	the	proportion	of	older	adults	in	the	
population.	There	are	currently	4.4	million	adults	aged	
60	and	above	in	South	Africa,	9.5%	of	whom	are	aged	
80	and	above	(Statistics	South	Africa,	2015).	This	older	
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population	is	expected	to	increase	to	7	million	by	2030	
(Statistics	South	Africa,	2014a).	The	country’s	fertility	
rate	of	2.3	is	lower	than	anywhere	else	on	the	African	
continent.	
The	legacy	of	the	1948	to	1994	Apartheid	era	remains	
a	challenge:	it	is	the	third	most	unequal	country	in	
the	world	and	unemployment	is	high,	particularly	
among	black	young	people	(CIA,	2016).	The	large	
inequalities	in	South	Africa	mean	that	the	country	has	
simultaneously	to	deal	with	both	increases	in	“diseases	
of	prosperity”,	associated	with	longer	life	expectancies,	
and	“diseases	of	poverty”	(Bongani	and	Benatar,	
2014).	The	“quadruple	disease	burden”	in	South	Africa	
comprises:	a	large	prevalence	of	communicable	
diseases	(especially	HIV/AIDS	and	tuberculosis);	non-
communicable	diseases	(such	as	high	blood	pressure	
and	diabetes);	high	maternal,	neonatal	and	child	death	
rates;	and	deaths	from	injuries	and	violence	(Rispel,	
2016).
The	HIV/AIDS	epidemic	has	had	a	major	impact	on	the	
population’s	health	and	associated	care	needs	and	
provision,	and	also	on	the	structure	of	families.	In	2003	
the	government	introduced	an	ambitious	programme	
to	provide	antiretroviral	therapy	(ART)	to	all	people	
with	HIV	infection.	Spending	on	HIV	increased	at	an	
annual	average	rate	of	48.2%	between	1999	and	2005.	
At	least	2	million	out	of	the	6	million	South-Africans	
infected	with	HIV	receive	ART	(Bongani	and	Benatar,	
2014).
Demographic and prevalence data
The	World	Alzheimer	Report	2015	estimated	that	in	
2015	there	were	nearly	186,000	people	living	with	
dementia	in	South	Africa,	of	whom	nearly	75%	were	
women.	By	2030	the	number	of	people	is	expected	to	
rise	to	nearly	275,000	(see	Figure	6.5).	
Increasing	numbers	of	adults	in	South	Africa	
are	affected	by	disorders	associated	with	
neurodegeneration	such	as	traumatic	brain	injury,	
alcohol	dependence	and	HIV	infection.	The	prevalence	
of	HIV-associated	dementia	(HAD)	is	15	to	30%	in	
untreated	populations	with	late-stage	disease.	Older	
adults,	already	at	increased	risk	of	non-AIDS-related	
dementias,	are	also	most	likely	to	have	untreated	HIV.	
It	is	difficult	to	quantify	the	impact	that	this	has	and	
will	have	on	the	numbers	of	people	with	dementia	(de	
Jager	et	al.,	2015).
Policy landscape and healthcare system context
National policy on dementia
At	present	there	is	no	national	dementia	plan	for	South	
Africa.	The	lack	of	policies	specifically	focused	on	
dementia	reflects	very	low	awareness	of	the	prevalence	
and	impact	of	dementia,	and	in	practice	results	in	very	
few	services	oriented	towards	people	with	dementia,	
except	for	some	memory	clinics	developed	by	
hospitals	and	community	services	provided	by	NGOs	
(Kalula	and	Petros,	2011).
There	has,	however,	been	important	investment	
in	broader	mental	health	services,	following	
implementation	of	national	policy	guidelines	in	1997.	
Since	then,	the	2002	Mental	Health	Act	emphasised	
the	human	rights	of	those	with	mental	health	conditions	
and	promoted	the	development	of	mental	healthcare	
within	the	general	health	system	and	community-based	
care	(Lund	et	al.,	2008).	In	2013,	the	National	Health	
Council	adopted	a	Mental	Health	Policy	Framework	
(MHPF)	and	the	Strategic	Plan	for	South	Africa.	This	
framework	includes	eight	key	objectives	which	aim	to	
further	transform	mental	health	services,	ensuring	that	
access	is	available	for	all	who	need	it	(Stein,	2014).	
This	Mental	Health	Policy	Framework	emphasises	
longer	term	aspirations	which	align	with	South	
Africa’s	broader	health	sector	development	goals	and	
endeavours	to	reduce	the	burden	of	untreated	mental	
disorders	across	the	country.	
Awareness	and	understanding	of	dementia	among	
the	population	is	very	low,	which	has	important	
implications	for	individuals’	propensity	to	seek	
healthcare	and	support	for	dementia,	and	may	also	put	
them	at	risk	of	abuse	and	harm	related	to	the	conflation	
of	dementia	symptoms	with	witchcraft	(Benade	2012,	
De	Jager	et	al	2015,	Khonje	et	al,	2015).	In	a	survey	of	
knowledge,	attitudes	and	practices	towards	people	
with	dementia	in	the	township	of	Khayelitsha,	28%	
of	the	sample	thought	that	dementia	was	associated	
with	witchcraft	and	26%	thought	it	was	a	punishment	
(14%	from	God	and	18%	from	the	ancestors).	15%	of	
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respondents	believed	traditional	healers	could	cure	
dementia	(Khonje	et	al.,	2015).
The health system context
The	Apartheid-era	inequities	are	reflected	in	both	the	
need	for	and	availability	of	health	and	social	care.	
Rural	areas	in	the	country	have	largely	underdeveloped	
infrastructures	and	few	health	or	social	care	services.	
South	Africa’s	health	system	consists	of	a	public	
sector	that	covers	the	majority	of	the	population,	a	
private	sector,	and	non-profit	sector.	The	disparity	
between	the	healthcare	services	available	to	those	
in	the	public	and	private	sector	is	illustrated	in	some	
striking	statistics	presented	by	Bongani	and	Benatar	
(2014):	annual	per	capita	expenditure	is	ten	times	
higher	in	the	private	sector	than	in	the	public	sector	
($1,400	compared	to	$140).	The	public	health	sector	
is	staffed	by	30%	of	doctors	in	the	country,	who	serve	
40	million	uninsured	people	(84%	of	the	population).	
Approximately	16%	of	the	population	have	private	
insurance,	which	provides	access	to	the	remaining	
70%	of	the	country’s	doctors,	who	work	full-time	in	the	
private	sector.	It	has	been	estimated	that	up	to	25%	of	
uninsured	people	pay	out	of	pocket	for	private	sector	
care.
Primary	healthcare	clinics	form	the	core	of	the	public	
health	systems.	They	are	the	first	point	of	access	
for	people	in	need	of	healthcare.	They	are	publicly	
funded	and	free	at	the	point	of	use.	There	are	currently	
4,200	such	clinics	in	South	Africa,	1,600	of	which	
have	been	built	or	upgraded	since	1994.	People	
who	require	specialist	treatment	can	be	referred	to	
district	hospitals	(the	second	tier	of	the	healthcare	
system).	There	are	also	academic	(tertiary)	hospitals,	
which	serve	as	teaching	hospitals	and	where	more	
advanced	diagnostic	procedures	and	treatments	are	
provided.	For	2.5	million	South	Africans,	their	nearest	
clinic	is	more	than	5	kilometres	away	from	their	homes	
(Jobson,	2015).
The	private	sector	is	mostly	financed	through	medical	
schemes.	There	are	more	than	110	schemes,	covering	
nearly	8	million	beneficiaries.	Care	is	provided	
via	independent	healthcare	providers	and	private	
hospitals.	There	are	238	private	hospitals,	188	in	urban	
areas	and	50	in	rural	areas	(Jobson,	2015).	
There	are	severe	workforce	pressures	in	the	public	
sector	in	South	Africa	(Rispel,	2016).	The	2012	National	
Health	Facilities	Baseline	Audit	surveyed	3,356	clinics	
and	community	health	centres	and	found	that	half	of	
them	had	no	visiting	doctors;	84%	had	no	assistance	
from	a	pharmacist	or	pharmacy	assistant;	11%	had	no	
lay	counsellors.	Despite	the	very	high	unemployment	
rates,	the	average	vacancy	rate	in	the	healthcare	sector	
across	South	Africa	is	31%,	ranging	from	13	to	40%	
across	different	provinces	(Jobson,	2015).
In	order	to	address	the	huge	imbalances	in	the	
healthcare	system,	the	South	African	government	
has	committed	to	implementing	a	National	Health	
Insurance	(NHI)	system.	The	White	Paper	published	
in	2015	commits	to	implementing	NHI	over	a	14-year	
period.	During	the	initial	first	five	years,	the	plans	will	
focus	on	strengthening	the	delivery	of	services	and	
improving	quality.	The	second	five-year	phase	will	
involve	rolling	out	an	NHI	card	to	all	of	the	population,	
introducing	unique	identifiers,	and	abolishing	out-of-
pocket	payments	in	public	hospitals.	The	third	and	
final	phase	will	focus	on	ensuring	the	functionality	of	
the	system.	It	is	envisaged	that	the	private	medical	
aids	may	supply	“top-up”	services	over	and	above	
the	publicly	covered	package	of	services.	The	funding	
mechanisms	for	the	new	NHI	scheme	have	not	yet	
been	decided	(Health	eNews,	2015).
Current diagnostic and healthcare pathways
There	is	limited	awareness	of	dementia	among	
health	professionals,	particularly	in	rural	areas.	
Primary	healthcare	services	concentrate	on	acute	
and	“treatable”	conditions	and	HIV	in	particular.	
Practitioners	often	consider	dementia	symptoms	to	be	
part	of	normal	ageing	and	have	no	understanding	of	
the	care	and	treatment	options	available	(Kalula	and	
Petros	2014,	De	Jager	et	al,	2015).	
The	lack	of	understanding	of	dementia	among	
healthcare	staff	can	mean	that,	even	when	dementia	
is	identified,	the	belief	that	there	is	nothing	than	can	
be	done	to	treat	it	can	result	in	people	being	excluded	
from	further	care.	For	example,	in	a	Soweto	township	
where	nurses	had	been	trained	to	discriminate	
between	dementia	and	delirium,	those	with	delirium	
were	referred	for	further	treatment,	whereas	those	with	
dementia	were	returned	home	for	family	care	(Prince	et	
al,	2007).
There	are	very	few	specialists	dedicated	to	dementia	
care.	South	Africa	has	fewer	than	ten	geriatricians	and	
fewer	than	five	old-age	psychiatrists	for	a	population	
of	over	4	million	older	people	(Kalula	and	Petros,	
2014).	Some	hospitals	have	opened	memory	clinics	
in	an	effort	to	improve	the	care	they	provide	to	people	
with	dementia.	Diagnostic	care	pathways	used	in	
these	clinics	differ	from	those	followed	in	private	
hospitals	in	South	Africa.	For	example,	a	detailed	
study	of	the	caseload	and	practices	at	a	clinic	in	
Cape	Town	suggests	that	some	of	the	“standard”	
screening	tools,	such	as	the	MMSE	and	other	tests	in	
the	neuropsychology	battery,	may	not	be	appropriate,	
resulting	in	false	positives	as	a	result	of	low	levels	of	
education	of	many	of	the	people	visiting	the	clinic.	Also	
the	clinic	did	not	use	brain	imaging	routinely,	which	
may	influence	diagnostic	accuracy	(Kalula	et	al,	2010).	
The	study	also	reported	that	lack	of	awareness	of	
dementia	among	primary	care	health	professionals	and	
family	members	may	result	in	delays	in	referrals,	which	
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may	explain	the	higher	severity	of	dementia	observed	
in	this	clinic	at	the	time	of	diagnosis,	compared	to	
international	data.	
The	use	of	anti-dementia	medication	is	very	low,	even	
among	those	who	are	diagnosed.	Cost	is	the	major	
barrier:	these	medications	are	not	included	in	the	
Essential	Drug	List	for	public	healthcare	facilities	and	
are	rarely	covered	by	private	health	insurance	plans	(De	
Jager	et	al,	2015).	The	report	from	the	memory	clinic	in	
Cape	Town	suggests	that	the	prescription	of	drugs	is	
primarily	focussed	on	the	management	of	behavioural	
symptoms;	the	review	found	anti-depressants	were	
prescribed	to	43%	of	patients,	despite	only	15%	
having	been	diagnosed	with	depression,	and	the	
most	common	dementia-specific	prescription	was	for	
traditional	anti-psychotics.	Only	2%	of	patients	who	
could	afford	acetylcholinesterase	inhibitors	had	them	
prescribed	(Kalula	et	al,	2010).
Analysis	of	prescription	data	from	a	national	
community	pharmacy	group	showed	that,	of	just	over	
575,000	people	who	were	prescribed	central	nervous	
system	drugs,	only	1,231	(2%)	people	had	been	
prescribed	medication	for	dementia.	In	total	5,264	
anti-dementia	drugs	were	prescribed	and	of	these	
46%	prescriptions	were	for	donepezil	and	37%	for	
memantine.	The	average	cost	per	product	was	(US)	
$76.44,	in	2010	prices.	The	study	also	found	that	there	
was	very	low	continuity	of	prescription:	nearly	half	of	
the	patients	only	had	one	or	two	prescriptions	during	
the	year	and	only	31%	were	prescribed	six	or	more	
times.	The	authors	consider	that	affordability	may	have	
played	a	role	(Truter	et	al,	2013).	The	study	also	reports	
that,	of	those	who	had	been	prescribed	anti-dementia	
drugs,	23%	were	also	prescribed	anti-psychotic	drugs,	
most	often	risperidone	(53%)	or	quetiapine	(31%).
Other care and support for people with 
dementia and their families
Most	of	the	care	to	people	living	with	dementia	
is	provided	by	families,	primarily	by	female	family	
members,	even	in	urban	areas.	Of	the	people	attending	
a	memory	clinic	in	Cape	Town,	79%	were	being	cared	
for	by	their	families	and	6%	were	in	care	homes	(Kalula	
et	al,	2010).
Welfare	payments	for	older	adults	and	their	family	
carers	in	the	form	of	the	Older	Persons	Grant	and	
Grant-in-Aid	are	expected	to	encourage	the	provision	
of	family	care	by	providing	financial	compensation	to	
those	who	cannot	work	as	a	result	of	providing	care.	
There	is	some	concern	that	the	most	vulnerable	older	
adults	–	likely	to	include	those	with	dementia	–	are	the	
least	likely	to	claim	either	grant.	
Alongside	family-based	care	provision,	South	Africa	
is	the	only	country	in	sub-Saharan	Africa	to	have	a	
developed	formal	care	system	for	older	people.	Public	
expenditure	on	long-term	care	amounts	to	0.2%	of	
GDP	(Scheil-Adlung,	2015)	and	there	is	also	private	
and	not-for-profit	sector	provision.	The	availability	
and	accessibility	of	formal	long-term	care	has	been	
strongly	shaped	by	the	Apartheid	policies	that	
privileged	institutional	care	for	white	older	people.	By	
1997,	87%	of	the	welfare	services	budget	was	spent	
on	residential	services	and	facilities,	primarily	for	
white	older	adults	(Ministry	for	Welfare	and	Population	
Development,	1997).	
Subsequent	policies	have	attempted	to	address	racial	
inequity	in	access	to	residential	facilities	and	public	
spending.	Current	provision	of	residential	care	is	
subsidised	only	for	older	adults	with	most	advanced	
functional	disability	and	who	qualify	for	the	means-
tested	Older	Persons	Grant.	To	receive	subsidies,	
older	adults	must	apply	directly	to	facilities.	However,	
facilities	are	overwhelmingly	concentrated	in	formal	
urban	areas	(79%),	with	few	located	in	rural	areas	
(16%)	and	informal	settlements	(5%)	that	contain	the	
highest	proportions	of	poor	older	adults	(Freeman,	
forthcoming).	
Community-based	care	and	support	services,	
promoted	as	alternatives	to	the	residential	care	model	
that	is	understood	to	be	culturally	challenging,	have	
proliferated.	These	are	largely	unregulated,	and	
typically	of	two	tiers:	competitive	private	for-profit	
home-based	nursing	care	services	that	cater	to	more	
affluent,	typically	urban	populations,	and	non-profit,	
often	under-resourced	services	offered	by	charitable	
or	faith-based	organisations	that	cater	to	populations	
of	poor	older	adults	without	recourse	to	family	or	
community	care.	Despite	policy	support	for	non-
residential	non-dementia	specific	long	term	care,	state	
subsidy	of	services	for	vulnerable	older	adults	is	widely	
considered	to	be	inadequate	(Freeman,	forthcoming).
A	qualitative	study	of	the	attitudes	and	responses	
of	staff	in	care	homes	to	distressed	behaviour	of	
residents	with	dementia	found	that	less	than	half	of	all	
the	staff	reported	having	received	specific	training	to	
care	for	people	with	dementia	and	those	who	did	had	
attended	only	a	one-day	workshop.	The	study	also	
found	that	none	of	the	homes	offered	any	structured	
activities	or	therapeutic	services	for	residents	with	
dementia.	Although	some	of	the	staff	members	
reported	using	medication	to	manage	distressed	
behaviour,	the	majority	reported	a	preference	for	care-
related	approaches	(Van	Wyk	et	al,	2016).
There	are	two	national	dementia	associations:	
Alzheimer’s	South	Africa	and	Dementia	SA.	As	well	
as	raising	awareness	and	campaigning	to	improve	
dementia	care	services	and	policy,	both	organisations	
provide	training	to	formal	and	informal	caregivers	and	
run	support	groups,	which	are	usually	led	by	a	trained	
caregiver	(Benade,	2012).	A	few	other	NGOs,	including	
99ImprovIng healthcare for people lIvIng wIth dementIa
alzheImer’s dIsease InternatIonal: world alzheImer report 2016
religious	groups,	also	provide	services	for	older	people	
(de	Jager	et	al,	2015).
Challenges that need to be addressed
A	recent	paper	by	De	Jager	et	al	(2015	p.190)	sets	
out	a	list	of	priorities	for	the	improvement	of	dementia	
healthcare	and	treatment	in	South	Africa:
•	 Robust	prevalence	data	using	culturally-relevant	
screening	tests
•	 Earlier	diagnosis	and	intervention	options
•	 De-stigmatisation	and	increased	awareness
•	 Increased	preparedness	and	service	provision
•	 Integration	of	older	persons’	needs	and	rights	
into	national	health	policies	across	all	sectors,	
e.g.	health	and	justice,	adequate	protection	of	
vulnerable	people	with	dementia	from	abuse	and	
neglect
•	 Prioritised	research	funding
•	 Education	at	all	levels,	including	communities,	to	
better	manage	people	with	dementia	and	enable	
them	to	live	meaningful	and	purposeful	lives
•	 Training	and	skills	development	for	healthcare	
providers	
•	 Career	advancement	for	professionals	in	geriatric	
medicine	and	related	disciplines
There	is	considerable	scope	for	improving	access	
to	health	and	social	care	services	for	people	with	
dementia.	There	is	limited	evidence	about	dementia	in	
South	Africa.	The	evidence	we	have	found	highlights	
the	importance	of	ensuring	that	primary	care	services	
have	adequate	staff,	knowledge	and	resources	to	
be	able	meet	to	the	needs	of	those	with	non-curable	
conditions	such	as	dementia,	the	barriers	to	access	to	
anti-dementia	drugs	as	a	result	of	their	lack	of	inclusion	
in	the	Essential	Drugs	List,	and	the	lack	of	support	to	
families	providing	care.
6.7 Dementia care in South Korea
The	Republic	of	Korea,	often	referred	to	as	South	
Korea,	is	located	in	East	Asia	and	constitutes	the	
southern	part	of	the	Korean	Peninsula.	It	shares	land	
borders	with	the	Democratic	People’s	Republic	of	
Korea	to	the	north,	and	maritime	borders	with	China	to	
the	west	and	Japan	to	the	east.	In	the	last	fifty	years	
South	Korea’s	economy	has	grown	very	rapidly.	It	is	
now	a	high	income	country,	with	GNI	per	capita	of	
$27,090	(World	Bank,	2015).	It	has	a	population	of	50	
million	and	is	the	world’s	15th	largest	economy.	
South	Korea	has	experienced	very	rapid	ageing	since	
the	year	2000;	between	2000	and	2015	it	experienced	
the	fourth	fastest	rate	of	ageing	in	the	world,	and	
between	2015	and	2030	it	is	expected	to	be	the	second	
fastest	ageing	country	in	the	world.	The	percentage	of	
the	population	aged	60	or	more	was	estimated	to	be	
18.5%	in	2015	and	is	projected	to	reach	31%	by	2030	
(UN,	2015).
Demographic and prevalence data
Using	data	from	the	2012	Nationwide	Survey	on	
Dementia	Epidemiology	of	Korea	(NaSDEK)	and	the	
2010	Census,	the	prevalence	of	dementia	in	2012	was	
estimated	to	be	of	9.18%	by	the	National	Dementia	
Institute.	Applying	age	and	gender	standardised	
dementia	rates	to	the	national	population	projections,	
in	2015	there	would	be	over	648,000	people	with	
dementia	in	South	Korea,	projected	to	increase	to	
nearly	1,272,500	by	2030	(National	Dementia	Institute,	
2016).
The	World	Alzheimer	Report	2015	estimates	were	
lower,	suggesting	that	in	2015	there	were	just	over	
478,000	people	with	dementia	in	South	Korea,	
increasing	to	just	over	a	million	by	2030	(see	Figure	
6.6).	
Policy landscape and healthcare system context
Cost of dementia
In	2013,	the	annual	cost	of	dementia	in	South	Korea	
was	estimated	to	be	about	US$	10	billion,	which	would	
represent	about	0.7%	of	its	GDP.	The	importance	of	
the	costs	of	dementia	as	a	share	of	GDP	is	expected	to	
rise	to	about	2%	by	2050	(Kim,	2016).
The	costs	of	caring	for	a	person	with	dementia	in	
South	Korea	were	estimated	to	be	US$	19,104	in	2015	
(National	Dementia	Institute,	2016).	A	previous	study	
reported	that,	of	the	total	costs	of	dementia,	38%	
were	direct	health	costs,	17%	were	direct	long-term	
care	costs,	and	45%	were	indirect	costs,	including	
the	opportunity	costs	of	unpaid	family	care	and	
productivity	losses.	The	costs	of	caring	for	people	with	
severe	dementia	were	found	to	be	2.7	times	higher	
Figure 6.6 
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than	for	people	with	mild	(questionable)	dementia	(Kim	
et	al,	2011).
National Dementia Plans and policy
South	Korea	is	now	on	its	third	National	Dementia	
Plan.	The	first	was	launched	in	2008	and	focused	
on	prevention,	early	diagnostic,	development	and	
coordination	of	infrastructures	and	management,	
and	improving	awareness.	The	second	plan,	in	2012,	
addressed	the	same	priorities	but	had	a	stronger	focus	
on	supporting	family	members.	In	2012	the	Dementia	
Management	Act	(DeMA)	established	a	statutory	basis	
for	organisation	of	the	National	Dementia	Plans.
Under	the	Dementia	Management	Act,	the	state	
is	required	to	produce	a	comprehensive	plan	for	
dementia	every	5	years.	The	Act	also	mandates	that	
the	state	should	manage	a	dementia	case	register	and	
collect	statistics	on	epidemiology	and	the	management	
of	the	condition.	This	has	led	to	the	‘Nationwide	Study	
on	the	Prevalence	of	Dementia	in	Korean	elders	2008’	
(Choi	et	al,	2009),	the	‘Study	on	Dementia	Prevalence	
2012’	(Ministry	of	Health	and	Welfare,	2013),	and	the	
forthcoming	‘Study	on	Dementia	Prevalence	2016’.
The	Act	also	established	institutions	to	coordinate	
dementia	treatment,	care	and	support.	The	National	
Institute	of	Dementia,	at	the	Seoul	National	University	
Bundang	Hospital,	has	a	central	management	role,	
and	coordinates	regional	Dementia	Centres	in	the	
17	regions	(13	have	been	established	so	far,	4	more	
are	expected	to	open	before	the	end	of	2016).	The	
Dementia	Centres	provide	education	to	healthcare	
professionals	and	conduct	research,	as	well	as	
establishing	and	running	local	awareness	campaigns,	
including	the	Dementia	Partners	programme	(Sim,	
2016).	The	Act	also	established	Dementia	Counselling	
Centres	in	every	Public	health	centre	and	the	National	
Dementia	Helpline.
The	3rd	National	Dementia	Plan	of	2016	aims	to	create	
a	dementia	friendly	society	to	enable	people	with	
dementia	and	their	carers	live	well.	The	four	principles	
of	the	plan	are:
1.  Community-based prevention and management of 
dementia
2.  Convenient and safe diagnosis, treatment, and care 
for people with dementia
3.  The reduction of the care burden for family 
caregivers of people with dementia
4.  Support for dementia research through research, 
statistics and technology
Current dementia policy priorities in South Korea 
include:
1.  The establishment of a user-based dementia 
management system with wider coverage and the 
consideration of the ‘care pathway’
2.  Improved balance and coordination between 
treatment, care and welfare services, using 
evidence-based planning and quantification of 
outcomes
3.  Building ‘Dementia-Friendly Communities’
Healthcare system context
South	Korea	achieved	universal	health	coverage	in	
1989,	12	years	after	the	introduction	of	social	health	
insurance.	Since	2000	there	has	been	a	single	payer	
national	insurance	system,	the	National	Health	
Insurance,	with	uniform	contributions	and	benefits.	
Prior	to	that,	there	were	three	different	types	of	
insurance	schemes	and	more	than	350	insurance	
providers	(Kwon,	2015).	A	small	proportion	of	the	
population	with	very	low	incomes	is	covered	by	the	
separate	Medical	Aid	Programme	(MAP)	(Robertson	et	
al,	2014).
The	delivery	of	healthcare	is	mostly	private,	except	
for	some	public	health	facilities	that	provide	medically	
necessary	services	at	central,	regional	and	municipal	
levels.	The	Ministry	of	Health	and	Welfare	has	a	central	
role	in	health	planning	and	policy	formulation	and	
implementation.	Regional	governments	are	responsible	
for	managing	regional	medical	centres	and	each	
municipality	is	in	charge	of	health	centres	and	sub-
centres	and	primary	healthcare	posts.
The	National	Health	Insurance	is	run	by	two	quasi-
public	bodies,	the	National	Health	Insurance	Service	
(NHIS)	and	the	Health	Insurance	Review	and	
Assessment	Service	(HIRA).
Although	there	is	universal	health	coverage,	out-
of-pocket	payments	(OOP)	are	high	and	there	is	no	
fee	regulation	for	private	providers.	This	means	that	
private	providers	have	incentives	to	induce	demand	
for	expensive	new	services	and	technologies	which,	
sometimes	because	there	is	no	evidence	that	they	are	
cost-effective,	are	not	included	in	the	National	Health	
Insurance	benefit	package.	Voluntary	health	insurance	
is	growing	in	importance.	
Patients	contribute	up	to	20%	of	the	costs	of	inpatient	
care	and	between	30	and	60%	of	outpatient	care	
costs.	There	are	exemptions	from	OOP	for	the	poor	
and	discounted	rates	for	those	with	low	incomes	
(Robertson,	2014).
There	is	no	gatekeeping	role	in	the	healthcare	system,	
which	means	that	people	are	able	to	choose	their	care	
providers.	Their	choices	reveal	a	high	preference	for	
high-tech	medical	care,	usually	preferring	to	access	
tertiary	care	hospitals	directly,	despite	having	to	pay	
higher	OOP.	Up	to	90%	of	primary	care	is	provided	
by	independent	private	providers	in	single-handed	
and	group	practices,	operating	from	both	clinics	and	
offices,	and	hospital	settings	(Robertson,	2014).
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Table 6.1 
Ministry of Health and Welfare official Key Performance Indicators (KPI) for the 3rd National Dementia Plan
KPI Current Goal (2018) Goal (2020) Note
General Yearly % increase in the 
dementia prevalence rates
(2012-15)
2.14%
(2016-18)
1.64%
(2018-20)
1.14%
Reduced increase in prevalence by 
early management of risk factors 
for dementia
Dementia Awareness score 64.7 75 80 Based on the Nationwide Survey 
on Dementia Awareness
Community Number of leading secondary 
schools and universities to 
overcome dementia
11 80 160 5 per metropolitan area in 2018, 
10 in 2020 
Number of Dementia Partners 100,000 300,000 500,000 -
Treatment & 
care for people 
with dementia
Introduction of the Family 
Caregiver Counselling Fee to NHI
- - - Introduce to the NHI in 2017
Introduction of 24-hour Visiting 
Respite Service
- - - Introduce in 2017
Addition of specialized care 
services for people with 
dementia in nursing homes
Pilot 
program
- - Introduce in 2016
Prevalence of physical abuse in 
older adults with dementia (%)
0.16 0.13 0.10 949 reports of physical abuse in 
2014
Family 
caregivers
Average QOL of at-home 
caregivers
5.23 5 4.7 Based on the Nationwide Survey 
on Dementia Care of Korea 
(14-point scale, lower scores 
indicate better quality of life)
Cumulative number of on/offline 
self-help groups
- 160 320 10 per metropolitan area in 2018, 
20 in 2020
Research & 
Statistics
Publication of the Dementia 
Research and Statistics Annual 
Report
- Publication - Publish in 2017
Source: National Institute of Dementia (2016)
In	2012,	there	were	34	regional	medical	centres	directly	
under	regional	governments	and	254	health	centres	
accountable	to	municipalities.	There	were	also	1,315	
Health	sub-centres	and	1,895	primary	healthcare	
posts,	providing	basic	health	services	in	areas	without	
easily	accessible	health	centres	(Kwon,	2015).	
Current diagnostic and healthcare pathways
The	first	National	Dementia	Plan	was	launched	as	a	
result	of	concerns	about	the	low	level	of	diagnosis	of	
people	with	dementia:	in	2008	up	to	67%	of	people	
with	dementia	had	not	been	diagnosed	(Jo	et	al,	
2008).	This	plan	introduced	the	National	Dementia	
Early	Detection	programme	(NDeED),	which	offers	
all	older	people	access	to	dementia	screening	and	
access	post-diagnostic	services	(including	the	
reimbursement	of	medication	if	this	is	prescribed).	
The	NDeED	programme	has	resulted	in	a	substantial	
increase	in	diagnosis	rates.	As	part	of	the	drive	to	
enhance	awareness	and	timely	diagnosis	of	dementia,	
a	self-screening	digital	app	“Check	Dementia”	has	
been	made	available,	as	well	as	a	National	Dementia	
Helpline	and	guidelines	to	help	people	reduce	their	risk	
of	dementia	(Kim,	2016).	
Out	of	6	million	people	over	the	age	of	65,	2	million	
people	are	screened	for	dementia.	One	third	of	them	
go	onto	the	next	stage	and	get	a	diagnosis	at	a	
government-run	centre,	and	the	other	two	thirds	either	
do	not	have	sufficient	symptoms	for	a	diagnosis,	or	
go	to	private	centres,	or	do	not	seek	further	help.	In	
the	end,	25%	of	those	screened	are	diagnosed	with	
dementia	(Kim,	2016).
Based	on	data	from	National	Health	Insurance	claims,	
the	total	number	of	people	who	used	in/outpatient	
medical	and	pharmaceutical	services	for	dementia	
treatment	under	the	National	Health	Insurance	was	
377,901	in	2014,	the	total	value	of	benefits	was	$912	
million	(USD)	(NHIS	&	HIRA,	2015).
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The	Dementia	Counselling	Centres,	set	up	in	every	
local	Public	Health	Centre,	provide	early	dementia	
screening.	This	service	is	financed	by	the	National	
Health	Promotion	Fund	and	local	government	and	in	
2015	it	was	used	by	52,000	people	(Ministry	of	Health	
and	Welfare,	2016).
People	with	dementia	may	be	prescribed	one	of	four	
suggested	medications	(Donepezil,	Galantamine,	
Rivastigmine,	Memantine)	and	can	claim	up	to	$26	
USD	per	month	towards	its	cost,	but	reimbursement	
is	subject	to	strict	criteria	which	require	Mini	Mental	
State	Exam	or	Clinical	Dementia	Rating	scores	to	
reach	a	certain	level	in	order	to	receive	insurance	
coverage.	A	study	of	the	persistence	in	anti-dementia	
pharmacological	treatments	found	that	more	than	3	in	
4	patients	discontinued	therapy	within	one	year	from	
initiation.	People	living	in	metropolitan	cities	had	better	
continuation	rates	than	those	in	other	areas,	which	may	
reflect	regional	variation	in	treatment	accessibility	and	
clinical	practice	(Ahn	et	al,	2015).
Other care and support for people with 
dementia and their families
Long-term care system context
In	2008,	Korea	introduced	a	mandatory	long-term	care	
social	insurance	scheme,	covering	all	older	people	
and	also	younger	people	with	particular	conditions	
such	as	dementia	and	stroke.	The	long-term	care	
insurance	(LTCI)	scheme	is	run	by	the	National	Health	
Insurance	Scheme	(NHIS),	which	added	an	additional	
contribution	to	the	existing	health	scheme	and	the	
government	provides	additional	funding	from	taxation.	
Eligibility	is	assessed	by	the	local	NHIS	offices.	
Initially	the	eligibility	assessment	only	considered	
ability	to	perform	Activities	of	Daily	Living	(ADLs),	
which	meant	that	people	with	dementia	were	
often	not	considered	eligible.	It	was	estimated	that	
approximately	27%	of	people	with	dementia	in	need	of	
care	had	been	excluded	from	services	under	the	LTCI	
(Ministry	of	Health	and	Welfare	2012,	cited	by	Chon,	
2014).	This	situation	has	now	been	addressed	and	
there	is	now	an	additional	“special	grade	for	dementia”	
eligibility	(Chon,	2014;	Yoo,	2016).	This	has	been	
enhanced	by	the	Dementia	Support	Policy	which	aims	
to	provide	support	specifically	to	people	who	have	mild	
dementia	with	no	or	little	physical	impairment.	Support	
can	include	day	and	night	care,	cognitive	stimulation	
training	by	trained	staff,	and	respite	for	caregivers	(Yoo,	
2016).
Those	who	are	eligible	for	LTCI	benefits	can	contract	
directly	with	provider	agencies,	and	benefits	are	mostly	
provided	in	kind.	The	basic	packages	of	care	are	set	
by	national	guidelines	which	define	the	maximum	
amount	of	benefits	for	each	category.	Residential	care	
or	nursing	home	care	is	provided	by	long-term	care	
facilities,	licensed	nursing	homes,	retirement	homes,	
and	licensed	residential	establishments.	Home	care	
or	community	care	includes	support	for	ADL	needs	at	
home,	bathing	service,	nursing	care	at	home,	and	day	
care	services.	Cash	benefits	are	only	available	to	those	
in	remote	areas	or	islands	where	there	is	no	formal	
care	provision.	When	cash	benefits	are	used,	these	are	
of	lesser	value	than	benefits	in	kind.	Quality	assurance	
is	based	on	staff	qualifications	and	staffing	ratios.	
People	who	want	to	work	as	care	workers	are	required	
to	complete	a	240-hour	training	course	and	pass	a	
national	qualification	exam	(Kwon	et	al,	2015).
In	2013,	over	115,000	people	for	whom	dementia	was	
reported	as	the	‘primary	disease’	were	beneficiaries	
of	LTCI.	They	represented	34%	of	the	total	number	
of	LTCI	beneficiaries.	Of	these,	63,000	were	in	care	
homes	and	52,000	received	home	care	benefits,	
representing,	respectively,	50%	and	25%	of	the	total	
number	of	beneficiaries	(data	from	the	NHIS,	provided	
by	the	National	Institute	of	Dementia,	2016).
Other care and support
Family	caregivers	provide	much	care	and	support	for	
people	with	dementia.	Data	from	a	2010	survey	shows	
that	people	with	dementia	received	on	average	299	
minutes	per	day	of	care	from	unpaid	family	caregivers,	
and	it	was	estimated	that	the	yearly	opportunity	cost	
of	that	care	per	person	amounted	to	US$	3,076	on	
average	(Kim	et	al,	2011).
As	well	as	health	and	long-term	care	services,	since	
2013	there	has	been	a	National	Dementia	Helpline,	
open	24	hours	a	day,	that	provides	information	on	
the	availability	of	practical	support,	as	well	as	giving	
emotional	support.	Approximately	20%	of	people	who	
call	the	helpline	ask	for	advice	on	providing	care	and	
seek	emotional	support.	People	can	approach	the	
National	Dementia	Helpline	via	its	online	presence	or	
through	a	mobile	phone	app	‘Companion’	(Kim,	2016).	
In	2015	the	Helpline	received	nearly	55,000	calls	and	its	
budget	for	2016	amounts	to	US$1.24	million	(Ministry	
of	Health	and	Welfare,	2015).
The	National	Dementia	Plans	have	also	involved	efforts	
to	create	dementia	friendly	communities	and	increase	
awareness,	including	a	campaign	to	encourage	people	
to	become	“Dementia	Partners”,	which	involves	
watching	a	30-minute	online	video	and	completing	a	
quiz	(Kim,	2016).
Challenges that need to be addressed
The	Republic	of	Korea	has	made	important	
commitments	to	improve	the	quality	of	life	of	people	
with	dementia	and	address	their	care,	treatment	and	
support	needs,	through	the	development	of	national	
dementia	policy,	ensuring	universal	coverage	for	both	
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Table 6.2  
Expenditure on LTC insurance by beneficiaries with dementia, in KRW million
2010 2011 2012  2013 Annual 
increase rate
Beneficiaries 
with dementia
Amount paid by beneficiaries  111,498        139,939        158,843        189,651 
18.80%Amount paid by insurer        758,121        915,792      1,008,834      1,266,841 
Total        869,619      1,055,731      1,167,677      1,456,492 
Source: National Assembly Budget Office. Status and Improvement of the Dementia Management. 2014.
health	and	social	care,	and	ensuring	that	the	needs	
of	people	with	dementia	were	considered	in	the	
LTIC	eligibility	criteria.	The	routine	collection	of	data	
provides	an	opportunity	to	monitor	the	degree	to	which	
needs	are	being	met	and	inform	future	policies.	
The	current	dominance	of	fee-for-service	payments	for	
healthcare	and	lack	of	a	gate-keeping	role	for	primary	
care	providers	is	resulting	in	incentives	for	mostly	
private	providers	to	induce	demand	for	care	that	may	
not	be	necessary	or	cost-effective,	and	in	people	
being	exposed	to	large	out-of-pocket	payments.	
To	ensure	the	sustainability	of	the	National	Health	
Insurance	System,	it	has	been	argued	that	it	necessary	
to	consider	a	stronger	gate-keeping	role	for	primary	
care	and	increase	the	role	of	prospective	payment	
and	capitation	(Kwon	et	al,	2015).	These	authors	also	
highlight	the	need	for	better	coordination	between	
health	and	social	care,	and	the	persistence	of	health	
inequalities	between	different	socioeconomic	groups,	
rural	and	urban	areas	and	between	genders	(Kwon	et	
al,	2015).
With	respect	to	long-term	care,	it	may	be	necessary	
to	strengthen	the	regulatory	and	monitoring	systems,	
which	are	considered	to	be	inadequate,	as	they	allow	
opportunistic	and	sometimes	illegal	behaviour	by	
service	providers	and	the	provision	of	care	of	poor	
quality	(Chon,	2014).
It	is	also	recognised	that	the	support	of	people	with	
dementia	in	long-term	care	facilities	requires	a	better	
management	system	and	improved	professional	
education	(Yoo,	2016).
6.8 Dementia care in Switzerland
Switzerland,	officially	known	as	the	Swiss	
Confederation,	is	a	federal	republic	organised	in	three	
levels	of	government:	the	federal	(confederation)	level,	
26	cantons	and	2352	municipalities.	Switzerland’s	
political	system	has	been	described	as	being	the	
closest	in	the	world	to	a	direct	democracy,	as	almost	
all	important	issues	are	decided	through	public	
referendum	(De	Pietro,	2015).	Most	of	the	country	is	
occupied	by	the	Alps	and	the	majority	of	its	8	million	
population	live	on	the	Swiss	plateau.
In	2015	the	Swiss	economy	generated	a	GDP	of	about	
$482	billion	(current	PPP),	with	the	third	highest	per-
capita	income	in	Europe	of	$58,600.	More	than	70	
percent	of	its	income	originates	in	the	services	sector,	
which	employs	an	even	higher	share	of	the	workforce.
Switzerland	is	one	of	the	countries	with	the	most	equal	
income	distribution	(Gini-coefficient	of	household	
incomes	of	28.7	in	2012)	and	unemployment	is	low,	
at	3.3	percent.	Switzerland	is	highly	dependent	on	
international	trade	and	since	the	financial	crisis	of	
2008	has	seen	slow	growth,	in	line	with	its	European	
neighbours.	This	has	led	to	stagnant	per-capita	income	
in	recent	years.	The	country	is	in	a	favourable	public	
finance	situation	with	a	public	debt	to	GDP	ratio	of	33	
percent	(2015	estimate)	and	a	small	budget	surplus	
(CIA,	2016).
Demographic and prevalence data
Although	there	have	been	several	epidemiological	
studies	that	recruited	representative	samples	of	the	
general	population,	none	of	these	was	purposely	
designed	to	estimate	the	prevalence	and	incidence	
of	dementia	and	its	impact.	Therefore,	there	are	at	
present	no	national	estimates	of	the	prevalence	of	
dementia	in	Switzerland.	However,	based	on	data	from	
similar	countries	and	on	national	demographic	data	
and	projections,	the	World	Alzheimer	Report	2015	
estimated	that	in	2015	there	were	just	under	134,000	
people	with	dementia	in	Switzerland.	By	2030	the	
number	of	people	is	expected	to	rise	to	194,000	(see	
Figure	6.7).	
Data	on	standardised	death	rates	(SDR)	for	
Switzerland	show	that	dementia	is	likely	to	be	an	
increasingly	important	cause	of	death.	Between	1995	
and	2012,	the	SDR	for	dementia	almost	doubled	for	
women	(from	17.6	to	33.9%)	and	increased	by	72%	
for	men	(from	16.7	to	28.7%).	This	large	increase	is	
likely	to	be	due	to	a	combination	of	changes	in	coding,	
proportional	reductions	in	mortality	for	other	causes	
(such	as	cardiovascular	diseases),	as	well	as	increases	
in	the	numbers	of	people	who	receive	a	diagnosis	of	
dementia	(De	Pietro,	2015).
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Policy landscape and healthcare system context
Policy-making	in	Switzerland	is	carried	out	in	
consultation	between	the	federal	government,	the	
cantons,	representatives	of	insurers	and	providers,	
and	public	participation.	In	this	context,	the	National	
Dialogue	on	Health	Policy	has	developed	several	
specific	national	strategic	planning	documents,	
often	related	to	a	wider	Health2020	strategy.	One	of	
these	strategic	planning	documents	was	the	National	
Dementia	Strategy	for	2014-2017,	which	was	approved	
by	the	National	Health	Policy	Dialogue	at	the	end	of	
2013	(FOPH,	2014).	Its	overarching	objectives	are:	the	
improvement	of	dementia	awareness	and	information,	
the	development	of	dementia-appropriate	services	
(including	improvements	in	diagnostic	and	care	
coordination),	improved	quality	of	care	(through	the	
development	of	care	guidelines	and	development	of	
dementia-specific	skills	among	all	involved	in	the	care	
of	people	with	dementia,	and	the	social	and	health	
workforce	at	large),	monitoring	activities	of	existing	
programmes	and	of	the	implementation	of	the	national	
strategy	at	a	cantonal	level;	and	improved	availability	of	
comparable	data	and	research	so	that	future	dementia	
care	planning	can	be	based	on	evidence.	
Costs associated with dementia
The	societal	costs	of	dementia	in	Switzerland	were	
estimated	to	be	6.9	billion	$US	in	2009.	The	highest	
percentage	of	costs	was	for	care	home	expenditure	
(48.1%),	followed	by	unpaid	care	(43.5%),	home	
care	(known	as	Spitex,	5.0%),	hospital	costs	(2.5%),	
general	practitioner	(GP)	visits	(0.4%),	anti-dementia	
medication	(0.4%)	and	memory	clinics	(0.2%)	
(ECOPLAN	2010,	Kraft	et	al,	2010).	Based	on	these	
estimates,	the	average	direct	healthcare	costs	per	
person	with	dementia	living	at	home	(including	hospital	
inpatient	stays,	GP	and	specialist	visits,	anti-dementia	
medication	and	memory	clinic	inputs)	was	3,644	$US	
per	year	in	2009.	This	figure	is	likely	to	be	higher	now,	
as	at	the	time	of	the	report	it	was	estimated	that	only	
about	a	third	of	those	affected	in	the	older	population	
had	a	diagnosis,	whereas	more	recent	reports	suggest	
that	the	proportion	may	now	be	higher,	as	there	has	
been	an	increase	in	the	number	(and	capacity)	of	
memory	clinics	(ECOPLAN,	2013).
Health system context
Since	1996	everyone	in	Switzerland	has	access	to	
healthcare	through	the	Mandatory	Health	Insurance	
(MHI)	system.	The	insurers	who	take	part	in	the	MHI	
system	cannot	refuse	to	insure	individuals,	and	the	
cantons	subsidise	people	who	otherwise	could	not	
afford	the	insurance	premiums.	The	premiums	are	
community-rated	and	usually	determined	at	canton	
level	and	cannot	take	account	of	the	person’s	age,	
gender,	income	or	health	conditions.	The	benefits	are	
regulated	by	the	federal	government	and	include	most	
GP	and	specialist	services,	inpatient	care	and	other	
services	prescribed	by	a	physician.	MHI	companies	
offer	types	of	policy,	which	differ	according	to	the	
amounts	that	people	have	to	pay	before	the	coverage	
kicks	in	(the	deductible),	and	the	degree	they	are	able	
to	choose	their	providers.	In	recent	years	there	has	
been	an	increase	in	the	policies	that	restrict	the	choice	
of	providers	(managed-care	style),	reaching	60%	in	
2013	(De	Pietro,	2015).
Expenditure	on	health	in	Switzerland	is	among	the	
highest	in	Europe;	in	2013	it	amounted	to	11.5%	of	
GDP	(US$	6,187,	measured	in	PPP),	although,	unlike	
in	other	countries,	this	includes	a	large	proportion	of	
long-term	care	costs.	Out-of-pocket	expenditure	is	
also	high	compared	to	other	European	countries,	at	
26%	(De	Pietro,	2015).	
The	Swiss	healthcare	system	gives	people	access	
to	any	physician	or	hospital	directly	(there	is	no	
gatekeeping	role	by	GPs)	and	most	ambulatory	care	
is	provided	by	self-employed	physicians.	However,	the	
growth	in	plans	that	restrict	access	to	physicians	(and	
that	involve	gatekeeping	and	often	care	coordination	
by	a	GP)	has	also	resulted	in	an	increase	in	physicians	
that	form	part	of	physician	networks	and	health	
maintenance	organisations	(HMOs)	(De	Pietro,	2015).
Current diagnostic and healthcare pathways
The	Swiss	Alzheimer’s	Association	maintains	that	less	
than	50%	of	people	with	dementia	are	diagnosed,	
with	the	main	barriers	to	diagnosis	being	identified	
as	societal	(lack	of	awareness,	denial,	stigma)	and	
professional,	including	lack	of	GP	training	and	
expertise	(Alzheimer	Europe,	2013).
In	Switzerland	dementia	can	be	diagnosed	by	GPs	
or	by	specialist	doctors.	GPs	are	likely	to	refer	more	
complex	cases	to	memory	clinics	or	multi-disciplinary	
teams,	but	people	are	also	able	to	self-refer	to	memory	
clinics	and	specialists	(Alzheimer	Europe,	2014).	
Nevertheless,	most	people	with	dementia	symptoms	
Figure 6.7 
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are	usually	diagnosed	by	a	general	practitioner	(FOPH,	
2014).	
The	frequency	of	visits	after	a	diagnosis	of	dementia	is	
at	the	discretion	of	the	doctor	responsible	for	the	first	
diagnosis.	Moreover,	anti-dementia	drugs	are	routinely	
prescribed	and	reimbursed,	but	they	tend	to	be	
discontinued	once	people	fall	below	a	certain	MMSE	
score,	which	is	used	to	inform	clinical	decisions	and	
as	a	marker	of	lack	of	response	to	the	symptomatic	
treatments,	despite	the	absence	of	the	validity	of	any	
such	MMSE	threshold	(Alzheimer	Europe,	2014).	In	
addition,	the	reimbursement	rules	are	that	AChEIs	
can	be	prescribed	until	the	MMSE	score	is	equal	to	or	
greater	of	10	points	(out	of	30),	and	memantine	can	
be	prescribed	(and	reimbursed)	to	people	with	MMSE	
scores	between	3	and	19	(ECOPLAN,	2010).
Among	people	in	care	and	nursing	homes,	two	surveys	
covering	different	cantons	found	that	just	over	40%	of	
residents	had	dementia	(47%	in	Bartelt,	2012	and	41%	
in	Curt	et	al,	2012).	However,	both	studies	also	found	
that	a	much	higher	percentage	of	residents,	68%	and	
82%	(Bartelt	2012	and	Curt	et	al,	2012	respectively)	
had	significant	cognitive	impairment	that	was	
compatible	with	dementia	or	mild	cognitive	impairment.
The	Bartelt	(2012)	study,	which	gathered	data	on	
over	26,500	residents	in	386	homes	in	14	cantons,	
also	collected	information	on	the	use	of	selected	
drugs.	Compared	to	residents	without	a	diagnosis	
of	dementia,	residents	with	dementia	were	more	
likely	to	have	been	prescribed	anti-psychotics	(44%	
compared	to	20%)	and	slightly	more	likely	to	have	
been	prescribed	anti-depressants	(46%	compared	to	
41%).	In	contrast,	they	were	less	likely	to	have	been	
prescribed	pain-relief	medications	(32%	compared	
to	36%	for	milder	pain	killers,	9%	compared	to	12%	
for	stronger	pain	relief).	Further,	of	those	who	had	
been	prescribed	anti-psychotics,	29%	were	still	
taking	them	six	months	later,	suggesting	inappropriate	
long-term	use,	given	the	association	with	risk	of	major	
cerebrovascular	events	and	mortality.
Despite	the	comprehensiveness	and	overall	good	
quality	of	the	existing	national	strategy/plan	(above),	
there	is	at	present	no	systematic,	standardised	
approach	to	the	care	of	people	with	dementia,	neither	
are	there	consistent	mechanisms	for	people	with	
dementia	and	their	families	to	access	information	
about	sources	of	care	and	support.	The	availability	of	
services	varies	widely	across	the	country	and	within	
cantons.	People	may	find	information	from	the	GP	or	
specialist,	social	workers,	sickness	funds,	counselling	
services.	In	this	context,	the	Alzheimer’s	Association	
plays	a	key	role	in	helping	people	navigate	the	system	
and	in	supporting	their	ongoing	needs	(Alzheimer	
Europe,	2014).	The	Swiss	Network	of	memory	clinics	
provides	the	standards	for	the	inpatient	and	outpatient	
services	concerning	diagnostic	procedures	and	
standards,	and	the	minimum	requirements	of	the	
service	that	needs	to	encompass	medical	specialists	
(geriatricians,	old	age	psychiatrists	or	neurologists)	
and	neuropsychologists.	However,	no	standard	
recommendations	for	long-term	care	standards	exist	
at	present	at	a	national	level,	and	memory	clinics	are	
mainly	responsible	for	diagnosis	and	treatment/drugs	
prescription.	
Other care and support for people with 
dementia and their families
The	MHI	covers	some	of	the	costs	of	long-term	care,	
when	this	is	prescribed	by	a	physician	and	after	a	
needs	assessment.	Care	can	be	provided	at	a	nursing	
home	or	by	home	care	services	(known	as	Spitex).	The	
amount	that	MHI	covers	depends	on	the	severity	of	
the	needs,	as	determined	by	the	needs	assessment.	
The	non-medical	costs	of	care	(social	and	recreational	
services)	and	hotel	costs	are	not	covered	by	the	MHI.	
For	institutional	care,	households	pay	about	37%	of	
costs,	the	MHI	covers	about	18%	and	the	old-age	
and	disability	insurance	also	covers	about	17%.	The	
remainder	is	funded	by	the	cantons,	municipalities,	
other	social	insurance	or	other	private	sources	(De	
Pietro,	2015).
Cantons	are	formally	responsible	for	the	organisation	
of	long-term	care	but	this	is	usually	delegated	to	the	
municipalities.	Institutional	care	is	usually	provided	
in	nursing	homes	or	nursing	departments	of	old-
age	or	disability	homes,	while	home	care	nursing	
services	are	provided	by	the	“Spitex”	services.	Family	
carers	provide	large	amounts	of	care,	and	there	is	
considerable	use	of	paid	informal	care	provided	by	
migrant	workers	(van	Holten,	Jähnke	&	Bischofberger,	
2013,	cited	in	De	Pietro,	2015).
A	survey	of	the	Swiss	Alzheimer’s	Association	found	
that	approximately	50%	of	people	with	dementia	
live	at	home,	and	the	other	half	in	care	homes.	They	
interviewed	people	living	at	home	who	are	in	touch	with	
services	and	found	that,	of	those,	over	50%	attend	
day	care	(63%	men,	49%	women),	55%	use	home	
care	services	provided	by	Spitex	(women	66%,	men	
49%),	about	25%	of	people	with	dementia	have	stayed	
in	care	homes	for	short	periods	of	time	and	17%	have	
used	specialised	information	services	(ECOPLAN,	
2013).	The	majority	of	people	who	receive	Spitex	home	
care	services	also	have	care	from	a	family	(usually	
unpaid)	caregiver.
There	is	no	national	system	of	financial	benefits	
for	unpaid	family	carers,	but	several	cantons	and	
municipalities	have	introduced	certain	daily	or	monthly	
payments	for	caring	relatives.	Some	cantons	have	
formalised	family	care	by	employing	relatives	through	
Spitex	providers.	Also,	family	carers	can	claim	pension	
benefits	if	their	pension	fund	contributions	have	been	
lowered	because	of	caregiving	(De	Pietro,	2015).
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The	Swiss	Alzheimer’s	Association	and	other	(private	
and	public)	service	providers	offer	a	wide	range	of	
services	for	people	with	dementia	and	their	family	
caregivers.	The	services	include	day	care	services,	
self-help	groups	for	people	with	dementia,	counselling	
services	and	Alzheimer	cafés.	They	also	offer	support	
and	respite	for	family	caregivers	and	dementia-friendly	
holidays	for	people	with	dementia	and	their	caregivers.	
The	Alzheimer’s	Association	has	also	embarked	on	a	
project	to	create	dementia	friendly	communities	which	
is	starting	to	deliver	more	innovative	services	which	
are	tailored	to	the	possibilities	of	the	different	villages	
(Swiss	Alzheimer’s	Association,	2016).
Challenges that need to be addressed
Switzerland	has	a	well-established	health	service	
which	guarantees	access	to	care	for	the	entire	
population,	and	there	is	general	satisfaction	with	the	
level	and	quality	of	care	(De	Pietro,	2015).	Based	on	
the	arguments	made	by	the	Alzheimer’s	Association	of	
Switzerland	(2016)	and	De	Pietro	(2015),	the	following	
should	be	addressed	to	better	meet	the	needs	of	
people	with	dementia	and	caregivers:
•	 Improved	awareness	of	dementia,	to	ensure	
that	people	and	professionals	understand	the	
difference	between	dementia	and	normal	ageing.
•	 Improvement	in	the	coordination	of	existing	
services.
•	 Development	of	dementia-specific	pathways	in	
hospitals.
•	 Improved	access	to	support	in	the	early	stages	of	
dementia	and	development	of	consistent	post-
diagnostic	support.	Many	of	the	benefits	from	the	
MHI	are	only	triggered	when	people	reach	high	
levels	of	physical	dependency.
•	 People	with	dementia	and	their	family	caregivers	
are	exposed	to	high	out	of	pocket	costs,	
particularly	where	people	spend	a	long	time	in	
nursing	homes.	Family	caregivers	who	give	up	their	
jobs	to	provide	care	are	also	exposed	to	financial	
risks	in	later	life.
•	 A	nationwide	epidemiological	study	should	be	
conducted	to	determine	dementia	prevalence,	
incidence	and	to	quantify	its	burden,	including	
costs	and	caregivers’	health	and	social	
circumstances.	Epidemiological	data	are	crucial	
to	inform	health	services	organisation,	improve	
quality,	standardisation,	and	comprehensiveness	
of	care,	and	reduce	direct	and	indirect	costs	
of	dementia	through	better	and	sustainable	
investments	in	the	health	and	social	sectors.
•	 Consideration	of	the	potential	for	improving	
efficiency	of	the	healthcare	system.	Current	health	
expenditure	is	already	relatively	high	and	the	
system	will	need	to	prepare	to	meet	the	needs	of	
larger	numbers	of	people	with	dementia	and	other	
chronic	conditions,	in	the	coming	decades.
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7.1 Care pathways modelling 
Introduction
We constructed illustrative healthcare pathways 
for people with dementia, for the purposes of the 
economic modelling exercise. Of course, people 
with dementia use healthcare services regardless 
of whether or not they have received a dementia 
diagnosis. However, our focus was upon dementia-
focused healthcare services, offered and received as 
a consequence of the condition having been formally 
identified. For high income countries, the specialist 
care pathways were based upon those reviewed in 
Chapter 11,2, supplemented by the UK NICE-SCIE 
clinical guideline3. We then created an alternative 
’task-shifted/task-shared’ care pathway, in which 
many activities were designated to be carried out by 
primary care physicians (PCPs) or case managers 
(primary care nurses) instead of specialists. We were 
then able to estimate the annual aggregate and per 
capita costs under each of these assumptions, both 
for the current year, and also as the coverage of these 
services was progressively scaled up from 50% to 
75% through to 2030. For low and middle income 
countries, we assumed that those people managed by 
specialist services would follow a similar care pathway 
to those in HIC. Currently, we assumed that 5% (low 
and lower middle income countries) to 10% (upper 
middle income countries) of people with dementia 
have received a diagnosis, and that all of these will be 
diagnosed and managed through the limited available 
specialist healthcare sector. We then assumed that 
an increase in coverage, to 50% by 2030, would 
be achieved through provision of evidence-based 
diagnosis and management provided by non-
specialist, mainly primary care services, with training 
and support from specialist services, where available. 
This care pathway was based upon the evidence-
based recommendations of the WHO Mental Health 
Gap Action Programme4,5, and its accompanying 
intervention guide6. 
All of the pathways were based upon the principle that 
continuing care would be provided to all patients, from 
the time of diagnosis, with regular reviews and follow-
ups. We divided the pathways into three phases; the 
first year post-diagnosis; a subsequent ‘continuing 
care’ phase; and an end-of-life phase in the last year 
before death. We estimated that, of the prevalent pool 
of people with dementia who had received a 
diagnosis, 16% would have received their diagnosis in 
the previous year, and 14% would be in the end-of-life 
phase. 
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Table 7.2  
Typical intensity/frequency of care inputs across the care 
pathway
Care component Estimated intensity of care
Diagnosis (Immediate 
follow-up plans after 
initial diagnosis)
No significant cognitive 
morbidity
No follow-up
MCI Every 9 months
Uncomplicated dementia Post-diagnostic support 
programme was the modal 
response
Initial treatment
AChEIs or memantine Rx Baseline assessment, one review 
on medication and six monthly 
when stabilised
Average duration of 
treatment (in months) for 
those that start treatment 
with AChEIs or memantine
40 months
Continuing care
Uncomplicated mild 
dementia
Annual review
Uncomplicated moderate 
or severe dementia
Every 9 months
BPSD Baseline assessment
Repeated assessments: 50%
3 visits on average
10% would require admission for 
assessment
25% would require referral to 
geriatrician or physician
Duration, frequency and intensity of care inputs, 
and casemix of clients
For the purpose of costing the care pathways, we first 
needed to estimate the duration of care inputs, the 
intensity/frequency of care inputs, and the casemix 
of clients by which care pathways would be stratified. 
We generated the estimates from a survey of the 
Medical and Scientific Advisory Panel of Alzheimer’s 
Disease International, and for the purposes of validity, 
compared these, where possible, with estimates from 
the literature. We received 23 responses to the survey, 
with 11 providing sufficiently complete data to be used 
to generate estimates. These responses came from 
practitioners working in 8 countries (Australia, United 
Kingdom, Greece, Netherlands, Spain, Switzerland, 
Turkey, USA). For the most part, estimates were fairly 
consistent among respondents, with a greater variance 
noted for BPSD admission for the assessment 
(number of days not minutes) and for the total duration 
of post-diagnostic support programme in months. 
We used the mean response, or the median when the 
distribution of responses was significantly skewed. 
Response to the survey questions are summarised in 
Tables 7.1 to 7.3 below.   
High income country care pathways
For the high income country specialist care pathway, 
activities in the year of diagnosis comprised: making 
the diagnosis; assessing eligibility for cognitive 
enhancer medication (acetylcholinesterase inhibitors 
(AChEIs) or memantine), and initiating these 
prescriptions where appropriate; providing post-
diagnostic support; offering cognitive stimulation 
therapy; offering caregiver education, training and 
support; assessing behavioural and psychological 
symptoms of dementia (BPSD) and providing 
interventions where appropriate. Continuing care 
would comprise: regular reviews; ongoing medication 
review for those taking AChEIs or memantine; case 
management; and a pathway for the assessment 
and management of newly incident BPSD. Dementia 
severity at time of diagnosis, and among continuing 
Table 7.1 
Typical duration of care inputs across the care pathway
Estimated time 
(in minutes, if not 
otherwise specified) 
Diagnosis*
GP appointment triggering referral 20
Memory clinic clinical assessment 65
Memory clinic neuropsychological 
assessment
90
Memory clinic neuroimaging n/a
Post-diagnostic feedback** 40
Initial treatment
Baseline assessment for AChEIs 30
Follow-up assessment for AChEIs 20
Continuing care
Routine review 25
BPSD baseline comprehensive 
assessment
30
BPSD admission for assessment 10 days
BPSD geriatrician assessment 20
BPSD management plan review 20
* In an audit survey of Australian memory clinics (2009) the total 
assessment time was a mean of 235 minutes7
** In the Australian audit the mean feedback time was 45 minutes7
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Table 7.3  
Specific questions regarding casemix
Question/care component Estimate
Diagnosis
At memory clinic presentation, what % of clients are considered to have the following 
conditions? *
No relevant cognitive 
morbidity?
17%
MCI? 27%
Mild dementia? 34%
Moderate dementia? 16%
Severe dementia? 6%
For the current memory clinic caseload, what % of clients are considered to have the 
following conditions?
MCI? 26%
Mild dementia? 38%
Moderate dementia? 25%
Severe dementia? 11%
Initial treatment
What % of clients present (at the time of diagnosis) with significant BPSD requiring 
further assessment/management planning?
20%
What % of all those who receive a diagnosis of dementia are considered eligible for 
AChEIs and/or memantine?
70%
What % of all those who are eligible for AChEIs and/or memantine start treatment? 
(treatment uptake)?**
80%
Continuing care
In one year of FU, what % of those with mild, moderate, and severe dementia, require 
assessment and a management plan for new BPSD problems
Mild dementia? 10%
Moderate dementia? 30%
Severe dementia? 50%
Notes
* For Dutch Memory Clinics audited in 2009, 59% of referrals were diagnosed with dementia, 24% with MCI and 15% with no cognitive disorder8. For 
the Croydon Memory Service audit, of those with a diagnosis of dementia, 84% had minimal or mild dementia, 16% moderate, and 1% severe at time of 
diagnosis9. For Australian Memory clinics (2009), 7% had no cognitive impairment, 20% had MCI, 69% had dementia, and 4% had no diagnosis7
** According to the Croydon Memory Service evaluation, 48% of those considered eligible for AChEIs or memantine commenced treatment9
care patients, was used to estimate the prevalence 
and annual incidence of BPSD. After initial 
assessment, it was assumed that a proportion of 
BPSD cases would require admission, referral to a 
geriatrician, intervention and follow-up. At the end-
of-life phase we assumed that additional palliative 
care assessments and services would be provided 
by a specialist palliative care nurse. A summary of 
the activities that we assumed could be shifted from 
specialist providers to non-specialists working at 
primary care level or in the community is provided in 
Box 7.1. 
Low and middle income country care pathways
For the low and middle income countries, it was 
assumed that dementia healthcare would be provided 
by a community healthcare worker (CHW) providing 
outreach in the community, a case manager (CM – 
facility-based primary care nurse) and the primary 
care physician (PCP). The key elements of the mhGAP 
guideline for dementia diagnosis and management 
are summarised in Box 7.2. Community case-finding 
by CHWs would be used to boost detection10,11, 
alongside indicated screening by PCPs of those 
presenting with subjective memory impairment 
before diagnosis was made by PCPs. It was assumed 
that 5% of patients would be referred to specialist 
services because of mhGAP ‘red flags’ identified at 
this stage (e.g. young onset, unusual presentation). 
Initial caregiver education, training and support 
would be provided by the CHW administering the 
10/66 Dementia Research Group ‘Helping Carers to 
Care’ intervention12,13. This includes assessment of 
needs for care, met and unmet, family circumstances, 
knowledge and beliefs, and behavioural and 
psychological problems. The mhGAP guidelines 
highlight the need for assessment and management 
of physical comorbidity to optimise physical health. 
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We assumed that this would be provided by the CHW 
through the forthcoming WHO Integrated Care for 
Older People (I-COPE) guideline for the assessment 
and management of physical comorbidity by the 
CHW, with referral pathways back to the PCP14. Post-
diagnostic support would be provided by the CHW. 
Cognitive stimulation would be provided by caregivers, 
trained by the CHW. Cognitive enhancer medication 
(AChEIs or memantine) could be initiated by the PCP, 
and follow-up provided by the CM. In the continuing 
care phase six-monthly routine review assessments of 
care arrangements, physical health and BPSD would 
be shared by the CHW and CM. Further intervention 
sessions, as required, would be provided by the CHW, 
with a proportion of patients referred back to PCP for 
clinical evaluation. We assumed that 20% would be 
referred back to specialist care services at this stage. 
At the end-of-life phase we assumed that additional 
palliative care assessments and services would be 
provided by the PCP and CM.
7.2 Costing methods
Estimation approach
In order to estimate the costs of the care pathways 
in each of the countries in 2015 and 2030, we 
constructed spreadsheet models to calculate the 
numbers of people who go through each stage of the 
care pathways (given the estimated numbers of people 
with dementia and the assumed diagnosis rates) in a 
given year. We then multiplied the numbers who go 
through each stage by the amount of contact time with 
different health professionals involved in that stage, 
and the other inputs used (neuroimaging, blood-
testing and anti-dementia drug prescriptions). Each of 
the inputs were then costed by multiplying the time or 
Box 7.1
Summary of task-shifted activities 
for the counterfactual task-shifted/
task-shared high income country 
care pathway
Activity Task-shifting from 
specialist care 
providers to 
Memory clinic assessment 20% PCP
80% CM
Post diagnostic feedback CM
Baseline assessment for 
AChEIs/memantine
PCP
Initial follow-up for AChEIs/
memantine
CM
Post-diagnostic support Community healthcare 
worker
Caregiver education, training 
and support
Community healthcare 
worker
BPSD assessment PCP
BPSD follow-up 20% PCP
80% CM
Case management CM
Ongoing review of AChEIs/
memantine
20% PCP
80% CM
Regular reviews 20% PCP
80% CM
PCP	=	Primary	Care	Physician
CM	=	Case	Manager		
(primary	care	practice	nurse)
Box 7.2
Key elements of WHO mhGAP
1.   Case-finding in the community by non-
specialist community health workers, with 
referral to primary care for assessment and 
diagnosis
2.  Targeted screening by primary healthcare 
facility non-specialists (nurses and/or doctors) 
of those referred from the community, 
and where indicated (subjective memory 
complaints), among attendees, followed by a 
brief diagnostic assessment
3.  Assessment of needs for care, met and 
unmet, family circumstances, knowledge 
and beliefs, behavioural and psychological 
problems, physical health status and nutrition
4.  Immediate attention interventions to address 
BPSD, and optimise physical and mental 
health 
5.  Prescribe acetylcholinesterase inhibitors, or 
memantine, where indicated
6.  Administration of a brief intervention to 
educate, support and train family carers 
7  Consider a cognitive stimulation intervention, 
training family carers to administer this at 
home
8.  Regular reviews of care arrangements, 
physical health status, and emergent 
behavioural and psychological symptoms 
(BPSD) 
9.  Non-pharmacological treatment/management 
of depression and BPSD
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amounts used by their unit costs. 
Data and unit cost sources
It was not possible in the time available to find a 
source of up-to-date comparable unit costs of 
care that covered all the elements of the dementia 
healthcare pathways for all the countries in the 
study. Therefore, we searched for published unit 
costs (sometimes available from costing studies) 
and also gathered information from academics or 
members of local Alzheimer Societies in each of the 
countries. To ensure we had a complete set of costs 
for each country, we also estimated an “internationally 
comparable” set of unit costs using UK data. To cover 
all the unit costs for the inputs used in the pathway, 
we used the UK’s Unit Costs of Health and Social Care 
volume produced by the Personal Social Services 
Research Unit17, which have been compiled using full 
economic costings. These have been complemented 
with NHS reference costs18, British National Formulary 
costs of prescriptions19, data from a study of models 
of diagnostic and assessment of dementia20, and cost 
information from specific interventions21,22. 
In order to convert the unit costs of healthcare in the 
UK to costs relevant to the countries in this study, we 
have used a similar approach to that used by Liu23, 
who also used UK unit costs to derive local costs for 
a number of low and middle income countries, by 
adjusting them for each of the countries using ratios 
estimated from local unit costs of care available for 
2008 from the WHO Choice database24. 
We then used the following method:
1.  Assemble the reference unit costs for all the 
services and interventions from the UK for 2014-15.
2.  Convert the UK unit costs to international dollars, 
according to purchasing power parity (PPP) for 
2015 obtained from the World Bank25.
3.  Calculate the ratio between the costs of services 
available from WHO CHOICE (expressed in 2008 
international dollars) for each of the countries and 
the UK. 
4.  Convert the UK costs expressed in international 
dollars (2015) to “local” unit costs by applying the 
ratios obtained for the differences between the 
countries in 2008 for similar services.
5.  Adjust the new local unit costs to reflect changes 
in PPP between the different countries and the 
UK between 2008 and 2015. This was done by 
calculating the change in PPP for all the countries 
between the two time points and indexing to the 
difference observed in the UK.
This method assumes that the relationships between 
the unit costs of healthcare services among all the 
project countries are fixed, except for changing in line 
with changes in PPP. An important consideration is 
that, under full economic costing, the cost of General 
Practitioner’s (GP) time in the UK is higher than that 
of a specialist doctor17. This is likely to reflect some 
very specific characteristics of the British healthcare 
system and the role of primary care that may not be 
relevant to all the countries in this study, and therefore 
we sought to adjust the costs of different types 
of doctors using local data (sometimes on wages) 
whenever possible.
Another cost item for which we have particularly 
looked for local costs information has been 
medication. To simplify the modelling, we considered 
only donepezil and memantine. An important 
consideration is that those drugs are now off patent 
in many countries (some may now be available as 
generics). The costs of drugs, therefore, will vary 
according to whether the drug is still under patent, 
the extent to which generics are prescribed in each 
country, and other prescription costs. For example, in 
Canada generic drugs represent 29% of the value of 
the pharmaceutical market, and 70% of the volume, 
whereas in Switzerland the figures are 18% and 17% 
respectively26. The most recent article comparing 
the costs of these medications internationally was by 
Suh et al27, and it reports, for a number of countries 
(including Mexico, South Korea and Switzerland), 
the costs of donepezil and memantine, in terms of 
the final price of drug paid by a government, a health 
insurer or a patient (not including mark-ups, taxes 
and other costs), in 2007. Given that the patent for 
donepezil expired in 201028 and that in most countries 
memantine is also off-patent (or about to become so 
as Supplementary Protection Certificates are expiring 
in many countries29), a new version of the study 
by Suh et al would help clarify the relative costs of 
cognitive enhancing drugs for people with dementia in 
different countries.
Box 7.3
Assumptions used in the modelling
The numbers of people with dementia in 2015 
and 2030, for each of the countries, are those 
estimated in the World Alzheimer Report 201515. 
Diagnostic rates are assumed to be 10% in 
LMIC and 50% in HIC in 2015 and to rise to 50% 
and 75% respectively by 2030.
Between 2015 and 2030, the unit costs of care 
are assumed to grow in line with the OECD 
projected GDP per capita, to reflect increases in 
the real costs of care16.
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Local cost information
Unlike the costs available from the UK’s Unit Costs of 
Health and Social Care volume, for most countries we 
only found data on fees, which – particularly where 
these fees are those reimbursed by a public payer – 
may not represent the full economic cost of providing 
the service. However, given the substantial differences 
in the relative costs of the different services and inputs 
observed between the countries in the study, we 
considered it preferable to include local data where 
possible.
All costs were converted to US dollars and, when they 
related to earlier years, they were uprated to 2015 
using the GDP per capita growth rates available from 
the World Bank’s Open Data website25.
Unit costs data for Canada
The unit costs of care in Canada vary by province. 
We were not able to find national figures, but used 
data from Ontario and assumed that there would not 
be a large disparity between Ontario and the other 
provinces and territories. We did not find unit costs 
produced using full economic costings or a single 
source. For the unit costs of doctors’ time, we used 
the reimbursement fees that health providers can 
charge to the insurance system30. For unit costs for 
nurses and community health workers, we used unit 
costs published in a study by the Ontario Health 
Technology Assessment services and assumed 
that the cost of a community health worker and a 
personal support worker would be equivalent31. The 
costs of neuroimaging were obtained from a study by 
Bermingham32 and the cost of donepezil was obtained 
from Ontario’s Drug Benefit Formulary Index33. 
Memantine is not covered by Ontario’s drug plan, as a 
generic version may not be available in Canada yet.
Unit costs for China
A Delphi panel on the diagnosis and treatment 
of people with dementia in urban China reported 
estimates of the costs of hospitalisations, biological 
analysis and neuroimaging34. There are large 
differences in the salaries of doctors in China between 
primary and secondary care settings, and between 
urban and rural areas. We did not find data on staff 
costs we could use directly, but we were able to use 
data on wages in different care settings from Wu et 
al35 to adjust the UK-based comparable unit costs to 
reflect the differences in doctors between different 
types of doctors and settings in China. Data on the 
costs of donepezil was available from a specialised 
website36.
Unit costs for Indonesia
We are grateful to ALZI (Alzheimer’s Indonesia) for 
consulting local experts, who provided costs of care 
for the costs of donepezil and memantine and MRI 
scans.
Unit costs for Mexico
For Mexico we found a recent study on the costs of 
neurocysticercosis37, which reported the unit costs 
of care for some staff and inputs included in the 
dementia care pathways (inpatient costs per day and 
CT/MRI scans). We have assumed that the costs for 
people with dementia, per unit of input, would be the 
same as for those with neurocysticercosis. For the 
difference between the costs of GPs and specialist 
doctors, we used the differential in wages available 
from the OECD Health Database26. For the costs of 
donepezil and memantine, we used data from Suh et 
al27, uprated to 2015 prices.
Unit costs for South Africa
Unit costs data for staff inputs was obtained from a 
study on the human resource and costs requirements 
for a task-shifted approach to primary mental 
healthcare in rural settings in South Africa38. Data on 
the costs of anti-dementia drugs were used from a 
study of prescription data39.
Unit costs for South Korea
A study on the cost-effectiveness of an opportunistic 
screening programme for dementia in South Korea 
provided data on the costs of anti-dementia drugs, 
MRI scans and blood tests40. We also obtained data 
from staff and hospital stay costs from a study of the 
economic burden of diabetes41. For drugs, we used 
uprated data from Suh et al27.
Unit costs for Switzerland
Alzheimer’s Society of Switzerland provided us with 
data for the Vaud canton for the costs of staff, MRI 
scans, drugs and dementia-specific blood tests. Data 
on the costs of hospital stays was obtained from a 
study on the relative prices of hospital stays in various 
OECD countries42.
Further details on the unit costs assembled for this 
report can be made available on request.
7.3 Results
The total costs of the dementia healthcare pathway 
are relatively small, particularly for 2015 when the 
rates of diagnosis are low (we have assumed 10% 
for LMIC and 50% for HIC, as described in section 
7.1). Compared to total health expenditure, the cost 
of the pathways ranges from 0.5% in South Korea, to 
0.007% in South Africa, suggesting that the cost of the 
pathways is reasonably affordable compared to overall 
health spending.
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In HIC, the cost of specialist pathway per person 
with dementia ranges from $682 (US) in Canada, to 
1,279$ in Switzerland. The task-shifted pathway is 
nearly 40% cheaper than the specialist pathway in 
Canada, although for Switzerland and South Korea 
the difference is smaller: 24% and 5% respectively. In 
the LMIC, the cost of the task-shifted pathway ranges 
from nearly 4$ per person with dementia in Mexico, 
to 13$ in China. Interestingly, these results are not in 
line with the order in which these countries would be 
ranked in terms of relative income levels. 
In order to understand the differences in the costs 
of the care pathway in the different countries, and 
also why the change from a specialist pathway to a 
task-shifted pathway makes a much bigger difference 
in Canada than in South Korea, it is important to 
consider the relative costs of the various components 
of the pathway across countries. As discussed in 
section 7.2, while differences in staff costs reflect to 
a large extent income levels in the different countries, 
there are very large differences in the unit costs of 
cognitive enhancer medication that reflect each 
country’s policy on generic medicines as well as other 
factors. Table 7.5 shows the proportion of the total 
costs of the pathway that are attributable to staff, 
Table 7.4 
Estimates of the cost implications of the healthcare pathways for Canada, China, Indonesia, Mexico, South Africa, South Korea 
and Switzerland for 2015, in US$ (and 2015 prices) 
Canada China Indonesia Mexico South 
Africa
South Korea Switzerland
2015 Specialist Task-
shifted
Task-
shifted
Task-
shifted
Task-
shifted
Task-
shifted
Specialist Task-
shifted
Specialist Task-
shifted
Cost of the 
pathways, in 
million US$
379 220 124 12 3 2 532 505 171 130
As % of GDP 0.0245 0.0142 0.0011 0.0014 0.0003 0.0007 0.0386 0.0367 0.0257 0.0196
As % of 
total health 
expenditure
0.203 0.118 0.022 0.047 0.010 0.007 0.511 0.486 0.217 0.165
Cost of the 
pathway per 
person with 
dementia US$
682 396 13 10 4 11 1,111 1,057 1,279 973
Cost of the 
pathway 
per person 
diagnosed with 
dementia US$
1,364 792 130 199 39 113 2,223 2,113 2,558 1,946
Note: Assuming 50% diagnosis rate in HIC (Canada, South Korea and Switzerland) and 10% in LMIC (China, Indonesia, Mexico and South Africa).
Table 7.5 
Proportional contributions to the total costs of the pathway
Canada China Indonesia Mexico South 
Africa
South Korea Switzerland
Specialist Task-
shifted
Task-
shifted
Task-
shifted
Task-
shifted
Task-
shifted
Specialist Task-
shifted
Specialist Task-
shifted
Staff 67.9% 50.4% 4.59% 16.60% 42.77% 15.16% 8.6% 4.2% 39.1% 23.3%
Neuroimaging 7.4% 2.5% 1.37% 1.62% 0.50% 0.53% 1.1% 0.2% 6.0% 1.6%
Anti-dementia 
drugs
19.7% 34.0% 91.98% 81.50% 54.72% 84.00% 88.8% 93.4% 48.0% 63.1%
Hospital stays 5.0% 9.6% 1.32% 0.22% 1.98% 0.25% 1.5% 1.8% 5.4% 8.0%
Other 0.1% 3.5% 0.7% 0.1% 0.0% 0.1% 0.0% 0.4% 1.4% 4.0%
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neuroimaging, medications, hospital stays and other 
elements. The table shows very large inter-country 
differences in the relative importance of medication 
costs compared to the other components of the 
pathway. For the task-shifted pathways, while staff 
costs represent 50% of costs in Canada, they only 
represent just over 4% in China and South Korea. In 
fact, the costs of medications represent over 90% of 
the costs of the pathway in China and South Korea, 
followed by 84% in South Africa, 81% in Indonesia 
and 63% in Switzerland. 
This relative importance of the costs of drugs also 
explains why in Canada, where drugs are relatively 
cheap, there is a much larger difference between the 
cost of the specialist and the task-shifted pathways, 
compared to South Korea and Switzerland. 
Between 2015 and 2030, we have assumed that the 
changes in the costs of the pathway will be driven 
by three variables: growth in the numbers of people 
with dementia, growth in the unit costs of care, and 
assumptions made about the increase in diagnostic 
coverage.
While the numbers of people with dementia will grow 
by at least a quarter in these 15 years, they will more 
than double for South Korea and nearly double for 
Mexico and Indonesia (Chart 7.1).
Given the assumptions explained earlier (section 7.2), 
which include an increase in the diagnosis rate to 
reach 75% in HIC and 50% in LMIC, and assuming 
that the differences between the costs of cognitive 
enhancer medications between countries remains the 
same, the costs of the care pathways in 2030 would 
be as detailed in table 7.6.
With regards the changes in the unit costs of care, 
we assumed that, between 2015 and 2030, unit costs 
will grow in line with growth in GDP per capita, as 
projected by the OECD16. This assumption was 
explored in the World Alzheimer Report 201515 
projections of the costs of dementia, which compared 
the performance of the consumer price index (CPI) 
and GDP per capita as predictors of the growth of 
the costs of care per person between 2010 and 2015. 
In the sensitivity analysis carried out for that study it 
was found that using the CPI may underestimate the 
growth in the costs of salaries and services in rapidly 
growing economies. Most studies that project the 
future costs of healthcare (for example, by the OECD43 
and the European Commission44) project together 
increases in consumption (or use) of healthcare 
services and increases in the unit costs of those 
services. In this report we project changes in volume 
and unit costs separately and, particularly because 
of the emphasis on staff costs of the pathways, using 
GDP per capita as a proxy for increases in wages was 
a reasonable assumption.
In order to illustrate the sensitivity of the estimates 
to pharmaceutical costs, in Table 7.7 we show the 
Chart 7.1 
% change in the numbers of people with dementia, 
2015 - 2030
Switzerland
South Korea
South Africa
Mexico
Indonesia
China
Canada
0% 20% 40% 60% 80% 100% 120%
Table 7.6 
Estimates of the cost implications of the healthcare pathways for Canada, China, Indonesia, Mexico, South Africa, South Korea 
and Switzerland for 2030, in US$, assuming differences in costs of cognitive enhancer medications remain as they are today
Canada China Indonesia Mexico South 
Africa
South Korea Switzerland
2030 Specialist Task-
shifted
Task-
shifted
Task-
shifted
Task-
shifted
Task-
shifted
Specialist Task-
shifted
Specialist Task-
shifted
Cost of the 
pathways, in 
million US$
756 438 2,660 384 48 26 1,652 1,568 334 251
As % of GDP 0.0357 0.0207 0.0094 0.0205 0.0025 0.0046 0.0804 0.0763 0.0362 0.0272
Cost per 
person with 
dementia US$
914 530 164 169 30 93 1,641 1,558 1,723 1,294
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impact of a policy scenario in which the cost of drugs 
in all the countries was the same as in England today 
(where generic versions of these medications are 
widely prescribed). By taking out the variation from 
drug prices, the results show that the cost difference 
between the specialist and task-shifted pathways for 
HIC is of approximately 40%. For LMIC the differences 
in pathway costs between countries become much 
smaller and, most importantly, the care pathways 
become much more affordable.
Discussion
Limitations
The estimates presented here show that the results 
are very sensitive to the assumptions made about the 
unit costs of care. As this project was carried out in a 
relatively short time, it was not possible to investigate 
thoroughly the unit costs in each of the countries. Our 
results demonstrate the importance of improving the 
ready availability of internationally comparable, up-to-
date information on the unit costs of care.
The costs of the pathways in context
The costs of the task-shifted pathways are relatively 
low compared to overall healthcare spending and are 
also low compared to estimates of the overall cost of 
healthcare services by people living with dementia. 
We have estimated that the cost of the pathway in 
2015, per person diagnosed, would range from $39 
per year in Mexico (or 3.9$ per person with dementia), 
to $2,113 in South Korea ($1,057 per person with 
dementia). The overall costs of healthcare use by 
people with dementia will include costs related to 
dementia as well as costs related to treating other 
health conditions. In the World Alzheimer Report 2015, 
the estimated direct yearly costs of healthcare per 
person with dementia ranged from $93 per person in 
the Asia South region, to $12,761 in North America. 
As discussed in other chapters, the implementation 
of dementia pathways could potentially result in a 
reduction of some of the other costs of health and 
social care; the costs due to late or missed diagnosis, 
and to poor quality of care, such as unplanned 
crisis admissions into hospitals. The overall costs 
of dementia, including the costs of social care and 
unpaid family care were estimated to range from $872 
in Asia South to $56,218 in North America per person, 
per year.
If low-cost generic anti-dementia drugs became more 
widely available, particularly in low and middle income 
countries, the healthcare pathways would become 
much more affordable.
Task-shifted pathways in the context of the 
healthcare systems in each country
Canada
Because the Canadian national clinical standards 
for dementia already emphasize the role of primary 
care in the diagnostic and routine care of people with 
dementia (see Chapter 6), the healthcare pathway 
of people with dementia in Canada is already in the 
process of task-shifting. The role of primary care 
doctors as gatekeepers also supports a task-shifted 
approach, as does the relatively high ratio (48%) of 
GPs as a proportion of all physicians26. The cost of 
donepezil is also relatively low in Canada, although 
memantine is not currently included in the drug plans 
of Ontario and possibly other provinces, as it is only 
now coming off patent protection and there is no 
generic version available yet. 
Table 7.7 
Estimates of the healthcare pathway costs in 2030 if the cost of anti-dementia drugs in all the countries was the same as in 
England (2015 prices in US$, uprated with each country’s projected GDP per capita growth rate)
Canada China Indonesia Mexico South 
Africa
South Korea Switzerland
2030 Specialist Task-
shifted
Task-
shifted
Task-
shifted
Task-
shifted
Task-
shifted
Specialist Task-
shifted
Specialist Task-
shifted
Cost of the 
pathways, 
in million 
US$
629 311 260 24 27 5 213 129 186 103
As % of 
GDP
0.0297 0.0147 0.0009 0.0013 0.0014 0.0009 0.0104 0.0063 0.0202 0.0112
Cost per 
person with 
dementia 
US$
761 377 16 11 17 17 212 120 960 530
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China
While a task-shifted approach in China could build 
on the existing infrastructure of rural primary care 
services to expand the reach of dementia care, 
there are important structural barriers that would 
need addressing. Because the existing primary care 
services are perceived as being of poor quality, and 
they do not have a gatekeeping role, people prefer 
to access care in secondary and tertiary hospitals, 
even if that is much more expensive and if it requires 
travelling long distances (see Chapter 6). The cost of 
anti-dementia drugs in China is very high, particularly 
compared to that of care, treatment and support 
delivered by staff, and so, without wide access 
to generic medicines and curbs on the ability of 
doctors to charge very high drug prescription fees to 
supplement their income, it may not be cost-effective 
to include anti-dementia drugs in the pathway.
Indonesia
In the context of the recent launch of Indonesia’s 
National Dementia Plan in 2016 and its universal 
health insurance programme in 2014, there is a 
potential opportunity to ensure that the expansion of 
healthcare coverage avoids some of the structural 
barriers to the implementation of task-shifted dementia 
care pathways, such as the lack of a gatekeeping 
role for primary care, and lack of awareness about 
dementia. For primary care to be able to take the 
central role required in a task-shifted pathway would 
require improved training of GPs as well as increased 
coverage. The cost of anti-dementia drugs is very high 
in Indonesia, particularly compared to staff and other 
healthcare costs.
Mexico
The financing and provision of healthcare in Mexico 
is fragmented, with different insurance systems that 
offer different levels of care, to different groups of 
people. The availability of healthcare services in 
Mexico is relatively low and primary care only plays a 
small role. Dementia-specific care is mostly provided 
at specialist level and in larger cities. The National 
Dementia Plan of 2014 involves an ambitious training 
programme for health professionals as well as raising 
awareness among the public (see Chapter 6). In order 
for Mexico to be able to develop task-shifted dementia 
care pathways it would be necessary to strengthen 
the role of primary care and ensure a consistency 
across the different insurance schemes. The costs 
of anti-dementia drugs in Mexico are relatively low, 
which means that, if there was an improvement in the 
diagnostic rates, the cost of increased prescriptions 
would be relatively low.
South Africa
South Africa’s healthcare system faces very important 
challenges from HIV/AIDs, tuberculosis and other 
“diseases of poverty”, while at the same time 
experiencing an increase in diseases associated with 
longevity. With regard to the adoption of dementia 
healthcare pathways, primary healthcare clinics are 
well established as the first point of access and there 
is experience, particularly in the mental health area, 
in task-shifted models of care. The main challenge 
appears to be the competing claims to limited 
resources, exacerbated by inequities in access to 
care, stigma about dementia and lack of professional 
training and awareness. Dementia drugs are not 
currently included in the Essential Drug List for public 
health facilities, reflecting the low priority status of 
dementia.
South Korea
South Korea is preparing for a very large increase in 
the numbers of people with dementia. It launched its 
third National Dementia Plan in 2016, with the main 
goals of creating a dementia-friendly society and 
enabling people with dementia and carers to live well. 
To meet these ambitious goals, in the context of a very 
large increase in the numbers of people with dementia, 
it will be important for South Korea to consider more 
sustainable ways to deliver care. The current system 
lacks a gatekeeping role for primary care providers 
and enables providers to induce demand for care that 
is not cost-effective or necessary. Without a reform 
of the current fee-for-service payment system and 
the introduction of a gatekeeping role for primary 
care, it would be difficult to implement a task-shifted 
healthcare pathway. The costs of anti-dementia drugs 
are high in South Korea.
Switzerland
Despite the adoption of a National Dementia Strategy 
for 2014-2017, at present the care of people with 
dementia lacks a systematic and standardised 
approach, and the rate of diagnosis of dementia, 
assumed to be 50%, seems relatively low for one 
of the countries with the highest per capita health 
spending in the world. While the Swiss system was 
characterised by no gatekeeping role by GPs and 
direct access to specialists, an increasing number 
of people are covered by health maintenance 
organisations (HMOs) that restrict access to specialists 
and involve a gatekeeping and care coordination role 
by GPs. The cost of drugs in Switzerland is very high, 
reflecting relatively low rates of generic medicines use.
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Policy implications
Structural barriers to the implementation of the care 
pathways:
•	 With	the	exception	of	Canada	and	South	Africa,	in	
most	of	the	countries	we	have	looked	at,	people	
are	able	to	access	specialist	care	directly,	without	
a	gatekeeping	role	for	primary	care.	The	ease	of	
access	to	specialist	care,	in	combination	with	a	
perception	that	primary	care	is	of	lower	quality	(a	
view	that	is	particularly	marked	in	China),	may	be	
important	barriers	to	the	take-up	of	a	task-shifted	
dementia	healthcare	pathway.
•	 The	prescription	costs	of	anti-dementia	drugs	
are	very	high	in	some	of	the	countries	(China,	
Indonesia,	South	Korea	and	Switzerland),	in	part	
because	of	drugs	remaining	under	patent,	lack	of	
consolidated	purchasing,	and	reluctance	to	use	
generic	medicines.	This	is	aggravated	in	some	
countries	by	doctors	using	additional	prescription	
fees	to	supplement	their	incomes.	Given	these	
very	high	costs,	it	may	be	that	those	drugs	would	
not	even	be	cost-effective	in	some	of	those	
countries,	particularly	when	the	cost	of	other	types	
of	treatment,	care	and	support	are	comparatively	
much	cheaper	due	to	low	wages.	Ensuring	that	
people	in	low-	and	middle-income	countries	have	
access	to	anti-dementia	drugs	at	equitable	prices,	
that	are	at	least	not	higher	than	in	high-income	
countries,	will	become	an	increasingly	important	
issue	particular	because	such	a	large	number	of	
people	in	LMIC	may	be	denied	access	due	to	lack	
of	affordability.	
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chapter 8
summary and conclusion 
8.1 Introduction – the scope of this 
report
For this year’s World Alzheimer Report, we have 
focused upon healthcare for people with dementia, 
and the systems and services required to deliver it. The 
backdrop to this report is the fundamental challenge 
faced by governments and health systems around the 
world – how can we increase the current very low levels 
of coverage of diagnostic, treatment and continuing 
care services, while maintaining or improving quality, 
and at the same time keeping costs under control? It 
seems self-evident that this requires an increase in the 
efficiency with which services are delivered. 
Accordingly, we have focused upon three main 
strategies:
1.   task-shifting and task-sharing, whereby care 
previously delivered by specialist services is 
transferred to non-specialists in community and 
primary care, trained and supported by specialists;
2.   case management, in which a new cadre of 
professionals is responsible for assessing, planning, 
facilitating and coordinating care for people with 
dementia and their carers;
3.   the introduction of care pathways, which 
systematise the planning, resourcing and delivery 
of continuing care, with explicit elements of 
assessment and care, facilitated communication 
and coordination of roles, and documentation and 
monitoring of processes and outcomes.
We have reviewed the latest evidence for the potential 
role of primary care services in delivering dementia 
healthcare (Chapter 2), the effectiveness of case 
management (Chapter 3), approaches for limiting 
and better managing hospitalisation of people with 
dementia (Chapter 4), and palliative and end-of-life 
care (Chapter 5).
Finally, in a selection of countries (Chapter 6), we 
explored the potential impact of task-shifting on future 
dementia healthcare costs, as numbers of people 
affected increase, and coverage of basic diagnostic 
and continuing care services improves (Chapter 7). 
Having defined outline healthcare pathways for people 
living with dementia for relatively well-resourced high 
income countries (HIC), and less well-resourced middle 
income country (MIC) settings, we estimated the 
increasing costs of care from 2015 to 2030, accounting 
for projected increases in the numbers of people living 
with dementia, and a projected increase in diagnostic 
coverage from 50% to 75% in HIC and from 10% to 
50% in MIC. We assumed that the increased coverage 
in MIC would be achieved through implementation of 
task-shifted care pathways, while for HIC we compared 
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specialist care pathways with more task-shifted 
alternatives. 
8.2 Summary of review findings
Models of healthcare delivery
Healthcare is at the core of the system of treatment 
and support for people with dementia and their carers. 
Healthcare professionals, and services have important 
roles to play across the course of the condition; 
promoting brain health; providing a timely diagnosis 
with post-diagnostic information and support; 
signposting community support services; initiating 
treatments where appropriate; optimising physical 
health and managing comorbidities; assessing and 
managing behavioural and psychological symptoms.
Dementia is not just another diagnosis on the 
lengthening list of comorbidities that most of us face 
as we age. It changes everything, not least future 
expectations of life, and independence. It impairs 
one’s ability to recognise and report new symptoms, 
seek help, and manage one’s own health conditions. 
Therefore, it has profound implications for the 
management of all health issues for the person with 
dementia, and the way that healthcare needs to be 
planned and delivered for people with dementia in 
general.
Healthcare for people with dementia needs to be 
•	 continuous;	treatment	options,	care	plans	and	
needs	for	support	need	to	be	monitored	and	
reviewed	as	the	condition	evolves	and	progresses	
•	 holistic;	treating	the	whole	person,	not	single	
conditions,	organs	or	systems,	mindful	of	that	
person’s	unique	context,	values	and	preferences
•	 integrated;	across	providers,	levels	of	care,	and	
health	and	social	care	systems
Currently, healthcare systems struggle to provide 
adequate coverage of diagnostic services, and 
care is too often fragmented, uncoordinated, and 
unresponsive to the needs of people with dementia 
and their families at the time when they arise.
In high income countries, dementia healthcare systems 
tend to be highly specialised, from diagnosis onwards, 
with very little formal recognition of the role of primary 
care services, or allocation of tasks to this sector. 
This is probably also true for low and middle income 
countries, where diagnostic coverage is low, but such 
services as are available are provided by a very limited 
number of specialists.
As the numbers of people affected and the demand 
for services increase, it is unlikely that full coverage 
of dementia healthcare services can be attained or 
afforded using the current specialist care model. There 
are other limitations too. Seamless and continuing care 
is beyond the capacity and reach of specialist services 
working in isolation. The specialist model of dementia 
care does not facilitate holistic management of, or 
care-coordination for, complex multimorbidities. These 
are core functions of primary healthcare. 
Task-shifting and task-sharing, including but not limited 
to increasing the role and competencies of primary 
healthcare services within the system, will be the core 
strategies for increasing the coverage of diagnosis and 
continuing care. Collaborative or shared-care models 
distribute tasks between primary and secondary care 
services in a structured and organised fashion. 
Case management may be an important strategy 
for increasing treatment coverage, and improving 
integration and coordination of care. More research 
is needed to clarify the best ways of delivering this 
promising intervention. Evidence to date suggests 
that case management needs to be adequately 
resourced by skilled staff with manageable caseloads, 
and implemented such that case managers have the 
authority to work with all stakeholders and providers. 
The introduction of evidence-based care pathways, 
linked to process and outcome indicators, should help 
to improve adherence to healthcare quality standards, 
and allow transparent monitoring of treatment 
coverage and effective treatment coverage. 
The role of primary care
We conducted a scoping review of recent research 
evidence on the role of primary care within the 
dementia healthcare system, including evidence 
regarding the effectiveness of primary care services 
in the detection and diagnosis of dementia, and in 
the provision of continuing care, when compared 
with specialist healthcare services. We also assessed 
evidence on strategies and interventions to enhance 
the quality of care provided by primary healthcare 
services. 
Dementia is currently under-detected, under-
diagnosed, under-disclosed, under-treated and 
under-managed in primary care. This reflects the status 
quo, in which the roles and responsibilities of primary 
care have not been explicitly defined, with minimal 
basic curriculum and in-service training, and where 
care processes are not supported by evidence-based 
clinical guidelines or care pathways. 
When primary care physicians (PCPs) do take 
responsibility for dementia care evidence suggests 
that this is similar in its outcomes to the care provided 
by specialists, even though care processes may be 
less scrupulously adhered to. There is much scope for 
improvement, with some well-evaluated examples of 
system and service level innovations to support a more 
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prominent role of primary care services in diagnosis, 
and post-diagnostic and continuing care.
Recognition of dementia in primary care can be 
boosted by in-service education and training, which 
seeks to alter attitudes and perceptions as well as 
providing technical skills, and when there is a practice-
based component in which specialists guide and 
mentor non-specialists to recognise and diagnose 
dementia. 
Indicated screening using cognitive tests can support 
timely diagnosis by responding to concerns raised by 
patients and carers. However, general screening, of 
all older attendees or all those registered to a primary 
care service, cannot currently be recommended, and 
should not be carried out, in advance of more research 
evidence on benefits, harms and cost-effectiveness. 
In most settings, dementia diagnosis is not explicitly 
recognised as being within the capacity of non-
specialist services. Nevertheless, we identified several 
successful examples of memory clinics established 
in primary care, and run by PCPs supported by nurse 
practitioners. No studies have compared the accuracy 
of diagnoses made by non-specialists and specialists. 
More research is needed into good practice for 
diagnostic disclosure (a ‘diagnosis well made’). Several 
studies indicate underperformance, and a need for 
more training and support for this important activity.
The post-diagnostic phase bridges from the ‘diagnosis 
well made’ to a system of continuing care in the 
context of declining function and increasing needs 
for care and support. One randomised controlled trial 
from the Netherlands indicated the outcomes of care 
in the year post-diagnosis with mild dementia were no 
worse when provided by PCPs than when provided by 
specialists1, and costs were similar2. However, this and 
other studies also suggest that some care processes 
are more commonly adhered to by specialists 
(including anti-dementia medication, information 
provided to carers, and referral to community support). 
The potential benefits of the full range of post-
diagnostic support activities (as for example advocated 
by Alzheimer Scotland in their ‘5 pillars’ model) have 
yet to be evaluated. The targeting and delivery of 
post-diagnostic support needs to be thought through 
carefully, since needs and preferences will vary 
considerably among people with dementia and their 
carers. In two recent large European randomised 
controlled trials no benefits for either the person 
with dementia or the carer could be identified from 
implementation of psychosocial education, training 
and support interventions in the early post-diagnostic 
phase. 
Primary care services struggle to deliver high 
quality continuing care for people with dementia, 
even in systems where their role has been made 
more explicit. Educational interventions alone have 
no impact on guideline adherence and evidence 
based management. There is some evidence that 
case management interventions may be beneficial. 
Appropriately skilled case managers could increase 
the capacity of primary care to respond to the needs 
of people with dementia and their carers, freeing up 
the PCP from time-consuming routine assessments, 
interventions, and care coordination activities. 
There have, as yet, been no evaluations of case 
management, located in primary care, with system 
level planning and resourcing to support that activity. 
Not surprisingly, research-led initiatives to introduce 
primary care case management without this support 
have had limited success.
Attention needs to be given to the optimal roles of 
specialists within a more task-shifted and task-shared 
healthcare model. Neurologists, psychiatrists and 
geriatricians have quite different clinical training, 
and, while sharing some generic skills, are unlikely 
to have equivalent competencies across the full 
range of activities linked to the assessment and 
management of dementia. Much of the activity where 
specialist expertise is generic could be taken on by 
non-specialists in primary care, while ensuring that 
the relevant specialist expertise can be accessed for 
complex assessment and management problems. 
Task-shifted models of care require specialist support, 
both while they are being established (design, training, 
handing over the task), and continuously thereafter 
(referral, supervision, mentoring and support). 
This requires modification of specialist roles and 
responsibilities, away from frontline patient care, 
and towards capacity-building activities at the lower 
levels of the health system. In low and middle income 
countries, expansion of the specialist sector will 
need to be balanced with investment in primary care 
services that are supported to deliver care with high 
coverage.
Care coordination, through case 
management
We conducted a scoping review of recent research 
evidence regarding the effectiveness of case 
management, wherever it is located within the health 
and social care system, with respect to outcomes for 
people with dementia and their carers, and evidence 
for improved efficiency of delivery of health and social 
care. 
The Case Management Society of America (CMSA) 
describes case management as “a collaborative 
process of assessment, planning, facilitation and 
advocacy for options to meet an individual’s health 
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need through communication and available resources 
to promote quality cost-effective outcomes”. 
Case management, in theory, has numerous potential 
benefits for people with dementia; reducing the burden 
of the disease; identifying and managing evolving 
needs over the disease course; facilitating access 
to services; and providing advice (including about 
advanced care planning). 
Despite a large number of trials, and some promising 
findings, the effectiveness of case management 
remains unclear. Positive effects (reduced or delayed 
transition into care homes, better adherence to care 
standards, and reduced unmet needs) were found in 
some studies. Evidence for effects on carer strain and 
psychological morbidity, and the quality of life of the 
person with dementia and their carer, is weak. 
The biggest limitation is the lack of evidence regarding 
the impact of case management on the efficiency 
with which healthcare is delivered, and overall cost-
effectiveness, mainly because most studies do not 
report on the relevant outcomes – service utilisation 
and cost. Effects on hospitalisation were generally not 
significant. While a few studies indicated a modest 
reduction in healthcare costs in the medium term, the 
absence of evidence on cost-effectiveness is striking.
The evidence-base is also limited because of the 
wide variation in the types of case management 
intervention studied. Some focused mainly on 
delivering information and support for carers, with little 
care coordination. Providers of case management 
included specialist dementia care services, primary 
care, community social care and third sector (non-
governmental) organisations. The intensity of the 
intervention, and the capacity of the case manager 
to perform their role also varied among studies. More 
research needs to be undertaken to clarify the effective 
components of case management, and the most 
effective modes of delivery.
Evidence to date suggests that effectiveness may be 
enhanced when there is; a manageable caseload for 
delivering interventions with the required intensity; 
clear role definition with adequate preparation and 
training; and empowerment of the case manager to 
access and coordinate care across providers and 
sectors. These factors should be borne in mind when 
developing new services. 
Most importantly, no opportunity should be lost 
for rigorous evaluation of this promising service 
innovation, whether as part of a research experiment 
(a randomised controlled trial), or a roll out into routine 
care. The necessary level of system-level planning, 
integration and support may be hard to achieve in the 
research/experimental context, so non-randomised 
evaluations of ‘real world’ scale up may provide the 
best evidence of potential effectiveness. 
Future evaluations need to include a comprehensive 
set of process and outcome measures, which should 
include service utilisation and cost, as well as clinical 
and quality of life outcomes for the person with 
dementia and their carer. Greater consistency in 
outcome measures would support future evidence 
synthesis through meta-analysis. 
Hospital care
We conducted a scoping review of hospitalisation of 
people with dementia seeking to clarify the extent of 
and reasons for hospitalisation, the associated harms, 
the excess healthcare costs, the effectiveness of 
approaches to avoid hospitalisation, and reduce harm 
and improve outcomes for those who are admitted. 
People with dementia are more likely to be admitted to 
general hospital than people of similar age and medical 
infirmity, particularly for falls-related accidents and 
injuries, urinary tract and respiratory infections, and 
chronic disease complications that might have been 
averted with better management in the community. 
On the other hand, people with dementia are less likely 
to be admitted for interventional procedures that could 
enhance quality of life, including cataract surgery, 
vascular catheterisation and stenting, cholecystectomy, 
and cancer care. 
In HIC the costs of healthcare are substantially 
higher for people with dementia than age-matched 
controls, with a substantial proportion arising from 
hospitalisation. The increased utilisation and costs 
(both for all healthcare services and for inpatient 
admissions) is apparent for at least the year prior to 
diagnosis, reaches a peak in the year after diagnosis, 
and then declines but still to an elevated level 
compared with matched controls. 
The process of hospital care is more complicated 
for people with dementia, with significant cost 
implications. They have longer hospital stays and 
require more nursing resources than others. At least 
some of the incremental costs may be intrinsic to the 
complexities of inpatient dementia care. 
People with dementia are particularly vulnerable 
to harm and poor outcomes in the context of an 
admission, most particularly from a constellation of 
hospital acquired infections, delirium, agitation and 
falls, all of which impact adversely on length of stay. 
Both delirium and dementia can reduce capacity 
for informed consent, and impair motivation and 
adherence with investigations, procedures, treatments 
and rehabilitation.
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Mortality rates are exceptionally high during admission 
and somewhat higher after discharge. However, the 
high mortality rates may reflect, in part, a tendency 
to admit people with dementia at the very end of life. 
In HIC, up to two-fifths of people with dementia die 
in hospital, while deaths in care homes are the most 
frequent outcome. In LMIC deaths in hospital are at 
least as common as in HIC. However, home is the 
commonest place of death, with almost no deaths in 
care home settings. 
More research is need into service and system level 
interventions to avoid hospitalisation, specifically 
of people with dementia. Community interventions 
have been mostly ineffective, although there is more 
evidence to support multidisciplinary assessment and 
management, than case management. Few of the 
interventions had a clinical medical focus, they did not 
target the common reasons for admission (control of 
chronic conditions, and prevention of unintentional 
injuries, acute infections and dehydration), and relied 
upon specialist secondary care providers with little 
interaction or integration with primary care. 
Emergency Departments are often the portal of 
admission for people with dementia, and represent a 
last chance to prevent unnecessary hospitalisation. 
The literature highlights the need for comprehensive 
multidimensional geriatric assessment, including 
detection of dementia and delirium. There have been 
no trials of interventions, but a non-randomised study, 
of a geriatric rapid assessment and triage service, did 
demonstrate reduced admissions, and shorter lengths 
of stay3. 
‘Hospital at home’ refers to services provided by health 
professionals in the patient’s own home, in situations 
when inpatient hospitalisation would otherwise be 
necessary. The cost-effectiveness of this approach 
has been demonstrated for conditions including 
pneumonia, exacerbations of chronic obstructive 
pulmonary disease, deep vein thrombosis, cellulitis and 
end-of-life care. While we identified several examples 
of such services being established for people with 
dementia, we could find no formal evaluations. A 
large randomised controlled trial is currently being 
conducted in the Netherlands, with results expected in 
20184.
Reducing rates of hospitalisation for people with 
dementia will likely require community-based and 
outreach services that are resource-intensive and 
maintained over relatively long periods of time. 
Therefore, while the costs of hospital admission are 
high and concentrated, the potential for cost-savings 
may be illusory. Furthermore, costs would be shifted 
from acute hospital to community health and social 
care, which would require adjustments to budgets and 
resource allocation. 
For people with dementia who are admitted to general 
hospital inpatient settings, there is a tension between 
prioritisation of task-centred acute care for the 
indication for admission, and the acknowledged need 
to provide person-centred dementia care. 
Advocated actions are mainly at the systems level, 
focusing on managerial and workforce development; 
providing an appropriate care environment; fostering 
a positive care culture; changing attitudes; and 
cultivating a better understanding of the challenges for 
the person with dementia, for carers, and for inpatient 
healthcare staff.
Most reviews and reports emphasise that simply 
introducing a mental health liaison service, or a 
dementia specialist nurse, or a special dementia 
care unit will not suffice. Unless these are properly 
integrated into the wider hospital and health service 
management structure, with clear ownership, they 
will struggle to function properly. What is needed is a 
wholescale restructuring of the culture of hospital care, 
which first and foremost accords adequate priority, in 
resources and planning, to the needs of people with 
dementia. 
Concern is expressed in all recent reviews at the lack 
of rigorous evaluation of services that commissioners 
are advocating and providers are implementing. Well-
conducted large scale randomised controlled trials, 
providing clear evidence of cost-effectiveness are 
largely lacking. 
There is a body of evidence that the quality of 
hospital care can be improved, with enhanced 
staff and service-user satisfaction, but evidence on 
the tractability of the key health system economic 
indicators (length of stay and readmission rates) is 
much weaker. 
Palliative and end-of-life care
We reviewed the latest evidence on palliative and end-
of-life care for people living with dementia, updating 
the review that we conducted for the World Alzheimer 
Report 2013.
Dementia is a life-limiting illness with no disease 
modifying treatments, and deaths of people with 
dementia are increasingly common. End-of-life care 
and advanced care planning are closely related issues, 
since advanced care planning allows people with 
dementia to think through, and state preferences for, 
future care options. Many important decisions will need 
to be taken at a time when their capacity to contribute 
to them may be significantly compromised.
Concerns have been raised regarding the lack of 
access for people with dementia to good quality 
end-of-life care, specifically specialist palliative care 
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services, although there is some evidence, from some 
HIC, that the situation may be improving.
The applicability of a palliative approach to dementia 
care continues to be debated, given the lack of 
consensus regarding the definition of ‘advanced’ 
dementia and the lack of a clearly demarcated ‘end-of-
life’ phase. Some have argued for its relevance across 
the disease course, while others contend that this does 
no more than restate the need for good quality person-
centred dementia care.
There may be no specific palliative phase; the specific 
goals of dementia care can include, at various phases, 
and to different degrees, prolonging life, improving 
function, and achieving comfort (palliation). While 
several studies and reviews have addressed the 
optimal time for a more palliative approach, none 
have done so from the perspective of the person with 
dementia, whose views should be paramount.
Advanced care planning discussions can be 
challenging for people with dementia, their families, 
and healthcare professionals. The optimal timing to 
initiate the discussions is debated, although there 
is consensus that advance decisions, if made early, 
will need to be revisited and reviewed over time. All 
professionals providing care for people with dementia 
need training in the required skills, and structured 
approaches for the discussion and recording of its 
outcomes may be beneficial.
People with dementia should be encouraged and 
enabled to exercise their autonomy in options for future 
care, consistent with their values and preferences. 
Early discussions with family carers that acknowledge 
the likely loss of decision-making capacity and their 
increasing role as proxy decision-makers would assist 
carers in assuming this role, and enhance their ability 
to judge the person with dementia’s best interests. 
Empowerment of people with dementia needs to be 
stressed, to emphasise that the palliative care agenda 
is focused upon their choices, and their quality of life, 
rather than cost savings. Palliative care avoids futile 
and burdensome interventions, while ensuring that 
everything possible is done to maintain comfort. The 
aim is to avoid ‘bad costs’ (healthcare that is ineffective 
and does not improve quality of life), while reinvesting 
in ‘good costs’ (care that enhances comfort and quality 
of life). 
Calls have been made for a better systematisation of 
palliative care for people with dementia, with structured 
care pathways, good practice supported by evidence, 
and identification of appropriate outcomes to allow the 
effects of interventions to be measured. 
Research to date has focused on the extent to which 
palliative care approaches are being applied in 
practice, and the barriers to their more widespread 
uptake and implementation. Much less research has 
been conducted into the outcomes of palliative care, 
and how these can be improved, with no trials of the 
effectiveness of advanced care planning, or palliative 
care at any stage of care. Current good practice 
guidelines are almost entirely based upon expert 
opinion and consensus. 
More clarity is needed regarding; the division of 
responsibilities among different health and social care 
disciplines; the structure and function of advanced 
care planning; the management of rising risk and 
increasing complexity; boundaries between disease-
modifying treatment and palliative care and between 
palliative and end-of-life care. 
There is also a policy gap regarding end-of-life care for 
people with dementia. While improving palliative care 
services for people with dementia is an acknowledged 
policy priority for many HIC governments, most 
current national dementia strategies do not adequately 
address the issue. In essence, the focus is upon living 
well with dementia, with relatively less attention to the 
complex medical, social and ethical management of 
the physical decline that leads to death.
There is an urgent need for more research, specific to 
the dementia field, regarding; preferences of people 
with dementia, and how these can be elicited; the 
implementation, benefits and harms of advance 
care planning; and the relative costs and benefits of 
palliative care assessments and services in the more 
advanced phases of the condition. Another major 
gap in the research literature is that of palliative care 
services and end-of-life issues for people with young 
onset dementia. 
8.3 Discussion and conclusion
Four main themes emerged from the reviews 
conducted for this report; the need to systematise care 
processes; the challenges of managing complexity; the 
need for more research to inform policy and practice; 
and the potential for efficiency, through moderating 
costs while scaling up coverage of basic dementia 
healthcare services. 
1. Systematisation of care processes
There is a need for much greater systematisation 
of care processes for people with dementia. This 
should include standards of care at different phases 
of the condition; role specification (‘who does what’); 
clear referral indications and pathways; and relevant 
process and outcome indicators to be measured. 
Taken together, this would constitute a care pathway 
for dementia, and care pathways are now a more or 
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less universal structural component of chronic disease 
care for other conditions (for example diabetes, 
hypertension, and cancer care). Care pathways are 
much more explicit than guidelines, strategies and 
plans, enabling service performance to be monitored 
and quality improvement strategies to be implemented. 
Arguably, the lack of explicit care pathways in 
dementia healthcare is the single largest contributor 
to fragmented care, and to the lottery that people with 
dementia and their carers experience in accessing 
care and support that is effective, responsive, and 
continuing. While, in principle, different elements of a 
fragmented care system can each designate their own 
care pathways, value is added when these interact with 
each other, or, preferably, can be wholly integrated. 
This is only likely to occur when there is a guiding 
hand with responsibility for the central planning and 
resourcing of the health and social care systems. This 
is a strength for many OECD countries, but some 
rich and well-resourced countries (notably the USA), 
and middle income countries (for example India and 
many countries in Latin America) are relatively weak 
in this regard. Governments in low resource countries 
generally retain control over their more limited 
healthcare systems. 
2. Managing complexity
Much more effort needs to be applied to the effective 
management of complex multimorbidities in dementia 
healthcare, in particular chronic physical health 
conditions. As highlighted in this review, this issue is 
given far too little attention in, for example; evidence-
based guidelines for management of other chronic 
diseases; the training of PCPs for dementia care; the 
role of case managers and the outcomes studied in 
trials of this intervention; the design of community 
interventions that aim to reduce hospitalisation rates; 
and the development of the palliative care approach to 
dementia care. Notably, of the few examples of care 
pathways identified in this review, only that developed 
by the WHO addressed the issue of comorbidity. 
There is evidence that chronic comorbid physical 
health conditions are undermanaged, with missed 
opportunities to improve function and avoid acute 
crises leading to hospitalisation. 
At the same time, we need to acknowledge the 
paucity of evidence to inform management of 
physical comorbidity. Dementia, as we have noted, 
changes everything. Aside from complicating the 
delivery of care, it may affect the nature of other 
conditions and their response to treatments. Most 
trials, even those conducted among older people, 
tend to exclude those with dementia, and/or complex 
multimorbidities, hence the evidence-base will not 
necessarily generalise to these groups. For example, 
antidepressant treatment for depression is moderately 
efficacious for older people in general, but probably 
not for people with dementia and depression5. We 
know very little regarding the benefits and harms of 
standard treatments for hypertension (antihypertensive 
medications) and dyslipidaemia (statins) for people with 
dementia, but we do know that blood pressure and 
cholesterol levels, and body mass fall with the onset 
and progression of dementia, regardless of treatment6. 
Likewise there is no evidence-base to guide the 
optimum management of diabetes in dementia, in 
particular the optimum target level of glycaemic 
control6. Hypoglycaemic attacks may be particularly 
harmful for people with dementia. 
There have been calls for people with dementia to 
be included in the debate about approaches to the 
management of multimorbidities in older people7. Their 
values and preferences may differ in important ways 
from those who do not live with dementia, as may the 
outcomes that are most important to them. Mortality, 
a key outcome for most cardiovascular disease trials, 
may be considered less important than quality of life, 
while side effects may be particularly undesirable. 
Beneficial or harmful effects on cognition may be 
particularly critical. In the management of complex 
multimorbidity, the relative priority to be accorded to 
interventions that might prolong life, improve function 
or increase comfort needs to be determined according 
to the best interests of the person with dementia, 
whether communicated autonomously, through an 
advanced directive or by a carer as proxy decision-
maker. 
We need to do more to help people with dementia 
to optimise their physical health, maintain their 
nutrition and hydration, and reduce their risks for falls, 
infection and delirium. Attention needs to be given to 
medication management and polypharmacy. These 
should be considered integral components of dementia 
healthcare, alongside the review of the condition 
itself and its cognitive, psychological and behavioural 
effects. Multidimensional geriatric assessment and 
management shows some evidence of efficacy in 
improving health outcomes and, possibly, reducing 
risk of hospitalisation. Such interventions should be 
well within the expertise of non-specialist primary care 
services. Arguably, the inadequate management of 
multimorbidity may represent the biggest weakness in 
the currently prevailing specialist models of dementia 
care, and the strongest argument for the greater 
involvement of primary care in the coordination and 
delivery of community care.
3. Need for more research
In the opening section of this review, we highlighted the 
priority that had recently been accorded to research 
questions relating to the effective and efficient delivery 
of health and social care for people with dementia. In 
each of the subsequent chapters we have identified 
important evidence gaps. The lack of experimental 
evidence from well-conducted randomised controlled 
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trials has been particularly striking. Thus, there is 
no evidence at all regarding the effectiveness of 
advanced care planning, or palliative care for people 
with dementia. Despite a large number of trials, there 
is no evidence regarding the cost-effectiveness of 
case management. No trials have been carried out 
of interventions specifically designed to prevent 
hospitalisation of people with dementia. There is very 
little evidence to support widely advocated innovations 
in hospital care for those that are admitted. We have 
also suggested the need for more task-shifting ‘non-
inferiority’ trials examining the quality, acceptability 
and safety of different elements of the care pathway, 
delivered by non-specialist compared with specialist 
services. The lack of evidence in these areas is 
notable given the strategic priority attached to them by 
policymakers. 
We would argue that there is a need for researchers 
to work more closely with policymakers, healthcare 
providers and research funders to ensure that research 
is relevant and translatable. The collaboration with 
policymakers and healthcare providers is particularly 
critical in the evaluation of health service and system 
innovations. Some of the interventions reviewed here 
seem naïve in their conceptualisation, in that they are 
delivered by the research team with little integration 
with existing services and systems. Such interventions 
have limited generalisability, and are likely to have 
limited efficacy. Policymakers and providers have 
the ability to implement innovations, and should be 
encouraged to do so in a way that permits evaluation, 
and, where possible, experiment. Researchers should 
work with policymakers and providers to ensure that 
the innovations that they propose to evaluate are 
policy relevant, fully implementable in the context of 
the research evaluation, and capable of being taken 
to scale in the event that effectiveness and cost-
effectiveness are demonstrated.
4. Coverage, costs and efficiency
Increasing the coverage of dementia care will increase 
the share of the population who are treated which, 
coupled with the increasing numbers of people 
affected, will require additional healthcare spending on 
dementia.
Countries around the world face a considerable 
challenge in scaling up dementia care in the context 
of increasing numbers of people affected. In Canada 
for example, numbers of people with dementia will 
increase 58%, from 556,200 to 885,700 from 2015 to 
2030. However, assuming that over the same period, 
treatment coverage increases from 50% to 75%, the 
numbers treated would more than double (an increase 
of 339%, from 278,100 to 664,275). In middle income 
countries the challenge is even greater. In China, for 
example, we are assuming that in 2015 only 10% 
or 0.95m of the 9.5m people with dementia would 
be receiving treatment. By 2030 numbers affected 
would have nearly doubled to 16.2m. Targeting 50% 
treatment coverage would mean 8.1m under treatment, 
a near nine-fold increase from 2015. 
In this context, a move towards a less specialised, 
more task-shifted model of care can be advocated on 
two grounds. First, mobilising the untapped potential of 
the non-specialist primary care workforce can alleviate 
resource constraints hence enabling scaling up to 
take place. This is a particularly critical issue for lower 
resourced low and middle income countries. Secondly, 
this strategy is likely to optimise productive efficiency. 
Productive efficiency is attained when more healthcare 
services are provided at a given quality and cost, or, 
alternatively, the same healthcare services are provided 
at a given quality, but at a lower cost8. Under either 
scenario, the costs of care per person are assumed 
to fall. In a task-shifted model of care, the human 
resource and fixed costs of non-specialist primary care 
should in principle be lower than those for hospital-
based specialist care. Our modelling exercise supports 
this assumption; in Canada the per capita cost of 
the task-shifted care pathway is 43% lower, and in 
Switzerland 25% lower than that of the specialist care 
pathway. The productive efficiency of the task-shifted 
pathway is clearly demonstrated in the case of Canada. 
Assuming a specialist care pathway, the total cost of 
the pathway would increase by 9% from 2015 to 2030, 
from $US379m to $756m. However, if the system were 
transitioned to a task-shifted model the cost in 2030 
would be $438m. This would imply that costs would 
have increased by only 16% despite a 339% increase 
in numbers of people with dementia treated.
The potential increases in productive efficiency 
associated with the introduction of a more task-shifted 
model of care are clearly attractive. However, it is 
important to consider the practical implications of such 
a transition. Non-specialists would be taking on new, 
and to some extent unfamiliar tasks, for which they 
will need training, mentoring, supervision and support, 
provided by specialists. As highlighted in Chapter 
6, and discussed in Chapter 7, the preparedness of 
primary care services to assume these roles will vary 
greatly among countries, with very different levels 
of population coverage, workforce resources and 
competencies, and capacity to provide continuing 
care for chronic diseases, as opposed to curative 
interventions for acute conditions. In-service training 
is therefore only one component of the system-
strengthening and capacity building that would be 
required. Whatever the baseline level, there would 
need to be greater investment in primary care services, 
including, possibly, the development of a new cadre of 
case managers to assist PCPs with continuing care. 
Case managers might focus on dementia care, care of 
frail and dependent older people in general, or chronic 
disease care in general depending upon the burden 
of disease, and the extent of unmet needs within each 
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population. In low and middle income countries, good 
quality continuing care for chronic diseases requires 
transformative system change9,10, which will not be 
achieved overnight. Change will be incremental, and 
in the course of this transition cost-savings will be 
unlikely to be realised. Over time, as tasks are shifted 
successfully to the primary care level, commissioners 
will be able to shift budgets from secondary to primary 
care and per capita costs of care may fall. In reality 
though, the main benefits of task-shifting may be the 
unlocking of resource capacity to meet the increasing 
demand. There is also the possibility that task-shifted 
and task-shared care may be of higher quality; more 
local, more holistic and personalised, and more 
comprehensive, integrated and continuous. This will 
only be achieved with the support and expertise of 
specialist services, but with more clearly defined roles 
and functions. 
Scaling up dementia care would seem to be affordable, 
in principle, in all countries included in our review. 
Current annual costs of core dementia healthcare 
pathways, per person treated, range from US$ 1364 to 
US$ 2558 in HIC and from US$ 40 to US$ 199 in MIC. 
The total costs of the dementia pathways are estimated 
to be around 0.2% of total health expenditure in the 
HIC and as little as 0.05% in the MIC. After scaling 
up, and accounting also for the increasing numbers 
of people with dementia, costs would have doubled 
in HIC (although this increase would be mitigated by 
a move towards a more task-shifted system of care) 
and increased 15- to 30-fold in MIC. Some of these 
increased costs of dementia healthcare pathways 
might be offset through increased coverage of good 
quality dementia care, reducing costs resulting from 
the lack of timely access to appropriate healthcare 
by people with dementia. For example, in the UK, the 
‘excess’ cost of unnecessary hospital admissions and 
their adverse consequences amounts to £265 million 
(US$ 351m) in the UK, or around £330 (US$ 437) per 
person with dementia. In HIC generally, the cost of 
social care for people with dementia, particularly that 
provided in care homes, dwarfs that of healthcare. 
There is good quality evidence, from many studies, that 
education, support and training for carers can delay or 
prevent transition into care homes11.
One critical issue remains to be discussed. The cost 
of anti-dementia drugs had a large impact on the total 
cost of the dementia healthcare pathway where low 
cost generic versions of acetylcholinesterase inhibitors 
and memantine were not yet available. This was 
particularly the case in middle income countries, where 
staff costs were, proportionately, relatively modest. 
Increased access to low-priced generic drugs by 2030 
would make the dementia pathways, for example, up to 
150% more affordable in Indonesia, and 92% in China. 
This will be a particularly important issue if and when 
new and more effective treatments become available.
The central goal of the G7 Global Action on Dementia 
is to develop a disease modifying treatment for 
dementia by 2025. This is likely to be beyond the vista 
of our modelling exercise, which projects costs through 
to 2030. However, the development and marketing of 
such treatments will raise important issues of equity 
and justice. The World Health Organization ‘Call for 
Action’ on dementia12, unanimously supported by 80 
nation states, refers to the inalienable human rights 
of those affected, and to the need to give special and 
focused attention to low and middle income countries, 
emphasising the need for;
“a universal health coverage and an equity-based 
approach in all aspects of dementia efforts, 
including facilitation of equitable access to health 
and social care for people living with dementia and 
their caregivers”.
We should not forget the lessons of the HIV/AIDS 
epidemic, where a global campaign, led by activists 
from low and middle income countries, was required 
to secure a supply of the new antiretroviral drugs 
at affordable prices. The rate limiting step, after the 
affordability of medications was addressed, was 
the weakness of healthcare delivery systems in low 
resource settings to identify and treat those affected. 
While much progress has been made, this problem is 
still being addressed. 
We need to focus, now, on achieving high coverage 
of dementia diagnosis and continuing care, both to 
ensure access to current evidence based treatments 
and support, and to create systems and platforms 
with the capacity to deliver, with equity, much more 
effective treatments in the future.
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